Retinoic acid signalling in human lung disease and repair by Ng-Blichfeldt, John-Poul
 1 
 
 
 
Retinoic Acid Signalling in Human Lung 
Disease and Repair 
 
 
 
A thesis submitted for the degree of 
Doctor of Philosophy 
Imperial College London 
 
 
by  
John-Poul Ng-Blichfeldt 
2014 
 
 
Department of Critical Care 
National Heart and Lung Institute 
Imperial College London 
London SW3 6LY 
 
 2 
Abstract 
 
The normal adult mammalian lung has a robust capacity to regenerate following 
injury, and evidence for alveolar regeneration was recently demonstrated in adult 
man. In contrast, mounting evidence suggests COPD/emphysema represents a failure 
of regeneration. COPD represents an enormous worldwide clinical and social burden, 
with currently no cure besides lung transplantation.  
 
An appealing therapeutic option is induction of endogenous lung regeneration using 
retinoic acid (RA), demonstrated to stimulate alveolar regeneration in animal models 
of emphysema. However, clinical trials investigating retinoids for chronic lung 
diseases have been disappointing. Thus, there is a profound stimulus to understand 
how the regeneration-inducing effects of RA in animal models translate to man. 
 
The molecular regulation of RA signalling in emphysema has not been investigated 
hitherto, and the role of RA in repair of specific human alveolar cell types, alveolar 
type 2 cells and lung microvascular endothelial cells, is unknown. Work in this thesis 
was conducted to address these questions. We demonstrated that CYP26A1, which 
breaks down RA, is enriched on an mRNA and protein level in emphysematous lung 
tissue. We also demonstrated using in vitro cell culture assays that RA is unlikely to 
directly regulate alveolar epithelial wound healing. In contrast, RA stimulated lung 
microvascular endothelial angiogenesis, likely via retinoic acid receptor alpha, and 
was associated with induction of angiogenic genes. 
 
Further work presented herein involved development of an ex vivo model of lung 
regeneration using precision cut lung slices (PCLS) derived from adult human distal 
lung tissue. We demonstrated that human PCLS retain architecture and viability 
through slicing, that 10% serum supplementation is inappropriate for long-term PCLS 
culture, and that human PCLS remain viable for at least 4 days in culture, suggesting 
they are amenable to development of an injury/repair model within this time frame.  
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1 Chapter 1 – Introduction 
 
1.1 Structure and function of the lung 
 
The primary function of the lung is to provide a surface area for efficient gas 
exchange, which is the uptake of oxygen from the atmosphere into the bloodstream 
and in parallel, the removal of waste carbon dioxide. This process is integral to the 
survival of air-breathing organisms, and occurs in the roughly 300 million tiny, 
exceptionally thin-walled, discrete gas exchange structures in the distal part of the 
lung, alveoli (1). The efficient transfer of large volumes of gases is permitted by a 
specialised design in which the vast alveolar surface are, on average around 70 m2 in 
humans, is intricately folded into the limited space of the thoracic cavity (1). The 
alveolar surface, which constitutes the respiratory zone of the lung, is connected to the 
atmosphere by a series of successively, dichotomously branching airways, beginning 
with the trachea and ending in thousands of terminal bronchioles, which collectively 
constitute the conducting zone of the lung (1). Distal to the conductive zone, alveoli 
are arranged as collections of sacs connected to a single terminal bronchiole, in such a 
way that several alveoli are ventilated in series by the same terminal bronchiole – this 
structure together represents a respiratory unit termed the pulmonary acinus. 
 
The transfer of gases between the atmosphere and the bloodstream occurs by passive 
diffusion across the alveolar-capillary membrane (ACM). The ACM is composed of 
three components: the alveolar epithelium, the capillary endothelium, and a slender 
layer of interstitum, which for nearly half the contact surface between capillary 
endothelium and alveolar epithelium is formed exclusively of the fused basement 
membrane of these two cell layers (Figure 1.1). In the regions where the basement 
membranes are separated, the interstitial space contains fine elastic fibres, small 
bundles of collagen fibrils, and the processes of fibroblasts, which collectively 
contribute to the elastic recoil of the lung and determine the tissue component of lung 
compliance (2). The structural properties of the ACM are suited to the transfer of 
gases due to its exceptional thinness, which in humans can reach around 0.6 µm.  
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Figure 1.1 Structure of the ACM 
A) Transmission electron micrograph cross-section of an alveolar capillary (C), 
within a septal wall between two alveolar spaces (A). Lumen of alveolar capillary is 
lined by endothelial cell cytoplasm, with nucleus in bottom corner (EN). Dark objects 
within capillary lumen are red blood cells. Alveolar surfaces are lined by AT1 
epithelial cell cytoplasm (E), which together with endothelial cytoplasm, forms the 
ACM. AT1 cell nucleus is visible at alveolar septal junction at bottom (EPI). ACM on 
right side (1) has minimal interstitium with fused basement membranes; ACM on left 
(2) contains some fine fibers (F), as well as fibroblast processes (FB), between 
endothelial and epithelial cytoplasms. X4,900. B) TEM of ACM in dog lung showing 
cytoplasms of AT1 cell (EPI) and microvascular endothelial cell (EN) with fused 
basement membrane (IN). X63,000. From: Weibel ER. (1973) (2) 
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Alveoli are lined internally by the alveolar epithelium. This is comprised of alveolar 
type 1 (AT1) cells, which have a squamous morphology and constitute ~95% of the 
alveolar surface, and alveolar type 2 (AT2) cells, which are cuboidal in shape and 
although occupy less surface area, comprise 60% of total alveolar epithelial cell 
number (3). A principle function of AT2 cells is the production of surfactant, which is 
packaged intracellularly in granules called lamellar bodies, and serves to lower the 
surface tension of the alveolar surface to prevent their collapse. AT2 cells also 
function as the progenitor cells of the alveolar epithelium, and are able to repopulate it 
after injury through proliferation and differentiation into AT1 cells (4). Most of the 
internal alveolar surface is provided by the attenuated, branching cytoplasm of AT1 
cells, which protrude over 50 µm from the nucleus and contain few organelles, 
providing minimal resistance for the transfer of gases (2). Surrounding alveolar units 
is a dense meshwork of alveolar capillaries, which resembles a sheet of blood flowing 
along the alveolar surface and extends through interalveolar walls, forming a 
continuum from the pulmonary artery to the pulmonary vein (2). Thus, deoxygenated 
blood pumped from the heart to the lung via the pulmonary artery becomes 
oxygenated within the alveolar capillary network, and once freshly oxygenated, is 
thence channelled via the pulmonary vein back to the heart, from where it is 
distributed to the rest of the body. Interspersed throughout the alveoli, underneath the 
layer of surfactant lining the alveolar walls, are a population of alveolar macrophages 
with phagocytic activity which function to remove foreign material such as carbon 
and dust particles, and thus protect the ACM. 
 
1.2 Cellular mechanisms of lung epithelial maintenance and repair 
 
The respiratory epithelium is continually in contact with the atmosphere, and is 
therefore particularly vulnerable to injury. To maintain structural integrity and 
preserve its gas exchange function, the lung constantly undergoes low-level 
homeostatic self-renewal. Furthermore, in response to a variety of injuries, the lung is 
capable of initiating endogenous regenerative mechanisms (5). Regeneration refers to 
the restitution of diseased, damaged or defective tissue into a functional state (6). 
Animal models have provided information about the cellular and molecular 
mechanisms involved in lung regeneration, outlined in Figure 1.2.  
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This thesis is primarily focussed on the alveolar regions of the adult lung. However, it 
is worth briefly considering our current understanding of the maintenance and 
regeneration of the adult proximal and distal airways, due to their close 
developmental relationship to the lung parenchyma, and the considerable progress 
which has recently been made in this regard. 
 
1.2.1 Airway epithelial homeostasis and repair 
 
The murine and human tracheal epithelium undergoes low rates of cellular turnover 
(7) and is comprised of a pseudostratified mucociliary epithelium containing basal 
cells (distinguished by expression of p63 and keratin 5 and 14 [Krt5/14]), Clara cells 
(distinguished by expression of Sgb1a1, also known as CC10, CCSP or uteroglobin), 
and ciliated cells. It was demonstrated with genetic lineage-tracing experiments that 
under normal conditions, Clara cells both undergo long-term self-renewal and 
repopulate the tracheal epithelium during steady-state homeostasis, whereas basal 
cells self-renew and generate Clara and ciliated cells at a much lower frequency (8). 
In contrast, following naphthalene- and SO2- induced injury to the murine tracheal 
epithelium, basal cells rapidly undergo asymmetric division to self-renew and give 
rise to Clara and ciliated cells, regenerating the tracheal epithelium (8, 9). 
Differentiation of basal cells to a secretory lineage was found to occur via an early 
progenitor (EP) intermediate phenotype characterised by expression of keratin 8 
(Krt8) (10). Following this, EPs differentiate into Clara cells, which in the murine 
trachea function as transit-amplifying cells, capable of further self-renewal or 
differentiation into ciliated cells (11). Clara cells are also capable of de-differentiating 
into basal cells following selective ablation of the basal cell pool. Following 
conditional induction of diphtheria toxin in Krt 5 + basal cells of murine airways, 
Clara cells proliferated, and began to express p63 and Krt 5, characteristic of basal 
cells, eventually contributing substantially to the basal cell compartment of proximal 
airways (12). Thus, differentiated epithelial cells of the respiratory tract may possess a 
higher degree of plasticity than previously thought. 
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The situation differs in the murine bronchioles (distal airways), which are comprised 
of columnar epithelium containing only Clara, ciliated and neuroendocrine cells 
without basal cells. In this region, Clara cells undergo long-term self-renewal and 
repopulate the ciliated compartment both during steady state homeostasis, and 
following hyperoxia-induced focal epithelial injury (11). Conversely, naphthalene-
induced airway injury causes targeted destruction of the majority of secretory cells in 
the bronchiolar epithelium. In such cases, a subpopulation of naphthalene-resistant 
Sgb1a1 expressing secretory cells (termed variant Clara cells) which are localised to 
neuro-epithelial bodies (NEBs) or bronchoalveolar duct junctions (BADJs) and are 
normally relatively quiescent, rapidly restore the secretory and ciliated cellular 
compartments (13, 14), which has led to such Clara cells being labelled as facultative 
stem cells (15). Thus in mice, diverse cellular mechanisms maintain and regenerate 
distinct portions of the airway epithelium (16).  
 
While in mice, basal cells are confined to the tracheal epithelium, in humans the 
pseudostratified epithelium containing basal cells extends throughout the airway from 
the trachea right down to the alveolar ducts (17), whereas Clara cells are largely 
absent from the trachea and become increasing in number toward the distal 
bronchioles (18). Using a clonal analysis technique examining benign, hereditable 
mitochondrial DNA mutations, Teixeira et al recently demonstrated that basal cells 
are responsible for maintaining the basal, Clara and ciliated epithelial cellular 
compartments in the proximal human airway epithelium during steady state 
homeostasis through asymmetric division and self-renewal, placing basal cells as the 
stem cells of the proximal human airway epithelium (19). Clara cell proliferation has 
been previously described in distal human bronchioles (18), however the precise 
cellular mechanisms responsible for the maintenance of the distal regions of the 
human airway epithelium have yet to be elucidated (20).  
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Figure 1.2 Mechanisms of lung epithelial regeneration 
Schematic diagram showing different potential mechanisms of epithelial regeneration 
along the proximo-distal axis of the mouse respiratory tract. Basal cells = red, Clara 
cells = orange, ciliated cells = blue, NEB = purple, AT2 cells = yellow, AT1 cells = 
grey, smooth muscle cells = pink. Red line indicates vascular network. 1) Clara cells 
self-renew and repopulate the trachea during steady state renewal in the proximal 
airways. 2) Basal cells of proximal airway can repopulate Clara and ciliated cell 
compartments following SO2 injury. 3) A subpopulation of Clara cells in proximal 
and distal airways (variant Clara) located near NEBs (green/purple) are resistant to 
naphthalene and repopulate Clara cell compartment following naphthalene injury. 4) 
In distal airways, Clara cells self-renew and repopulate Clara and ciliated 
compartments following injury. 5) BASCs located near BADJs (green/yellow) can 
differentiate into AT2 and Clara cells in vitro and proliferate following PNX. 6) AT2 
cells replenish the alveolar epithelium by self-renewal and differentiation into AT1 
cells during steady state and following alveolar epithelial injury. Adapted from: 
Rawlins E & Hogan BL (2006) (5). Abbreviations: NEB, neuroendocrine body; AT1, 
alveolar type 1; AT2, alveolar type 2; BASC, bronchoalveolar stem cell; BADJ, 
bronchoalveolar duct junction, PNX, pneumonectomy. 
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1.2.2 Alveolar epithelial homeostasis and repair 
 
The cellular mechanisms which regulate alveolar maintenance and regeneration are 
less well understood, but are beginning to be elucidated and are distinct from those 
which govern the airways. Early experiments using histology and tritiated thymidine 
(H3-Tdr) incorporation to measure DNA synthesis following NO2-induced alveolar 
injury in rats, suggested that AT2 cells function as the progenitor cells of the alveolar 
epithelium (21). This was recently confirmed with genetic lineage-tracing 
experiments, using a CreER-lox system with an inducible, heritable reporter under the 
control of the SPC promoter. In response to bleomycin, which caused widespread 
death of AT1 cells, AT2 cells proliferated rapidly and gave rise to a significant 
population of both AT2 and AT1 cells, repopulating the alveolar epithelium (22, 23) 
(Figure 1.3).  
 
Bleomycin-induced alveolar injury is associated with induction of diffuse pulmonary 
fibrosis, and in this model a fraction of newly generated AT2 cells were found to arise 
from Sgb1a1+ cells, as well as cells which do not express SPC (22), possibly from 
cells expressing integrin α6β4 (24). In a subsequent study using the inducible SPC 
promoter-driven reporter mouse model, but inducing injury targeted to a proportion of 
resident AT2 cells, the remaining AT2 cells were the major cell type repopulating 
both the AT2 compartment through clonal expansion, and the AT1 compartment 
through differentiation (23) (Figure 1.3). Furthermore, under normal steady state 
conditions, AT2 cells maintained the AT2 pool through low levels of proliferation, 
and gave rise to small numbers of AT1 cells, in accordance with the low rate of 
cellular turnover of the alveolar epithelium (23), thus confirming the status of AT2 
cells as the progenitor cells of the alveolar epithelium.  
 
It is controversial whether cells other than AT2 cells are capable of significantly 
repopulating the alveolar epithelium. Bronchioalveolar stem cells (BASCs) were 
described co-expressing Sgb1a1 and SPC and which were localised to the BADJ in 
normal murine lung (25). BASCs were capable of differentiating into both AT2-like 
and Clara-like cells in vitro (25) and proliferated during post-pneumonectomy (PNX) 
lung growth (described below) in parallel with resident AT2 cells (26). While the 
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contribution of Sgb1a1 expressing cells to the reconstitution of the alveolar 
epithelium in vivo has been suggested to be minor (11), the issue is still controversial 
(20, 27). One group reportedly identified mouse lung progenitor cells characterised by 
EpCAMhi CD49fpos CD104pos CD24low, which formed AT2-like and Clara-like cells in 
an in vitro colony-forming assay, although whether this capacity is retained in vivo 
was not determined (28). Another study demonstrated p63-expressing cells 
repopulated the alveolar epithelium in a mouse model of alveolar regeneration 
following sublethal H1N1 infection (29). While p63 expressing basal cells are usually 
confined to the trachea in mice, in this model by 11 days post infection, numerous p63 
expressing cells were observed in the damaged parenchyma, and rare cells within this 
population were found to form Krt5 expressing ‘pods’ which preceded the formation 
of alveolar-like structures in vivo. Furthermore, the formation of Krt5 pods was not 
evident in the bleomycin model of alveolar regeneration (29). Thus, it appears that the 
cellular mechanisms which reconstitute the alveolar epithelium after injury may 
depend on the injury model used (5).  
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Figure 1.3 Genetic lineage tracing to show renewal of alveolar epithelium by AT2 
cells following targeted AT2 ablation and after bleomycin injury 
A) AT2 cells self-renew following injury. Sftpc-CreER;Rosa-DTA/Rosa-Confetti 
mouse were given low-dose tamoxifen to induce conditional ablation of a fraction of 
AT2 cells and induce heritable expression of 4 reporters in remaining AT2 cells. 
Confetti reporters: nuclear GFP (nGFP), cytoplasmic YFP (YFP), membrane cyan 
(mCFP), and cytoplasmic RFP. 10 weeks later, clonal patches of cells labeled with 
reporters are visible, indicating clonal expansion of AT2 cells. From: Barkauskas et al 
(2013) (23). B) AT2 cells differentiate into AT1 cells following injury. Adult Sftpc-
CreER;ROSA-Tomato mice were given tamoxifen to induce heritable expression of 
the RFP variant tdTomato in AT2 cells. Bleomycin was administered intratracheally 
and 60 days later lungs examined with confocal microscopy. B1 on the left, a portion 
of AT1 cells (Aqp5+) co-express Tomato, indicating they derived from lineage-
labelled AT2 cells. From: Rock et al, (2011) (22). Abbreviations: GFP, green 
fluorescent protein; YFP, yellow fluorescent protein; CFP, cyan fluorescent protein; 
RFP, red fluorescent protein; AT1, alveolar type 1; AT2, alveolar type 2. 
A 
B1 
B2 
B3 
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1.3 Endogenous programmes of whole-tissue lung regeneration 
 
The adult mammalian lung possesses endogenous programmes regulating alveolar 
destruction and regeneration, which can be activated by either external or internal 
stimuli. Caloric restriction in mice leads to the rapid onset of alveolar destruction 
resembling human emphysema (30, 31) through alveolar cell apoptosis and 
proteolytic degradation of the septal interstitium (32). It was shown that re-initiation 
of ad libitum feeding in these mice leads to an increase in alveolar wall cell number 
and DNA content, and eventually to alveolar dimensions identical to those in normal 
animals, indicating endogenous alveolar regeneration (31). A similar phenomenon 
was observed in ovarectomised female mice, which exhibited a rapid loss of alveolar 
number and surface area – oestrogen replacement in these mice induced endogenous 
alveolar regeneration with restitution of alveolar dimensions similar to normal mice 
(33, 34). Several lines of evidence suggest conservation of these programmes in the 
adult human lung. For example, patients with anorexia nervosa, which involves a 
voluntary restriction of caloric intake, displayed reduced lung density measured by 
computed tomography (CT), characteristic of early emphysematous lung destruction 
(35). Furthermore, lung function in women was found to oscillate with phases of the 
menstrual cycle, and correlated with levels of circulating endothelial progenitor cells, 
suggesting hormonally driven lung remodelling (36).  
 
The capacity for endogenous lung regeneration in adults is further illustrated with 
post-PNX lung growth. Surgical excision of a lobe or an entire lung causes an 
increase in non-uniform mechanical strain on the residual parenchyma (37), initiating 
a species- and age-dependent compensatory growth of the remaining lobes into the 
resulting cavity (reviewed in (38, 39)). During post-PNX growth, DNA synthesis is 
stimulated in parenchymal cell types such as BASCs, AT2 cells, microvascular 
endothelial cells, interstitial fibroblasts, and platelet-derived growth factor receptor 
alpha (PDGFR-α) -expressing lipofibroblasts, and results in new-alveolar 
development (40). Alveolarisation in in this model is also associated with 
elastogenesis by lipofibroblast-derived α-SMA positive myofibroblasts (41). In 
parallel, the microvascular network exhibits angiogenesis focused in subpleural 
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regions, corresponding to regions of enhanced growth within the regenerating lung 
which are exposed to greatest mechanical stretch (42).  
 
Post-PNX lung growth is a robust model of re-alveolarisation due to involvement of 
all cell types of the parenchyma, and because it is not complicated by aberrant repair 
processes such as inflammation, fibrosis, and ultrastructural derangement (38). Post-
PNX lung growth is distinct from complete structural regeneration as observed in the 
salamander limb, and whole-body regeneration in planaria, in that the missing lobe 
does not re-grow orthotopically from the site of bronchial amputation. Nevertheless, 
the growth of the remaining lobes following PNX involves neo-alveolarisation and 
recovery of lung function parameters (40, 43) including gas exchange (44), and is 
therefore considered to be an instance of tissue regeneration (38). Conservation of this 
capacity in the adult human lung was suggested by a recently published case study, in 
which a patient exhibited compensatory lung growth 15 years following left PNX, 
with the remaining lobes expanded into the thoracic cavity (45). Using inhalation of 
hyperpolarised helium-3 gas coupled with magnetic resonance imaging (MRI), it was 
determined that the lung growth involved neo-alveolarisation, as the alveolar 
dimensions were similar to that observed in normal lung (45).  
 
Little is known about interstitial cells during lung maintenance and regeneration, 
largely due to a lack of specific markers (22). Lung mesenchymal stem cells (LMSCs) 
have recently been identified, which are resident within parenchymal interstitium. 
LMSCs from mice and humans were shown to self-renew, form clonal colonies, and 
have adipogenic, osteogenic and chrondrogenic differentiation potential (46, 47). 
LMSCs were shown to turn over at a rate of ~2.26% per day during the steady state in 
the adult mouse lung (48).  This suggests that LMSCs may contribute to maintaining 
the interstitium of the adult lung. LMSCs have been isolated by flow cytometry as 
CD45-, CD31-, Sca-1+, Epcam-, however the isolated cells remained a heterogeneous 
population containing lipofibroblasts and non-lipofibroblast cells, and thus it is 
unclear if a single cell type can renew all interstitial components of the adult lung (46, 
49). 
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1.4 COPD and emphysema: the clinical burden 
 
Some forms of lung injury cause alveolar destruction which stabilises and is not 
spontaneously reversible, leading to alveolar insufficiency. This is clinically 
represented by emphysema, part of a spectrum of disorders described by chronic 
obstructive pulmonary disease (COPD) in adults, and is modelled in adult animals 
with various injuries such as intratracheal instillation of elastase, chronic cigarette 
smoke exposure, and genetic manipulation (reviewed in (50, 51)).  
 
Chronic obstructive pulmonary disease (COPD) represents a significant global 
clinical burden. COPD is defined as a disease of persistent, progressive airflow 
limitation, comprised of varying contributions of the distinct anatomic lesions of 
emphysema, chronic bronchitis and small airway/vascular remodelling (52). These 
result in airflow obstruction, reduced alveolar ventilation and reduction in gas 
diffusing capacity, and lead to breathlessness and progressive decline in quality of life 
due to chronic hypoxemia/hypercarbia, and secondary indications such as cachexia 
and systemic inflammation (53). The primary risk factor for COPD is exposure to 
cigarette smoke, although the disease is perhaps best understood as the clinical 
consequence of an interaction between environmental factors and a currently poorly 
understood predisposition (54). In the UK, COPD currently affects around 820,000 
people, although it is estimated that 3 million people in the UK have the disease (~5% 
of the population) with around 2 million undiagnosed (55). On average, the 
prevalence of COPD as defined by spirometry is ~5-15% across industrialised 
countries (56). COPD represents a significant national economic burden, costing the 
NHS £800 million a year and causing the loss of 24 million working days a year, with 
the cost of lost productivity being estimated at around £2.7 billion (55). Globally, 
COPD is predicted to rise from the sixth to the third leading cause of death by 2020 
(57). The alarming increase in global mortality due to COPD is projected to occur due 
to a worldwide epidemic of smoking, particularly in developing countries (58).  
 
Currently, there are no disease-modifying treatments, and existing therapeutic options 
remain palliative. Patients who stop smoking exhibit improved survival rates and a 
slowing in the decline of lung function, but lung function abnormalities are not 
reversed. Pharmacological intervention is largely limited to control of symptoms 
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associated with chronic bronchitis, and does not treat the underlying condition (59). 
Lung transplantation is sometimes the only option for the severely affected, but has 
amongst the lowest survival rates of all solid organ transplants (60). Thus, there is a 
desperate need to develop novel therapeutic approaches.  
 
1.4.1 Emphysema: an inability to regenerate? 
 
Emphysema is a disease of alveolar destruction characterised by progressive, largely 
irreversible airspace enlargement distal to the terminal bronchioles (52). Patients with 
emphysema suffer significant effects on health-related quality of life, with reduced 
gas diffusing capacity causing dyspnea (shortness of breath) and reduced exercise 
tolerance (61). The pathological mechanisms underlying the progression of 
emphysema are multifactorial and include premature senescence and increased 
apoptosis of lung parenchymal cells (62), disruption of the oxidant/antioxidant and 
protease/antiprotease balance, and sustained inflammation (reviewed in (63, 64)).  
 
Importantly, the emphysematous lung, both in animal models and clinical 
emphysema, does not spontaneously regenerate even after cessation of smoking or 
removal of the original insult, suggesting defective regenerative mechanisms (65, 66). 
Several lines of evidence support this idea. AT2 and endothelial cells in the 
parenchyma of emphysematous human lung exhibit increased markers of senescence, 
implying lowered capacity for regenerative proliferation (67). Fibroblasts isolated 
from emphysematous lung also display increased senescence and lower proliferative 
capacity (68, 69). Emphysematous human lung fibroblasts in vitro produce lower 
levels of hepatocyte growth factor (HGF), a signalling molecule which promotes 
epithelial repair and angiogenesis (70). Similarly, reduced levels of endogenous HGF 
correlated with progression of alveolar destruction in a rat model of elastase-induced 
emphysema (71). The WNT/β-catenin pathway, which is implicated in development 
and regeneration of diverse organs, was found reduced in alveolar cells in 
emphysematous human lung and animal emphysema models (72). Thus, regenerative 
mechanisms may contribute towards the inability of the emphysematous lung to 
effectively repair.  
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Retinoic acid (RA), derived from vitamin A, controls a signalling pathway involved 
in organ regeneration across phylogeny (Introduction 1.5). An emerging body of 
evidence suggests that RA signalling is altered in COPD/emphysema. For example, 
decreased serum retinol (a precursor to RA) preceded decline in lung function in 
COPD patients (73), and vitamin A deficiency (VAD) in rats causes onset of 
emphysematous alveolar destruction (74, 75). The hypothesis that transcriptional 
control of RA signalling is altered in clinical emphysema forms the basis of Chapter 3 
in this thesis. 
 
The notion that defective regenerative mechanisms contribute towards emphysema 
suggests that stimulating endogenous regenerative programmes may be a viable 
therapeutic approach. In support of this, a number of agents capable of stimulating 
endogenous repair pathways have shown promise in animal models at enhancing 
endogenous lung regeneration following PNX and inducing alveolar regeneration in 
emphysematous lung. These include HGF (76), adrenomedullin (AM) (77), 
palifermin (N-terminally truncated recombinant human keratinocyte growth factor, 
KGF, also known as FGF7) (78), basic fibroblast growth factor (bFGF, also known as 
FGF2) (79), simvastatin (34), and RA (Introduction 1.10). RA is of particular interest 
as it was the first agent used to demonstrate the proof of concept that a regenerative 
approach may be a viable therapeutic option for the treatment of emphysema - 
seminal experiments conducted in 1997 by Massaro & Massaro showed the ability of 
RA to induce alveolar regeneration in elastase-induced emphysema in rats (80). 
Furthermore, RA is the only agent thus far explored in clinical trials for emphysema, 
due to the striking success of pre-clinical studies and its established safety profile in 
humans (Introduction 1.11). 
 
1.5 What is retinoic acid? 
 
RA is a low molecular weight (300.4 g/mol) lipophilic molecule which drives a 
signalling pathway with evolutionarily conserved roles in development, patterning 
and regeneration in diverse organisms. RA regulates the transcription of a wide 
assortment of genes through interaction with cognate type 2 nuclear receptors (RARs, 
and retinoid X receptors, RXRs), and controls a variety of cellular events in a highly 
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context-specific fashion, including proliferation, differentiation, and apoptosis, both 
throughout embryonic development and during adult tissue homeostasis and repair. 
The RA pathway is critically involved in early embryonic development, regulating 
transcriptional programmes involved in patterning and morphogenesis of various 
organs. Disturbances in RA signalling during this period, through disruption in RA 
pathway genes or through vitamin A deficiency (VAD), can result in various 
developmental disorders including central nervous system (CNS) abnormalities, limb 
and skeletal defects, ocular and craniofacial defects, cardiac malformations, foregut 
endoderm defects and renal and lung agenesis (81). Conversely, excess RA during 
development (through maternal supplementation) is teratogenic and can lead to a 
range of congenital defects including craniofacial, cardiac, thymic and CNS defects in 
animals and humans (82, 83). Thus, the magnitude of RA signalling must be 
exquisitely controlled both temporally and spatially for the proper development of a 
range of tissues and organs. 
 
The cellular effects of RA are determined by the complex integrated functions of 
intracellular retinoid binding proteins, enzymes involved in the sequential metabolism 
of vitamin A precursors into biologically active RA, enzymes involved in the 
catabolic breakdown of RA, and nuclear receptors which transduce the signal and 
initiate gene transcription. A summary of the RA pathway is presented in Figure 1.4 
 
RA is a form of Vitamin A, which is a generic term that encompasses a group of 
unsaturated organic compounds, distinguished by the presence of a beta-ionone ring 
to which an isoprenoid chain is attached, called a retinyl group. Vitamin A includes a 
variety of species such as retinol (alcohol), retinal (aldehyde), RA (carboxylic acid), 
retinyl esters and provitamin A carotenoids. With the exception of the visual system 
which requires retinal, the biological actions of vitamin A are mediated by RA, which 
can exist as 3 isomers: all-trans RA (ATRA), 9-cis RA, and 13-cis RA, although most 
of the biological effects of RA can be attributed to the all-trans configuration (Figure 
1.5). For mammals including humans, vitamin A is an essential nutrient and cannot be 
synthesised de novo, and thus must be provided in the diet. RA is derived from dietary 
vitamin A, which enters the body in the form of retinyl esters (predominantly retinyl 
palmitate or retinyl acetate) found in meat, or in the form of provitamin A 
carotenoids, found in plants (summarised in Figure 1.5).  
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Figure 1.4 RA pathway 
Schematic representation of the RA signalling pathway. Green boxes indicate 
enzymes involved in RA metabolism, blue indicates receptors, and purple indicates 
binding proteins. Abbreviations: RBP4, retinol binding protein 4; STRA6, stimulated 
by retinoic acid 6; ADH, alcohol dehydrogenases; RDH, retinol dehydrogenases; 
CRBP, cellular retinol binding protein; RA, retinoic acid; RALDH, retinaldehyde 
dehydrogenases; CRABP, cellular retinoic acid binding protein; CYP26, cytochrome 
P450 subfamily 26; RAR, retinoic acid receptors; RXR, retinoid X receptors. 
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1.5.1 Absorption of vitamin A in the small intestine 
 
In the adult, retinyl esters (REs) and carotenoids obtained from the diet are absorbed 
into enterocytes, the absorptive epithelial cells of the small intestine. The most 
important plant-derived sources of provitamin A carotenoids are α-, β-and γ- carotene 
and cryptoxanthin, although β-carotene predominates. In humans, <50% of dietary 
carotenoids are absorbed, and their absorption largely depends on the presence of 
adequate fats in the diet, which stimulate pancreatic enzyme secretion and provide the 
lipid components for intestinal chylomicron assembly (described below) (84). 
Provitamin A carotenoids enter enterocytes via a mechanism involving a specific 
membrane receptor, scavenger receptor class B, type 1 (SR-B1) (85). The activity of 
SR-B1 is regulated by RA signalling by the intestinal transcription factor ISX, 
providing a diet-responsive negative feedback mechanism capable of controlling the 
further intake of provitamin A carotenoids (86). Once inside enterocytes, provitamin 
A carotenoids are converted into retinol via sequential enzymatic reactions, firstly 
into retinal by β-carotene-15,15’-dioxygenase, and then into retinol by retinal 
reductase (87). 
 
REs are the main sources of vitamin A from meat, particularly in the form of retinyl 
palmitate. REs are hydrolysed either directly in the intestinal lumen by pancreatic 
triglyceride lipase (PTL), or in the brush border membrane by phospholipase B, into 
retinol. Retinol is then absorbed through the apical membrane of enterocytes via a 
saturable carrier-mediated process at physiological concentrations, and by passive 
diffusion at pharmacological concentrations. To date, no specific transport protein has 
been identified that mediates retinol uptake into enterocytes, however it is likely to be 
specific for retinol, and possible candidates are RBP4 receptor 2 (RBPR2) in mice, 
and stimulated by retinoic acid 6 (STRA6) in humans (both described below) (87, 88).  
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Figure 1.5 Molecular structures of retinoids.  
A) Molecular structures of retinol and the 3 isomers of RA: all-trans RA, 9-cis RA 
and 13-cis RA. B) A summary of retinoid metabolism. From: McDonald (2009) (89) 
 
Once in the cytoplasm of enterocytes, retinol is solubilised by associating with 
cellular retinol binding protein-2 (CRBP-2). CRBP-2 is a small protein of molecular 
A 
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weight of 16 kDa, and is encoded for the CRBP2 gene which is mapped to 
chromosome 3q23 in humans (90). CRBP-2 is highly abundant in mature enterocytes 
of the small intestine, and represents 0.4% of total soluble protein in the jejunal 
mucosum in humans (91). CRBP-2 functions to traffic retinol to lecitihin:retinol 
acyltransferase (L:RAT) within microsomes of the endoplasmic reticulum. L:RAT 
catalyses the esterification of retinol into REs, which are then incorporated into 
triacylglycerol-rich absorptive lipoproteins called chylomicrons. In contrast to other 
dietary neutral lipids, REs are not packaged at significant levels into other 
lipoproteins such as low-, intermediate-, or high-density lipoproteins (84). 
 
RE-complexed chylomicrons are exocytosed from the basolateral surface of 
enterocytes and carried via lymphatics into the bloodstream. They are then broken 
down by the enzyme lipoprotein lipase (LPL) present on the luminal surface of 
vascular endothelial cells of the circulatory system, generating chylomicron remnants 
which retain almost all of the newly absorbed REs. 75% of RE-complexed 
chylomicron remnants are delivered to and absorbed by parenchymal cells of the 
liver, hepatocytes, while the remaining 25% are taken up by extra-hepatic tissues 
including the lung (92).  
 
1.5.2 Vitamin A storage in the liver 
 
The liver is the primary storage site for retinoids in the body, storing > 80% of total 
body vitamin A in vitamin A-sufficient animals as REs, particularly as retinyl 
palmitate. RE-complexed chylomicron remnants generated following dietary 
absorption are delivered to hepatocytes, where chylomicron remnant triglycerides are 
broken down. This liberates REs, which are then hydrolysed into retinol and 
transferred to neighbouring specialized perisinusoidal hepatic cells called stellate cells 
(also called Ito cells, fat-storing cells or lipocytes). Retinol is re-esterified into REs 
(predominantly retinyl palmitate and retinyl stearate) via the catalytic activity of 
L:RAT within stellate cells, for storage in the form of cytoplasmic lipid droplets. REs 
stored in the liver can be mobilized into the bloodstream through further hydrolysis 
into retinol, which is exported to the circulation bound to retinol binding protein 4 
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(RBP4). Thus, liver RE stores serve to provide a pool of retinoids which can be 
deployed in order to maintain plasma retinol levels for delivery to target organs (93). 
 
1.5.3 Delivery of vitamin A to target tissues 
 
RBP4 functions as a physiological carrier of retinol in the blood for delivery to target 
organs, and for the maintenance of plasma retinol levels, which are tightly regulated. 
RBP4 is a plasma binding protein of the lipocalin family primarily synthesised in the 
liver, is composed of a single 21 kDa polypeptide chain, and is encoded for by the 
RBP4 gene mapped to chromosome 10q23 in humans (94). 95% of plasma retinol-
bound RBP4 (holo-RBP4) is associated with liver-derived transthyretin (TTR) in a 
1:1 mol:mol ratio. TTR is a large (55 kDa) homotetrameric protein with a dimer of 
dimers quaternary structure, and its binding to RBP4 effectively increases the 
molecular weight of RBP4 and serves to protect it from glomerular filtration, reducing 
renal clearance of RBP4. Retinol secreted by the liver circulates bound to the RBP4-
TTR complex, and is distributed throughout the body to diverse tissues. The release of 
RBP4-bound retinol from the liver is strictly controlled, therefore except during 
severe VAD and in some disease states, plasma retinol concentrations remain 
relatively constant despite wide fluctuations in dietary vitamin A intake (95).  
 
RBP4 is not critical for supplying peripheral tissues with retinol under conditions of 
vitamin A sufficiency, evidenced by RBP4 knockout mice which are viable and fertile 
under vitamin A sufficient conditions (96). These mice exhibit a significant reduction 
in circulating plasma retinol levels (12.5% of wild-type levels), and are incapable of 
mobilising hepatic retinol stores. However, levels of hepatic retinol and retinyl esters 
increase with time and are significantly higher in RBP4-/- than wild type mice at 5 
months of age, suggesting vitamin A absorption and storage are not affected by loss 
of RBP4. When fed a vitamin A sufficient diet, RBP4 knockout mice appear largely 
phenotypically normal, except for transient cardiac abnormalities, and visual defects 
apparent at 4 weeks which reverse by 24 weeks, suggesting that dietary vitamin A is 
capable of maintaining tissue vitamin A supply through mechanisms other than 
RBP4. A possible alternative delivery mechanism is by RE-complexed chylomicron 
remants. In healthy animals and humans with an adequate supply of dietary vitamin 
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A, in the post-prandial state the circulation sees a rapid increase in the concentration 
of RE-complexed chylomicron remnants (97, 98). Thus, it appears that diet-derived 
circulating RE-complexes are capable of supplying peripheral tissues with retinoids 
even in the absence of RBP4.  
 
However, RBP4 knockout mice are exquisitely sensitive to vitamin A deficient 
conditions. Upon continual feeding with a vitamin A deficient diet, these mice exhibit 
a marked phenotype consistent with VAD due to an inability to mobilise liver retinoid 
stores (96, 99). Thus, RBP4 functions to ensure an adequate supply of retinoids to 
peripheral tissues in the face of fluctuations in vitamin A intake, acting as an 
evolutionary safeguard for the maintenance of organ and tissue function in times of 
vitamin A scarcity, which are common for most, if not all animals living in natural 
environments. 
 
The mechanism by which retinol is taken up by target tissues remained elusive for 
many years, although indirect evidence strongly suggested the involvement of a cell-
surface receptor (100). Recently, 2 membrane-bound receptors capable of mediating 
retinol uptake have been identified which show distinct regions of expression in mice, 
STRA6 and RBPR2 (88, 101). 
 
STRA6 is an integral transmembrane protein of 74 kDa composed of 9 
transmembrane domains, including an essential extracellular RBP4-binding domain 
between domain helices VI and VII. STRA6 was deemed a new type of cell-surface 
receptor, as unlike other membrane transport mechanisms it employs neither cellular 
energy (as does active transport) nor a pre-existing substrate electrochemical gradient 
(as do ion channels or facilitated transport). Rather, STRA6 mediates retinol uptake 
through extracellular uncoupling of retinol from holo-RBP bound to the RBP binding 
domain, and transport of retinol across the membrane via a transmembrane pore, in a 
mechanism dependent on the intracellular binding of 2 proteins involved in retinoid 
storage, L:RAT, and cellular retinol binding protein 1 (CRBP-1) (102). In the absence 
of this binding, newly released retinol actively inhibits the further release of retinol 
from additional holo-RBP4 by STRA6, whereas binding of L:RAT or CRBP1 to the 
intracellular domains of STRA6 permits transport of retinol across the membrane  
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(103). This mechanism provides control and specificity in the cellular uptake of 
retinol, and prevents excessive accumulation of free retinol.  
 
Mutations in the human STRA6 gene have been linked to congenital defects 
comprising a broad spectrum of abnormalities including anopthalmia, cardiac defects, 
pulmonary hypoplasia, diaphragmatic hernia and mental retardation, collectively 
referred to as Matthew-Woods syndrome (104, 105), indicating the crucial role of 
STRA6 in mediating the normal development of a wide range of organs in man. 
Correspondingly, STRA6 is expressed in a wide assortment of tissues that have a high 
demand for retinoids. However, STRA6 not found in the liver or intestine of mice, 
where retinol uptake is proposed to be mediated by another receptor, RBPR2.   
 
RBPR2 is an integral membrane protein with some amino acid homology to STRA6, 
and shares a number of structural similarities such as having a similar mass (70.1 
kDa) and 9-11 transmembrane domains (88). RBPR2 is capable of binding RBP4 and 
mediating intracellular uptake of retinol from holo-RBP4. Interestingly, RBPR2 is 
primarily expressed in the liver and intestine of mice, where STRA6 is not expressed. 
Furthermore, the expression of RBPR2 and STRA6 are regulated in opposite ways by 
RA signalling: RA suppresses RBPR2 expression whereas RA upregulates STRA6. In 
addition, the levels of liver retinol stores inversely correlate with liver RBPR2 
expression (88). Therefore, it may be that RBPR2 and STRA6 provide a receptor-
mediated mechanism by which retinol homeostasis is controlled by the vitamin A 
status of mice: vitamin A sufficiency may suppress RBPR2-mediated intestinal and 
liver uptake of retinol for storage, while promoting STRA6-mediated peripheral tissue 
retinol uptake, whereas VAD may promote RBPR2-mediated intestinal and liver 
uptake and storage of retinoids while inhibiting STRA6-mediated peripheral tissue 
retinol uptake.  
 
The RBPR2 gene is conserved in humans, however it is present as two distinct genes, 
as exons encoding a longer RBPR2 chain located on chromosome 9q corresponding 
to the C terminus 70% of the mouse protein, and as other exons encoding a shorter 
RPBR2 chain located on chromosome 9p and corresponding to the N terminus 30% of 
the mouse protein (88). It is not currently known whether the products of the two 
human RBPR2 genes interact to assemble a functional RBP4 receptor, or whether the 
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mouse RBPR2 undergoes post-translational proteolysis to yield a shorter functional 
fragment corresponding to either of the 2 human RBPR2 genes.  
 
In contrast to the severe polymalformative congenital defects observed in humans 
with STRA6 mutations, mice lacking STRA6 do not exhibit any physiological or 
morphological abnormalities, with the exception of the eye which showed a persistent 
hyperplastic primary vitreous body (106). Furthermore, except for the eye, STRA6-
null mice did not exhibit abnormal tissue retinoid content. One possible explanation 
for this discrepancy is that retinol absorption and storage in STRA6-null mice is 
normal due to the action of RBPR2, which is capable of mediating intestinal and liver 
retinol uptake. Therefore, retinoid delivery to tissues in STRA6-null mice may be 
accomplished by diet-derived RE-complexed chylomicrons, enabling adequate supply 
of vitamin A to the periphery for their maintenance and function. The mechanism by 
which RE-complexed chylomicrons deliver vitamin A to peripheral tissues is 
currently unclear. In the liver, retinyl ester hydrolysis occurs as the chylomicron 
remnants are internalised by hepatocytes during the early stages of endosome 
formation (107). It is has not been firmly established which enzyme(s) are responsible 
for RE hydrolysis once inside hepatocytes, although one of several carboxyesterases 
may be involved in this process. Whether RE-chylomicron complexes are capable of 
directly entering cells in peripheral organs either through passive diffusion or through 
a receptor-mediated mechanism, and if REs are hydrolysed to retinol once inside 
cells, remains to be determined.  
 
1.5.4 Intracellular transport of vitamin A and synthesis of RA 
 
Upon transfer to the cytoplasm in cells other than enterocytes, retinol is solubilised by 
binding to CRBP-1. CRBP-1 is composed of a single 14.8 kDa polypeptide chain, 
encoded by the CRBP1 gene mapped to chromosome 3q23 in humans (108). CRBP-1 
is closely related to CRBP-2 with which it shares 56% sequence homology, however 
unlike CRBP-2 which is mainly found in the small intestine, CRBP-1 exhibits a wide 
tissue distribution in man, mainly in the testes and liver, with lower levels in spleen, 
kidney and lung (109). CRBP-1 and -2 both belong to the family of intracellular lipid-
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binding proteins (iLBPS), and hence bind their ligand retinol within a 10-stranded 
antiparallel β-barrel with the polar head-group of retinol directed inwards (110).  
 
Unbound retinol is a promiscuous substrate, and CRBP-1 functions as a chaperone, 
able to protect efficient retinol metabolism. CRBP-1 directs retinol to the microsome, 
either to L:RAT for its esterification, or to retinol dehydrogenases (RDH) for 
oxidation to retinal. The involvement of CRBP-1 in mediating esterification of retinol 
was demonstrated by transgenic mice lacking CRBP-1, which displayed greatly 
reduced hepatic retinyl ester levels, with increased rates of retinyl ester clearance 
(111). However, these mice otherwise appeared phenotypically normal when fed a 
vitamin A sufficient diet, suggesting that in these conditions, CRBP-1 is not essential 
for maintaining RA signalling in peripheral tissues. Whether CRBP-1 promotes 
esterification or oxidation of retinol depends on the intracellular ratio of retinol-bound 
to retinol-unbound CRBP-1 (holo-/apo-CRBP-1). CRBP-1 not bound to retinol (apo-
CRBP-1) can stimulate the hydrolysis of RE via bile salt independent retinyl ester 
hydrolases (REH), and also inhibit retinol esterification by L:RAT, thus increasing 
intracellular levels of retinol (93). Therefore, CRBP-1 serves to maintain a steady-
state concentration of intracellular retinol available for RA biosynthesis. Retinol-
bound CRBP-1 (holo-CRBP-1) directly interacts with various retinol dehydrogenases 
to which it unloads retinol for its conversion to retinal.  
 
The oxidation of retinol to retinal can be catalysed by 2 classes of enzyme: members 
of the alcohol dehydrogenase (ADH) family, which are cytosolic medium chain 
reductases (MDR), and members of the retinol dehydrogenase (RDH) family, which 
are membrane-bound short chain dehydrogenases/reductases (SDR). Non-specific 
ADH can oxidise retinol to retinal in vitro and display widespread overlapping 
patterns of expression in vivo. However, disruption of single and compound ADH 
genes do not produce embryonic defects, reflecting their functional redundancy with 
regards to retinol metabolism (93). At least 3 RDHs are physiologically involved in 
converting retinol into retinal: RDH1, RDH10 and DHRS9 in mice (RDH16, RDH10 
and DHRS9 in humans respectively). It has been demonstrated that during 
embryogenesis, RDH10 is the critical isoform for oxidation of retinol during the 
biosynthesis of RA, as mice lacking RDH10 display greatly reduced RA synthesis and 
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severely disrupted morphological development resulting in embryonic lethality at 
~E10.5 (112). RDH10 is highly conserved among species, with 98.6% protein 
sequence identity between mouse and human. Whether RDH10 is critical in 
mediating oxidation of retinol to retinal in adult tissues, or whether other RDHs or 
ADHs are capable of supporting this process in the absence of RDH10 in adults, 
remains to be established.  
 
Once synthesised, retinal is rapidly and irreversibly catalysed to ATRA by either of 
three enzymes: retinaldehyde dehydrogenase-1 (RALDH-1), RALDH-2 and RALDH-
3 (also known as ALDH1A1, ALDH1A2 and ALDH1A3 respectively). RALDH-1, 
RALDH-2 and RALDH-3 exhibit distinct, non-overlapping expression patterns 
during mouse embryogenesis, suggesting that RA synthesis is highly regulated both 
temporally and spatially by each RALDH in an organ-specific manner (113). The 
genes encoding RALDH-1, RALDH-2 and RALDH-3 are located on two 
chromosomes in humans: RALDH-1 on chromosome 9, and RALDH-2 and RALDH-
3 on chromosome 15 separated by 43 megabases. RALDH-1, RALDH-2 and 
RALDH-3 are 501, 518 and 512 amino acids respectively, share high (> 60%) 
sequence homology, and are highly conserved between species (114, 115).  
 
Mice with targeted disruptions in RALDH-1 are viable and appear largely normal, 
except for significantly reduced liver RA synthesis and disruptions in the dorsoventral 
patterning of the retina (116). Of all the RALDH enzymes, RALDH-2 is most critical 
in mediating the body-wide biosynthesis of RA during development, as mice lacking 
RALDH-2 suffer severe morphological abnormalities including heart, neural tube and 
limb defects in utero, resulting in embryonic lethality at ~E10.5 (117). The 
requirement of RA synthesis specifically by RALDH-2 during development was 
illustrated by maternal administration of ATRA to RALDH-2 mutants, which resulted 
in near complete rescue of phenotype. RALDH-3 knockout mice developed normally 
in utero except for severe malformations of the ocular and nasal regions, including 
choanal atresia, or blockage of the back of the nasal passage, resulting in these mice 
dying from respiratory arrest at birth (118). These defects could be partially restored 
with maternal RA administration.  
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The precise roles of RALDH-1, RALDH-2 and RALDH-3 in RA synthesis in adult 
tissues are incompletely understood. Each RALDH displays distinct, non-overlapping 
patterns of expression in the adult mouse olfactory epithelium (119) and RALDH-2 
and RALDH-3 appear in non-overlapping bands of expression in the adult mouse hair 
follicle (120). Distinct patterns of RALDH expression have also been observed in the 
post-natal mouse lung: RALDH-1 was expressed in bronchial and alveolar 
epithelium, whereas RALDH-2 expression was confined to the bronchial epithelium 
and pleura (79). A semi-quantitative PCR analysis suggested differential patterns of 
RALDH expression adult human tissues (121), however the role of each RALDH in 
RA synthesis in adult humans has not been systematically investigated.  
 
Once synthesised, newly generated RA either binds to cellular retinoic acid binding 
protein-1 (CRABP-1), which directs it towards degradation by cytochrome P450 
subfamily 26 (CYP26) enzymes, or binds to cellular retinoic acid binding protein-2 
(CRABP-2), which directs RA towards the nucleus for interaction with cognate 
receptors to mediate signal transduction. Alternatively, RA is secreted and taken up 
by target cells in the immediate vicinity to signal in a paracrine fashion. Paracrine 
signalling by RA is particularly critical during embryogenesis, during which RA is 
usually generated by components of the mesoderm, and activates signalling in cells in 
the adjacent endoderm (81). 
 
1.5.5 Intracellular transport of RA by CRABP-1, and its degradation 
 
CRABP-1 and CRABP-2 are highly homologous iLBPs with high specificity for RA 
(122) and are located on chromosome 15q24 and 1q21.3 in humans respectively 
(123). Despite sharing 74% sequence identity, CRABP-1 and CRABP-2 exhibit 
distinct patterns of expression in during mouse development, and appear to have 
contrasting roles in mediating the fate of newly synthesised RA in vitro (124). 
CRABP-1 was demonstrated to enhance the degradation of RA by directing it to 
enzymes responsible for its oxidative catabolism, the CYP26 enzymes. In vitro, 
overexpression of CRABP-1 in F9 teratocarcinoma cells reduced their sensitivity to 
the biological effects of RA (125), and increased the catabolism of RA to inactive 
polar metabolites (126). However, transgenic mice with targeted disruption of the 
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CRABP-1 gene appeared essentially normal, with no clear phenotype compared to 
wild type mice (127). Therefore, its function in vivo remains unclear, and the 
significance of high level of conservation of CRABP-1 between species and restricted 
pattern of expression during embryogenesis remain incompletely understood. 
 
The distribution and levels of RA must be strictly regulated both during 
embryogenesis and in adult tissues. An important mechanism controlling this is the 
action of CYP26 enzymes, which catalyse the oxidative catabolism of RA. CYP26s 
are members of the cytochrome P450 superfamily, which comprise a group of 
monooxygenases that catalyse reactions involved in the metabolism of drugs and 
endogenous molecules such as cholesterol, steroids and other lipids. Three CYP26 
enzymes are currently known in mammals, CYP26A1, CYP26B1 and CYP26C1, and 
the genes encoding them have been mapped to chromosomes 10q23-24, 2p13, and 
10q23 respectively in humans (128-130). Each CYP26 shares 43-51% amino acid 
sequence identity, and are predicted to range from 50 to 60 kDa in mass with possible 
glycosylation, which is typically observed in other cytochrome P450s. CYP26s are 
localised to the endoplasmic reticulum, and catalyse the oxidation of RA into more 
polar metabolites that are more amenable to rapid excretion, such as 4-oxo-RA, 4-
hydroxy-RA, 18-hydroxy-RA, and 5,6 or 5,8-epoxy-RA (131). Expression of CYP26s 
is tightly controlled both temporally and spatially during development. Excessive RA 
during embryogenesis is highly teratogenic and can be profoundly deleterious. The 
critical role of CYP26 enzymes is to regulate endogenous RA levels during 
embryogenesis, with expression often complementary to the expression of RALDH-2.  
Mice with CYP26A1 disruptions displayed severe abnormalities consistent with 
teratogenic effects of excess RA, and impaired distribution of RA along the anterio-
posterior axis, with abnormal patterning of the hindbrain, vertebrae and tailbud (132), 
as well as spina bifida and truncation of the lumbosacral region (including renal, 
urogenital tract and hindgut abnormalities) (133). CYP26B1 was found to regulate the 
timing of male germ cell maturation in the foetal testis (134), wheras CYP26C1 was 
reported to prefer 9-cis-RA as a substrate (4).  
 
CYP26s display distinct patterns of expression in adult tissues. CYP26A1 is 
expressed highly in the liver, with lower expression in the brain and testis. CYP26B1 
is thought to be the predominant isoform in the lung, and is expressed highly in the 
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brain, liver, and T-cells in the gut. In contrast, CYP26C1 is mainly expressed during 
development, although it is found at low levels in several adult tissues including 
adrenal gland, lung, spleen, testis and brain (131). CYP26A1 is highly induced by 
RA, and has at least four RA response elements (RAREs) located within 2.2 kb 
upstream of its transcription start site in its promoter region (131). Thus, induction of 
CYP26A1 provides a negative feedback regulatory mechanism to protect tissues from 
exposure to inappropriately high levels of RA. CYP26B1 and CYP26C1 both lack 
RAREs in their promoter regions, and their regulation is incompletely understood.  
 
Some oxidised products of CYP26 activity were suggested to be biologically active, 
although this issue has been controversial. 4-oxo-RA was reported to modulate 
positional specification during Xenopus development (135), and rescue the phenotype 
of vitamin-A deficient quail embryos (136). However, the oxidised products of 
CYP26 activity are generally not considered to be biologically important in mammals. 
Support for this concept came from an elegant experiment by Niederreither et al. in 
2002, which employed transgenic mice with targeted compound disruptions in both 
CYP26 and RALDH-2 (137). If the oxidative products of CYP26 activity are critical 
for development, the CYP26-null phenotype should be compounded by the additional 
heterozygous loss of RALDH-2, whereas if CYP26 products are not biologically 
essential, partial loss of RALDH-2 should ameliorate the phenotype. The authors 
found that mice who were both CYP26-/- and RALDH-2+/- no longer exhibited early 
embryonic lethality (as mice are with disruptions only in CYP26A1) and remarkably 
most were viable, survived into adulthood and were fertile. Furthermore, CYP26-/-, 
RALDH-2+/- mice exhibited complete rescue of spina bifida and urogenital tract 
defects, whereas other abnormalities were partially rescued such as hindbrain and 
vertebrate development (137). This is in agreement with the notion that in the 
developing mouse, the main function of CYP26 appears to be to limit overexposure to 
RA. Thus, the concerted action of RALDH and CYP26 enzymes function as a source 
and a sink of RA respectively, and serve to tightly regulate local levels of RA. 
 
1.5.6 Intracellular transport of RA by CRABP-2, and its transport to the 
nucleus 
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Newly synthesised RA can also bind to CRABP-2. In contrast to CRABP-1, CRABP-
2 facilitate RA signalling by directing RA to the nucleus to its cognate receptors, 
RARs and RXRs (described below). CRABP-2 in the absence of RA is predominantly 
cytoplasmic. Upon ligand binding, RA induces a conformational change in CRABP-2 
which generates a tertiary structural feature acting as a nuclear localisation signal, 
enabling interaction with importin α and nuclear targeting (138). The CRABP-2-RA 
complex then translocates to the nucleus, where it directly interacts with RAR (139). 
RA-bound CRABP-2 forms a short-lived intermediate complex with RAR, permitting 
the transfer of RA to RAR/RXR heterodimers, followed by the rapid dissociation of 
CRABP-2 from RAR and its recycling back to the cytoplasm (139). The ability of 
CRAPB-2 to enhance RA signalling through RARs was demonstrated by 
overexpression of CRABP-2 in cultured cells, which significantly increased the 
ability of exogenous RA to induce the expression of an RA reporter (122, 140). 
Conversely, diminished expression of CRABP-2 in vitro rendered cells hyposensitive 
to the effects of RA (139). The potentiating effects of CRABP-2 on RA-mediated 
RAR transactivation appear to be important when levels of RA or RAR are limiting, 
whereas in conditions of RA excess, RA is capable of activating RAR independently 
of CRABP-2. The role of CRABP-2 in vivo is currently unclear, as CRABP-2-null 
mice appeared largely phenotypically normal, with only a minor limb abnormality 
(141). It was further demonstrated that CRABP-1 does not functionally compensate 
for CRABP-2 loss in mice, as mice lacking both CRABP-1 and CRABP-2 also 
appeared normal (141). It remains to be explored if yet other, unidentified 
intracellular proteins capable of binding and solubilising RA in the cytosol, or other 
intracellular transport mechanisms, are able to compensating for the loss of CRABP-
2. However, if CRABP-2 is only critical during RA deficiency, it may be 
hypothesised that the phenotype of CRABP-2 null mice will become apparent under 
conditions of VAD, although this remains to be established. 
 
1.5.7 RARs 
 
The transcriptional effects of RA are mediated by direct associations with RARs, 
which associate as heterodimers with RXRs. RARs and RXRs are ligand-activated 
transcription factors of the type 2 nuclear receptor superfamily. This superfamily 
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includes several receptors capable of modulating gene transcription through 
interactions with non-steroid lipophilic ligands, such as thyroid hormone receptor 
(THR), vitamin D receptor (VDR) and PPAR-γ.  
 
The primary natural ligands for RARs are all-trans RA (ATRA) and 9-cis-RA, 
whereas ATRA has very little binding affinity for RXRs. As with other members of 
the type 2 nuclear receptor superfamily, RARs are localised in the nucleus bound as 
heterodimers to RXRs. In the absence of RAR agonist, the RAR/RXR heterodimer 
exists bound to specific RARE DNA sequences in the promoter regions of RA target 
genes in association with a corepressor complex. The complex includes the 
corepressor proteins NCoR or SMRT, which associate with RARs via a conserved 
alpha helical structural feature, the CoRNR box (142). The complex also includes 
associated factors such as histone deacetylases (HDACs) or DNA-methyl transferases 
which maintain the chromatin in an inactive, condensed configuration, repressing 
transcription. Ligand binding induces a conformational change in RARs, causing the 
release of corepressors and promoting association with a diverse group of coactivator 
proteins such as ACTR or DRIP/TRAP, which bind to the ligand-binding domain of 
the RAR/RXR via a conserved LXXLL motif (where L is leucine and X is any amino 
acid) (143). This allows recruitment of additional proteins to form the coactivator 
complex. The complex includes proteins with histone acetyltransferase and/or histone 
arginine methyltransferase activity, which are able to modify chromatin structure, 
shifting it towards an open configuration which is permissive for activation of 
transcription. The coactivator complex also functions to bridge the transcriptional 
machinery to RARs, recruiting the RNA polymerase II holoenzyme and its associated 
TFII transcription factors to the promoter region (144). 
 
As with other nuclear receptors, RAR and RXRs exhibit a modular structure 
comprising 6 conserved domains, termed regions A-F (Figure 1.6). The C-terminal 
region contains a highly conserved DNA-binding domain (DBD; region C) which 
confers sequence-specific DNA recognition. The DBD contains 2 zinc fingers and a 
COOH-terminal extension (CTE). The 2 alpha helices of the zinc finger motifs cross 
each other at a perpendicular, forming the core of the DBD folding region, resulting 
 48 
in a single globular domain. The DBD specifically associates with RAREs in the 
promoter regions of RA-response genes (145).  
 
Towards the N-terminal region is situated the ligand-binding domain (LBD; region 
E), which is moderately conserved in sequence but highly conserved in structure 
between various nuclear receptors. The structure is an alpha helical sandwich fold, 
composed of 12 conserved alpha helices and a beta turn situated between helix 5 and 
6. The LBD contains 3 functionally important features: the ligand-binding pocket, the 
main dimerisation domain, and the ligand-dependent activation function-2 (AF-2). 
The ligand-binding pocket comprises hydrophobic residues forming a cavity within 
the interior of the LDB, with a shape that matches the volume of the ligand, which 
contributes to the selectivity of ligand binding. The dimerisation domain functions as 
the interface for the binding of RXRs, allowing the formation of RAR/RXR 
heterodimers, and is composed mainly of helices 9 and 10 of the LBD. The AF-2 is 
composed of helix 12, which upon ligand binding undergoes a conformational change 
that stabilises the ligand interaction while allowing the recruitment of transcriptional 
coactivators (146).  Situated between the LBD and the DBD is a flexible hinge 
domain (region D), which allows the 2 flanking domains to adopt different 
conformations. This regions also influences intracellular trafficking and subcellular 
distribution as it contains a nuclear localisation signal.  
 
The N-terminal region contains 2 domains (regions A and B) which collectively form 
the activation function-1 (AF-1). In contrast to the AF-2 which is highly structured, 
the AF-1 is poorly structured in aqueous solution (147). The AF-1 interacts with a 
variety of transcriptional coregulators, through a mechanism independent of ligand 
binding, but it is capable of synergising with the ligand-dependent AF-2 to enhance 
the upregulation of gene expression. Different isoforms of a given RAR differ only in 
the sequence of region A of the AF-1. This gives rise to differential preferences for 
ligand-independent coregulator binding to the AF-1, contributing toward isoform-
specific, cell-type and developmental stage-dependent AF-1 mediated transcriptional 
effects (145). Region F, positioned C-terminal to the LBP, is present in RARs, while 
it is absent in RXRs. It is highly variable in length and sequence among the different 
RAR subtypes, and while its function is currently unclear, it is phosphorylated at 
multiple positions that may modulate RAR behaviour (146).  
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There are three RAR subtypes, RAR-α, RAR-β, and RAR-γ, originating from distinct 
genes which in humans have been mapped to chromosomes 17q21, 3p24, and 12q13 
respectively (148). For each RAR, several isoforms exist which arise from alternative 
splicing and differential usage of two promoters (P1 and P2). Two major isoforms 
exist for RAR-α (α1 and α2), four for RAR-β (β1, and β3 initiated at the P1 promoter 
and β2 and β4 initiated at the P2 promoter) and two for RAR-γ (γ1 and γ2). Each 
isoform diverges from the others only in their N-terminal region (149).  
 
The roles of individual RARs in vivo have been elucidated with genetic studies 
involving targeted disruptions of various RAR genes. Mice with deletions of RAR-
α1, RAR-β2 or RAR-γ2 appear largely phenotypically normal, suggesting that the 
remaining isoforms of a given RAR subtype are capable of functionally compensating 
for the losses (150-152). In contrast, mice with deletions of all isoforms of a given 
RAR subtype are generally viable yet exhibit mild forms of abnormalities present in 
VAD animals. For example, RAR-α, RAR-β and RAR-γ null mice all display growth 
retardation, RAR-α and RAR-γ null male mice suffer from sterility due to testicular 
defects, and RAR-γ null mice exhibit squamous metaplasia of epithelia, all 
phenotypic manifestations which resemble those found in VAD animals (150). Mice 
lacking all isoforms of a RAR subtype also display various tissue abnormalities 
reflecting areas where each receptor is highly expressed, including lung defects, 
which will be described later in this chapter. The relatively mild phenotype of mice 
lacking all isoforms of a RAR reflects functional redundancies between RARs. In 
contrast, mice lacking all isoforms of two RAR subtypes, such as RAR-α /β, RAR-α 
/γ and RAR-β /γ die in utero or at birth from severe developmental abnormalities 
including the complete range of defects found in newborns with VAD (150, 153). 
Thus, RA-liganded RARs have critical roles in the morphogenesis and development 
of many organs in vivo. 
 
1.5.8 RXRs 
 
In contrast to RARs, ATRA has very little binding affinity for RXRs. Rather, 9-cis-
RA, a steroisomer of RA, has been identified as a high affinity ligand for RXRs, 
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capable of binding to and activating RXRs in in vitro transactivation reporter assays 
(154). However, the in vivo existence of 9-cis-RA is controversial due to conflicting 
reports regarding its isolation from tissues (155). Recently, 9-cis- RA was reportedly 
identified in mouse pancreas using liquid chromatography-tandem mass spectrometry 
(LC-MS/MS), where it was suggested to regulate glucose-stimulated insulin secretion 
(156). However, 9-cis-RA has not been unambiguously identified in other mammalian 
tissues, including the lung, and thus its physiological relevance remains unclear and it 
is not certain whether 9-cis-RA is the actual natural ligand for RXRs. Other naturally 
occurring lipids have been proposed to be endogenous RXR ligands, such as phytanic 
acid, a branched-chain fatty acid, and docosahexaenoic acid, the n-3 polyunsaturated 
fatty acid derived from fish oil (155). 
 
As with RARs, there are three RXR subtypes, RXR-α, RXR-β, and RXR-γ, 
originating from distinct genes which in humans have been mapped to chromosomes 
9q34, 6p21, and 1q22-23 respectively (157). Two isoforms exist each for RXR-α (α1 
and α2), RXR-β (β1 and β2) and RXR-γ (γ1 and γ2), that differ from one another in 
their N-terminal domain. RXRs function as promiscuous heterodimerisation partners, 
with the capacity to bind to other type 2 nuclear receptors such as VDR, THR and 
PPARγ, in addition to RAR. Heterodimers formed by RXR and RAR cannot be 
activated by an RXR agonist alone, but only by an RAR agonist, a phenomenon 
referred to as ‘subordination’ (157). However, when RARs are bound to ligand, an 
RXR agonist can trigger additional transcriptional activity leading to a synergistic 
activation. Thus, the role of RXRs in the RAR-RXR heterodimer appears to be to 
permit RAR activation by RAR agonists, and to potentiate transcriptional activity in 
the presence of RXR agonists.  
 
Mice with targeted RXR disruptions have provided insights into their role during 
development. Mice lacking RXR-α die in utero at ~E14.5 predominantly due to 
cardiac failure, although they also display ocular defects similar to VAD foetuses 
(158, 159). Therefore, RXR-α has an indispensible role in transducing RA signalling, 
in driving myocardial and ocular development. In contrast, mice possessing 
compound disruptions in both RXR-β and RXR-γ do not exhibit developmental 
defects, and remain viable even with additional loss of a single RXR-α allele (160). 
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This suggests that RXR-β and RXR-γ are not critical for embryonic development, and 
even a single copy of RXR-α is sufficient to fulfil the roles of RXRs. However, RXR-
β and RXR-γ null mice who reach adulthood exhibit impaired locomotion related to 
dysfunction of the dopamine signalling pathway, suggesting a role for these receptors 
in brain development and function (161). 
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Figure 1.6 Nuclear receptor domains, and structure of DNA-bound RAR/RXR 
heterodimer 
A) Schematic representation of the 6 structural and functional domains (A-F) of 
nuclear receptors (including RARs and RXRs). Green boxes indicate evolutionarily 
conserved DNA binding domain (DBD) and ligand binding domain (LBD), and blue 
boxes indicate variable sequences. The DBD is composed of two zinc-finger motifs 
and mediates sequence-specific DNA recognition. Transcriptional regulation is 
mediated by the LBD, which contains a ligand-binding pocket, a dimerisation surface 
and a ligand-dependent transcriptional activation function (AF-2). The N-terminal 
A/B region contains a ligand-independent activation function (AF-1). The F region is 
present in RARs but not RXRs and the function is unclear. B) Structure of the full-
length RXR–RAR heterodimer was reconstructed from crystal structures of the DNA-
bound and 9-cis-RA-bound RXR–RAR DBD and LBD heterodimers. Dotted lines 
indicate domains with unresolved structures. Helices are represented as ribbons and 
labelled from H1 to H12 (LBD) or α1 and α2 (DBD). Helix H12 (AF-2 AD) is shown 
in red in each subunit. The short LBD β-strands are labelled S1 and S2. 9-cis-retinoic 
acid in RAR and RXR LBDs is represented by green stick lines. The orange spheres 
in the DBD indicate Zn2+ ions. Adapted from de Lera et al. (2007) (162). 
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1.5.9 RAREs 
 
RAR/RXR heterodimers bind to RAREs located in the promoter regions of target 
genes. RAREs are composed of two copies of a core hexameric motif separated by a 
defined number of nucleotides, taking the form of: PuG(G/T)TCA (X)n 
PuG(G/T)TCA, where Pu is any purine base, and (X)n is the number of nucleotides 
separating the two repeats. It was demonstrated that the spacing between the two 
repeat motifs serves as a recognition code for various nuclear receptors. The classical 
RARE is a motif comprised of direct repeats separated by 5 (DR5) nucleotides, which 
preferentially bind RARs (145). However, RAR/RXR heterodimers also bind to direct 
repeats separated by 1 base-pair (DR1) or 2 base-pairs (DR2). Each repeat within an 
RARE binds one half of the heterodimeric receptor complex. On DR5 and DR2 
elements, the RXR occupies the 5’ motif while the RAR partner occupies the 3’ 
motif, whereas on DR1 elements, the heterodimer binds in the opposite orientation, 
with RXR binding 3’ and RAR binding 5’ (163). RARE sequences have been 
identified in the regulatory regions of numerous known RA target genes, including 
those directly involved in the RA pathway such as the P2 promoters of RAR-β and 
RAR-α, CRBP-1, CRABP-2, CYP26A1, as well as other genes such as laminin B1 
and Hox genes (164). This allows ligand-bound RAR/RXR heterodimers to directly 
control a wide variety of transcriptional programs, including those involved in 
regulating the RA pathway, providing an important self-regulatory mechanism. 
 
The existence of multiple isoforms of each RAR and RXR subtype allows an 
enormous number of possible combinations of partners within the heterodimer, each 
potentially with their own cell-specific and temporal pattern of activity, regulated 
further by differential interactions with coregulator proteins. This multiplicity 
generates the capacity for enormous diversity in effects, which allows for tightly 
controlled yet pleiotropic consequences of RA signalling, enabling the regulation of 
dramatic and intricate cellular and tissue-level events such as observed during 
development and organ regeneration. 
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1.6 Molecular regulation of regeneration – a developmental perspective 
 
The earliest systematic investigation of animal regeneration was reported in the early 
18th century by René-Antoine Réaumur, who described limb regeneration in 
freshwater crayfish, noting in 1712 that ‘Nature gives back to the animal precisely 
and only that which it has lost, and she gives back to it all that it has lost’ (165). 
Following this were the pioneering observations of the Swiss naturalist Abraham 
Trembley. Wading through wetland in 18th century rural Holland, Trembley 
discovered the remarkable ability of a simple pond-dwelling organism, the Hydra 
(Hyrda vulgaris), to reconstitute its entire body after resection. He supported these 
observations with rigorous scientific methodology, and thus is widely considered one 
of the pioneers of modern experimental biology (165).  
 
Trembley’s experiments on Hydra regeneration, published in his Mémoires in 1744, 
were followed by the works of Charles Bonnet and Lazzaro Spallanzani, who made 
detailed descriptions of regeneration in numerous other creatures. A century later, the 
field of regeneration experienced resurgence in interest by investigators such as 
Thomas Hunt Morgan in the late 19th century, in part due to a rise in research efforts 
in the closely related field of embryology (165). It subsequently became clear that 
development and regeneration are closely entangled, and constitute overlapping 
mechanisms. 
 
Regenerative ability is widely distributed throughout the animal kingdom, and 
examples of highly regenerative organisms, capable of replacing missing structures or 
regenerating the entire body plan, are present throughout most extant metazoan phyla. 
However, regeneration is not universal. It is frequently found present in certain 
species but absent in other closely related species, which sometimes exist in the same 
ecological niche. Thus in these species, who fall prey to the same ecological 
tribulations, regeneration does not provide a selective survival advantage (166). A 
hypothesis which accounts for this evolutionary variability is that, like development, 
regeneration is a primordial trait of metazoans, although regeneration has been 
subsequently lost independently through separate evolutionary events (167, 168).  
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It was further postulated that regeneration is a consequence of the persistence of 
developmental processes in the adult. According to this hypothesis, regeneration and 
development share evolutionarily conserved mechanisms (168). Evidence in support 
of this includes molecular similarities between vertebrate development and 
regeneration. For example, homeobox (Hox) genes and sonic hedgehog (shh) 
signalling have critical roles in regulating patterning and morphogenesis during both 
amphibian limb development and regeneration (169, 170). In the lung, notch 
signalling regulates both airway epithelial specification during development, and 
basal cell identity during regeneration (10, 171). Thus, insights gained from 
developmental biology are likely to inform our understanding of the molecular 
regulation of adult regeneration.  
 
Regeneration can be broadly classified into that which requires cell proliferation to 
replace the missing structure, and that which doesn’t (168). Regeneration which 
doesn’t require proliferation is called morphallaxis, and is exemplified by Hydra 
which is capable of replacing missing structures by transdifferentiation of existing 
cells. For example, a decapitated Hydra will develop a new head by respecification of 
nearby cells, although the animal will be smaller in the short term. Cellular division in 
specialised interstitial stem cells over time will lead to growth of the remaining 
organism to normal size (172). 
 
Regeneration that does require cellular division is called epimorphosis. This in turn 
can be subdivided into blastemal and non-blastemal driven processes (168). Blastemal 
regeneration involves rapid wound healing over the amputation site, resulting in 
formation of a specialised wound epidermis, directly underneath which forms a 
blastema. The blastema is a specialised structure composed of dedifferentiated cells, 
capable of proliferating and re-differentiating to regenerate the missing structure. This 
kind of regeneration results in a virtually identical replacement, and occurs in many 
species throughout phylogeny. Well-known examples are regeneration of salamander 
limbs, zebrafish hearts and fins, whole body regeneration in planaria, and seasonal 
regeneration of deer antlers. 
 
Non-blastemal epimorphic regeneration involves cell proliferation, but does not 
require the assembly of uncommitted cells at the injury site. Instead, the cellular 
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source of regeneration is either transdifferentiation or limited dedifferentiation of 
adjacent cells which then proliferate to reconstitute lost tissue, or the proliferation and 
differentiation of resident tissue-specific progenitor cells (168). This type of 
regeneration occurs during organ regeneration in adult animals, both during low level 
physiological turnover and following more substantial injury leading to complete or 
partial repair. Examples of each type of non-blastemal epimorphic regeneration are 
lens regeneration in salamanders, and liver and bone regeneration in humans 
respectively (168).  
 
RA signalling has emerged as an evolutionarily conserved pathway regulating 
developmental morphogenesis and patterning, as well as organ regeneration across 
phylogeny. For example, the sea-squirts Botrylloides leachi and Polyandrocarpa 
misakiensis, in the phylum Tunicata, can both undergo whole-body regeneration, and 
both processes are regulated by RA signalling through a RAR homologue (173, 174). 
 
The axolotl, or Mexican salamander, can regenerate its limbs, tail, jaw, ocular tissue, 
gills and parts of the heart and brain after amputation. RA signalling is activated in 
the mesenchyme during axolotl limb development (175), whereas during limb 
regeneration, RA signalling is activated in epidermal tissue, and regeneration can be 
prevented by using disulphiram to inhibit RA synthesis (175, 176). Administration of 
RA to the amputation site can result in formation of extra or longer structures than 
were amputated, a process called ‘super regeneration’ which involves respecification 
of the proximodistal axis of the regenerating limb (177).  
 
Zebrafish are able to regenerate their heart, fins and skin. RA is involved in zebrafish 
heart development, when it specifies the embryonic cardiac progenitor pool (178). In 
adult zebrafish, heart injury leads to rapid induction of RALDH-2 driven RA 
synthesis in the endocardium surrounding the injury site, which stimulates the 
initiation of cardiomyocyte regeneration (179). Similarly, RA signalling is necessary 
for fin development in zebrafish embryos (180), while during fin regeneration in 
adults (which is epimorphic), RA signalling regulates the assembly, proliferation and 
survival of the blastema (181). 
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The only known instance of blastemal-based epimorphic regeneration in the 
mammalian kingdom is the annual shedding and regeneration of deer antlers. 
Immediately after old antlers are shed, a blastema forms, leading to regeneration of 
highly innervated and vascularised antler bone and cartilage. Induction of RA 
signalling was demonstrated in the epidermis, perichondrium, and sites of bone 
formation during deer antler regeneration (182). This demonstrates that RA has 
conserved roles in regulating regeneration across nature. 
 
Regeneration of more complex structures in adult mammals often involves the 
recruitment and proliferation of resident progenitor cells, although the mechanisms 
vary with the organ studied. Several instances of mammalian regeneration are 
regulated by RA. For example, adult mice lacking hepatic retinoid stores due to 
disruption of L:RAT display impaired liver regeneration after hepatectomy (183). 
Similar conserved roles for RA signalling have been identified in coordinating the 
development and regeneration of the kidney (184, 185) and pancreas (186, 187) in the 
mouse. 
 
As described earlier (Introduction 1.2), the lung is a highly plastic organ capable of 
low-level cellular turnover and regeneration following injury. There is considerable 
evidence that lung regeneration involves the initiation of developmental pathways (5). 
It is within this framework that we will discuss the current understanding of RA 
signalling in the regulation of adult mammalian lung regeneration. First, the present 
state of knowledge regarding the involvement of RA in lung development is 
described. 
 
1.7 Overview of lung development 
 
The mature lung consists of two highly branched tree-like systems, the airways and 
the vasculature, which develop in a coordinated manner from the earliest stages of 
embryonic development through to the generation of alveoli in the postnatal period 
(summarised in Figure 1.7).  
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The earliest detectable event in lung development is at embryonic day 9 (E9.0) in the 
mouse, when respiratory progenitors expressing the transcription factor Nkx2.1 
(Titf1) can be first identified in the ventral wall of the anterior foregut endoderm 
posterior to the thyroid. From this region, at E9.5 in the mouse and ~28 days in the 
human, two primary lung buds appear (188). In parallel, the single foregut tube 
anterior to the lung buds separates into two, developing into a dorsal oesophagus that 
leads into the stomach and a ventral trachea that connects to the lung buds. Once the 
lung buds emerge, they protrude into the surrounding mesenchyme, and between E9.5 
and E16.5 in the mouse and between 7 and 16 weeks in human, they undergo 
branching morphogenesis (188). This is the ‘pseudoglandular stage’, in which a series 
of secondary buds emerge from the primary buds in a highly stereotyped manner, 
eventually generating a complex tree-like structure ending in thousands of terminal 
tubules (189).  
 
The mesoderm which surrounds the primary lung buds provides paracrine signals for 
stimulating epithelial growth and differentiation, and also provides many of the 
diverse cell types of the lung interstitium (188). From the pseudoglandular stage 
onwards, multipotent progenitors in the distal mesoderm are exposed to a series of 
inductive signals that control their commitment to different lineages, including 
pericytes, parabronchial smooth muscle, myofibroblasts, and lipid-laden fibroblasts 
underlying AT2 cells. The development of the lung vasculature occurs in close 
association with airway development during branching morphogenesis, originating 
from the mesodermal vascular plexus at the apex of developing lung buds. 
After E16.5 in the mouse, lung development transitions into the canalicular stage 
(E16.5 - 17.5 in the mouse, 16-24 weeks in human), during which time the terminal 
buds become narrower. Following this is the saccular stage (E18.5 – postnatal day 5 
[P5] in the mouse, 24-36 weeks in human), in which the terminal buds develop 
numerous small sacs which are the precursors to alveoli (188). In parallel, the nascent 
vasculature forms close associations with the alveolar epithelium, forming what will 
eventually become the ACM.  
 
At the end of the saccular stage, the lung contains alveolar precursors with walls made 
of thick primary septae, a central layer of connective tissue contained between two 
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capillary networks, from which alveoli form. From P5 onwards in mouse, and from 
~36 weeks through to adolescence in humans, is alveolarisation. During this stage, 
alveolar precursors subdivide into smaller units, alveoli, by the process of septation to 
generate the functional units of gas exchange. Alveolarisation is a largely postnatal 
event in mammals including humans, and can be partitioned into periods of initial 
alveolarisation, microvascular maturation, and late alveolarisation (190). 
 
The airspaces initially subdivide by secondary septation (Figure 1.7). One of the two 
capillary layers in the primary septal walls folds to make a crest, supported by smooth 
muscle cells, elastic fibres, and collagen fibrils, and emerges into the airspaces to 
form secondary septae which still contain a double capillary network. This typically 
lasts from just before birth until 2 weeks in mice (191) and until 1-2 years in human 
lungs (192). Subsequently, the double capillary network restructures into a single 
capillary network by microvascular maturation. This occurs from P14-21 in rats, and 
from 0-3 years in human lungs. Microvascular maturation involves attenuation of the 
interstitial layer between the two capillary networks, resulting in the two networks 
eventually coming into contact with each other and merging their lumens to form a 
single capillary network. Following this is late alveolarisation, a further process of 
alveolar subdivision. It has been demonstrated that half of alveolar septae are formed 
after the single capillary network has matured, and is permitted by local duplication of 
the single capillary network to allow new septal eruption (190).  
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Figure 1.7 Lung development stages and the regulation of RA signalling. 
Illustration of secondary sepatation in postnatal rat lung. 
A) Classical stages of lung development. In the embryonic stage (E9-12 in mice, 
weeks 3-7 in humans), the primary lung buds emerge from the foregut endoderm. A 
series of bifurcation events leads to branching morphogenesis during the 
pseudoglandular stage (mice: E12-15, humans: weeks 5-17). At the end of branching 
morphogenesis, the terminal buds become narrower, during the canalicular stage 
(mice: E15-17, humans: weeks 16-26). Following this is the saccular stage, when 
immature sacs that are the alveolar precursors develop (mice: E17-birth, humans: 
weeks 26-36). Sac walls contain a thick layer of interstitium with a double capillary 
network. During the alveolar stage (mice: postnatal, humans: weeks 36 to 
adolescence), the airspaces subdivide through septation to yield alveoli. B) Schematic 
diagram illustrating secondary septation in postnatal rat lung. One of the two capillary 
layers in the primary septum folds to make a crest (arrows). Formation of elastic 
fibres (dark spots), collagen fibrils and proliferation of smooth muscle cells are 
closely linked with alveolar formation. Secondary septae retain a double capillary 
network. From: Burri (2006) (193). 
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1.8 RA signalling in lung development 
 
Lung development, from the embryonic stage through to postnatal alveolarisation, is 
tightly regulated by a complex network of reciprocal endodermal-mesodermal 
interactions. Genetic mouse studies have provided important information regarding 
the transcriptional control of lung morphogenesis (reviewed in (188, 194, 195)). In 
particular, the temporal and spatial regulation of RA signalling is critical for lung 
development to proceed properly. 
 
Initial evidence for a critical role of RA signalling in lung development came from 
early studies of maternal VAD in rats, which caused severe malformations in 
offspring including diaphragmmatic hernia and lung agenesis (196). This phenotype 
was reproduced in RAR α/β2 double mutant mice, which are embryonic lethal and 
exhibit left lung agenesis and right lung hypoplasia (197). Single RAR mutant mice 
exhibit few abnormalities at this stage, suggesting functional redundancy between 
RARs at the early stages of lung development (197). This implicates RA signalling in 
the initiation of lung development. In support of this, RA signalling was found to be 
necessary for the initial specification of Nkx2.1-expressing cells in the prospective 
lung endoderm in ~E9.0 mouse lung (198).  
 
From E9.0- E10.0 when the primary buds first emerge, mesodermal RALDH-2 
expression can be observed, which activates RAR-mediated RA signalling throughout 
the developing endoderm and mesenchyme (199). During this time, RA signalling 
inhibits TGF-β signalling, allowing mesoermal FGF10 expression in the presumptive 
lung field which signals through endodermal FGFR2b (198, 200). In parallel, RA 
suppresses the endogenous Wnt antagonist Dkk1, allowing Wnt activation in the lung 
primordium (201). Both RA-mediated FGF10 and Wnt activation are critical in 
allowing the initial outpouching of the primitive lung buds from the foregut endoderm 
(Figure 1.8).  
 
In the pseudoglandular stage as branching morphogenesis proceeds, the primitive lung 
epithelium differentiates to give rise to phenotypic diversion between proximal and 
distal regions, and this is regulated by changes in RA signalling. RALDH-2 and RAR 
expression is prevalent in the developing lung throughout the period of branching 
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morphogenesis, however active RA signalling in the epithelium and mesenchyme 
declines through to E16.5. This is due to endodermal CYP26A1 induction from E10.5 
which restricts RA signalling in the distal primary buds, which is necessary to allow 
development of secondary (lateral) buds at the onset of branching morphogenesis 
(199). CYP26A1 expression exhibits a proximal-distal gradient during branching 
morphogenesis with highest expression in distal buds, resulting in a gradient of active 
RA signalling with highest levels in the proximal regions and lowest levels in the 
distal regions. In parallel, from E11.0 - E18.0, COUP-transcription factor II (COUP-
TFII) is expressed in the distal mesenchyme, which antagonises RA signalling (199). 
Thus, restriction of RA signalling in the distal lung is necessary for branching 
morphogenesis to proceed. This was demonstrated further with addition of RA to 
embryonic lung explants, which sustained an immature proximal-like phenotype and 
prevented normal distal development (202).  
 
The growth of the secondary lung buds during branching morphogenesis requires the 
establishment of a distal signalling centre at the apex of the buds, which involves 
cross-regulation between a network of evolutionarily conserved signalling pathways 
driven by FGF10, bone morphogenic proteins (BMP), TGF-β, WNT, SHH, and RA. 
These mediate reciprocal interactions between the nascent lung epithelium and 
mesenchyme, and are themselves regulated by endogenous antagonists representing 
feedback loops. Together, they regulate the size of endodermal and mesodermal 
progenitor pools by controlling the balance between their proliferation and 
differentiation (188). Maintenance of branching morphogenesis is particularly 
dependent on FGF10 and BMP4 signalling in the distal signalling centre, which serve 
as an endodermal chemoattractant and a distalising factor respectively.  
 
During branching morphogenesis, the role of RA in regulating FGF10 signalling 
shifts from a permissive to an inhibitory role. Downregulation of RA signalling in 
distal regions becomes necessary to maintain FGF10 and BMP4 signalling in the 
distal signalling centre, allowing bud promotion and outgrowth (199, 203) (Figure 
1.8). In contrast, in proximal regions active RA signalling is maintained, where it 
inhibits branching and allows maturation of bronchial tubules via RAR-β activation in 
the airway epithelium and adjacent mesenchyme (203, 204). Thus, regulation of RA 
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signalling controls lung development throughout the pseudoglandular stage, by 
repressing branching in the proximal regions, and by its inhibition allowing branching 
morphogenesis in distal regions. 
 
Downregulation of RA signalling in the distal epithelium is required for alveolar 
epithelial specification during canalicular and saccular stages. This was demonstrated 
using a dominant active RAR-α transgene under the control of the surfactant protein 
(SP)- C promoter, which prevented SP-A and SP-B induction (markers of late AT2 
cell differentiation) and inhibited T1α expression, whose induction is necessary for 
AT1 cell differentiation (205). Constitutive RAR-α activation also maintained 
GATA6 expression, whose downregulation is required for AT1 cell development. At 
E18.5, constitutive RAR-α activation had also impaired the formation of saccules, 
instead resulting in tubules with morphology of immature distal epithelium (205). In 
contrast, constitutive RAR-β activation resulted in a more mature distal epithelium 
compared to constitutive RAR-α activation, however it was still less differentiated 
than wild type lungs and displayed a thick mesenchymal layer inappropriate for gas 
exchange. Exogenous ATRA was also demonstrated to reduce SP-A expression in 
human foetal lung explants (206). Thus, RA signalling through epithelial RAR-α and 
RAR-β is permissive for immature distal epithelial specification, but must be 
downregulated for differentiation of AT2 and AT1 cells during sacculation. 
 
RA signalling is re-activated in the postnatal distal lung to regulate alveolarisation. 
Just prior to birth, endogenous lung retinyl ester stores are mobilised to more 
biologically active compounds, coinciding with increased morphological maturation 
(207). RALDH-1 and RALDH-2 expression peak in the early post-natal period in 
mouse lung, while absolute levels of endogenous lung ATRA decline during P4 to P9, 
suggesting rapid utilisation of locally synthesised ATRA during alveolarisation (79). 
The cellular source of RA during this stage was postulated to be lipid-laden 
fibroblasts, which were demonstrated to synthesise and secrete ATRA (208). Their 
close apposition to AT2 cells (209) and their localisation at sites of septal eruption 
during alveolarisation (208) suggest that lipid-laden fibroblasts may act as the 
proximal source of paracrine ATRA during this period. It was demonstrated that 
administration of RA to neonatal rats stimulated alveolarisation (210), and another 
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study found ATRA rescued alveolar hypoplasia caused by caloric-restriction-induced 
intrauterine growth retardation (IUGR) in rats (211). In contrast, neonatal 
administration of disulphiram, which inhibits aldehyde dehydrogenases including 
RALDHs, was found to disrupt normal alveolarisation in mice (212), further 
implicating RA signalling in the control of postnatal lung development. 
 
1.8.1 Antagonistic effects of GC signalling and RA in lung development 
 
As described earlier, antenatal GC has been implicated in ‘new’ BPD, characterised 
by alveolar insufficiency which may persist into adulthood. GCs prevent alveolar 
development by inhibiting septal outgrowth, and causing premature maturation of the 
microvascular network (213). GCs including Dex act via nuclear receptors and are 
likely to inhibit alveolarisation through multiple molecular mechanisms. One 
mechanism may be that neonatal GC administration interferes with RA signalling 
during alveolarisation. Dex was found to reduce the expression of RAR-β (214), and 
both CRBP-1 and CRABP-1 (215) in the lungs of neonatal rats in vivo, and maternal 
dex stimulated rapid depletion of retinoid stores in the lungs of foetal rats just prior to 
birth (207). 
 
RA can protect from many of the adverse effects of GCs on alveolarisation when 
administered concurrently (216). For example, administration of RA to neonatal rats 
prevented the low alveolar number and decreased surface area caused by Dex (210). 
This may be by protecting from Dex-induced dysregulation of RA signalling, as RA 
was found to prevent Dex-induced downregulation of CRBP-1 (215). Another 
mechanism may be through effects on postnatal microvascular development. Dex 
treatment in neonatal rats led to premature microvascular maturation, with evidence 
of increased contacts between the two capillary layers and their precocious fusion 
(217). Neonatally administered Dex also decreased the expression of the angiogenic 
factor midkine, and this was prevented by concurrent treatment with RA (218). 
Moreover, a microarray study revealed that Dex-induced inhibition of septation in 
neonatal rats was associated with downregulation of vascular endothelial growth 
factor receptor 2 (VEGFR2), and RA prevented this (214). Thus, RA may control 
alveolarisation at least partly through regulation of microvascular growth. Several 
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lines of evidence suggest that the microvascular endothelium is critical in mediating 
lung regeneration in the adult. The hypothesis that RA signalling regulates 
angiogenesis during lung regeneration is discussed in chapter 5 of this thesis. 
 
1.8.2 RAR control of alveolarisation 
 
Transgenic mice lacking individual RARs develop severe alveolar abnormalities, 
providing strong evidence that RA signalling is required for postnatal alveolarisation. 
RAR-β null mice exhibit premature maturation of alveoli, with smaller and more 
numerous alveoli than wild type mice, suggesting an inhibitory role of RA signalling 
through RAR-β during alveolarisation (219). Mice with deletions of RAR-γ, which is 
expressed in the distal regions of the lung during early lung development (204), 
develop larger, less numerous alveoli with reduced lung elastin content compared to 
wild type mice when assessed at P28 (after initial alveolarisation) (220). This suggests 
that RA signalling through RAR-γ positively regulates postnatal alveolarisation. 
RAR-α null mice exhibit normal alveoli up to P14. However, alveolarisation in these 
mice halts at this stage and remains static up to P50, whereas wild type mice exhibit 
continued alveolarisation from P14-P50 (221), corresponding to the period of late 
alveolarisation (190). This suggests that early and late alveolarisation are regulated by 
RA signalling differentially through RAR- α, -β and -γ (Figure 1.8).  
 
In aggregate, the data outlined above suggests RA signalling is critical for the earliest 
stages of embryonic lung development, must be downregulated to allow distal 
branching morphogenesis but maintained in proximal regions to allow airway 
maturation, and must be reactivated in the early postnatal period to control postnatal 
alveolarisation through differential activation of RARs. 
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Figure 1.8 RA signalling in lung development 
A) During the embryonic stage, RA signalling is required for activation of FGF10 and 
WNT signalling for primary lung buds to emerge from the foregut endoderm. Foregut 
explants from RALDH2 null mice (-/-) exhibit complete lung agenesis at 4 days (*), 
compared with wild type explants (Wt). Th, thyroid; Ht, heart; Li, liver; St, stomach; 
Lu, lung; pancreas, ventral, Pv; dorsal, Pd. From, Desai et al (2006) (222). B) During 
the pseudoglandular stage, RA signalling must be restricted in the distal lung to 
permit FGF10 signalling and progression of branching morphogenesis. Whole-mount 
in situ hybridization of day 11 mouse lung (dorsal view) shows patterns of RALDH2 
and Fgf10 expression are largely complementary during early branching 
morphogenesis. RALDH2 is downregulated in distal lung (arrows). From Malpel et al. 
(2000) (199). C-D) RA signalling regulates alveolarisation through RAR-γ, RAR-β 
and RAR-α. C) RAR-γ null mice display larger, less numerous alveoli than wild type 
littermates (Wt) at P28. Paraffin embedded H&E sections of mouse lung inflated at 
standard pressure, at same magnification. From McGowan et al. (2000) (220). D) 
RAR-β null mice display smaller, more numerous alveolar than wild type littermates 
A B RALDH2 FGF10 
C 
D 
Wt RAR-γ  -/- 
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(Wt) at P4. Histological sections of mouse lung inflated at standard pressure, at same 
magnification. From: Massaro et al. (2000) (219). E) RAR-α regulates alveolarisation 
after the perinatal period (corresponding to later alveolarisation). RAR-α null mice 
display normal alveoli at day 14 but significantly smaller alveolar surface area (Sa) 
compared to wild type littermates (Wt) at P50. Similarly, alveolar number and 
alveolar volume were significantly different between RAR-α null mice and Wt. From 
Massaro et al. (2003) (221). 
 
1.8.3 RA signalling in human lung development 
 
Several lines of evidence suggest that a requirement for RA signalling is conserved in 
human lung development. Children born in an area of rural Nepal with endemic VAD 
exhibited reduced lung function, determined with spirometry, at 9-13 years of age. 
When mothers were given vitamin A supplementation before, during and for 6 
months after pregnancy, their children exhibited improved lung function measured at 
9-13 years, compared to children of untreated mothers (223). Recently, congenital 
mutations in STRA6 have been linked to a spectrum of clinical defects including lung 
dysgenesis and alveolar capillary dysplasia, as well as anophthalmia, cardiac defects 
and diaphragmatic hernia, identified as Matthew-Wood Syndrome (104, 105).  
 
Altered RA signalling was suggested to contribute to the pathogenesis of congenital 
BPD, the primary risk factor for which is extreme prematurity. Infants with BPD 
exhibited significantly lower plasma retinol compared to control infants, and a higher 
proportion of infants with BPD were categorised as vitamin A deficient (< 10ug/dl) 
(224). In a large randomised controlled trial in which extremely premature infants 
were given vitamin A postnatally for 4 weeks, the incidence of BPD was significantly 
reduced from 62% to 55% in the placebo treated group (225). Although a small 
reduction, this provides evidence that RA signalling is critical to proper lung 
development in humans, and suggests that interventions involving retinoids may be 
useful to modify lung disease in man. 
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1.9 Role of RA signalling in adult lung maintenance and repair 
1.9.1 RA regulation of airway epithelial maintenance and repair 
 
The cellular events in lung regeneration are outlined earlier (Introduction 1.2). 
Numerous developmental pathways have been implicated in proximal airway 
epithelial regeneration. For example, notch signalling, which regulates airway 
specification during development, stimulates basal cell differentiation to a secretory 
lineage following tracheal injury in the adult (10). Sox2, a transcription factor that 
controls proximal airway specification during development, also regulates basal cell 
proliferation during tracheal epithelial repair following SO2 injury (226). In addition, 
the Wnt/β-catenin pathway, which is critical to lung development, was found to 
regulate basal cell proliferation and differentiation into Clara and ciliated cells in the 
adult mouse trachea following injury (227). Several lines of evidence suggest that RA 
signalling is also critical for lung maintenance and repair. 
 
Early experiments of Wolbach and Howe in 1925 demonstrated that VAD in adult 
rats caused dramatic changes in the airway epithelium, resulting in focal proliferation 
of basal cells, and metaplasia from mucociliary into stratified keratinising epithelium 
(228). Interestingly, this effect was reversible upon re-initiation of a normal vitamin A 
sufficient diet (229). It has since been demonstratd that airway epithelial cell culture 
requires retinoids for maintenance of a mucociliary pseudostratified phenotype in 
vitro, provided the cells are cultured on an appropriate substrate at an air-liquid 
interface (230). RA was also shown to regulate mucous differentiation of human 
tracheobronchial epithelial cells through RAR-α, and to a lesser extent RAR-γ (231). 
Together, this suggests that RA signalling has an important role in regulating airway 
epithelial specification.  
 
1.9.2 RA in the molecular regulation of alveolar epithelial maintenance and 
repair 
 
Alveolar epithelial maintenance and regeneration involve multiple processes 
including AT2 cell proliferation, AT2 cell migration over the basement membrane, 
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and differentiation of AT2 cells into AT1 cells (232). Each of these processes must be 
tightly regulated, and published data suggests a key role for RA signalling.  
 
Similar to airway epithelium, developmental signalling pathways have been 
implicated in alveolar epithelial maintenance and repair. For example, AT2 migration 
over a denuded basement membrane following alveolar epithelial damage is regulated 
by FGF7 (keratinocyte growth factor, KGF) (233). The molecular control of AT2 cell 
migration and the role of RA in this process form the basis of Chapter 4 in this thesis.  
 
Specification of AT2 cell identity (whether AT2 cells self-renew or asymmetrically 
divide to produce daughter AT1 cells) and AT2 cell proliferation in the adult lung 
must be tightly controlled during alveolar epithelial maintenance and regeneration. In 
vivo studies of AT2 specification in the adult lung are limited. Most insights into this 
process have been derived from studying in vitro AT2 to AT1 trans-differentiation. In 
this model, primary AT2 cells cultured in defined media spontaneously lose 
expression of AT2 markers (e.g. SPC) and begin to express AT1 markers (e.g. AQ5 
and T1α), while morphologically changing from a cuboidal to squamous AT1-like 
phenotype over the course of 8 days (234). Using this approach, WNT signalling 
through TCF4, and RXR signalling were found to be upregulated during AT2 to AT1 
trans-differentiation, and furthermore RXR-mediated signalling was shown to directly 
regulate the process (235). RXR-mediated signalling does not necessarily involve RA, 
however further indirect evidence suggests a role of RA signalling in AT2 
specification. 
 
Trans-differentiation of primary rat AT2 to AT1 cells in vitro was found to require 
autocrine TGF-β1 signalling via Smad4 (236), which antagonises BMP4 signalling, 
which must be downregulated for proper AT1 differentiation (237). It was 
demonstrated that ATRA administered to VAD rats induced TGF-β family member 
expression in the alveolar epithelium, particularly in AT2 cells (238). In this study 
only TGF-β2 and 3 upregulation was observed, however this suggests that RA 
signalling via the TGF-β pathway may regulate AT2 specification in vivo. However, 
no direct evidence for a role of RA in adult alveolar epithelial specification has been 
found thus far. 
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It has been demonstrated that in adult mouse lung, AT2 cell proliferation is controlled 
by intracellular p38α MAP kinase signalling (239). Conditional deletion of p38α 
resulted in AT2 hyperplasia, and was associated with induction of epidermal growth 
factor receptor (EGFR) (239). Indirect evidence suggests RA signalling also has a role 
in regulating AT2 proliferation. ATRA was reported to induce proliferation of adult 
rat AT2 cells in vitro when plated at sub-confluence, whereas at confluence RA 
inhibited AT2 proliferation (240). Thus, RA signalling appeared to regulate cell-
contact-dependent AT2 proliferation in vitro, suggesting following loss of cell-
contacts after injury in vivo, RA signalling may have a similar role. In support of this, 
while normal rats responded to ozone alveolar damage with a large increase in AT2 
proliferation, VAD significantly reduced AT2 proliferation following ozone exposure 
(241). Furthermore, AT2 cells isolated from VAD adult rat lungs exhibited impaired 
activity of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine 
synthesis and a marker for cell growth and differentiation, further suggesting 
decreased RA signalling impairs AT2 proliferation (74). It is not clear from these 
experiments if the alveolar epithelium is a direct target of RA, or if RA induces other 
lung cell types to modulate AT2 cells in vivo, although the data suggests a role for RA 
signalling in AT2 proliferation. 
 
1.9.3 RA signalling affects alveolar epithelium through epithelial-mesenchymal 
interaction 
 
The regulation of AT2 identity and behaviour is controlled by intrinsic factors, and by 
the immediate anatomical and molecular micro-environment, or niche (242). Niches 
regulate behaviour through cell-matrix and cell-cell contacts, and instructive signals 
such as cytokines and growth factors. The alveolar epithelium, as with epithelia in 
other tissues, is closely associated with the underlying mesenchyme (243). For 
example, alveolar fibroblasts are closely associated with AT2 cells, with which they 
form intricate cellular contacts with numerous cytoplasmic extensions protruding 
through the underlying basement membrane (209). It is likely that in the adult lung, 
the mesenchyme is a source of instructive signals which serves to modulate and 
maintain AT2 cell, as is the case with stem cells of the intestinal epithelium (242). 
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Mesenchyme-derived factors may mediate the effect of RA signalling on the alveolar 
epithelium. In support of this, in pseudoglandular stage mouse lung explants, RA 
stimulated epithelial proliferation via indirect effects on the surrounding mesenchyme 
(244).  
 
The niche maintaining AT2 proliferation and differentiation potential may be 
provided by PDGFR-α expressing lipofibroblasts (23). Lipofibroblasts (lipid-laden 
fibroblasts, lipid interstial cells, LIC) are a subpopulation of fibroblasts that are 
characterised by the presence of large lipid droplets containing retinol (208), and are 
located throughout the parenchymal interstitium in contact with AT2 cells and 
microvascular endothelial cells (245). Lipofibroblasts concentrate at the tip of 
elongating alveolar septa during postnatal alveolarisation, suggesting that they are 
involved in driving new alveolar growth (246). It was recently demonstrated that 
when cultured in suspension in vitro, isolated AT2 cells proliferate and form 
‘alveolospheres’, self-renewing spherical bodies comprised of AT2 and AT1-like 
cells lining a central lumen, which resemble alveoli. It was further demonstrated that 
this was dependent on the presence of PDGFRα-expressing lipofibroblasts (23). The 
lipofibroblast-dervied factor(s) which maintain alveolospheres were not identified in 
this study. However, lipofibroblasts synthesise and secrete biologically active ATRA, 
(208) and therefore it is possible that lipofibroblast-secreted RA acts as a paracrine 
stimulus directly on AT2 cells. 
 
1.9.4 RA signalling in lung interstitial maintenance 
 
The previous section focussed on the epithelial compartment of the lung, however the 
lung is a complex organ with many different cell types. Situated in the interstitium is 
a mixture of mesoderm-derived cells such as fibroblasts, lipofibroblasts, 
myofibroblasts, adipocytes, vascular and airway smooth muscle, pericytes, 
lymphatics, and microvascular endothelial cells. Maintenance of the parenchyma as a 
whole depends on coordinated upkeep of all cell types of the lung. Studies with VAD 
suggest a key role for RA in interstitial maintenance. VAD in adult rats led to 
progressive thinning and destruction of alveolar septa leading to emphysema, 
confirmed by histology and morphometry (74, 75). Furthermore, VAD caused a 
 72 
decrease in alveolar elastin fibre concentration, and tropoelastin (TE) mRNA 
expression, in adult rat lung, while RA administration restored these parameters and 
partially normalised lung mechanics (247). VAD also caused a decrease in alveolar 
collagen content in adult rats, which was reversed by RA administration (248). 
Collagen and elastin within alveolar walls are critical for providing the mechanical 
properties of the lung, and are produced by interstitial cells such as fibroblasts (245). 
Therefore, RA signalling appears to be required for maintenance of the parenchymal 
interstitium.  
 
In support of this, RA was shown to have biological activity in lung fibroblasts in 
vitro. RA was demonstrated to induce elastin synthesis in rat neonatal fibroblasts in a 
mechanism dependent on PDGR-α autocrine signalling (249, 250). RA stimulated 
elasin synthesis in an adult human lung fibroblast cell line via a CRABP-2 dependent 
mechanism (251). It was also demonstrated that RA protected against radiation- and 
bleomycin-induced lung fibrosis in mice in vivo, suggesting the ability of RA to 
modulate pro-fibrotic mechanisms by interstitial components of the lung (252). 
 
1.9.5 Effects of RA on post-PNX lung growth 
 
Several lines of evidence implicate RA signalling as an important mediator of 
endogenous lung regeneration. Lung regeneration following PNX involves a 
transcriptional programme similar to that observed during late alveolarisation (253) a 
period of lung development regulated by RAR-α activation (221). Capacity for post-
PNX lung growth decreases with age, and is associated with reduced clonogenicity 
and increased myofibroblastic differentiation of resident LMSCs (254). LMSCs 
isolated from aging mice exhibited reduced expression of RALDH-3 and RBP4 (255), 
suggesting that age-related disturbances in RA signalling in LMSCs contribute to the 
reduced capacity for post-PNX lung regeneration.  
 
Several studies, have examined the effect of RA administration on post-PNX lung 
growth. In rats, RA given concurrently with the PNX procedure as a once-off 
intraperitoneal injection enhanced post-PNX lung growth, resulting in greater lung 
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volume, weight, cell proliferation and EGFR expression compared with controls when 
measured at 21 days (256).  
 
Further studies were performed in the canine model of post PNX lung growth, in 
which RA was given concurrently with surgery as a 3 or 4 month long oral dosing 
regimen (257-260). In dogs, the right and left lungs normally comprise ~58% and 
~45% of total lung volume and diffusing capacity respectively (39). Following 
excision of the left lung, the remaining right lung can compensate for tissue loss 
without induction of regeneration by recruiting remaining alveolar-capillary reserves 
and remodelling of remaining structures (39). Excision of the right lung however 
results in a greater loss of tissue, for which the residual left lung cannot compensate. 
Instead, alveolar regeneration is induced, normalising alveolar morphology and 
restoring alveolar-capillary surface areas to that of two lungs (39). RA treatment 
following right PNX induced an increase in alveolar density at 4 months post-
operation (Figure 1.9). This resulted from a 50% increase in endothelial capillary 
density and a 25% increase in alveolar septal density, whereas epithelial volume was 
unchanged (259), suggesting that RA preferentially increased capillary formation. 
However, this did not result in improved lung function at 4 months (260). When 
assessed 16 months after cessation of RA treatment, the volume density of the 
microvascular endothelium remained significantly higher in the RA treated group, and 
there was a greater presence of double capillary profiles compared to controls (258) 
(Figure 1.9). This is suggestive of stimulation angiogenesis in the regenerating lung 
by RA. However, at 20 months post operation, the double capillaries had not matured 
into a single capillary network, suggesting that factors other than RA are necessary 
for proper remodelling of the microvasculature. Furthermore, RA increased the 
thickness of the ACM basal lamina, and increased the volume of the septal 
interstitium, including collagen fibres and matrix (258). Importantly, gas diffusing 
capacity was not significantly different between the two groups. Thus, improvements 
in lung function by RA were offset by altered ACM ultrastructure. In contrast, RA 
had no effect in dogs following left-PNX, which does not stimulate regeneration 
(257). This suggests that the effect of RA in the canine PNX model requires other 
signalling pathways concurrently activated during lung regeneration.  
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The above studies suggest a direct role of RA signalling in microvascular and 
interstitial cells during post-PNX lung regeneration. This agrees with the role of RA 
in antagonising GC signalling-mediated microvascular maturation during 
alveolarisation (discussed earlier 1.8.1). Several lines of evidence suggest a critical 
role for angiogenesis and endothelial-derived signals in adult lung regeneration. For 
example, VEGF administration enhanced alveolarisation during post-PNX lung 
growth in mice (261), and after hyperoxic lung injury in rats (262). Furthermore, 
endothelial-derived matrix metalloproteinase 14 (MMP14) generated byVEGFR2 and 
FGFR1 activation was required to initiate and sustain post-PNX lung regeneration 
(263). The hypothesis that RA signalling regulates lung regeneration through 
microvascular angiogenesis forms the basis of chapter 5 in this thesis.  
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Figure 1.9 RA modulates post-PNX growth 
RA administration modulates endogenous lung regeneration in canines following 
right-PNX. A) Lungs of canines administered RA concurrently with PNX exhibit 
smaller and more numerous alveoli at 16 months compared with placebo-treated 
animals at the same time point (light micrograph, bar = 100 µm). B) RA 
administration increases the incidence of double capillary profiles within alveolar 
regions of pneumonectomised dogs compared with placebo-treated animals. Example 
electron micrograph of double septal capillary from RA-treated dog shown (bar = 2 
µm). From: Ravikumar et al. (2011) (258) 
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1.10 RA-stimulated lung regeneration in animal models of emphysema 
 
The ability of RA to modulate endogenous lung regeneration in adult animal models 
suggests that stimulation of RA signalling may be able to induce alveolar regeneration 
in emphysematous lung. Thus, the RA pathway may represent a viable therapeutic 
target for induction of alveolar regeneration. Proof of this concept was demonstrated 
by the pioneering experiments of Massaro and Massaro in a rat model of elastase- 
induced emphysema (80). 
 
1.10.1 RA treatment of elastase-induced emphysema 
 
In the elastase model of emphysema, a single bolus of either porcine pancreatic 
elastase (PPE) or human neutrophil elastase (HNE) is instilled intratracheally into an 
animal, most frequently mice or rats. This causes an acute haemorrhagic and 
inflammatory response including neutrophil and macrophage infiltration, and up-
regulation of proinflammatory mediators such as TNFα, IL-1β, IL-6 and IL-8 (51). 
The inflammation is cleared within 7-20 days. The elastase proteolytically degrades 
elastin located in the alveolar septal walls causing their destruction, resulting in 
enlargement of alveolar spaces. Alveolar destruction progresses long after any 
elastase can be detected, suggesting other destructive processes are involved. Thus 
elastase-induced emphysema mimics some aspects of the clinical disease. 
 
Massaro & Massaro demonstrated that systemic RA administration caused a striking 
reversal of elastase-induced emphysema in adult rats (80). In this study, alveolar 
damage from intratracheal PPE was allowed to stabilise over 25 days, after which RA 
was given intraperitoneally for 12 days before the animals were sacrificed. RA 
resulted in a decrease in number of emphysematous lesions, and an increase in 
alveolar number, specifically in the numbers of small alveoli, with a decrease in lung 
volume indicative of improved lung elastic recoil (80) (Figure 1.10).  
 
This study was quickly followed by several others. Tepper et al. used a similar 
regimen of intratracheal elastase to induce stable alveolar destruction in adult rats, but 
followed 9 weeks later by either intraperitoneal administration of RA or vehicle (264). 
Alveolar density was assessed with high-resolution computer tomography (CT). 
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Critically, this group also performed lung function tests including measurements of 
lung volume and gas diffusion capacity (DLCO). They found RA had beneficial 
effects on total lung capacity and residual volume following elastase injury compared 
to vehicle treated rats, although RA did not have an effect on lung compliance, forced 
flows, or DLCO. RA treatment also caused a trend towards increased alveolar density 
measured by CT when compared to elastase-treated mice without RA (264). 
Subsequently, Belloni et al. confirmed the results of Massaro & Massaro by 
demonstrating an improvement in alveolar number and dimensions in elastase-treated 
rats following RA treatment, while also demonstrating an increase in alveolar cell 
proliferation following RA in elastase-injured animals but not in uninjured animals 
treated with RA, suggesting RA only induces proliferation in response to injury (265). 
This group also assessed lung function in elastase-RA treated animals. No difference 
in compliance was observed between elastase-vehicle and elastase-RA treated rats, 
although RA significantly improved the ratio of alveolar-arterial oxygen pressure 
difference to PO2, suggesting an improved diffusion capacity caused by RA treatment 
after elastase-induced emphysema (265). Ishizawa et al. induced emphysema through 
intratracheal elastase in adult C57BL/6 mice, and found that RA administration 3 
weeks after injury significantly improved the mean chord length (Lm, a measure of 
the distance between alveolar walls) compared to mice treated with vehicle, an effect 
potentiated by concomitant treatment with granulocyte colony-stimulating factor (G-
CSF) (266). This suggests that the regenerative effects of RA on the lung in the 
elastase model of emphysema are not species specific.  
 
Other studies using the elastase-model in adult animals failed to find a significant 
effect of RA. Lucey et al. used adult FVB mice, initiating intraperitoneal RA 
administration 22 days following elastase treatment, however they failed to find an 
improvement in alveolar dimensions or in lung elastin and collagen mRNA (267). 
Similarly, Fujita et al. used adult C57BL/6 mice but did not find that RA 
administration reversed the pathological changes induced by elastase (268). In a study 
using Fisher 344 rats, neither intraperitoneal injections nor inhaled aerosolised ATRA 
improved lung histology in elastase-injured animals, despite the inhalation method of 
RA administration resulting in high concentrations of RA in the lungs (269). Adult 
Brown Norway rats treated with intratracheal elastase also did not exhibit 
improvement following intraperitoneal administration of RA, as assessed by proton 
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MRI and histology (270). Nishi et al. administered elastase to adult rabbits, followed 
14 days later by an RA treatment regimen lasting 2 weeks, however they failed to find 
an effect of RA either in terms of lung compliance or gas-exchange surface area 
(271). 
 
The conflicting results may in part be associated with different sensitivities to RA 
depending on the strain of animal used. Stinchcombe & Maden demonstrated that the 
dose required to induce regeneration in dexamethasone (Dex) -treated NIHR mice did 
not result in regeneration in ICR mice, whereas after increasing the dose by 5x in ICR 
mice, alveolar regeneration was observed (272). Therefore, the pharmacokinetics of 
RA metabolism may differ between strains and species. 
 
The most recent study investigating RA treatment in the elastase-model of 
emphysema was conducted by Seifart et al (2011), using the original protocol by 
Massaro & Massaro, involving adult (6 week old) Sprague-Dawley rats, and using 
stereology and immunohistochemistry, and measurement of pro-inflammatory 
markers (273). RA caused a significant improvement in the alveolar dimensions of 
elastase-treated rats compared with vehicle-treated elastase-injured rats, measured by 
Lm of acinar airspaces (alveoli and alveolar ducts). However, the Lm and mass-
specific volume of distal airspaces were still significantly higher in the elastase-RA 
group than in uninjured rats, indicating that RA treatment caused a partial but not 
complete recovery from the elastase injury. Elastase treatment alone caused a 
decrease in the expression of soluble elastin, which was significantly ameliorated by 
RA treatment. Interestingly, the authors also found that alveolar septae became 
thicker after elastase treatment, and that RA treatment following elastase further 
increased their thickness. Furthermore, the fraction of the alveolar surface covered in 
AT2 cells was significantly lower in elastase-RA rats, than in elastase-vehicle rats or 
uninjured rats whether or not they were treated with RA. Elastase induced the 
expression of the pro-inflammatory factors TNF-α, IL-1, CINC-1 and NF-kB, in 
alveolar macrophages, and this was not modified by RA treatment. Several matrix 
metalloproteases (MMPs) and tissue inhibitors of metalloproteases (TIMPs) were also 
analysed. Elastase caused an increase in expression of MMP-7, MMP-9, MMP-12, 
TIMP-1 and TIMP-2 in alveolar macrophages compared to uninjured animals, and 
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subsequent RA treatment significantly reduced the expression of MMP-12, TIMP-1, 
and TIMP-2 in these macrophages, suggesting RA is capable of modulating the 
proteolytic environment of the lung following elastase injury.  In support of this, 
while MMP-2 and TIMP-1 were increased in the BAL fluid of elastase-treated rat 
lungs, subsequent RA treatment reduced BAL activities of MMP-2 and TIMP-1. 
Therefore in this study, RA resulted in a partial improvement of the emphysematous 
pathology associated with elastase treatment in adult rats.  
 
The elastase-emphysema model is useful due to the rapid onset of pathological 
changes, the ability to cause emphysematous lesions after a single dose, and due to 
the appearance of histological lesions which in part mimic those seen in the clinical 
disease. However, the model may differ considerably from human emphysema, whose 
primary risk factor is chronic exposure to cigarette smoke. Elastase-emphysema 
results in an acute inflammatory state which is rapidly resolved, whereas human 
emphysema involves an ongoing, progressive low-level pro-inflammatory state. 
Furthermore, the detailed mechanisms of the proteolytic attack on the lung matrix 
caused by elastase are probably very different from those caused by chronic smoke 
exposure. Therefore, according to Wright et al., the elastase model is inferior to a 
model involving the long-term exposure of animals to cigarette smoke (51). 
 
1.10.2 RA treatment of cigarette-smoke-induced emphysema 
 
Chronic cigarette-smoke exposure (usually on the order of 6 months) applied to small 
laboratory animals such as mice and guinea pigs generally induces pathological 
symptoms that resemble mild human COPD (GOLD stage 1 or 2). The pathological 
lesions include emphysema, airflow obstruction, and small airway and vascular 
remodelling, and better resemble the human disease than the elastase model (51). 
Chronic smoke exposure typically produces enlarged alveolar ducts, which worsen 
with increasing amount of smoking and are anatomically similar to mild centrilobular 
emphysema found in human cigarette smokers. Moreover, similar to human 
emphysma, the parenchyma between alveolar ducts of smoke-exposed animals 
becomes abnormal, with increases in size and numbers of pores of Kohn that connect 
adjacent alveoli (51). 
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RA has been found to be beneficial in this model. Adult rats were exposed daily to 
cigarette smoke for 6 months to cause emphysema, measured by a decrease in tissue 
desmosine, an increase in BAL elastin peptides, and increases in destructive index 
and mean linear intercept (Lm). Subsequent oral administration of RA for 1 month 
resulted in reduction in these parameters by 125%, 51%, 68% and 74% respectively 
(274). Similar improvements in these parameters were also observed with the oral 
administration of Palovarotene (RO44753), a retinoic acid receptor-gamma (RAR-γ) 
agonist. Furthermore, in a separate study RA administered concurrently with cigarette 
smoke prevented the pathological changes in lung function and proteolytic activity in 
adult rats (275). Conversely in a guinea pig model, RA administration concurrent with 
smoke exposure failed to prevent or reverse the development of emphysematous 
lesions (276). However, this study failed to find a significant difference in serum RA 
levels between RA-treated and untreated animals, which the authors suggested may 
be due to the length of time between last RA dose and the serum analysis (24 hours) 
but may also be due to rapid catabolism or clearance of RA. Therefore, it is unclear 
whether RA levels within the lungs were increased by systemic RA administration. 
March et al. induced emphysema with chronic cigarette smoke exposure for 15 weeks 
in 2 strains of mice, A/J mice and B6C3F1 mice, causing alveolar airspace 
enlargement, however neither subsequent intraperitoneal injection nor inhalation of 
ATRA were able to reverse the emphysema (277). The reason for the discrepancies is 
unclear, however it has been noted that cigarette smoke per se depletes retinol in rat 
lungs (278) while substantially increasing it in guinea pig lungs, therefore species-
specific differences in RA metabolism may have influenced the effects of RA 
treatment (279).  
 
Overall, the excitement generated by the initial findings of Massaro & Massaro has 
been complicated by subsequent controversies over the effects of RA in animal 
models of emphysema. This may be due to differences in retinoid metabolism 
between species, differences in treatment protocols between labs, and fuelled by our 
lack of detailed understanding of the mechanisms of disease pathogenesis in each 
model. More consistent results of a pro-regenerative effect of RA have been observed 
in models of alveolar insufficiency caused by developmental disruption of 
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alveolarisation. 
 
1.10.3 RA in the treatment of developmentally failed septation 
 
Developmental alveolar insufficiency is represented clinically in premature neonates 
who develop ‘new’ bronchopulmonary dysplasia (BPD) often as a consequence of 
antenatal glucocorticoid (GC) treatment. Infants who are born prematurely often 
exhibit immature alveolar epithelium incapable of generating sufficient surfactant. A 
consequence of this is an inability to keep the airspaces inflated, preventing the infant 
from breathing properly. This can lead to respiratory distress syndrome (RDS), a life-
threatening condition which requires mechanical ventilation. However, ventilation by 
itself or in combination with high oxygen levels, fluid overload, pulmonary 
infections, or sepsis can cause an acute pulmonary inflammation that may result in 
chronic lung diseases of immaturity such as BPD. As inflammation is considered a 
primary mediator of injury in the pathogenesis of BPD, GCs, particularly Dex, have 
been administered antenatally to reduce inflammation and to accelerate lung 
maturation and improve surfactant synthesis (280). While GCs have been effective in 
facilitating extubation from the ventilator and reducing both mortality associated with 
RDS and airway injury, GCs have deleterious effects on alveolarisation, which has 
led to a higher frequency of defective alveolar development in surviving neonates, 
termed ‘new’ BPD. Postnatal alveolarisation is largely prevented by GCs, which 
accelerate alveolar wall thinning and fusion of the two capillary layers, and inhibit 
septal outgrowth resulting in alveolar simplification (213). 
 
This can be replicated in animal models with neonatal GC administration, in 
particular with the use of Dex (281). Animals treated with Dex in the immediate 
postnatal period exhibit disrupted alveolar development and develop a distal lung 
characterised by enlarged alveolar spaces resembling emphysematous lesions, which 
persists through to adulthood. Several studies have demonstrated the ability of RA to 
induced alveolar regeneration in this model.  
 
Massaro & Massaro treated rats with Dex from P4 to P13, preventing postnatal 
septation and causing the development of larger, less numerous alveoli, which 
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persisted to adulthood (P36). RA treatment from P24 to P36 caused significant post-
hoc septation, during which time alveolar volume decreased and alveolar number 
increased (282). In another study, Dex administered to neonatal TO mice from P2-7 
and again from P10-14, disrupted alveolar development and caused a significant 
reduction in alveolar dimensions. Subsequently, a 10 day RA treatment regimen in 
from P42 (adult mice) caused a significant improvement in Lm and alveolar surface 
area, resulting in levels close to normal (212) (Figure 1.10). This was repeated with 2 
different mouse strains, ICR and NIHS mice. Following Dex treatment in both strains 
of mice, RA treatment in adults caused improvements in alveolar dimensions and 
surface area (272). Although a higher dose was required for ICR mice, RA-induced 
alveolar regeneration does not appear to be strain-specific in this model (272). 
Another study using the TO mouse strain replicated the initial success of RA 
treatment on inducing regeneration of Dex-treated lungs (283). However, there was 
considerable variation in the response of the mice to RA, with some mice exhibiting 
complete alveolar regeneration, some exhibiting a partial response, and failing to 
respond. The reasons for this variation are currently unclear. Several natural and 
synthetic retinoids were used to determine the receptor responsible for RA-induced 
regeneration. Interestingly, a synthetic retinoid agonist selective for retinoic acid 
receptor-alpha (RAR-α) induced regeneration completely in 4 animals, and partially 
in 6 animals. A synthetic retinoid selective for retinoic acid receptor-beta (RAR-β), 
had a moderate effect on improving Lm of Dex treated mice, whereas a RAR-γ 
selective agonist had no effect. In the same study, RA treatment induced regeneration 
in a Dex-treated transgenic mouse with a null mutation in RAR-β, suggesting that 
RAR-β is not necessary for the RA-stimulated regenerative response. This 
collectively suggests that the pro-regenerative effect of RA may be mediated through 
RAR-α activation in the Dex model (283). 
 
These studies demonstrate that the induction of alveolar regeneration Dex-treated rats 
and mice is reproducible. The discrepancy between these results and the less 
consistent successes with the elastase and cigarette-smoke models of emphysema may 
reflect differences in underlying disease mechanisms between these models. 
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Figure 1.10 RA-induced lung regeneration  
A – C) Retinoic acid abrogates elastase-induced emphysema in adult rat lung. A) 
Alveolar regions of control rat lung fixed to a standard inflation pressure B) Elastase-
induced alveolar destruction C) RA treatment reverses elastase-induced emphysema 
in adult rat lung. From: Massaro and Massaro (1997). D – C) Retinoic acid induces 
alveolar regeneration in a dexamethasone model of disrupted alveolar development in 
mouse. D) Alveolar regions of control mouse lung E) Alveolar simplification 
resulting from perinatal dexamethasone exposure (P2-P14) F) Retinoic acid induces 
alveolar regeneration when administered to adult dex-treated mice (P30-P42). From: 
Hind and Maden (2004) (212). 
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1.10.4 RA treatment in transgenic models of emphysema 
 
Additional studies have focussed on transgenic mouse models of impaired alveolar 
development. Alveolarisation is tightly regulated by many signalling pathways 
involving numerous transcription factors and growth factors. A large number of 
transgenic murine models harbouring mutations in one or more of these factors have 
been generated which fail to develop alveoli properly (reviewed in (194, 195)). In 
addition to this is the tight-skin (Tsk) mutant, which was originally identified as a 
spontaneously mutant strain heterozygous for a mutant allele of the matrix protein 
fibrillin-1 which compromises fibrillin-1 activity. Tsk mice consequently display 
impaired alveolarisation and enlargement of alveoli that persists throughout life. In 
this model, RA administered to adult animals significantly improved alveolar 
dimensions and number compared to control Tsk mice (282). Another study used a 
transgenic mouse model in which conditional expression of a soluble dominant-
negative FGF receptor (dnFGFR) under the control of the SPC promoter, and 
therefore expressed exclusively in AT2 cells, during the prenatal period caused 
septation and alveolar simplification. RA administration in adulthood caused alveolar 
regeneration in this model (284). In another transgenic mouse model in which TNF-α 
was overexpressed under the control of the SPC promoter, mice exhibited progressive 
airspace enlargement, however RA administration did not cause regeneration (268).  
 
1.11 RA in clinical trials for emphysema 
 
The success of RA in stimulating de novo alveolar regeneration in many of the pre-
clinical models of emphysema, despite the success being mixed, led to the rapid 
approval of early stage clinical trials for emphysema patients. The use of ATRA in a 
clinical setting was facilitated by its already established state-of-approval by the U.S. 
Food and Drug Administration (FDA). ATRA had been well-recognised for its 
effectiveness at treating acute promyelocytic leukemia (APL) (285), for 
dermatological uses (286), and had also been tested experimentally for use as a 
chemopreventive and antineoplastic agent for solid tumours (287).  
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1.11.1 Pilot study 
 
The first trial was a pilot study conducted by Mao et al in 2002 (250). The study used 
a 6 month, double-blind, placebo-controlled crossover design with 20 patients (16 
male and 4 female former smokers, mean age 66), who all had heterogeneously 
distributed moderate to severe emphysema confirmed by CT. Patients were treated 
orally with either 3 months of ATRA (50 mg/m2/d) or 3 months of placebo, followed 
by a 3 month crossover phase. There was considerable variability in the plasma levels 
of ATRA at all time points measured (3h after first doses at study start, week 3, and 
week 8), and 12 of 20 patients exhibited more than 25% reduction in plasma ATRA 
levels at week 3 or week 8, with 7 of these exhibiting more than 50% reduction. This 
reduction was attributed to ATRA inducing its own catabolism when administered 
frequently. Serial blood samples demonstrated that RA significantly reduced plasma 
MMP-9, suggesting modulation of blood antiprotease/protease balance (288). 
However, no significant differences were observed between measurements made 
before, and after, ATRA treatment, in terms of extent of emphysema evaluated by CT, 
lung function indices (FEV1, FEV1/FVC, VC, FRC, DLCO), or quality of life scores, 
measured up to 6 months following the initiation of the study (250). It is possible that 
the lack of significant clinical improvements were due to the short duration of the 
study, as effects of ATRA may take longer than 6 months to manifest, or due to the 
lack of non-treated control group. Nevertheless, ATRA was generally well tolerated 
with only mild side effects (skin dryness, transient headache, hyperlipidemia, mild 
transaminase elevations, and musculoskeletal pains). 
 
1.11.2 FORTE trial 
 
The second trial, the Feasibility of Retinoids for the Treatment of Emphysema study 
(FORTE), was conducted by Roth et al in 2006 (289). The study used a randomised, 
double-blind, placebo-controlled crossover design with 148 patients of a mean age of 
65.8, with moderate-to-severe COPD and a primary component of emphysema. 
Patients were split into 3 groups, each receiving either low dose ATRA (1mg/kg/d), 
high dose ATRA (2mg/kg/d), or 13-cis-RA (1mg/kg/d). ATRA was administered 4 
days a week with a 3 day drug holiday weekly to try to minimise toxicity and ATRA 
autocatabolism. Within each treatment group, half received either active drug or 
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placebo for 6 months (phase 1), followed by a 3 month crossover phase (phase 2). 
Lung function and quality of life were assessed at baseline and at 3, 6, 9, and 18 
months. Importantly, this study was considered a feasibility study and not powered as 
a definitive trial, as according to post hoc analysis considerably more patients (224) 
would have been required to detect a 10% change in FEV1 when taking into account 
its baseline variability. Overall, there were no significant improvements observed in 
spirometric indices at the end of phase 1. Interestingly there was a significant decline 
in gas diffusing capacity (DLCO) after 6 months in the high-dose ATRA group, while 
after discontinuation of retinoid treatment, measured at 18 months this had 
significantly improved to equal or slightly higher than baseline values in this group. 5 
of 25 patients (20%) in the high-dose ATRA group exhibited a significant 
improvement in CT scores (CT responders) at 9 months, compared to 4 of 66 
participants (6%) in the other treatment groups. The CT responders in the high-dose 
ATRA group tended to be patients with highest initial plasma ATRA levels, and 
ATRA levels significantly correlated with the magnitude of change in CT density at 9 
months. Furthermore, quality of life indices exhibited a clinically and statistically 
significant improvement from baseline in the high-dose ATRA at 9 months (after both 
phases were complete), which was not observed in the other treatment groups. Thus, 
in this study, significant but delayed improvements were observed in DLCO, CT 
scores and quality of life indices in the high-dose ATRA group. The initial decline in 
the DLCO in the high-dose ATRA group was notable, as it was only observed in this 
group and was followed by a significant improvement by 18 months to levels that 
were slightly higher than baseline (DLCO % predicted: 39.9% at baseline, 35.4% at 6 
months, 42.4% at 18 months). The authors suggested that this reflected an initial 
reparative remodelling of the ACM, which preceded further remodelling and 
improvement in lung function, although they did not rule out drug-induced pulmonary 
toxicity.  
 
An important consideration for clinical trials using orally administered RA is delivery 
of drug to the lung. Measurements of lung retinoid levels are not feasible in living 
patients, so serum RA levels can be measured as a surrogate. Therefore, the 
pharmacokinetics of low-dose ATRA, high-dose ATRA and 13-cis RA were 
examined in more detail using the data gathered from the FORTE trial (290). 
Pharmacokinetic profiles of each treatment were using plasma ATRA levels measured 
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prior to and immediately following the first dose, and following a later dose (follow-
up: after 2-4 weeks in half the subjects and 12-16 weeks in the other half). High-dose 
ATRA resulted in significantly higher peak plasma ATRA levels (Cmax) at study 
start and at follow-up, with more patients exhibiting plasma ATRA in a biologically 
active range (>100ng/mL) at study start, compared to low-dose ATRA or 13-cis RA. 
Cmax of both high- and low-dose ATRA peaked at 3 hours following dose, with rapid 
clearance over the subsequent 12 hours. Cmax of both high- and low-dose ATRA 
were significantly lower at follow-up compared to study start, attributed to auto-
induction of ATRA catabolism, despite the inclusion of a drug holiday in the dosing 
regime. In contrast, 13-cis RA exhibited steady state plasma levels over the course of 
12 hours after both initial dose and at follow up dose, attributed to gradual isomerism 
of ATRA. At follow up, Cmax of 13-cis RA exceeded levels found in the low-dose 
ATRA group, although were consistently lower than those found in the high-dose 
ATRA group. The autoinduction of ATRA catabolism represents a considerable 
therapeutic obstacle for the administration of ATRA in emphysema patients. 
Furthermore, it is not clear if this is a widespread phenomenon or specifically related 
to changes in level of ATRA metabolising enzymes (CYP26A1, B1 and C1; described 
below) in patients with emphysema. Data presented later in this thesis (Chapter 3) 
provides evidence that CYP26A1 expression is elevated in the lung tissue of patients 
with emphysema, which may be important with regards to prospective ATRA 
treatment in this patient group. Nevertheless, the correlation between improvements 
in DLCO, CT score, and quality of life indices, with plasma ATRA levels in the 
FORTE study provided evidence of a biological activity of ATRA in the lungs of 
emphysema patients.  
 
1.11.3 Palovarotene: REPAIR study 
 
The recognition that ATRA induces its own catabolism, and that blood ATRA levels 
varied widely between patients, shifted the focus towards synthetic retinoids with 
more stable pharmacokinetic profiles, which did not induce their own catabolism. 
Therefore, the subsequent 2 clinical trials involved a novel RAR-gamma agonist, 
palovarotene (R667, RO-3300074) developed by Roche Holding AG (291). The 
rationale for this choice of compound was that palovarotene was reported to induce 
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alveolar regeneration in a rat model of cigarette-smoke induced emphysema (292) in a 
replication of the original Massaro & Massaro study, and RAR-γ is critical for 
promoting alveolar formation during postnatal alveolarisation (220). 
  
The first trial using palovarotene was the Retinoid treatment of Emphysema in 
Patients on the Alpha-1 International Registry (REPAIR) study, conducted by Stolk et 
al (293, 294). The study population was 262 patients with CT-confirmed emphysema 
secondary to alpha-1-antitrypsins deficiency (AATD) of the Pi Z or Pi Null genotype. 
The rationale was that these subjects develop emphysema at a younger age than the 
general population with smoke-induced emphysema, and therefore may be more 
amenable to treatment. Furthermore, these patients have less comorbidities than 
subjects with smoke-induced emphysema with the same degree of reduced lung 
function, and therefore represent a more homogeneous population. The study used a 
randomised, multicentre, double-blind, placebo-controlled, parallel-group design 
conducted at 16 sites across Europe. Subjects were randomised using a 1:1 ratio and 
received either 5mg of palovarotene or matching placebo once daily for 1 year. The 
primary outcome measurement was lung density measured by CT, with secondary 
outcomes measurements of spirometric indices (FEV1, FVC), gas diffusing capacity 
(DLCO, KCO), exercise capacity (incremental shuttle walk tests, ISWTs), and quality 
of life questionnaires. All patients in the study exhibited a decline in CT density 
scores and lung function measurements, indicative of emphysema progression, over 
the course of the year. No significant differences in CT scores were observed between 
placebo and palovarotene-treated groups. Marginal reductions were observed in rate 
of decline in spirometric indices and gas diffusion capacity in the palovarotene group 
compared to the placebo group, but these did not reach significance, although it was 
noted that given the baseline variability, the study was underpowered to detect a 
statistical difference in these parameters. However, it was observed that palovarotene 
appeared to protect against the effect of exacerbations on decline in CT density 
scores, compared with the placebo group. Nevertheless, the authors concluded that 
overall palovarotene did not result in any significant improvements in this study.  
 
 
 89 
1.11.4 Palovarotene: TESRA 
 
The second study using palovarotene was a phase 2 trial conducted on patients with 
cigarette-smoke induced emphysema, Treatment of Emphysema with a Selective 
Retinoid Agonist (TESRA), conducted by Jones & Rames et al (295). The study used 
a double-blind, placebo-controlled, randomised, multicentre design with 492 patients 
with smoke-induced emphysema confirmed by CT, with patients randomly assigned 
5mg/day oral palovarotene (329 patients) or placebo (160 patients), taken daily for 2 
years. The primary endpoint was FEV1 change at two years from baseline, with CT 
scores and other lung function scores as secondary endpoints. The data has only been 
published in abstract form, and so detailed information is not currently available. The 
available information states that palovarotene did not show significant efficacy in the 
overall treatment population compared to the placebo group. However, when patients 
were analysed according to localisation of the emphysema, those with disease 
predominantly in the lower lung exhibited significant benefits compared to the 
placebo treated group. Patients with lower lung emphysema showed a significant 
reduction in the decline of FEV1, gas diffusing capacity, and exercise capacity (6 
minute walk distance) compared with placebo controlled group (Figure 1.11). This 
exciting data is suggestive of a disease modifying effect in the subset of patients with 
lower lobe emphysema, and the full report of the study is awaited eagerly. 
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Figure 1.11 Palovarotene slowed decline in FEV1 in patients with lower lobe 
emphysema – data from TESRA study 
Data from the Treatment of Emphysema with a Selective Retinoid Agonist (TESRA) 
study. TESRA was a two-year phase-2 double-blind, randomised, placebo-controlled 
multi-center study to assess safety and efficacy of a 5 mg/day regimen of the RAR-γ 
selective agonist palovarotene in 492 patients with cigarette smoke-induced 
emphysema. Theere was no significant effect of palovarotene overall after 2 years. 
However, post-hoc analysis demonstrated that in patients with lower lobe 
emphysema, palovarotene significantly reduced lung function decline, suggestive of a 
disease-modifying effect. From: Jones and Rames (2011). 
 
 
 
 
 
 
 
 
 
 
 
 91 
1.11.5 Inhaled ATRA: a case study 
 
An additional case study published by Frankenberger et al in 2009, described the 
treatment of a single patient with severe emphysema using inhaled liposomal ATRA. 
The patient was a never smoker with a normal AAT genotype, yet displayed extensive 
basal centrilobular emphysema according to high-resolution CT; the cause of disease 
was unknown (296). The patient was given ATRA treatment 3 times a week starting 
with a dose of 0.1 mg, with a weekly increase up to a final dose of 3mg ATRA for a 
total of 4 weeks, and then continued on 1 mg ATRA 4 times a week for a further 5 
months. There were no side-effects reported, and at the end of the study period the 
patient exhibited an improvement in FEV1 from 16% predicted to 21% predicted, and 
an increase from 400 m to 615 m in the 6 minute walking test. Additional biochemical 
analysis showed a decrease in desmosine excretion over the study period, suggestive 
of decreased elastin degradation, and a decrease in exhaled isoprostane and in serum 
interleukin (IL)-13, suggestive of reduced inflammation. This was only a case study 
of a single patient with no control group, however the results suggest a beneficial 
effect of ATRA administered by inhalation. 
 
The clinical studies described represent for the large part what is currently known 
about RA in human lung regeneration. In vitro models of human alveolar regeneration 
are extremely limited, and while the mouse studies of RA-induced lung regeneration 
have generated excitement, their relevance to man is qualified by critical differences 
between animal models and human disease, as well as inter-species differences in 
drug metabolism and absorption, anatomy and physiology. Thus, there is a great need 
to investigate the role of RA signalling in alveolar repair processes using human 
models. There is also a necessity to develop further models of human lung 
regeneration with which to study RA signalling in human alveolar repair, with the aim 
of better understanding how to apply retinoids to the therapeutic induction of 
regeneration in patients with chronic lung disease. Before we examine these issues, 
we must first consider the RA pathway and its ability to initiate dramatic and diverse 
transcriptional events 
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1.12 Cellular and molecular mechanisms of RA-induced lung regeneration: 
what do we know so far? 
 
Very little is known about the cellular and molecular mechanisms involved in RA-
mediated lung regeneration. In mice with disrupted alveolar development by 
overexpression of dnFGFR in AT2 cells, (1.10.4), RA was able to induce 
regeneration, whereas further conditional induction of dnFGFR expression inhibited 
RA-induced lung regeneration, suggesting FGF signalling is critical for RA-induced 
regeneration (284). However, dnFGFR overexpression did not reduce parenchymal 
cell proliferation after RA treatment, suggesting RA-induced cell proliferation does 
not require FGF. An increase in α-SMA positive cells within regenerating alveolar 
septae was observed 1 week after cessation of RA treatment, which was inhibited by 
overexpression of dnFGFR in AT2 cells. This resulted from inhibition of 
differentiation of PDGFRα-expressing lipofibroblasts into α-SMA positive 
myofibroblasts. Thus, RA-mediated alveolar regeneration is in part mediated by 
transition of alveolar lipofibroblasts into myofibroblasts, in a mechanism dependent 
on FGF signalling (284).  
 
The dnFGFR2 used in this study inhibits signalling of FGF1, FGF3, FGF7 and 
FGF10, suggesting that at least one of these FGF family members are critical for RA-
induced lung regeneration. These FGF members are involved in early lung 
development, and the transition of PDGFRα-expressing lipofibroblasts into α-SMA-
expressing myofibroblasts is a critical event during postnatal alveolar development 
(297). Therefore, this study provides evidence that RA-mediated lung regeneration 
recapitulates some aspects of postnatal alveolar development (284). However, the 
increase in α-SMA expression was only observed 1 week after cessation of RA 
treatment, suggesting that RA does not directly induce transdifferentiation of 
lipofibroblasts into myofibroblasts, and that other intermediary steps are involved.  
 
No other studies have investigated the cellular or molecular regulation of RA-induced 
lung regeneration. There is particularly a lack of information about specific cell types 
involved in the response. Outstanding questions include: which cell type(s) does RA 
directly activate during RA-induced lung regeneration? What mediates alveolar 
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epithelial growth, and what is the role of the vascular system during the process? How 
does RA-induced regeneration in animal models of emphysema translate to man? 
Furthermore, do RA pathway disturbances contribute to human chronic lung disease? 
There is currently a lack of human studies of RA signalling in human lung repair, 
partly due to a scarcity of human models of lung regeneration. Thus, the development 
of new, clinically relevant human models of lung regeneration is of great importance. 
These will be critical issues in the future development of retinoid-based regenerative 
therapies for human lung disease, and are a primary focus of this thesis. 
 
1.13 Hypothesis and aims 
 
We hypothesise that RA signalling is critical in regenerative processes in adult human 
distal lung. Therefore, deficient RA signalling may lead to emphysema, whereas 
sufficient RA, either through adequate endogenous supplies, or administration of RA, 
may promote alveolar regeneration by directly stimulating microvascular 
angiogenesis and/or alveolar epithelial repair.  
 
This project has three primary aims: 1) To characterise the transcriptional regulation 
of RA pathway in distal lung tissue of patients with clinical emphysema; 2) To 
investigate the role of RA signalling in in vitro models of human lung repair 
focussing on critical cell types of the alveolar-capillary barrier, AT2 cells, and lung 
microvascular endothelial cells; 3) To develop a more complex ex vivo model of 
human lung regeneration using precision cut lung slices (PCLS) derived from human 
lung tissue. 
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Figure 1.12 Schematic representation of the hypothesis to be tested in this thesis 
The role of RA signalling in the adult human lung. The role of RA in stimulating 
interstitial lung components was not addressed in this thesis. 
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2 Chapter 2: Materials and Methods 
 
2.1 Materials 
 
2.1.1 General Reagents 
 
2-mercaptoethanol  Sigma-Aldrich (M-7522)  
2-Propanol VWR (ALFA22906.K7) 
Ammonium Acetate VWR (153164R) 
Ascorbic acid Sigma-Aldrich (A-7631) 
Bovine serum albumin (BSA) Sigma-Aldrich (A7030)  
Butylated hydroxytoluene (BHT) BDH (28067) 
Dimethyl sulphoxide (DMSO)  Sigma-Aldrich (D5879)  
Distilled, deionised water (dd H2O) Millipore water purification system 
Dulbecco's phosphate buffered saline Sigma-Aldrich (D8537)  
      solution (PBS without Ca2+) 
 Dulbecco's phosphate buffered saline  Sigma-Aldrich (D8662)  
      solution (with Ca2+)  
 Ethanol Fisher Scientific (E/0650DF/17)  
Ethidium bromide solution  Sigma-Aldrich (E1385)  
Ethyl acetate Sigma-Aldrich (650528) 
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich (E6511)  
GELRED nucleic Acid Gel Stain Cambridge Bioscience (BT41003) 
HEPES Sigma-Aldrich (H7006)  
Methanol Fisher Scientific (M/4000/17) 
Methyl acetate Sigma-Aldrich (45999) 
Methylthiazolitetrazolium (MTT)  Sigma-Aldrich (M2128) 
MitoTracker Red CM-H2XRos  Molecular Probes (M7513) 
Parafomaldehyde Sigma-Aldrich (P6148) 
Phosphate buffered saline tablets Sigma-Aldrich (P4417) 
Prolong Gold Molecular Probes (P36935) 
RNase Zap Sigma-Aldrich (R2020) 
Triton X-100 BDH (30632)  
Tween 20  Roche  (P1379) 
WST-1 Roche (05015944001) 
 
2.1.2 Retinoid and inhibitors 
 
13-cis-retinoic acid Sigma-Aldrich (R3255) 
9-cis-retinoic acid Sigma-Aldrich (R4643) 
All-trans Retinal Sigma-Aldrich (R2500) 
All-trans-Retinoic Acid Sigma-Aldrich (R2625) 
AM580 (RAR-α agonist) Sigma-Aldrich (A884) 
BMS 453 (RAR-β agonist) Tocris Bioscience (3409) 
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BMS 493 (pan-RAR antagonist) Sigma-Aldrich (B6688) 
CD1530 (RAR-γ agonist) Tocris Bioscience (2554) 
ER 50891 (RAR-α antagonist) Tocris Bioscience (3823) 
Retinol Sigma-Aldrich (95144) 
Retinyl Acetate Sigma-Aldrich (46958) 
Retinyl Palmitate Sigma-Aldrich (R1512) 
 
2.1.3 Molecular Biology Reagents 
 
10mM dNTP Mix Invitrogen (18427-013) 
25 bp DNA ladder Invitrogen (10597-011) 
Dithiothreitol (DTT)  Invitrogen (Y00147) 
M-MLV Reverse Transcriptase Invitrogen (28025-013) 
Oligo (dt)12-18 primer Invitrogen (18418-012) 
PCR Tubes and Caps Qiagen 
Quanti Tect SYBR Green PCR Kit Qiagen (204143) 
Quantitect Primer Pairs Qiagen 
Rnase Sigma-Aldrich (R4875) 
RNase free DNase set Qiagen (79254) 
RNasin Plus RNase Inhibitor  Promega (N2615) 
RNeasy MiniKit Qiagen (74106) 
Taqman Fast Advanced Master Mix Applied Biosystems (4444965) 
Taqman primer/probe sets Applied Biosystems 
 
 
2.1.4 Antibodies 
 
2.1.4.1 Primary antibodies 
 
Alpha smooth muscle actin polyclonal rabbit Gene Tex (GTX112862) 
Aquaporin 5 polyclonal goat Santa Cruz (sc-9890) 
PECAM-1 mouse antibody Sigma-Aldrich (P8590) 
Phospho-serine H3 antibody Cell Signaling (9701) 
Pro-surfactant protein C rabbit Millipore (AB3786) 
RALDH 1 polyclonal rabbit antibody Sigma-Aldrich (HPA002123) 
RALDH 2 polyclonal rabbit antibody Sigma-Aldrich (HPA010022) 
CYP26A1 (481-495) rabbit antibody Sigma-Aldrich (C6498) 
2.1.4.2 Secondary antibodies 
 
Alexa Fluor 488 F(ab')2 goat anti-rabbit Molecular Probes (A11070) 
Alexa Fluor 488 donkey anti-goat  Molecular Probes (A11055) 
Alexa Fluor 594 donkey anti-goat Molecular Probes (A11058) 
Alexa Fluor 594 rabbit anti-mouse  Molecular Probes (A11062) 
Alexa Fluor 594 goat anti-rabbit Molecular Probes (A11012) 
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Anti-rabbit IgG, HRP-linked Antibody Cell Signaling (7074) 
 
2.1.5 Cell Culture Reagents 
 
2.1.5.1 A549 cells 
A549 cells 
European Collection of Cell 
Cultures (86012804) 
Dulbecco's modified eagles medium Sigma-Aldrich (D6546)  
Foetal calf serum  Invitrogen (10108-165)  
Glutamine  Invitrogen (25030-024)  
Penicillin/Streptomycin  Invitrogen (15140-122)  
Phosphate buffered saline  Sigma-Aldrich (D8662)  
Trypsin (0.25%) + EDTA (1mM)  Invitrogen (15400-054)  
 
 
2.1.5.2 Human lung microvascular endothelial cells (HLMVEC)  
 
Detach Kit  Promocell (CC-41210)  
EGM -2 growth medium with supplements  Lonza (CC3162)  
EGM-MV2 growth medium with supplements  Lonza (CC3202)  
Endothelial Growth Medium MV2  Promocell (CC-2022)  
HLMVEC Lonza (CC 2527)  
HLMVEC Promocell (C 12281) 
Reagent Pack (Trypsin, HEPES, TNS) Lonza (CC5034)  
 
2.1.5.3 Primary human alveolar type 2 cells (AT2)  
 
DCCM-1 Medium React Scientific (05-010-1A) 
DNase 1 Sigma-Aldrich (DN-25) 
Heat Inactivated Newborn Calf Serum Life Technologies (26010) 
PureCol, type 1 collagen Advanced Biomatrix (5005-B) 
Trypsin (from bovine pancreas) Sigma-Aldrich (T8003) 
 
2.1.5.4 Lung slice culture and preparation  
 
Agarose - Type IX-A, Ultra-low Gelling Temperature Sigma-Aldrich (A2576) 
Amphotericin B solution Sigma-Aldrich (A2942) 
Dulbecco’s Modified Eagle’s Medium (high glucose) Sigma-Aldrich (D5796) 
Feather Disposable Microtome Blade - S35 VWR (LEIC08310E) 
Gentamicin 10mg/ml solution Sigma-Aldrich (G1272) 
Hank's Balanced Salt Solution Sigma-Aldrich (H6648) 
L-Glutamine 200mM solution Sigma-Aldrich (G7513) 
Penicillin/Streptomycin Sigma-Aldrich (P0781) 
RPMI-1640 Sigma-Aldrich (R7638) 
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Vancomycin Sigma-Aldrich (V1130) 
 
 
2.1.6 Equipment 
 
2.1.6.1 General 
 
Boeco M- 240 R centrifuge Hettich 
CK40 Phase contrast microscope  Olympus UK 
EL800 plate reader with Gen 5 (Biotek) software  Biotek  
Hawk 15/05 centrifuge Sanyo GallenKemp 
Hettich Rotina 46R swing bucket centrifuge  Hettich 
Krumdieck tissue slicer Alabama Research & Development 
Lab-Tek II Chamber Slide  (8-well) Nunc 
Leica DM 2500 Fluorescent Microscope Leica 
Nano-drop ND1000 spectrophotometer Lab tech International 
µ-slide Angiogenesis Ibidi (81506)  
 
2.1.6.2 HPLC 
 
HiPersolv Chromanorm HPLC Grade Acetonitrile VWR (20060-360) 
RP18 Lichrosorb column Phenomenex (LIRP18-5-250A) 
SecurityGuard Analytical Guard Cartridge System Phenomenex (KJ0-4282) 
Varian Prostar Autosampler 410 Agilent Technologies 
Varian Solvent delivery system 9012 Agilent Technologies 
Varian Variable wavelength UV-VIS Detector 9050 Agilent Technologies 
 
2.1.6.3 PCR 
 
BioDoc-It Imaging System UVP 
epMotion 5075 (automated 384-well plate loader) Eppendorf 
PTC-225 Peltier Thermal Cycler MJ Research 
RG-6000 RT-qPCR machine  Corbett  
ViiA7 (qPCR Machine) Applied Biosystems 
 
2.1.6.4 Western blot 
 
iBlot Gel Transfer Device Invitrogen 
Mini-gel tank Invitrogen 
 
2.1.6.5 Kits 
 
Cytotoxicity Detection Kit (LDH)  Roche (11 644 793 001)  
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Human VEGF DuoSet ELISA R&D Systems (DY293B) 
 
2.1.7 Company Locations 
 
Advanced Biomatrix San Diego, CA, USA 
Agilent Technologies Santa Clara, CA, USA 
Alabama Research and Development Munford, AL, USA 
Applied Biosystems California, USA 
BDH Poole, UK 
Biotek Seattle, WA, USA 
Cambridge Bioscience Cambridge, UK 
Cell Signaling Technologies Beverley, MA, USA 
Eppendorf Hamburg, Germany 
Gene Tex Irvine, CA, USA 
Hettich Tuttlingen, Germany 
Ibidi Martinsried, Germany 
Invitrogen Carlsbad, CA, USA 
Lab tech International East Sussex, UK 
Leica Solms, Germany 
Lonza Wokingham, UK 
Millipore Darmstadt, Germany 
MJ Research Quebec, Canada 
Molecular Probes Eugene, OR, USA 
Nunc Roskilde, Denmark 
Olympus UK Southend, UK 
Phenomenex Torrance, California, USA 
Promega Madison, WI, USA 
Promocell Heidelberg, Germany 
Qiagen Limburg, Netherlands 
R&D Systems Abingdon, UK  
Roche Mannheim, Germany 
Santa Cruz Dallas, TX, USA 
Sanyo GallenKemp Etten Leur, Netherlands 
Sigma-Aldrich Poole, UK 
Tocris Biosciences Bristol, UK 
UVP Upland, CA, USA 
VWR Leicestershire, UK 
Waters Milford MA, USA 
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2.2 Methods 
 
2.2.1 General Methods 
 
2.2.1.1 Centrifugation 
 
Centrifugations for volumes under 2 ml were performed in a fixed angle bench top 
centrifuge, either Hawk 15/05 (Sanyo GallenKemp, Etten Leur, Netherlands) or 
Boeco M- 240 R (Hettich, Germany). For larger volumes, a Hettich Rotina 46R swing 
bucket centrifuge was used (Hettich). Centrifugation speeds are presented as the 
relative centrifugal force (e.g. RCF) or centrifuge rotor speed (RPM) followed by 
time, temperature and brake. 
2.2.1.2 Cell counting 
 
Cells were counted under a phase contrast microscope (CK40, Olympus UK, 
Southend, UK) using a haemocytometer (improved Neubauer model). The total cell 
number in the four corner squares (1 mm3) was counted. Cells were included that 
were completely within the boundaries of the squares or if they overlapped the top 
and right border of squares but not if they overlapped bottom and left border. 
Appropriate dilutions and repeat counts were performed to ensure the total number of 
cells fell between 100 and 400. The total number of cells in suspension was calculated 
using the following formula: 
Total cell count / ml = Cell count for all four squares x 10,000 x dilution factor 
 4 
 
2.2.1.3 Statistical analysis 
 
Parametric data are presented as mean plus or minus standard error of the mean (± 
SEM), while non-parametric data are presented as median with inter-quartile ranges. 
Statistical analysis of normally distributed data was performed using the unpaired 
student’s t-test for comparison of 2 groups and a one-way analysis of variance 
(ANOVA) followed by Dunnett’s post test for comparison of 3 or more groups. 
Analysis of non-parametric data was performed using a Mann Whitney test for 
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comparison of 2 groups and a Kruskal Wallis test followed by Dunn’s post test for 3 
or more groups. Data were analysed using GraphPad Prism version 6.00 (GraphPad 
Software Inc, San Diego, CA). Statistical significance was defined at the 95% level 
throughout, p < 0.05. 
 
2.2.2 Molecular Biology 
2.2.2.1 Ribose nucleic acid (RNA) extraction 
2.2.2.1.1 RNA extraction from isolated cells 
 
Total RNA was extracted from cultured cells using the RNeasy mini Kit (Qiagen, 
Manchester, UK) according to the manufacturers protocol. Following 
culture/treatment, supernatants were removed, cells were washed once with PBS, and 
then lysed with the provided lysis buffer (RLT buffer). The cell lysate/buffer solution 
was mixed with equal volumes of 70% ethanol, creating conditions that promote 
selective binding of RNA to the RNeasy membrane. 700 µl of the mixture was added 
to an RNeasy mini spin column and centrifuged to fix total RNA to the column. The 
RNA in the column was then washed with further washing buffers and finally eluted 
using RNase-free H2O into the provided 1.5 ml tubes, and used or stored at -20 oC 
(summarised below). 
mRNA Extraction (inc DNA Digest) 
 
RLT buffer mixed with β-mercaptoethanol (β-ME; 10 µl β-ME per 1 ml buffer RLT). Cells 
harvest immediately at appropriate time point in 350 µl buffer RLT. 
 
 
 
Buffer RLT/cell sample mixed with equal volume (350 µl per well) 70% ethanol. 700 µl of 
sample transferred to RNeasy spin column and centrifuged for 15 seconds at ≥ 8000g. 
Discard the flow-through. 
 
 
Add 350 µl Buffer RW1 to the RNeasy spin column. Centrifuge for 15 seconds at ≥ 8000g to 
wash the spin column membrane. Discard the flow through. 
 
 
 
Add 70 µl RDD Buffer (fridge) to 10 µl DNase 1 (-20 oC). Mix by gently inverting and 
centrifuge briefly to collect all residue from sides of the tube. Add directly to membrane and 
leave to stand at RT for 15 minutes. 
 
 
Add 350 µl Buffer RW1 to the RNeasy spin column. Centrifuge for 15 seconds at ≥ 8000g to 
wash the spin column membrane. Discard the flow-through. 
 
 
 
Add 500 µl Buffer RPE to the RNeasy spin column. Centrifuge for 15 seconds at ≥ 8000g to 
wash the spin column membrane. Discard the flow-through. 
 
 
Add 500 µl Buffer RPE to the RNeasy spin column. Centrifuge for 2 minutes at ≥ 8000g to 
wash the spin column membrane. Discard the flow-through. 
 
 
Place the RNeasy spin column in a new 1.5 ml collection tube. Add 30-50 µl RNase-free 
water directly to the spin column membrane. Centrifuge for 1 minute at ≥ 8000g to elute the 
RNA. Store at – 20 oC. !
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2.2.2.1.2 RNA extraction from lung tissue 
 
Total RNA was extracted from whole lung tissue following homogenisation, using the 
RNeasy mini Kit (Qiagen) according to the manufacturers protocol. For 
homogenisation, ~ 30 mg lung tissue was transferred to a microcentrifuge tube 
containing the provided lysis buffer (RLT buffer). A sterile hypodermic syringe fitted 
with a sterile 20-gauge needle was used to homogenise the tissue, after which the 
sample was centrifuged at ≥ 15,000 g for 2 minutes to pellet the tissue debris. The 
supernatant was mixed with equal volumes 70% ethanol. 700 µl of the mixture was 
added to an RNeasy mini spin column and centrifuged to fix the RNA to the column. 
The remainder of the extraction protocol was identical to that used for cellular RNA 
isolation (i.e. from step 3 onward). 
 
RNA concentration and purity were determined by measuring spectrophotometric 
absorption at 260 nm to 280 nm with a Nano-drop ND1000 spectrophotometer (Lab 
tech International, East Sussex). Only samples with a ratio of A260/280 of ~ 2.0 were 
used.  
 
2.2.2.2 Reverse transcription (RT) protocol 
 
All reagents were defrosted on ice prior to reverse transcription. Using the RNA 
concentration value obtained from nanodrop analysis, the volume containing 1.0 µg 
of RNA was calculated. This volume was diluted in RNase free water to 10 µl, and 
then incubated with oligo (dT) primer (1 µl) and 10 mM dNTP mix (1 µl) at 65 oC for 
5 minutes, then chilled on ice. 5x First strand buffer (4 µl), DTT (0.1M, 2µl) and 
RNasin (1 µl) were added and the mixture gently mixed and warmed to 37 oC for 2 
minutes. M-MLV Reverse Transcriptase (200U/µl, 1 µl) was added, and the mixture 
gently mixed by pipetting up and down, and incubated at 37 oC for 50 minutes, and 
subsequently at 70 oC for 15 minutes to terminate the reaction. The synthesised cDNA 
(RT+ve) was used for PCR reactions either immediately, or was stored at -20 oC until 
required. For some experiments (end-point RT-PCR, described below), RT-ve RT 
reactions were prepared. This comprised exactly the same reaction components as 
RT+ve reactions, except 1 µl dd H2O instead of MMLV-RT. Reactions were 
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conducted under identical conditions. RT-ve cDNA was used to ensure the absence of 
contaminating DNA in all subsequent reaction reagents. 
 
2.2.3 Polymerase chain reaction (PCR) 
2.2.3.1 Basic principles of reverse transcription polymerase chain reaction (RT-
PCR) 
2.2.3.1.1 Reverse transcription 
 
RNA is converted into complementary DNA (cDNA) by the process of reverse 
transcription (RT) – cDNA is subsequently used as a substrate for PCR amplification. 
RNA extracted from tissue or cells can be non-specifically transcribed into cDNA 
using a poly(T) primer (oligo dT), or specifically transcribed using gene-specific 
primers. Moloney murine leukaemia virus reverse transcriptase (MMLV-RT) is the 
most commonly used reverse transcriptase. This thesis used MMLV-RT in 
conjunction with an oligo dT that hybridises to the poly(A) tail of mRNA. With these 
reagents, all mRNA within a sample is transcribed, and polymerisation commences 
from the poly(A) end and proceeds in a 3’ to 5’ direction (summarised in Figure 2.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 The principle of reverse transcription 
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2.2.3.2 The polymerase chain reaction (PCR) 
 
The polymerase chain reaction, first described by Saiki et al in 1985 (298), is a 
technique in which a specific sequence of DNA is amplified through successive 
rounds of DNA polymerase catalytic activity. The target DNA sequence can be 
amplified either directly from the genome, or from short fragments of DNA. Thus 
cDNA generated from RNA can be subjected to PCR for the amplification of 
sequences derived from transcripts of a gene of interest. Specificity of amplification is 
provided by the design of synthetic oligonucleotides complementary to DNA 
sequences surrounding the target region of interest. These primers bind to the DNA, 
and form a starting point for a heat-stable DNA polymerase (Taq polymerase) to 
catalyse the synthesis of a replicate strand of DNA, using an excess of 
deoxynucleotides as the substrate. As the reaction proceeds through repeated cycles, 
each newly generated strand provides a template for a further round of replication, 
allowing the exponential amplification of the initial target DNA sequence 
(summarised in Figure 2.2). 
 
Each PCR cycle consists of 3 steps: 
 
1. Denaturation: Reaction mixture is heated briefly to 94 ºC to disrupt the hydrogen 
bonds between the two strands of double stranded DNA (dsDNA), resulting in 
their dissociation into single strands. 
2. Annealing: The reaction mixture is cooled to 55-65 ºC, and the primers bind to 
the complementary DNA sequences through hydrogen bonds. 
3. Extension: The reaction temperature is increased to 72 ºC, the optimal 
temperature for Taq polymerase to attach to the cDNA segment at the 3’ position 
of the primer, and extend the primer by adding dNTPs that are complementary to 
the template in a 5’ to 3’ direction. Provided there is an excess of reagents, the 
amount of target DNA is doubled. Extension of the original template produces 
strands longer than the target sequence, whereas extension of the subsequent PCR 
products generates further DNA strands only of the length of the target sequence. 
Since the products are amplified exponentially, after several cycles the DNA 
strands of the target length greatly outnumber the longer sequences. 
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A final elongation step after all rounds of PCR cycles ensures that any remaining 
single strands of DNA are fully extended. 
 
 
 
 
 
 
 
 
Figure 2.2 Basic principle of polymerase chain reaction. 
Abbreviations: dNTPs, deoxyribonucleotide triphosphates. 
 
2.2.3.3 End-point RT-PCR 
 
End-point PCR uses the PCR reaction to amplify a target segment of DNA. At the end 
of a specified number of cycles, the amplified product is the predominant component 
of the reaction mixture. The mixture can then be separated by agarose gel 
electrophoresis alongside a DNA ladder containing DNA fragments of known size, 
which can be used to determine the size of the amplified fragment and thus the 
specificity of the reaction. As end-point RT-PCR is not quantitative, it was used to 
determine whether or not a target gene was expressed in a sample. 
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2.2.3.4 Quantitative RT-PCR (RT-qPCR) 
 
Quantitative (‘real-time’) analysis of the PCR product as amplification occurs has 
been permitted by the recent development of dsDNA binding dyes, and dual-labelled 
oligonucleotide probes (which emit a fluorescent signal upon cleavage). The amount 
of PCR products generated after each cycle can be quantified by measurement of the 
fluorescent signal. The quantitative measurement of RT-qPCR is the threshold cycle 
(CT), which is the PCR cycle at which the fluorescent signal of the reporter dye 
crosses a threshold level, which is arbitrarily placed during the exponential phase of 
the amplification. The numerical value of the CT is inversely related to the amount of 
amplicon in the reaction, thus RT-qPCR allows the determination of the extent to 
which a particular gene of interest is expressed (299). RT-qPCR data can be presented 
as absolute or relative expression levels. Absolute expression uses a standard curve 
comprising known concentrations of a transcript to provide the exact copy number, 
often presented as copy number per cells. Relative expression presents expression of a 
target gene relative to an internal control (reference gene) whose expression does not 
change between treatment conditions/groups. RT-qPCR data was analysed using 
relative expression methods in this thesis. Two RT-qPCR systems were used in this 
thesis: SYBR Green 1 (a dsDNA binding dye) and a Taqman-based approach (which 
uses dual-labelled oligonucleotide probes).  
 
2.2.3.4.1 RT-qPCR: SYBR Green 
 
SYBR Green 1 is a DNA binding dye that has undetectable fluorescence when 
unbound to DNA, but which fluoresces upon incorporation into dsDNA. SYBR Green 
1 will bind to any available dsDNA, including both the amplified target DNA, and 
non-specific PCR products and primer dimers. The fluorescence originating from 
target DNA products can be distinguished from that originating from non-specific 
products by analysis of a melt curve generated at the end of the final RT-qPCR 
sequence. The SYBR Green-based RT-qPCR in this thesis was performed using a 
Rotor-Gene 3000 PCR system (Corbett Research, Mortlake, Sydney, Australia). 
SYBR Green-based RT-qPCR was used when the expression of a small number of 
target genes relatively few samples were being assessed, as the maximum capacity of 
the Rotor-Gene 3000 machine is only 72 reactions. An advantage of the system is that 
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it is relatively simple and inexpensive compared to alternative quantitative RT-PCR 
approaches. The basic principle of SYBR Green-based RT-qPCR is summarised in 
Figure 2.3. 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Schematic representation of SYBR Green-based RT-qPCR 
Abbreviations: dsDNA, double stranded DNA; ssDNA, single stranded DNA. 
 
2.2.3.4.2 RT-qPCR: Taqman 
 
Taqman-based RT-qPCR uses dual-labelled oligonucleotide probes with sequences 
specific for the target DNA sequence, instead of free-form fluorescent dyes, and thus 
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fluorophore and a quencher, which suppresses the ability of the cycler’s light source 
(laser) to excite the fluorophore. During the annealing step, the probe anneals to the 
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nascent DNA strand in the 3’ direction away from the primer. Upon reaching the 
Taqman probe, the 5’-3’ exonuclease activity of the Taq polymerase cleaves the probe 
from the DNA, and in doing so dissociates the fluorescent dye from the quencher, 
permitting the excitation of the dye by the cycler’s laser which generates a fluorescent 
signal which can be detected and quantified. Thus the signal is highly specific for the 
target DNA sequence. The fluorescence detected is directly proportional to the 
fluorophore released and the amount of DNA target sequence present in the PCR 
reaction. The Taqman-based RT-qPCR in this thesis was performed in 384-well plates 
and was used when large numbers of genes and samples were being assessed. The 
basic principle of Taqman-based RT-qPCR is summarised in Figure 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.4 Basic principle of Taqman-based RT-qPCR 
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2.2.4 PCR protocols 
2.2.4.1 End-point RT-PCR 
2.2.4.1.1 Primer selection 
 
Primers for GAPDH were purchased as pre-mixed forward and reverse Quantitect 
primer combinations (Qiagen). All other primers were designed using the free 
OligoPerfect™ Designer software from Life Technologies 
http://tools.lifetechnologies.com/content.cfm?pageid=9716. Primer sequences were 
ensured to cover an exon-exon boundary to minimise amplification of genomic DNA, 
and are listed in Table 2.1, and were synthesised by Life Technologies. Primers 
arrived as lyophilised powders, and were reconstituted to 100 µM stock solutions with 
dd H2O prior to use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1 Primers used for end-point RT-qPCR.  
Abbreviations: Tm, annealing/melting temperature; GC, guanine and cytosine content 
(%) 
 
Gene$ Primer$pair$ Tm$ GC$ Loca0on$ Length$ Amplicon$size$
RAR#α$ $$Fwd:$GCTGGGCAAATACACTACGAA$ 60$ 48$ 1066$ 21$ 97$
$ $$Rev:$GCACTTGGTGGAGAGTTCAC$ 60$ 55$ 1163$ 23$ $
RAR#β$ $$Fwd:$GCCTTCTCAGTGCCATCTG$ 60$ 58$ 1348$ 19$ 70$
$ $$Rev:$TTATCTACTTTTGTCGGTTCCTCA$ 60$ 38$ 1418$ 24$ $
RAR#γ$ $$Fwd:$GGGCATCAGCACTAAGGGA$ 60$ 58$ 1646$ 19$ 103$
$$Rev:$ACATTTCAGGGTTCTCCAGCAT$ 60$ 45$ 1749$ 22$
RXR#α$ $$Fwd:$CTTCCTTCACCAAGCACATCT$ 60$ 45$ 969$ 22$ 93$
$ $$Rev:$AAGAAGCCCTTGCACCCCT$ 60$ 58$ 639$ 19$ $
RXR#β$ $$Fwd:$CTCCTTGCCACAGGTCTTCA$ 60$ 55$ 1366$ 20$ 113$
$$Rev:$CATCCTCATGTCACGCATTTG$ 60$ 45$ 1479$ 22$
RXR#γ$ $$Fwd:$CCACCCAGCTCTCAGCTAA$ 60$ 58$ 583$ 19$ 75$
$ $$Rev:$CGGGAAGCCCTGGTAAGG$ 61$ 67$ 658$ 18$ $
RALDH#1$ $$Fwd:$TTGCGCTACTGTGCAGGTTG$ 60$ 55$ 443$ 20$ 103$
$$Rev:$GCCACATACACCAATAGGTTCA$ 60$ 45$ 546$ 22$
RALDH#2$ $$Fwd:$ACCTTTACAAGACATGAACCCATT$ 60$ 38$ 567$ 24$ 130$
$ $$Rev:$TCTGCTGGCTTAATAACTACTGTA$ 60$ 38$ 697$ 24$ $
RALDH#3$ $$Fwd:$TTCTCACCCTCAGATCAACAAG$ 60$ 45$ 839$ 22$ 73$
$$Rev:$CGCAGCTTCTTTAACCAGTTTTC$ 61$ 43$ 912$ 23$
CYP26A1$ $$Fwd:$AGCCACATCTCTGATCACTTAC$ 60$ 45$ 969$ 22$ 108$
$ $$Rev:$CTTGTTGTCTTGATTGCTCTTGC$ 61$ 43$ 1077$ 23$ $
CYP26B1$ $$Fwd:$GTCCGTGACGCTGCTGCT$ 61$ 67$ 60$ 18$ 175$
$$Rev:$TCTCCCTCCGCGACGACT$ 61$ 67$ 235$ 18$
CYP26C1$ $$Fwd:$ACCCTCCGCTGGATGCTG$ 61$ 67$ 100$ 18$ 156$
$ $$Rev:$TCTTGAACACTGTCCCATAGC$ 60$ 48$ 256$ 21$ $
CRBP#1$ $$Fwd:$GGAAGATGTTGGTCAACGAGAA$ 60$ 45$ 323$ 22$ 89$
$$Rev:$GCTTCAGCAAGTTGGCGATTTT$ 60$ 45$ 412$ 22$
CRBP#2$ $$Fwd:$GGCTGGAAGCAGTGGATTGA$ 60$ 55$ 368$ 20$ 96$
$ $$Rev:$GTCGCCATCATTTCTTTTTGAACA$ 60$ 38$ 464$ 24$ $
CRABP#1$ $$Fwd:$GCACTGGGTGTGAACGCC$ 61$ 67$ 169$ 18$ 84$
$$Rev:$GTGGATGTCTTGATGTAGAACTG$ 61$ 43$ 253$ 23$
CRABP#2$ $$Fwd:$CCCTGTAAGAGCCTGGTGAA$ 60$ 55$ 379$ 20$ 181$
$$Rev:$GCCACTCACTCTCGGACG$ 61$ 67$ 560$ 18$
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2.2.4.1.2 End-point RT-PCR amplification 
 
Prior to PCR, cDNA was diluted to a working concentration of 10 ng/µl in dd H2O. 
End-point RT-PCR amplification was performed in 25 µl reaction solutions 
containing QuantiTect SYBR Green PCR Master Mix (2 x, 12.5 µl), forward primer 
(10 µM, 2.5 µl), reverse primer (10 µM, 2.5 µl), cDNA (10 ng/ µl, 2 µl), and dd H2O 
(5.5 µl). Reactions were conducted in duplicate, with appropriate controls (including 
reverse transcription negative, RT-ve, and blank controls), using a PTC-225 Peltier 
Thermal Cycler (MJ Research, Quebec, Canada). The cycling conditions were 
specific to each primer and are presented in Table 2.2. The optimum number of PCR 
cycles was determined experimentally by analysis with gel electrophoresis. 
 
  
 
 
 
 
 
 
 
 
Table 2.2 Cycling conditions used for end-point RT-PCR.  
* An annealing temperature of 55 ºC was used for all primer sets except RAR-α, 
RAR-β and RAR-γ, which used 56 ºC. ** PCR reactions were sustained for 34 cycles 
for all primer sets except RALDH-1, RALDH-2, RALDH-3 and CRABP-2, for which 
32 cycles were used. 
 
2.2.4.1.3 Gel electrophoresis and imaging 
 
Agarose gel electrophoresis was used to analyse the reaction products of the end-point 
RT-PCR visually, and compare the size of the amplified fragment with a DNA ladder 
run alongside to ensure specificity of the reaction. In addition, reaction contamination 
could be excluded by analysing an RT-ve control, and blank control. Gels were 
visualised using a BioDoc-It UV camera (UVP, Upland, CA, USA). The protocol is 
as follows. 
34 cycles** 
Stage Temperature+(ºC) Time
Activation 95 10-minutes
Denaturation 94 40-seconds
Annealing-(Tm)- 55-* 60-seconds
Extension 72 60-seconds
Final-Extension 72 10-minutes
Hold 4 Indefinitely
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2.2.4.2 SYBR Green-based RT-qPCR 
2.2.4.2.1 Primers 
 
SYBR Green-based RT-qPCR was used in this thesis to examine the expression of 
RAR-β in A549 cells after treatment with ATRA. The RAR-β primer was the same as 
that used for end-point RT-PCR (Table 2.1). GAPDH was used as a reference gene. 
The GAPDH primer was a Quantitect reference gene primer set (Qiagen, Manchester, 
UK). 
 
2.2.4.2.2 PCR amplification 
 
Prior to PCR amplification, cDNA was diluted to a working concentration of 10 ng/µl 
in dd H2O. SYBR Green-based RT-qPCR amplification was performed in a 20 µl 
reaction solution containing QuantiTect SYBR Green PCR Master Mix (2 x, 10 µl), 
forward and reverse primer mixture (10 µM each, 4 µl), template cDNA (10 ng/µl, 
1.6 µl), and RNase-free water (7 µl). The protocol for the PCR reaction is outlined 
Agarose gel electrophoresis protocol 
 
1. Make gel: 
 
• 1.5g Agarose added per 50 ml TBE buffer (3% agarose) and heat to 
boil. Allow to cool slightly and then add Ethidium Bromide (10 mg/ml) at 
1:50,000 dilution, or GELRED nucleic acid gel stain at 1:10,000 
dilution.  
 
2. Assemble tray and pour in molten agarose 
 
3. Allow to set (approximately 20 minutes) 
 
4. Remove comb and place gel and case in box 
 
5. Add running buffer to cover gel 
 
6. Make 5x loading buffer (300 µl glylcerol to 700µl TBE buffer and 1 
grain of bromomphenyl blue) and vortex 
 
7. Add 6 µl loading buffer directly into 25 µl PCR reaction sample, and 
mix by pipetting 
 
8. Load 10 µl each sample mixture into appropriate wells. Add DNA 
ladder if required 
 
9. Connect to power source. DNA runs from negative to positive. 
 
10. Cover with lid and run at 120 V for ~ 2-3 hours or until loading buffer 
dye has travelled far enough 
 
11. Turn off, remove gel from box and visualise under UV camera !
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below. The loading volumes of reagents and samples are presented for duplicate 
reactions. 
 
 
2.2.4.2.3 Quantification of gene expression 
 
Gene expression for SYBR Green-based RT-qPCR was quantified with a relative 
quantification method. PCR reactions using cDNA from untreated cells were given an 
arbitrary value of 1. Serial dilutions of the same cDNA sample were included in the 
PCR run (1.0, 0.5, 0.1, 0.01). After amplification, the Rotor Gene 3000
 
system 
software generated a standard curve. From this, the PCR efficiency was calculated by 
the software, and used to calculate relative expressions for other experimental 
samples. After each PCR run, the software generated a report including sample labels, 
template amounts, cycle threshold (Ct) values and standard deviations. After PCR 
completion, a melting step was conducted to ensure specificity of PCR products. 
Single peaks were observed with all the PCR reactions used in this thesis. 
 
 
PCR amplification protocol 
 
1) Prepare primers according to manufacturer’s instructions: ! Add 50 µl each of 100 µM forward and reverse primer stocks to 400 µl RNase free 
H2O to make a 10 µM mixture of forward and reverse primers. 
 
2) Calculate total volume of SYBR Green and primer mixture according to sample 
number (N) using the formula: 2.5 x N x volume required (this allows enough for 
duplicate wells, with excess) ! SYBR Green volume = 2.5 x N x 10 µl ! Primer volume (including forward and reverse) = 2.5 x N x 4 µl 
 
3) Mix these thoroughly, and add 14 µl per RT-PCR tube. 
 
4) Add 4.4 µl dd H2O per RT-PCR tube 
 
5) Add 1.6 µl diluted cDNA (1 µg/100 µl) per RT-PCR tube.  
 
6) Make up each RT-PCR tube in duplicate 
 
7) Load PCR tubes to Rotor-Gene 3000 system. Set up running programme and start 
the amplification process "
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2.2.4.3 Taqman-based RT-qPCR 
 
Taqman-based RT-qPCR was used in this thesis to examine the expression of RA 
pathway genes in human lung tissue, and to assess the transcriptional response of 
HLMVECs to incubation with ATRA.  
2.2.4.3.1 Selection of primer/probe sets 
 
All primer/probes were pre-designed, inventoried sets purchased from Applied 
Biosystems (Life Technologies). For each gene, the primer/probe set with the best 
available coverage was chosen. Thus the primer/probe sets used do not detect gene 
products with similar sequence (homologs) or off-target sequences, and are designed 
across an exon-exon junction and so do not amplify genomic DNA. Furthermore the 
sets do not target the 5' untranslated region (UTR), which can have variable sequence 
between transcripts. A summary of all Taqman primer/probe sets used in this thesis is 
presented in Table 2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3 Taqman primer/probe sets used in this thesis 
Inventoried primer/probe sets from Applied Biosystems 
 
Taqman&primer/probes& Catalogue&number&
B2M$ Hs99999907_m1$
GUSB$ Hs99999908_m1$
VEGFA$ Hs00900055_m1$
VEGFR2$(KDR)$ Hs00911700_m1$
VEGFR1$(FLT1)$ Hs01052961_m1$
MDK$ Hs00171064_m1$
RALDH1$(ALDH1A1)$ Hs00946916_m1$
RALDH2$(ALDH1A2)$ Hs00180254_m1$
RALDH3$(ALDH1A3)$ Hs00167476_m1$
CYP26A1$ Hs01075675_g1$
CYP26B1$ Hs01011223_m1$
CYP26C1$ Hs01596345_m1$
RARA$ Hs00940446_m1$
RARB$ Hs00977140_m1$
RARG$ Hs01559234_m1$
RBP1$ Hs01011512_g1$
RBP2$ Hs00188160_m1$
CRABP1$ Hs00171635_m1$
CRABP2$ Hs00275636_m1$
RXRA$ Hs01067640_m1$
RXRB$ Hs00232774_m1$
RXRG$ Hs00199455_m1$
LRAT$ Hs00428109_m1$!
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2.2.4.3.2 PCR amplification 
 
Prior to PCR amplification, cDNA was diluted a working concentration of 10 ng/µl. 
Taqman-based RT-qPCR was performed in 384 well plates in a ViiA7 (Applied 
Biosystems, Carlsbad, CA, USA). 384 well plates were loaded with an epMotion 
5075 (Eppendorf, Hamburg, Germany). Each well contained a reaction mixture of 10 
µl total volume, containing: Taqman Universal PCR Mastermix (5 µl) (Applied 
Biosystems), Primer/probe (0.5 µl), dd H2O (2 µl), and cDNA (10 ng/µl, 2.5 µl). The 
cycling conditions are presented in Table 2.4. 
 
 
  
 
 
 
40 cycles 
 
Table 2.4 Cycling conditions used for Taqman based RT-qPCR 
 
2.2.4.3.3 Quantification of gene expression 
 
Following Taqman-based RT-qPCR, gene expression was quantified using a relative 
quantification method, the comparative CT or 2-∆∆CT method (299). This method uses 
the CT values of the target gene and the reference gene to calculate the fold change in 
target gene expression between two samples. The equation is as follows: 
 
Fold change = 2 - ∆∆CT 
 
or, if expanded to its fullest form: 
 
2 - ∆∆CT = [(CT target gene – CT reference gene) sample A 
- (CT target gene – CT reference gene) sample B] 
 
Stage Temperature+(ºC) Time+(mm:ss)
UNG$incubation 50 02:00
Polymerase$activation 95 00:20
Denature 95 00:01
Anneal/extend 60 00:20
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(from (300)). The comparative CT method makes several assumptions, including that 
the efficiency of the PCR is close to 1 (i.e. the ‘2’ at the beginning of the equation) 
and that the PCR efficiency of the target gene is similar to the internal control gene. 
Nevertheless, the   2 - ∆∆CT method is a widely used method of RT-qPCR analysis due 
to its ease of use and ability to present data as ‘fold change’ in expression (299). In 
this thesis, sample B was the control sample, and sample A was the experimental 
sample (either the diseased sample in the case of the patient sample analysis, or the 
treatment sample in the case of the ATRA treatment). After PCR amplification, raw 
CT values were imported from the RT-qPCR machine to Excel, where the above 
equation was used to calculate fold change in expression for each experiment. 
 
2.2.5 Immunohistochemistry/Immunocytochemistry 
 
Immunohistochemistry (IHC) is a technique which allows the determination of the 
presence and spatial distribution of a target protein within a biological tissue sample. 
Immunocytochemistry uses a similar principle for the detection of proteins within 
cells. Both techniques exploit the presence of antigens present on the protein of 
interest, which can be detected with the use of corresponding specific primary 
antibodies. Subsequently, modified secondary antibodies can be applied which 
specifically bind to the primary antibodies, and enable the primary antibody-antigen 
interaction to be visualised. The secondary antibody modifications which permit 
visualisation are either a conjugated enzyme, such as horseradish peroxidase which 
catalyses a colour-producing reaction when incubated with 2,2'-diaminobenzidine 
(DAB), or a conjugated fluorophore, which allows visualisation by 
immunofluorescence. IHC in this thesis used both types of secondary antibody, while 
immunocytochemistry used immunofluorescence. IHC with DAB used the Vectastain 
Peroxidase ABC Elite kit (Vector Labs), whereas immunofluorescence used 
antibodies conjugated to fluorophores, which were visualised using a fluorescence 
wide-field microscope DM 2500 Microscope (Leica, Solms, Germany). IHC was used 
in this thesis to determine protein expression in precision cut lung slices (PCLS) and 
in paraffin sections from patient whole lung tissue samples. Immunocytochemistry 
was used to examine proliferation of A549 cells in following scratch assay in culture. 
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The basic principle of IHC/immunocytochemistry with immunofluorescence is 
depicted in Figure 2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 The basic principle of antigen-based immunological detection assays 
(including immunohistochemistry and immunocytochemistry).  
Abbreviations: UV light, ultraviolet light. 
 
2.2.5.1 PCLS fixing and slide preparation 
 
PCLS were removed from wells and placed immediately into 5 ml 4% 
paraformaldehyde (PFA) in PBS. PCLS were fixed at 4 ºC for 1-2 weeks. PCLS were 
then transferred to 5 ml PBS and delivered to the Leukocyte Biology Histology core 
facility (Lorraine Lawrence, Leukocyte Biology Section, National Heart and Lung 
Institute, Imperial College London) for paraffin embedding and sectioning.  
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sample 
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Incubation with unlabelled 
primary antibody 
Unbound primary 
antibody washed away 
Incubation with fluorophore-
conjugated secondary 
antibody 
Unbound secondary 
antibody washed away 
UV 
light 
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wherever antigen is located 
Step 1 
Primary antibody 
Step 2 
Secondary antibody 
 117 
2.2.6 Immunohistochemistry protocols 
2.2.6.1 Rehydration and antigen retrieval 
 
Paraffin embedded PCLS sections were rehydrated by incubation in successively 
more aqueous solutions. Following rehydration, antigen retrieval was performed with 
15 minute incubation in EDTA at 100 ºC, to facilitate primary antibody binding. 
Following antigen retrieval, sections were either processed for IHC immediately, or 
stored at 4 ºC overnight until IHC the following morning. The protocol for 
rehydration and antigen retrieval is outlined below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6.2 Immunohistochemistry 
 
Immunohistochemistry was performed on sections by incubation with primary 
antibodies, followed by incubation with fluorophore-conjugated secondary antibodies. 
The concentrations of primary and secondary antibodies were specific to the 
antibodies used and are outlined in Table 2.5. Following IHC, slides were visualised 
with a DM 2500 fluorescent microscope (Leica) and images acquired with QWin 
software (Leica). 
Rehydration and Antigen Retrieval Protocol 
 
Materials: EDTA (Sigma-Aldrich), NaOH 1N, HCL, Histoclear (National 
Diagnostics), Ethanol, PBS (without Ca or Mg), Triton-X 
 
Preparation:  Make up 1mM EDTA antigen retrieval buffer. Add 0.37g EDTA 
to 1000ml H2O. Adjust pH to 8.1 with NaOH 1N to increase (use HCL if pH 
rises too high). Warm up water bath to 100ºC. Prepare PBS with 0.1 % Triton-
X. Add 500 µl Triton-X to 500 ml PBS. 
 
Protocol: 
1. Rehydrate paraffin sections by incubating in successively more aqueous 
solutions: 
1. Histoclear for 10 minutes 
2. Histoclear again for 10 minutes 
3. 100% ethanol for 5 minutes 
4. 95% ethanol for 5 minutes 
5. 70% ethanol for 5 minutes 
6. H2O for 5 minutes 
7. Wash 3 x PBS for 5 minutes 
2. Place slides carefully into warmed up histology jar, and incubate in EDTA 
at 100oC for 15 minutes 
3. Remove histology jar containing EDTA and slides and allow to cool down 
on bench for 20 minutes 
4. Wash slides in PBS twice 
5. Put in PBS containing 0.1% Triton-X and leave in solution (can leave 
overnight in fridge) 
6. Proceed with IHC 
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IHC was also performed using horseradish peroxidase-conjugated secondary 
antibody, and DAB used for visualisation. For DAB-stained paraffin tissue sections, 
haematoxylin was used as a counter stain. Slides were visualised using DM 2500 
microscope (Leica) and images acquired with QWin software (Leica). The protocol is 
as follows. 
 
 
 
 
 
 
 
Immunohistochemistry for paraffin tissue sections protocol 
 
Materials: PBS (without Ca or Mg), Triton-X, Prolong Gold, Slides, 
Coverslips, PAP pen (Sigma-Aldrich), primary antibody, secondary antibody 
 
Preparation: Prepare PBS with 0.1 % Triton-X (PBS-Tx) 
Dilute primary antibody. Dilute at appropriate concentration into PBS w 0.1% 
Triton-X. 
Dilute secondary antibody. Dilute secondary antibody at appropriate 
concentration into PBS w 0.1% Triton-X (100ul x per slide) NB: Centrifuge 
secondary antibody at ≥ 8000 g and pipette from top - removes 
clumps.  
 
Protocol: 
1. Label slides: ‘lung slice, *date sliced*, *specific slice used*, *date of 
staining*. Leave room for label of primary antibody used, and dilution. 
2. Take slide out from buffer and dry glass around tissue, leaving a small 
oval. Draw around this with PAP pen water repellent to prevent 
antibody dilutions from spreading away from the tissue. 
3. Add 100 µl primary antibody dilution to 2 slides, and 100 µl PBS-Tx to 
1 slide (negative control) 
4. Incubate in humid chamber for 1 hour at room temperature 
5. Wash 3x in PBS, for 3 minutes at a time 
6. Add 100 µl 1:200 secondary antibody to inside PAP pen oval on slide 
7. Incubate for 1 hour in humid chamber 
8. Wash 3x PBS for 3 minutes each 
9. Dry around tissue, including wiping off PAP pen oval 
10. Add 1 drop Prolong Gold 
11. Carefully add a coverslip (place edge first on slide and gently lower), 
and leave overnight in dark to set 
Immunohistochemistry (DAB staining) protocol  
  
Day 1 (~2 hours) 
 
1. Deparaffinise and hydrate tissue section through graded alcohol or xylenes in 5 mins 
aquaclear, 1min ETOH each. 
2. Rinse in tap water 5 minutes on gentle shake. 
3. Draw around sections with wax pen and allow to dry. 
4. Incubate 3% H2O2 (dilute 30% 1:10 in distilled water) 5 minutes. 
5. Wash in PBS 5 minutes x 3. 
6. Pipette 400 µl blocking solution (10% FCS in PBS w 0.2% Triton) onto section and 
incubate for 45 minutes at RT. 
7. Incubate with primary antibody diluted in blocking solution at 4oC overnight. Use box 
with wet tissues inside – cover in foil. 
 
Day 2 (2-3 hours) 
 
8. Wash in PBS 5 minutes x3 at RT 
9. Incubate for 30 minutes at RT with 250 µl biotinylated secondary antibody: 
- 1 ml PBS containing 15 µl normal serum + 5 µl biotinylated antibody stock  
10. Wash in PBS 5 mins x3 
11. Incubate with 250 µl Vectastain ABC 30 min RT: 
- 20ul A added to 1ml PBS followed by addition of 20 µl B (this must be 
prepared at least 30 mins before)  
12. Wash in PBS 5 minutes x3 at RT 
13. Incubate with 250 µl peroxidase substrate solution:  
- Add 1 drop of DAB to 1ml of its buffer. Pipetter onto section and develop colour 
under microscope (Cyp26A1 reveals in 60 seconds). 
14. Rinse in water. At this point can perform haematoxylin counter stain. 
 
-- Haematoxylin nuclear counter stain -- 
  
Preparation: Make acid alcohol solution (1%): Hydrochloric acid (1ml), 70 % ethanol in 
ddH2O (50 ml). 
 
1. Wash deparaffinised, re-hydrated, DAB-stained sections briefly in ddH2O. 
2. Stain in Harris haematoxylin solution for 8 minutes. 
3. Wash in running tap water for 5 minutes. 
4. Dip in and out quickly in 1 % acid alcohol. 
5. Wash under running tap water for 1 minute. 
 
------------- 
 
15. Remove excess water, mount with Crystal mount and allow to dry overnight. !
!
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Table 2.5  Antibody concentrations 
 
2.2.6.3 Cell fixing (A549 cells) and immunocytochemistry protocol 
 
A549 cells were seeded into Lab-Tex II 8-well chamber slides (Nunc, Roskilde, 
Denmark) at 80,000 cell per well in 400 µl DMEM-1 supplemented with 2mM 
glutamine, 10% FBS (heat inactivated), 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were grown to confluence before being quiesced in serum free 
Immunohistochemistry (DAB staining) protocol  
  
Day 1 (~2 hours) 
 
1. Deparaffinise and hydrate tissue section through graded alcohol or xylenes in 5 mins 
aquaclear, 1min ETOH each. 
2. Rinse in tap water 5 minutes on gentle shake. 
3. Draw around sections with wax pen and allow to dry. 
4. Incubate 3% H2O2 (dilute 30% 1:10 in distilled water) 5 minutes. 
5. Wash in PBS 5 minutes x 3. 
6. Pipette 400 µl blocking solution (10% FCS in PBS w 0.2% Triton) onto section and 
incubate for 45 minutes at RT. 
7. Incubate with primary antibody diluted in blocking solution at 4oC overnight. Use box 
with wet tissues inside – cover in foil. 
 
Day 2 (2-3 hours) 
 
8. Wash in PBS 5 minutes x3 at RT 
9. Incubate for 30 minutes at RT with 250 µl biotinylated secondary antibody: 
- 1 ml PBS containing 15 µl normal serum + 5 µl biotinylated antibody stock  
10. Wash in PBS 5 mins x3 
11. Incubate with 250 µl Vectastain ABC 30 min RT: 
- 20ul A added to 1ml PBS followed by addition of 20 µl B (this must be 
prepared at least 30 mins before)  
12. Wash in PBS 5 minutes x3 at RT 
13. Incubate with 250 µl peroxidase substrate solution:  
- Add 1 drop of DAB to 1ml of its buffer. Pipetter onto section and develop colour 
under microscope (Cyp26A1 reveals in 60 seconds). 
14. Rinse in water. At this point can perform haematoxylin counter stain. 
 
-- Haematoxylin nuclear counter stain -- 
  
Preparation: Make acid alcohol solution (1%): Hydrochloric acid (1ml), 70 % ethanol in 
ddH2O (50 ml). 
 
1. Wash deparaffinised, re-hydrated, DAB-stained sections briefly in ddH2O. 
2. Stain in Harris haematoxylin solution for 8 minutes. 
3. Wash in running tap water for 5 minutes. 
4. Dip in and out quickly in 1 % acid alcohol. 
5. Wash under running tap water for 1 minute. 
 
------------- 
 
15. Remove excess water, mount with Crystal mount and allow to dry overnight. !
!
Antibody)concentrations
Host Reactivity Optimal
Primary)antibodies: concentration
Alpha smooth muscle actin polyclonal Rabbit Human 1:100
Aquaporin 5 polyclonal Goat Human 1:100
PECAM-1 Mouse Human 1:100
Phospho-serine H3 polyclonal Rabbit Human 1:500
Pro-surfactant protein C polyclonal Rabbit Human 1:500
RALDH 1 polyclonal Rabbit Human 1:50
RALDH 2 polyclonal Rabbit Human 1:50
CYP26A1 (481-495) Rabbit Human 1:5003Western3blot
1:10003IHC
Secondary)antibodies:
Alexa Fluor 488 Donkey Goat 1:200
Alexa Fluor 594 Rabbit Mouse 1:200
Alexa Fluor 594 Goat Rabbit 1:200
Alexa Fluor 488 F(ab')2 Goat Rabbit 1:500
HRP-Conjugated Goat Rabbit 1:50003Western3blot
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media for 2-24 hours prior to initiation of scratch assay (2.2.10.1). After 18 hours, 200 
µl media was removed and replaced with 200 µl 4% PFA to make a final 
concentration of 2% PFA. Slides were incubated at room temperature for 15 minutes. 
Each well was washed twice with 400 µl PBS. 400 µl PBS containing 0.1% Triton-X 
and 1% bovine serum albumin (BSA) (PBS-BT) was added to each well, and the 
slides incubated for 1 hour at room temperature. PBS-BT was aspirated and replaced 
with 150 µl primary antibody, diluted appropriately into PBS-BT, and the slides 
incubated overnight at 4 ºC. The next day, each well was washed four times with PBS 
containing 0.1% Tween. 150 µl secondary antibody diluted appropriately into PBS-
BT was added to each well and the slide incubated for 45 minutes at room 
temperature. Each well was then washed four times with PBS. The glass wells were 
then removed, and 1 drop of Prolong Gold was added to each of the 8 squares. A 
coverslip was carefully placed over the well, and the edges sealed with nail varnish, 
which was then left to dry. Immunofluorescence was visualised under a DM 2500 
Microscope (Leica) and images acquired with QWin software (Leica). 
 
2.2.7 Western Blot 
2.2.7.1 Principle 
 
Western or immuno-blotting is an antibody-based technique for identifying and 
quantifying specific proteins in cell or tissue homogenates. In the technique, total 
protein is extracted from a sample and is separated according to molecular weight by 
gel electrophoresis. The separated proteins are transferred onto a nitrocellulose 
membrane, commonly polyvinylidene fluoride (PVDF). The membrane is incubated 
with a blocking agent (milk or BSA) to shield off-target antigens, followed by 
incubation with a primary antibody specific for the protein of interest. Following 
washes to remove unbound primary antibody, the membrane is incubated with a 
secondary antibody which binds to the primary antibody. The secondary antibody is 
conjugated to horseradish peroxidase, which when incubated with a specific 
chemiluminescent substrate, generates a light signal which can be detected with 
photographic film, which relates to the amount of target protein fixed to the 
membrane. Western blotting was used in this thesis to determine CYP26A1 protein in 
lung tissue homogenates from patients with emphysema compared to control.  
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2.2.7.2 BCA protein assay 
 
The bicinchoninic acid (BCA) assay is a colorimetric assay for determining total 
concentration of protein in a solution. Protein standards consisting of serial dilutions 
of BSA between 25 and 2000 µg/ml in distilled water, or diluted samples (25 µl) were 
added to 96-well micro-titre plate in duplicate. BCA reagent (50:1, reagent A:B, 
200µl) was added to each well. Absorbance was measured at 595 nm using a plate 
reader. The absorbance of cell lysis buffer alone was measured as a blank control. 
Unknown protein concentrations were calculated using a standard curve. 
2.2.7.3 Protein extraction from whole lung tissue 
 
Whole human lung tissue was obtained from Biobank, respiratory Biomedical 
Research Unit (BRU), Royal Brompton and Harefield NHS Foundation Trust, under 
BRU Advanced Lung Disease (ALD) Biobank ethics, reference number 10/H0504/9. 
Total protein was extracted from ~ 30 mg whole lung tissue by homogenising in lysis 
buffer with a sterile 19 gauge needle and 1 ml syringe. Lysis buffer consisted of 10x 
Cell lysis buffer (Cell Signalling Technologies #9803) diluted in ddH2O, containing 
phosphatase and protease inhibitors. Once extracted, protein extracts were kept on ice 
for a maximum of 2 hours, and then used immediately.  
2.2.7.4 Western Blot protocol 
 
Protein concentrations were determined using the BCA assay (above). For each 
sample, 12 µl containing 20 µg of protein, 4x loading buffer, DTT, diluted in 1 x lysis 
buffer, was loaded into each well of a NuPage 4-12% Bis-Tris gel (Invitrogen). A 
Spectra protein ladder (Thermo Scientific) was run alongside for comparison. Protein 
was transferred to nitrocellulose membrane with iBlot (Invitrogen). Membranes were 
blocked in 5 % non-fat milk in TBS-T. Primary and secondary antibodies were each 
diluted at the appropriate concentrations in 5 % non-fat milk in TBS-T. Antibody 
incubations were for 1 hour at RT on a roller, separated by a 3x wash in TBS-T. 
Membrane was incubated with Pierce ECL plus chemiluminescent substrate (Thermo 
Scientific) and signal visualised with photosensitive film (Invitrogen). Band intensity 
was quantified with Image J analysis software. The protocol is as follows. 
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Western Blot Protocol 
1. Calculate 20 µg protein in µl using Excel and Prism 
2. Add per lane: 20 µg sample, 3 µl buffer, 1 µl DTT, 1x lysis buffer up to 12 µl 
3. Make master mix enough for 1.3x volume needed. 
Running gel 
Preparation: Wash components of XCell Surelock Mini Gel tank (Invitrogen) with distilled 
water, and assemble. Dilute 20 x MOPS SDS running buffer (Invitrogen) in ddH2O.  
Protocol: 
1. Remove white strip from pre-cast gel. 
2. Gently ease out comb using thumb. 
3. Put gel into tank with black lettering facing outwards, and close white leaver at back. 
4. Pour in 1x MOPS SDS running buffer into middle of tank to top, and ensure wells are 
filled. Then pour running buffer to half way into rest of tank. 
5. Wash each well with 0.5 ml running buffer to remove bubbles. 
6. Load fermentus spectral ladder (12 µl) and then load samples. 
7. Fit lid. 
8. Run at 150 V for ~ 1 hour, until dye reaches end of gel. 
9. Check buffer level periodically. 
Transfer using iBlot (Invitrogen) 
Preparation: Put distilled water into large white weighing boat and soak a filter paper in it. Open 
BOTTOM part of machine inlay and place in machine. 
Loading machine and transfer: Use green plastic knife to cut gel ridge on back of western 
cassette. Use metal lever to loosen back casing from cassette. Cut off gel comb. Wet green lever 
and slide in to carefully loosen gel. Transfer gel onto BOTTOM with ladder on left. Put wet filter 
paper on top. Use white roller to squeeze out air bubbles. Put TOP on top section with metallic 
side up. Roll over to remove bubbles. Put sponge into top of machine with metal bits lining up. 
Turn on iblot machine on back (should be on programme 3) and press start – takes 7 mins 
Blocking 
Preparation: Make TBS-Tween (20Mm Tris – 1.21g, 137Mm NaCl  - 4g, Add 400ml dH2O and 
pH to 7.4., then top up to 500ml. Add 500ul TWEEN 20 (0.1%)). Make blocking solution (5% 
non-fat milk powder in TBS-T). 
To block non-specific binding, incubate membrane in 20 ml blocking solution on tilter – 1 hour at 
RT. 
Incubate in primary antibody 
Incubate in primary antibody at appropriate concentration diluted in blocking solution for 1 hour 
at RT on roller.  
Secondary antibody 
1. Wash blot 3 x 15 mins in TBS-T on roller at RT. 
2. Incubate in HRP-linked secondary antibody for 1 hour at room temperature on a shaker.  
!
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2. Add per lane: 20 µg sample, 3 µl buffer, 1 µl DTT, 1x lysis buffer up to 12 µl 
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filled. Then pour running buffer to half way into rest of tank. 
5. Wash each well with 0.5 ml running buffer to remove bubbles. 
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7. Fit lid. 
8. Run at 150 V for ~ 1 hour, until dye reaches end of gel. 
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BOTTOM part of machine inlay and place in machine. 
Loading machine and transfer: Use green plastic knife to cut gel ridge on back of western 
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!
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2.2.8 High performance liquid chromatography (HPLC) 
 
2.2.8.1 HPLC machine components and principle  
 
High performance liquid chromatography (HPLC) is an analytical chemistry 
technique used to separate the components of a mixture, in order to identify and 
quantify each component. In this technique, pumps pass a pressurised liquid solvent 
(the mobile phase) containing the sample mixture through a chromatography column 
filled with a solid, granular adsorbant material (the stationary phase). The components 
of the sample are separated through differential interactions with the internal 
components of the chromatography column, leading to different flow rates for each 
component and distinct elution times which are characteristic of each sample 
constituent. A summary of the basic principle of HPLC is presented in Figure 2.6. 
 
 
 
 
 
 
 
 
 
Development 
Preparation: Prepare ECLplus Western Blot substrate: Mix reagent A and B at a 40:1 dilution (i.e 
1ml A to 25ul B). Clean yellow envelope with ethanol then water. 
Protocol: 
1. Put membrane face up onto yellow envelope. 
2. Add 1 ml ECLplus onto top of each membrane and incubate for 5 minutes.  
3. Close yellow envelope gently, and squeeze out bubbles and excess liquid. 
4. Go to dark room with cassette, film, and a pen. 
5. (Only use white tissues). Use ethanol to clean the machine cassette, then water. 
6. Turn off main lights, leaving red light on. 
7. Open photosensitive film in dark. Cut one corner for orientation. 
8. Open cassette and place film on top of membrane. 
9. Leave to expose (length of time specific to antibody and sample). 
10. Take out film and put into developing machine – film will automatically roll in. 
11. Superimpose developed film onto membrane and use pen to mark ladder bands. 
!
!
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Figure 2.6 Schematic diagram of the HPLC setup. 
 
HPLC was used in this thesis to investigate the elution properties of retinoids in tissue 
samples. Retinoids are lipid molecules, and so to separate them a chromatography 
column with a hydrophobic packing material was selected, thus this was reverse-
phase HPLC (normal-phase HPLC uses a column with a hydrophilic core).  
2.2.8.2 Preparing retinoid standards 
 
Retinoid standards (all-trans retinoic acid (ATRA), 9-cis retinoic acid (9-cis RA), 13-
cis retinoic acid (13-cis RA), retinol, retinal, and retinyl acetate) were purchased from 
Sigma-Aldrich, and dissolved in ethanol to make 0.1 mg/ml stock solutions. Retinoid 
stock solutions were stored under argon gas at – 20 ºC in foil-wrapped glass tubes for 
a maximum of 1 month until use.  
2.2.8.3 Extracting retinoids from lung tissue 
 
Retinoids were extracted from whole human lung tissue according to the method of 
Kane and Napoli (301). The method employs a two-step acid-base extraction that 
recovers multiple retinoids, including RA, retinol, RE, and RA polar metabolites. All 
procedures were performed under dim light, with foil-wrapped containers, on ice, to 
Solvent 
A 
Solvent 
B Pump 
Solvent delivery 
system 
Sample 
Auto-sampler 
Injector 
 
HPLC column 
(Packing material) 
Detector 
Waste 
Computer data station 
Chromatogram 
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minimise retinoid degradation. Whole lung tissue was homogenised by freezing in 
liquid nitrogen and pulverising with a ceramic pestle and mortar, to yield a powder. 
3.2 g of tissue was weighed and transferred to 4 ml PBS. The first extraction step used 
6 ml 0.025 M potassium hydroxide (KOH) followed by 10 ml hexane extraction. 
After centrifugation to separate the polar and organic phases, the hexane phase was 
transferred to a foil-wrapped glass tube and kept on ice. The second step used 480 µl 
4 M hydrogen chloride (HCL) followed by 10 ml hexane extraction. After 
centrifugation, the hexane phase was carefully removed and the two hexane phases 
pooled. The organic solvent was evaporated under nitrogen with gentle heating at 25-
30 ºC. The residue was resuspended in 50 µl acetonitrile (ACN), and stored at – 80ºC 
until HPLC analysis. The protocols for the tissue homogenisation and retinoid 
extraction are outlined below. 
 
Extracting Retinoids for HPLC Protocol 
 
Materials:  
! Ceramic pestle and mortar for homogenizing tissue 
! PBS for homogenizing tissue 
! Liquid nitrogen 
! Sterilins for containing tissue 
! 20ml hexane 
! Graduated 1ml & 10ml glass pipettes with electronic pipette processor 
! Plastic stripettes for solvents 
! 50 ml Falcon tubes 
! 16x150mm disposable glass culture tube 
! Vortex 
 
Preparation: 
Make 200ml 0.025M KOH in ethanol into a plastic bottle. Solution can be stored at room 
temperature for future use. 
! Need 1.4g KOH pellets in 10ml EtOH to make 2.5M 
! Then dilute x 100 to get 0.025M (Take 2ml of the above and add to 200ml EtOH) 
Make 200ml 4M HCL in fume hood into a glass bottle. Solution can be stored at room 
temperature for future use. 
! 11.65M HCL stock solution available 
! For 4M, dilute the 11.65M HCL stock 2.91 times: 
! To prepare 200ml 4M HCL, 68.7ml of HCL stock, 131.3ml H2O 
 
Tissue homogenisation protocol: 
! All procedures performed in dim light 
! Homogenize tissue with liquid nitrogen and pestle and mortar: 
1. Cool down pestle and mortar with liquid nitrogen. Also cool any containers which will 
come into contact with tissue. 
2. Place small amount of tissue in bottom of mortar 
3. Add a small volume of liquid nitrogen to freeze tissue and make it brittle 
4. Pulverise with pestle until a powder. Pound and twist, repeat. 
5. Put 50ml falcon into an empty sterilin to keep it upright. Zero scales. !
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2.2.8.4 HPLC method and analysis 
 
Retinoids were analysed using an HPLC method adapted from the method of Rühl 
and Schweigert (302). The HPLC system consisted of a Varian 9012 solvent delivery 
system (Agilent Technologies, Santa Clara, CA, USA) connected to a PC-interface 
with Galaxie Chromatography software (Agilent Technologies) as a controller. 
Samples were housed in a Varian Prostar Autosampler 410 (Agilent Technologies) for 
loading. A Varian 9050 variable wavelength UV-VIS detector (Agilent Technologies) 
Retinoid extraction protocol: 
1. Cool spatula in liquid nitrogen and use it to weigh out 3.2 g tissue into the 50 ml Falcon 
tube. 
 
2. Add 4 ml PBS. Use all of this for extraction 
 
3. Add 6 ml 0.025M KOH in ethanol to tissue homogenates and vortex mix (at least 10s) 
 
4. Add 20 ml of hexane and vortex for 10s 
 
5. Centrifuge at 1,000 x g for 1-3 min to separate phases 
 
6. Draw off organic (top) phase containing non-polar retinoids into a new 16 x 150 mm 
disposable glass culture tube (keep on ice until evaporation) 
 
7. To the bottom layer add 4M HCL (480 µl) and vortex mix for 10s 
 
8. Add 20 ml hexane and vortex for 10s 
 
9. Centrifuge at 1,000 x g for 1-3 min to separate phases 
 
10. Draw off organic (top) phase containing RA and polar retinoids (Do not disturb bottom 
layer as destroys RA). Add to other organic phase and mix.  
 
11. Split the 40ml of organic phase into several smaller vials (12 glass tubes) to speed up the 
evaporation process. Evaporate under nitrogen with gentle heating at 25-30 ºC on hot 
block 
 
12. When there is a small amount left in each vial, combine into one and evaporate the rest 
 
13. Keep evaporated samples on ice until resuspension 
 
14. Resuspend in 50 µl acetonitrile and vortex for 20s. Adjust HPLC software so it takes in as 
little volume of liquid as needed 
 
15. If precipitate forms, can: ! Spin in centrifuge and carefully remove top layer for use, or ! Filter through glass wool 
 
16. Store at -20 ºC until analysis. (However samples are stable for 2-3 days at room 
temperature in amber vial) "
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was used as a detector. The eluents were degassed using helium prior to mixing, then 
passed through a SecurityGuard pre-column (Phenomenex) before reaching the 
analytical column (Spherisorb ODS2, 3 µm, 125 x 4.00 mm (Waters) embedded in the 
autosampler. A multilinear gradient was formed from solvent A (methanol) and 
solvent B (60 mM aqueous ammonium acetate solution:methanol (1:1, v/v)). The 
optimised method consisted of the following steps: 0.0 min 45% B, 20.0 min 1% B, 
20.5 min 45% B, 35.0 min 45% B (Chapter 3.2.2). The flow rate was adjusted at 0.7 
ml/min and the column was heated at 45 ºC. The detection wavelength was 354 nm. 
To calibrate the system, a mixture of the 6 retinoid standard stocks were diluted 1:10 
into the initial mobile phase solvent (90% solvent B, 10% solvent A [retinoid standard 
mixture]) and passed through a 0.45um filter before being placed into an amber auto 
sampler vial for analysis, and 10 µl injected through the HPLC system. For the 
examination of endogenous retinoids in human lung tissue, 10 µl of retinoid standard 
mixture was first injected into the machine in triplicate, followed by 2 runs of mobile 
phase to clean the machine. This was immediately followed by injection of 10 µl 
retinoid tissue extract in duplicate. The resulting chromatograms were compared to 
the standard chromatograms for identification of retinoids. An outline of the protocol 
is as follows. 
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High performance liquid chromatography (HPLC) protocol 
 
Mobile phase constituents: 
Solvent A – Methanol 
Solvent B - 60 mM aqueous ammonium acetate solution (in dd H2O):methanol (1:1 v/v)  
 
HPLC method: 
Multilinear gradient with the following steps: 0.0 min 90% B, 8.0min 45% B, 17.0min 1% B, 
41.0min 1% B and 41.5 min 90% B. Flow rate is 0.7 ml/min, and column is heated at 45 ºC 
 
Protocol: 
1) Filter solvents prior to use: filter solvent A through a 0.6 µm Teflon filter, and filter solvent 
B through a 0.6 µm nylon filter. 
2) Degas solvent A and solvent B in separate glass bottles with helium for 10 minutes prior 
to use 
3) Turn on all equipment (detector lamp take ~ 45 minutes to warm up). Set lamp to 354 
nm. Turn on computer and open ‘Galaxie’ HPLC analysis software. 
4) Feed pumps from machine into filtered mobile phase constituents  
5) Press ‘lamp’ button, and ‘series’ on autosampler 
6) Prime the solvent delivery system by passing each solvent through to remove air 
bubbles: ! Turn black valve to ‘open’ ! Press A/B/C flow and set A to 100 % with flow rate 4.5 ml/min (can be 
increased). Pass solvent through until all air bubbles in piping have been pumped 
through. ! Repeat with C set to 100 %. 
7) Switch off solvent delivery system, and turn black valve to ‘closed’ 
8) Equilibrate column (with pre-column) at initial eluent conditions (90 % solvent B) at 0.7 
ml/min for ~ 30 minutes, until pressure reading on solvent delivery system has stabilised, 
and until the absorbance measurement on the computer display has stabilised. 
9) Prepare retinoid standards by diluting stock solutions 1:10 into initial eluent (90% solvent 
B, 10% solvent A). Place into amber vials and into autosampler 
10) Set up method in Galaxie software to accommodate the multilinear gradient. 
11) Inject 10 µl of retinoid standards (either individually or in mixture) into the machine in 
triplicate to assess variability in performance. Continue to inject retinoid standards until 
resultant chromatograms appear identical 
12) Equilibrate the column for 10 minutes between runs with initial eluent 
13) To examine retinoid content of tissue extracts, inject 10 µl retinoid standard mixture into 
the machine in triplicate. Subsequently perform 2 runs with pure mobile phase to clean 
the machine 
14) Immediately inject 10 µl retinoid tissue extract in duplicate. Compare the resulting 
chromatograms to the standard chromatograms for identification of retinoids 
15) Using Galaxie software, a precise value for the elution times of the various constituents of 
retinoid standards can be obtained. Use these values to compare the elution times of the 
components of the retinoid tissue extract to identify endogenous retinoids in human 
tissue "
 129 
2.2.9 Cell culture protocols 
2.2.9.1 A549 cells 
 
A549 cells are an immortalised cell line derived from human lung alveolar cell 
carcinoma and have properties of alveolar type 2 epithelial cells (303). A549 cells 
were purchased from European Collection of Cell Cultures (cat # 86012804) and 
maintained in Dulbecco’s modified eagles medium (DMEM) supplemented with 
2mM glutamine, 10% FBS (heat inactivated), 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were maintained in culture in a humidified atmosphere of 5% 
CO2 in air at 37 ºC. Cells were passaged after reaching 95% confluence using 0.25% 
trypsin + 1mM EDTA for 5 minutes. Trypsin activity was terminated using 10% FBS 
supplemented DMEM and cells were pelleted by centrifugation for 5 minutes at 190 g 
at room temperature. Cells were resuspended in culture media, counted and seeded at 
appropriate densities in NUNC 6, 48 and 96 well microtitre plates for RNA 
extraction, scratch wound healing assay, or toxicity assay respectively.  
 
2.2.9.2 Primary human alveolar type 2 cells 
2.2.9.2.1 Tissue acquisition 
 
Primary human alveolar type 2 (hAT2) cells were isolated from lung tissue surplus to 
diagnostic requirements from pulmonary resections at the Royal Brompton and 
Harefield NHS Foundation Trust, obtained under Biomedical Research Unit (BRU) 
Advanced Lung Disease (ALD) Biobank ethics, reference number 10/H0504/9. hAT2 
cells were isolated according to the original protocol by Witherden and Tetley (304). 
The protocol is as follows. 
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2.2.9.2.2 Primary hAT2 isolation and culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following isolation, hAT2 cells were maintained in DCCM-1 (React Scientific, 
Ayrshire, UK) with 10 % NCS until day 3 (step 18). At this point media was gently 
aspirated and replaced with serum-free DCCM-1 media for cells to quiesce prior to 
wound-healing experiment. Isolated hAT2 cells were not passaged. 
ATII Isolation and Culture 
Materials: Trypsin solution (0.25% in Hanks Balanced Salt Solution), NCS, DNase, DCCM-1, 
PureCol 
Preparation: Prepare collagen coated plate 24 hrs before isolation of ATII cells. Prepare a 
1% solution of PureCol (3mg/mL collagen) in sterile filtered dd H2O and add 150 µl to each 
well (48 well plate). Evaporate dd H2O to overnight in a cell-culture hood.  
Filter defrosted trypsin, DNase and NCS (need 50ml aliquot (~20ml NCS) per piece of tissue) 
through 0.2 µm filter. Warm DCCM-1 (with Pen/Strep and Glutamine, and amphotericin B (5 
ml/L)) to room temperature. 
Protocol: 
1) Using tweezers and 50 ml syringe (with needle), pass 1 litre of sterile 0.15M NaCl 
through the tissue to remove blood and macrophages by injecting into vessels and 
airways. Gently use the blunt side of the tweezers to rub off blood and debris from the 
surface. Repeat this procedure until the perfusate runs clear, and the tissue appears 
grey/white in colour (takes about 1hr).  
2) Inject 20 ml trypsin solution into the tissue through airways/vessels and incubate at 
37 oC for 45 minutes, during which time inject a further 15 ml trypsin solution every 15 
minutes to a total of 45 ml trypsin. 
3) Remove the tissue from the incubator, aspirate trypsin solution, and inject tissue with 
4 ml NCS (stops trypsin action). 
4) Cut the tissue into small pieces and add an equal ratio of DNase and NCS (7-8ml 
each). DNase is used to degrade glutinous DNA released from ruptured cells during 
the mincing process. 
5) Continue to homogenise the tissue using the scissors, and when homogenate is 
small enough to pass into a standard Pasteur pipette, pipette the homogenate into a 
centrifuge tube. 
6) Bring the volume of the homogenate up to 40 ml using DNase and shake by hand for 
5 mins. 
7) Filter the tissue suspension into 150 ml Sterilin container using an aluminium mesh, 
then pass this filtrate through a 40 µm filter into a centrifuge tube. 
8) Centrifuge at 1300 g for 10 minutes at 20 oC. 
9) Remove the supernatant and resuspend the pellet with 40 ml of DCCM-1/DNase 
mixture (1:1). 
10) Split this solution into two T-75 flasks and incubate for 2 hours at 37 oC. Non-ATII 
cells will adhere to the flask. 
11) Collect the supernatant carefully and centrifuge at 1300 g for 10 minutes at 20 oC. 
12) Prepare 50 ml of DCCM-1 media with 10% NCS and sterile filter. Resuspend the 
pellet in 2-5 ml of this media. 
13) Dilute 10 µl of suspension to 100 µl with media. 
14) Use 10 µl of this to count the cells with a haemocytomer. If too many, can dilute with 
media. Presented is a mixed population of cells. ATII cells can be distinguished as 
spherical bodies, sharply outlined with black, and a reddish centre when the 
microscope focus is adjusted. 
15) Dilute appropriately to give a final well concentration of 300,000 cells / 0.3 ml well (48 
well plate) and incubate overnight at 37 oC. 
16) Carefully check wells next day. ATII cells should begin to selectively adhere to the 
bottom of the collagen coated plates, whereas non-ATII cells should remain in 
suspension.  
17) Gently wash after 48 hours. 
18) After a further 24 hours, serum starve in preparation for wounding on day 4. 
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2.2.9.3 Human lung microvascular endothelial cells (HLMVECs) 
 
Primary HLMVEC were purchased from either Lonza (Wokingham ,UK) or 
Promocell (Heidelberg, Germany). HLMVEC from Lonza are isolated from post 
mortem normal human lung tissue at BioWhittaker’s cell culture facility and shipped 
at passage 3. HLMVEC from Promocell are isolated from post mortem normal human 
lung tissue at Promocell’s cell culture facility and shipped at passage 3. Cells from 
both suppliers were maintained in microvascular endothelial cell growth medium-2 
(EGM-2MV, Lonza, or Endothelial Growth Medium MV2, Promocell) supplemented 
with 5% FBS and the provided growth factors and antibiotics ( 
Table 2.6). Media from Lonza and Promocell are virtually identical (except Promocell 
did not contain antibiotics) and were used interchangeably with no discernable effect 
on cellular phenotype, behaviour or growth. They were maintained in culture in a 
humidified atmosphere of 5% CO2 in air at 37 ºC. Cells were passaged when 60-70% 
confluent using Trypsin/EDTA for up to 5 minutes, until ~ 90% of cells were 
detached from the growth flask. Trypsin activity was terminated using trypsin 
neutralising solution (TNS). The cells were centrifuged at 220 g for 5 min at room 
temperature and re-suspended in culture medium. After around passage 8, cell growth 
pattern or morphology altered, at which point cells were disposed of and a new vial of 
lower-passage cells thawed. Cells were used at passage 3-8 for all experiments. 
Component	   Volume	  (ml)	  
Human	  recombinant	  epidermal	  growth	  factor	  (hEGF)	   0.5	  
Vascular	  endothelial	  growth	  factor	  165	  (VEGF165)	   0.5	  
Human	  fibroblast	  growth	  factor-­‐basic	  (hFGF-­‐b)	   2.0	  
Human	  recombinant	  insulin-­‐like	  growth	  factor-­‐1	  (R3-­‐IGF-­‐1)	   0.5	  
Ascorbic	  Acid	   0.5	  
GA-­‐1000	  (Gentamycin	  and	  amphotericin)	   0.5	  
Hydrocortisone	  *	   0.2	  
Foetal	  Bovine	  Serum	  *	   25	  
 
Table 2.6 Growth factors and supplements added to microvascular endothelial 
growth medium for HLMVEC culture 
Lonza and Promocell microvascular endothelial cell culture media contained the same 
supplements, except Promocell media did not contain antibiotics. * Hydrocortisone 
and foetal bovine serum were removed for angiogenesis experiments. 
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2.2.9.4 Cell seeding densities (cells per cm2) 
 
Table 2.7 summarises the cell seeding densities for each cell type according to plate 
format, unless otherwise stated in the specific methods for each chapter. 
 
Table 2.7 Seeding densities for each cell type according to well format 
Presented as cells per cm2. * Density of crude cell suspension prior to hAT2 
adherence to well. Abbreviations: N/A, not applicable; HLMVEC, human lung 
microvascular endothelial cells; hAT2, primary human alveolar type 2 cells. 
 
 
2.2.10 In vitro cell assays 
2.2.10.1 Scratch assay 
2.2.10.1.1 Principle 
 
The scratch assay is an in vitro model used to assess the molecular and cellular 
processes involved in the repair of a scratch wound to a monolayer (305). A linear 
scratch wound is manually generated on a cell monolayer with a P200 pipette tip, 
inducing a repair response whereby the cells surrounding the wound migrate inwards 
to cover the denudated area. The technique is widely used for the study of cellular 
migration in diverse cell types, due to its relative simplicity and inexpensiveness, and 
as a multi-well plate format is often used many treatment conditions can be examined 
simultaneously. A summary of the technique is presented in Figure 2.7. The assay 
relies on acquiring photographs of exactly the same region of scratch at the beginning 
and end of the assay to minimise confounding effects of variability in shape of the 
scratch along its axis. This is facilitated by the generation of a groove on the 
underside of the plate with a scalpel. The point at which the groove on the underside 
96 well plate 48 well plate 24 well plate 6 well plate µ-slide (Ibidi)
(x104) (x104) (x105) (x105) (x104)
Surface area: 0.32 cm2 0.75 cm2 2 cm2 9.6 cm2 0.196 cm2 
A549 1.0-1.5 3.5-3.8 0.9-1.0 4.5-5.0 N/A
HLMVEC 0.32 N/A N/A 1 2.15
hAT2 N/A 40.0 * N/A N/A N/A
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of the plate and the scratch on the monolayer intersect serve as a reference point for 
photograph acquisition. 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Outline of the scratch wound healing assay.  
Abbreviations: FBS, foetal bovine serum 
 
2.2.10.1.2 Scratch wound healing assay protocol 
 
 A549 cells (3.5 x 3.8 104 cells per ml) in 0.3 ml of culture media were seeded in 
complete medium into wells of a 48-well plate. Cells were grown to confluence over 
24 hours, after which they were serum starved in serum-free medium for 2-24 hours. 
Following this, media were aspirated, and a single linear scratch was generated on the 
monolayer using a P200 pipette tip. Monolayers were immediately washed twice with 
PBS to remove cell debris, and 1 ml complete medium containing appropriate 
concentrations of treatment were added to each well. Wells were immediately 
examined under a phase contrast microscope (with camera attached) at 10 x 
magnification, and an image taken at the point where the scratch intersected with the 
groove underneath the plate. Plates were incubated at 37 ºC for 16 – 24 hours until the 
positive control (10% FBS) had nearly, but not completely, closed. Wells were then 
examined and an image taken at the same point where the scratch intersected with the 
P200 
pipette tip 
 
Cell monolayer in culture 
Linear scratch generated 
on monolayer surface 
Groove on 
underside 
of plate Image 
Image 
Scratch closes with time 
 (16 – 20 hours in 10 % 
FBS) 
 
Time = 0 
hours 
Time = 16-20 
hours 
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groove underneath the plate. Images were analysed in Image J and the area covered 
by the cells during the assay was calculated with Excel. 
 
 
 
 
2.2.10.2 Matrigel-based angiogenesis assay 
2.2.10.2.1 Principle 
 
Scratch wound healing assay protocol 
 
Preparation: Using a scalpel blade, lightly etch a straight line along the diameter of each well on 
the underside of a 48 well plate.  
 
Media: ‘Complete’ media: DMEM, 100 U/ml penicillin and 100 µg/ml streptomycin, 2mM 
Glutamine, 10% FBS. ‘Serum free’ media: DMEM, 5ml Pen/Strep, 5ml Glutamate (no FBS). Add 
treatment to media prior to addition to wells. 
 
Protocol: 
1.) For 48 well plate, add 3.5 - 3.8x104 cells in 0.3 ml ‘complete’ medium to each well.  
 
2.)  Shake plate gently forwards and backwards and from side to side, to make sure cells are 
evenly distributed in the well.  
 
3.) Leave for 24 hours for cells to attach to bottom of well, and grow into a confluent 
monolayer. Cells need to be completely confluent for scratch wounding. 
 
4.) Serum starve cells before assay: 24 hours after seeding (or when confluent), remove 
media from all wells (including +ve control), wash with PBS, then add 0.3 ml serum free 
medium. 
 5.) After 2- 12hours, create scratch on monolayer using sharp end of p200 pipette tip, 
perpendicular to the line etched into the underside of the wells. The intersection between 
scratch and scalpel etch serves as point of reference when observing wound closure.$$
 
6.) Aspirate media, and wash debris away with PBS twice. It is essential to remove all debris 
and floating cells, as they can reattach in the middle of the wound, which, later during the 
analysis, are indistinguishable from migrated cells. 
 
7.) Refill wells with 0.3 ml appropriate media. Put experimental media into each of the wells 
at this point. 
 
8.) Take a photo of the wound at the scalpel etch intersection at 10x magnification. 
 
9.) After 16 – 20 hours, take photos of all wells at the scalpel etch intersection at 10x 
magnification 
 
10.) Use Image J to quantify area of wound closure. 
 
11.) Export pixel counts to Excel. Quantify wound closure by subtracting final count from 
original count. 
 $
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The Matrigel-based angiogenesis assay is an in vitro model system in which 
endothelial cells are seeded onto a gelled basement membrane extract, Matrigel, after 
which they settle and spontaneously form into a network of capillary-like tubules with 
a central lumen (306). The assay is a widely used model with which to identify 
inhibitors or stimulators of angiogenesis, as well as genes and signalling pathways 
involved in angiogenesis. The assay involves a complex series of events including 
endothelial cell adhesion, migration, protease activity and capillary formation. The 
Matrigel-based angiogenesis assay was used in this thesis to investigate the effect of 
RA pathway modulation on the capillary formation of HLMVECs. An outline of the 
experiment is provided in Figure 2.8. The angiogenesis assays in this thesis used 
Matrigel as the basement membrane substrate, although other substrates can be used 
such as fibrin (307). Matrigel is advantageous over alternative substrates as it is 
composed of basement membrane constituents, which is the natural substrate for 
endothelial cells in vivo (306). Furthermore, tube formation on Matrigel occurs within 
4 hours, compared to up to several weeks with alternative substrates (306). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Outline of the Matrigel-based angiogenesis assay 
2.2.10.2.2 Measuring angiogenesis - Quantifying tube length 
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In the published literature, various features of the capillary network have been used to 
quantify extent of angiogenesis, such as total length of tubes, number of branching 
points, tube number, length of individual tubes, or a combination of these (308). We 
used total tube length per field of view as it is easy and rapid to quantify with image 
analysis software (Image J), and has been widely used to measure the effects of 
angiogenic factors on angiogenesis, including the effect of ATRA on human 
umbilical vein endothelial cells (HUVECs) (309, 310). Furthermore, total tube length 
is more objective a measure than length of individual tubes or tube number, as it does 
not require a decision about where an individual tube begins or ends, which can be 
subjective as tubes are often connected to each other. As previously described by Park 
et al (311), we defined a “tube” as a linear structure between two or more discrete 
endothelial cells. Tube length was measured with Image J analysis software, by 
drawing a line along each tube using the ‘freehand line tool’ and measuring the length 
of the lines in pixels (Figure	  2.9), as previously described (312).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 - Quantification of tube length using Image J analysis software 
 
HLMVECs seeded on solidified Matrigel in angiogenesis µ-slides (Ibidi) were 
incubated for 4 hours at 37 ºC. Following this, digital images were acquired (A) and 
exported to Image J, where the freehand line tool was used to trace over the length of 
tubes (B). 
 
 
2.2.10.2.3 Matrigel-based angiogenesis assay protocol 
 
A B 
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The assay medium for angiogenesis experiments was EGM2-MV (Lonza) or 
Endothelial Growth Medium MV2 (Promocell), containing all provided supplements 
except hydrocortisone and FBS. Prior to assay, Matrigel (growth factor reduced, BD 
Biosciences) was thawed on ice and diluted 1:1 with ice-cold assay medium. 10 µl 
diluted Matrigel was transferred to the inner wells of a µ-slide Angiogenesis (Ibidi) 
and allowed to solidify at 37 ºC for 1 hour. HLMVECs were trypsinised for up to 5 
minutes, after which the trypsin was neutralised with TNS. Following this, cells were 
pelleted at 190 g for 5 minutes, and the pellet resuspended in room temperature assay 
medium. Cells were counted with a haemocytometer, and further diluted in an 
appropriate volume of assay medium to a concentration of 200,000 cells per ml (2x 
final assay concentration). In parallel, treatments were diluted in assay medium to 2x 
final assay concentration. Subsequently, 100 µl 2x cell suspension and 100 µl 2x 
assay medium were combined to yield 200 µl cell/treatment media mixture at the 
appropriate concentration for the assay. 50 µl of cell/treatment media mixture was 
carefully transferred into each well in triplicate. Slides were immediately incubated in 
humidified air containing 5% CO2 at 37 ºC for 4 hours. Following this, each well was 
examined under a phase contrast microscope and digital images acquired. Either of 
two methods for analysing tube networks was used. 3 non-overlapping images were 
taken per well at 10 x magnification, total tube length per field of view measured with 
Image J, and the mean tube length of 3 images calculated. Alternatively, 1 image was 
taken of the whole well at 4 x magnification, and total tube length per well quantified 
with Image J. The analysis method used for each experiment is described in the 
specific methods. An outline of the protocol follows. 
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2.2.11 Precision cut lung slices (PCLS) 
 
2.2.11.1.1 Principle 
 
Precision cut lung slices (PCLS) is a model system in which lung tissue is processed 
into small discs of defined diameter and thickness, which are then maintained in 
culture. The PCLS in this thesis used tissue derived from whole human lungs obtained 
from America. A diagram of the tissue acquisition process is presented in Figure 2.10 
. As indicated, there were 2 periods of cold ischemia between the death of the donor 
and the generation of PCLS. 
 
Whole human lungs unfit for transplantation from non-heart beating donors which 
met selection criteria (Table 2.8) were obtained via a contract established with the 
International Institution for the Advancement of Medicine (IIAM) in the USA 
together with the Tissue Governance Manager at our institution, ensuring compliance 
with The Human Tissue Act (HTA 2004) code of practice relating to the import and 
export of human bodies, body parts and tissue. Information was anonymised but 
demographic data and donor medical history were provided. Approval by the National 
Research Ethics Service was not deemed necessary as our proposed study did not 
involve NHS patients. Lungs were cooled in situ with 50 ml/kg 4 ºC preservation 
solution, consisting of Perfadex (Vitrolife, Sweden) supplemented with 20,000 IU 
heparin (LEO Laboratories, Denmark), 3 ml THAM (Northwick Park Hospital, UK), 
0.6 ml calcium chloride (Martindale Pharmaceuticals, UK) and 8 ml glyceryltrinitrate 
(Hameln pharma, Germany). Lungs were transferred in 1 litre of preservation solution 
on ice by airfreight to the intensive care unit (ICU) of Royal Brompton and Harefield 
Trust (RBHT), London, England. The cold ischaemic time between organ 
procurement and arrival at ICU, RBHT was a maximum of 36 hours, as stipulated in 
the contract to improve the quality of donor lungs, and constitutes the first period of 
cold ischemia – the mean cold ischaemic time during this period was 34 ± 4 hours (Dr 
Alastair Proudfoot, personal communication). Once at ICU, lungs were immediately 
connected to ex-vivo lung perfusion (EVLP) and sustained for 8 hours. Following 
EVLP, the right-middle lobe was surgically excised and placed in storage buffer 
overnight for processing into PCLS the following day, which constitutes the second 
period of cold ischemia – a maximum of 12 hours. 
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Table 2.8 Donor criteria for ex vivo human lungs  
Courtesy of Dr Alastair Proudfoot. Abbreviations: HBsAb, Hepatitis B surface 
antibody; EBV, Epstein Barr virus; CMV, cytomegalovirus; PA, pulmonary artery; 
MRSA, Methicillin-resistant Staphylococcus aureus 
 
 
 
 
 
 
 
 
Table 2.9 Clinical characteristics of accepted lungs for EVLP (n=10) 
Courtesy of Dr Alastair Proudfoot 
 
 
In addition, some experiments used porcine PCLS generated from whole pig lungs. 
Pig lungs were obtained from a local abbattoir where pigs are treated according to 
European Union legislation guidelines. The trachea was cannulated, the lungs gently 
inflated several times with room air, and the trachea clamped in inflation. The main 
!
Clinical variable Criteria 
Age 16 - 65 years 
Smoking history Smokers or non-smokers 
Cold Ischaemic Time <36 hours 
Warm Ischaemic Time (if donation 
after cardiac death) 
< 1 hour from cross-clamp time 
Serology HIV, HBsAb, EBV, CMV negative 
Bacteriology Sputum culture –ve, MRSA -ve 
Time on ventilator <10 days 
Radiology Absence of dense consolidation Diffuse shadowing 
consistent with pulmonary oedema or ALI 
Oxygenation PaO2:FiO2 ratio >200mmHg 
Anatomical Adequate PA cuff or trachea 
Absence of lung contusions or haemorrhage or 
persistent pneumothorax 
Clinical'Characteristics Results
Age$(years) 54±13
Male/Female$(%) 60/40
PaO2:FiO2$ratio$on$acceptance$of$lungs 370±221
Total$cold$ischaemic$time$(hrs) 34±4
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pulmonary artery (PA) was cannulated and flushed with 2 litres of 4 °C preservation 
solution. Lungs were transported in 1 litre of preservation solution surrounded by 
crushed ice to ICU, RBHT. The EVLP conditions, and subsequent steps to generation 
of PCLS, were identical to that used for human lungs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Schematic representation of human donor lung procurement 
Abbreviations: ICU, intensive care unit; EVLP, ex-vivo lung perfusion. 
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2.2.11.1.2 EVLP Principle 
 
Human EVLP is a technique in which whole lungs are ventilated ex-vivo at low tidal 
volume with atmospheric gas, and the vascular system perfused with a blood-
substitute for extended periods of time. The aim of EVLP is to sustain the lungs in a 
physiological state, during which time various physiological and biochemical 
measurements can be made. It was originally used to assess the quality of lungs 
obtained from non-heart-beating donors (313), and has since been used to recondition 
high-risk lungs into a suitable state for clinical transplantation, potentially increasing 
the pool of donor lungs available for transplant (314). Current work in our group 
focuses on applying the EVLP system as a means of sustaining human lungs unfit for 
transplantation under normothermic physiological conditions (315) with the aim to 
developing an experimental ex-vivo model of human acute lung injury (ALI). EVLP 
was performed by Dr Alastair Proudfoot, in the ICU, RBHT. The basic principle of 
EVLP is summarised in Figure 2.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Schematic representation of the EVLP setup  
Courtesy of Dr Alastair Proudfoot 
Ven$lator*
Pulmonary*Vein*
Reservoir*
Centrifugal*
pump*
Flow*
Probe*
Oxygenator*
Pulmonary*Artery*
Heater/*
Cooler*
Trachea*&*Bronchi*
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2.2.11.1.3 EVLP Method 
 
Once lungs arrived at ICU, they were inspected for contusions, and suitability for 
connection to EVLP circuit: at least 2cm of main pulmonary artery (PA), a left atrial 
cuff (closed system) or intact pulmonary venous drainage, and at least 5 cm of 
trachea. Then, the main PA was cannulated (Vivoline, Sweden) and the left atrium 
cannulated with a conical cannula (Vitrolife, Sweden, closed system), or the 
pulmonary veins were left open to air (open system). The trachea was cannulated with 
an endotracheal tube and secured with 2.0 silk. The lungs were transferred to the 
perfusion container (Vivoline, Sweden) and connected to the perfusion circuit and 
ventilator. The perfusion circuit (Maquet, Germany) was connected to an 
ECMOtherm II heat exchanger (Medtronic, USA). A paediatric nasogastric tube was 
inserted via a side-port into the PA cannula and connected to a pressure transducer to 
allow continuous PA pressure monitoring. The circuit was de-aired with 1.35 litres 
perfusion solution (high glucose DMEM containing 5% human albumin solution). 
Perfusion was started at the highest flow rate that maintained PA pressure at less than 
15 mmHg, to avoid hydrostatic damage. Following re-warming to 37 °C, ventilation 
was commenced (Evita XL, Drager, Germany) with settings as follows: tidal volume 
300mL, respiratory rate 10/min, positive end-expiratory pressure 8 cm water and 
fraction of inspired oxygen 0.21. Perfusate flow rate was increased incrementally to a 
target of 0.8 litres per minute without exceeding a target PA pressure of 15 mmHg. In 
experiments using a closed system, the left atrial pressure was maintained at less than 
5mmHg by adjusting the height of the reservoir. In experiments, using an open 
system, the pulmonary veins were left open to air and assumed to have a pressure of 0 
mmHg.  
 
Lungs were maintained on EVLP for 8 hours. During this time, physiological 
parameters including PA pressure, perfusate flow rate, dynamic compliance and peak 
airway pressure were measured at 1 hourly intervals. Pressures were measured with 
standard pressure monitoring equipment (Edwards Lifesciences, USA), flow rate was 
measured with an ultrasonic flow probe (Maquet, USA), and compliance and airway 
pressure measurements were recorded continuously from the ventilator (Evita XL, 
Drager, Germany). Pulmonary vascular resistance and lung compliance remained 
stable for the duration of EVLP (Dr Alastair Proudfoot, personal communication). 
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Biopsies taken before EVLP and after 8 hours EVLP were examined by a pulmonary 
pathologist blinded to experimental conditions, and revealed no histological evidence 
of lung injury (Dr Alastair Proudfoot, personal communication). 
 
After EVLP, the right middle lobe was surgically excised at the parent bronchus and 
immediately placed in storage buffer (HBSS with 100 U/ml penicillin and 100 µg/ml 
streptomycin) and stored for a maximum of 12 hours at 4 ºC until PCLS generation 
the following morning. This overnight storage accounts for the second period of cold 
ischemia. Previous reports have demonstrated no adverse effects of cold overnight 
storage of human lung tissue in buffer when compared with tissue immediately 
processed into slices (316).  
 
2.2.11.2 Lung slice protocols 
 
PCLS were generated from agarose-inflated right middle or lingular lobes derived 
from human lungs post-EVLP, or intermediate lobe derived from porcine lungs post-
EVLP. PCLS were generated using a Krumdieck Tissue Slice (Alabama Research and 
Development, USA) at 4 ºC. Immediately after slicing, PCLS were transferred into 
12-well culture plates containing 1 ml culture medium per well. Slices were then 
washed, and maintained in a cell-culture incubator at 37 ºC in humidified air 
containing 5% CO2.  
 
2.2.11.2.1 Materials and media: 
 
• Sterile, cell-culture grade 12-well multiwell plates (Nunc) 
• Storage buffer: HBSS containing 100 U/ml penicillin, 100 µg/ml streptomycin 
• Slicing buffer: HBSS containing 100 U/ml penicillin, 100 µg/ml streptomycin 
• For agarose inflation injection method: low-temperature gelling agarose (Sigma) 
dissolved in HBSS at 3% w/v, cooled to 37 ºC overnight in water-bath 
• For agarose inflation instillation method: low-temperature gelling agarose 
(Sigma) dissolved in HBSS at 2% w/v, cooled to 37 ºC overnight in water-bath 
• Culture media: RPMI-1640 (Sigma) supplemented with 4 mM glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin, 1.25 µg/ml Amphotericin B, 50 µg/ml 
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vancomycin, 20 µg/ml gentamycin. The same media was used for human and 
porcine PCLS, with the exception that some experiments with porcine PCLS used 
culture media supplemented with 10 % FBS. 
 
2.2.11.3 Human PCLS protocol 
2.2.11.3.1 Agarose inflation protocol (Injection method) 
 
Prior to this project, a closely affiliated laboratory (Department of Gene Therapy, 
Imperial College London) used an injection method to inflate lung tissue with molten 
3% agarose according to a previously published protocol (316). Use of this method 
was necessary due to their source of tissue being resected lung specimens with only 
partially intact visceral membranes, resulting in leakage of agarose of lower 
concentrations. Injection of agarose allows continual introduction of molten agarose 
deep within the tissue. We applied this method for lung tissue from one donor (donor 
6), as it was a resected lung tissue specimen with a partially intact visceral membrane. 
The protocol is as follows. 
 
 
 
 
 
2.2.11.3.2 Agarose inflation protocol (Instillation method) 
 
A disadvantage of the injection method is the inability to regulate the instillation 
pressure, which may give rise to overdistention of alveoli resulting in tissue damage 
(317). As our source of tissue was whole human lungs, from which we could obtain 
Inflating with agarose (Injection method): 
1.) Place lobe on cutting tray filled with ice. 
2.) Locate main airway, and insert plastic cannula into it. 
3.) Remove pump from 50ml plastic syringe, and attach to cannula.  
4.) Pour 37 ºC molten agarose into syringe, replace pump, and gently inflate lobe at ~ 2ml per 
second. 
5.) Keep slowly pumping agarose into lobe, filling up syringe when empty, until roughly 4ml 
agarose per gram of lobe has been used, or until lobe feels fully inflated. 
6.) Quickly clamp airway to prevent agarose leaking out. 
7.) Leave inflated lobe in cold room for 1-2 hours, until agarose has solidified. !
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the entire right middle lobe with a complete parent bronchus and intact visceral 
membrane, where possible we were able to instil the lobe with molten agarose using a 
gravity perfusion apparatus according to the original protocol by Placke & Fisher 
(318), which we adapted for human lung (Figure 2.12). The agarose inflation protocol 
using the instillation method is as follows.  
 
 
2.2.11.3.3 Processing inflated lobe into cores: 
 
Following solidification of agarose, the lobe was processed into cores for subsequent 
PCLS generation. The following procedure was performed at 4 ºC. The agarose-
inflated lobe was cut into serial sections roughly 2 cm thick using a sharp microtome 
blade, from periphery of lobe inwards. The surfaces of each section were carefully 
inspected to identify alveolar regions (with minimal airways, vessels, and connective 
tissue). A weighted coring tool 8 mm in diameter (Alabama Research & 
Development) was used to take cylindrical cores from predominantly alveolar regions 
of tissue (Figure 2.13). For cilia beating experiments, cores with a small airway (< 1 
mm) in the centre. Cores were immediately placed into ice cold slicing buffer prior to 
PCLS generation.  
 
Inflating lung tissue with agarose (Instillation method): 
 
1) Place whole lobe on ice. 
2) Attach a large sterile syringe without plunger with flanges facing upwards to a standard 
laboratory clamp, and position above the lobe.  
3) Firmly attach a sterilized silicone hose to the basal opening of the syringe.  
4) Slowly pour 37 ºC molten agarose into the syringe and allow to travel into the hose until 
no air remains, and clamp the end of the hose to prevent leakage 
5) Cannulate the silicon hose into the parent bronchus of the lobe, and release the hose 
clamp to allow instillation of agarose.  
6) Instil roughly 800 - 900 ml of agarose solution per lobe.  
7) Maintain the level of the agarose solution at 20 cm above the lobe for the duration of the 
instillation to sustain a constant transpulmonary hydrostatic pressure, with the aim of 
preventing over-distention and baro-trauma to the alveolar regions of the lobe.  
8) Once the lobe is inflated to vital capacity, the elastic recoil of the lobe should prevent any 
further instillation. At this point, clamp the parent bronchus to prevent leakage of agarose.  
9) Place the inflated lobe immediately on a tray on ice and allow to solidify for 1 hour at 4 
ºC.  !
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2.2.11.3.4 Protocol for generating PCLS with Krumdieck Tissue Slicer: 
 
Tissue cores were cut into 500 µm thick slices by a Krumdieck tissue slicer (Alabama 
Research & Development) filled with 4 ºC slicing buffer, according to the method of 
Stefaniak et al. (319) (Figure 2.14). The slices were transferred into 1 ml culture 
media in 12-well plates, and immediately inspected under a microscope to ensure 
acceptable intactness of slice. The slicing protocol is outlined below. 
 
 
 
2.2.11.3.5 Washing and culturing slices: 
 
After slices are generated, it is important to remove cellular debris and pro-
inflammatory cytokines generated by the slicing procedure (317). Initially after 
slicing, PCLS were each washed with 1ml culture media 9 times over the course of 3 
hours, and then allowed to stabilize overnight in 1ml media each in 12-well plates. 
The next morning culture media was refreshed, at which point the experiment was 
considered initiated (day 1). PCLS were cultured with a rotating multiwell plate 
system adapted from the method of Dogterom (320). Multiwell plates were housed 
over the duration of the experiment in a modified stand which rotated the plates (1 
RPM) at a 40o angle in a humidified incubator at 37 ºC (5% CO2, 95% ambient air) 
(Figure 2.15). The rotating stand aids in preventing the buildup of a chemical 
gradient, while ensuring oxygenation of PCLS (317). Culture media was refreshed 
Generating lung slices with Krumdieck vibratome: 
1.)   Assemble slicing microtome according to instructions 
2.)   Fill slicing machine with slicing buffer 
3.)   Insert a core into the microtome, and replace the weight on top 
4.)   Set thickness to 500 µm (each turn of dial is 200 µm, so 2.5 turns) 
5.)   Turn microtome on 
6.)   Set blade mode to ‘intermittent’ 
7.)   Set speed to ~ 12 
8.)   Make sure switch is on ‘cycles’ and not ‘>1’ 
9.)   Turn switch to ‘on’ to begin slicing 
10.)  Discard first slice as edge may be rough 
11.)  Transfer slices, to wells of a 12-well tissue culture plate containing 1ml culture media. 
12.)  Check integrity of slices under microscope, and discard if slices are broken !
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every 2 days after the beginning of the experiment. Every effort was made to maintain 
a sterile environment for the duration of the slice culture. 
 
2.2.11.3.6 Porcine PCLS generation 
 
Porcine pigs were sustained on EVLP under the same conditions as human lungs. 
Following EVLP, the intermediate lobe was excised and placed in storage buffer 
overnight at 4ºC. The next morning, the lobe was inflated with molten 37 ºC low-
temperature gelling agarose using the installation method. Subsequently, porcine 
PCLS were generated and washed with the same method used for human PCLS 
described above. As with human PCLS, the final media refreshment the morning after 
the slicing was considered the initiation of the experiment (day 1). Plates were housed 
in identical conditions to human PCLS over the duration of the experiment in a 
modified stand, which rotated the plates (1 RPM) at a 40o angle in a humidified 
incubator at 37oC (5% CO2, 95% ambient air). 
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Figure 2.12 Instillation of human lobe with 2 % w/v low-temperature gelling 
agarose using a gravity perfusion apparatus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 Sectioning of inflated lobe, and taking cores 8mm diameter 
A) Agarose inflated lobs were cut into serial sections ~2cm thick. B) A sharp coring 
tool was used to make 8mm diameter cores 8mm. Cores were transferred to the 
Krumdieck Tissue Slicer for generation of PCLS. 
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Figure 2.14 Krumdieck Tissue Slicer 
A) The Krumdieck Tissue Slicer is filled with 4 ºC slicing buffer (not shown), which 
fills the glass vessel into which freshly cut PCLS emerge. B) Top-down view of the 
Tissue Slicer (without slicing buffer). Tissue cores are immobilised within a 
cylindrical sheath and a weight placed on top. 2 motors contribute to the Tissue 
Slicer’s function. The first moves the tissue core repeatedly into contact with the 
blade at an adjustable speed (yellow arrow). The second vibrates the blade 
perpendicular to the motion of the tissue core (green arrow). During the slicing 
procedure, the freshly cut slices are swept into the glass vessel (represented by dotted 
black line), where they float in slicing buffer until retrieval. 
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Figure 2.15 Incubation of lung slices 
A) A complete, freshly cut PCLS in culture media, of 8mm diameter and 500 µm 
thickness. B) PCLS are cultured in multiwell plates housed in a rotating stand (1 
RPM) at a 40º angle in a humidified incubator (5% CO2, 95% ambient air). C) A 
Human PCLS at 4x magnification. An alveolar region with a small airway is shown. 
 
 
 
A 
B 
C 
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2.2.12 Cell/tissue viability assays 
 
2.2.12.1 MTT  
 
MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) is a yellow 
tetrazolium dye that is reduced into purple formazan within metabolically active cells. 
The cellular mechanism of MTT reduction involves a reaction with NADH or similar 
reducing molecules which transfer electrons to MTT, catalysed by cellular reductases 
(321). The formazan product accumulates intracellularly as an insoluble precipitate, 
and thus must be solubilized before it can be quantified spectrophotometrically. When 
cells die, they lose the ability to convert MTT into formazan, thus formation of colour 
indicates cell viability. In a homogeneous cell population, the amount of formazan 
generated is directly proportional to the number of viable cells over a wide range. 
MTT was used to determine the toxicity of treatments in A549 cells. After treatments, 
supernatants were removed, cells washed with buffer and incubated at 37°C with 1 
mg/ml MTT in medium for 15 minutes (optimised previously in our lab for A549 
cells). Following incubation, MTT solution was removed completely and the plates 
dried. Formazan dye was dissolved in DMSO for 15 minutes and the absorption 
measured at 550nm. The protocol is as follows. 
 
 
 
MTT assay protocol (A549 cells) 
 
Reagents: MTT working solution: 1 mg/ml MTT in pre-warmed cell culture medium; 
Dimethylsulphoxide (DMSO) 
 
Protocol: 
1) Aspirate supernatants 
 
2) Add 100 µl of MTT working solution per well on a 96 well plate 
 
3) Incubate at 37 ºC for 15 minutes 
 
4) Remove MTT working solution completely and leave the plate to dry 
 
5) Add 100 µl of DMSO per well, and place plate on plate shaker for 10 minutes until the 
formazan has completely dissolved 
 
6) Read at 550 nm OD 
!
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2.2.12.2 WST-1 
 
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate) is a water soluble tetrazolium salt which is reduced to a bright yellow 
water-soluble formazan product at the extracellular membrane of metabolically active 
cells. WST-1 is reduced via a mechanism dependent on the glycolytic production of 
NADH in viable cells (322), and has been extensively used to investigate cellular 
viability and proliferation in culture (321). WST-1 is advantageous over MTT in that 
the formazan product does not have to be solubilised with DMSO, and thus following 
WST-1 incubation, the supernatant can be directly measured spectrophotometrically 
to give an indication of cell viability.  WST-1 was used in this thesis to investigate the 
toxicity of drug compounds in HLMVECs, and to assess the viability of PCLS. After 
drug treatments or at the appropriate time points, supernatants were removed, the cells 
or PCLS washed with buffer, and then incubated in a rotating incubator at 1 RPM at 
37°C with WST-1 diluted 1:10 in medium for 2 hours for HLMVEC, or 4 hours for 
PCLS. Following incubation, the supernatants were transferred to individual 
microcentrifuge tubes and centrifuged at ≥ 8,000 g for 2 minutes to remove cell 
debris. The supernatants were transferred to optically clear 96-well plates in triplicate 
and the absorption measured at 450 nm. The protocol is as follows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WST-1 assay protocol (LHMVEC and PCLS) 
Reagents: WST-1 working solution: 1:10 dilution of WST-1 in pre-warmed cell culture media 
Protocol: 
1) Aspirate supernatants 
 
2) Add appropriate volume of WST-1 working solution (100 µl to 96 well plate [LHMVEC], 1 
ml to 12-well plate [PCLS]). 
 
3) Incubate at 37 ºC for 
 ! LHMVEC    2 hours ! PCLS          4 hours 
 
4) Remove WST-1 working solution supernatant and transfer to individual microcentrifuge 
tubes 
 
5) Centrifuge at ≥ 8,000 g for 5 minutes to remove cell debris 
 
6) Transfer 100 µl supernatant to each well of optically clear 96-well plate. Perform in 
triplicate. 
 
7) Read at 450 nm OD "
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2.2.12.3 Precision cut lung slice (PCLS) viability assays 
 
2.2.12.3.1 Lactate dehydrogenase release 
 
Lactate dehydrogenase (LDH) is a cytosolic enzyme which is released into the 
supernatant after loss of cellular membrane integrity, and is a widely used marker of 
cell death for in vitro cell culture studies (323). The LDH assay was used in this thesis 
to assess the viability of PCLS over time in culture. The activity of released LDH was 
measured with the use of Cytotoxicity Detection Kit (LDH) (Roche). PCLS 
supernatant was removed, and incubated with the provided tetrazolium salt substrate 
mixture. This allows a coupled enzymatic reaction to proceed in which the LDH 
present generates a water-soluble formazan dye, which can be quantified by its 
absorbance at 500 nm. A protocol for the LDH assay is outlined below. 
 
 
 
 
 
 
 
 
!
LDH assay protocol 
 
Reagents: Reconstitute the lyophilisate (Catalyst, bottle 1) in 1 ml double dist. water for 10 min 
and mix thoroughly. Dye solution (bottle 2) is ready to use. Reaction mixture for 100 tests: Shortly 
before use, mix 250 µl of bottle 1 with 11.25 ml of bottle 2. 
 
Protocol: 
1) Transfer 1 ml supernatant to labelled 1.5 ml microcentrifuge tube. Immediately add fresh, 
warm media back to the slice and return to incubator. 
 
2) Centrifuge supernatant at ≥ 12,000 g to remove cell debris  
 
3) Transfer supernatant into fresh tubes. This media can be stored for several days at ~4oC  
 
4) Transfer 100 µl supernatant per well into corresponding wells of an optically clear 96-well 
plate. Perform in triplicate 
 
5) Add 100 µl Reaction mixture (freshly prepared) to each well and incubate for 30 minutes 
at room temperature. During incubation period the plate should be protected from light 
(wrap in foil and/or put in drawer)  
 
6) Measure absorbance in a plate reader at 490 nm. 
 !
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2.2.12.3.2 Cilia beating assay 
 
Airway epithelial cells possess motile cilia, which are slender organelles that project 
from the apical surface of the cells into the airway lumen, and which beat in 
coordinated waves. Ciliary beating is dependent on ATP hydrolysis (324), and 
therefore measuring the proportion of the airway luminal surface covered by beating 
cilia be used as an indicator of PCLS airway metabolic activity (325). An advantage 
of the assay is that the PCLS are maintained after measurement, allowing longitudinal 
measurements to be taken from each PCLS. Slices used for the assay must contain a 
small airway (<1 mm). Therefore during the slicing procedure prior to coring, the 2cm 
sections of tissue were inspected for presence of small airways, and cores were taken 
to include an airway in the centre. Freshly generated PCLS transferred to multiwell 
plates were immediately inspected under a phase contrast microscope to ensure the 
airway was intact. Where possible, the airways of up to 6 individual slices per each 
time point were microscopically examined for ciliary beating in the epithelial-luminal 
border. Ciliary beating was calculated in Photoshop CS3 (Adobe) as a proportion of 
the total circumference of the airway lumen. The protocol is outlined below. 
PCLS cilia beating protocol 
1. During the PCLS generation, at the stage where cores are made, carefully examine the 
surface of the 1 cm thick agarose-inflated lung tissue sections for small airways (<1 mm 
diameter). Take cores with small airways in centre 
2. Proceed with PCLS generation. If possible, make 6 slices containing different small 
airways in centre of slice. Transfer to individual labelled wells 
3. Examine under microscope for intact airways 
4. Wash and incubate PCLS overnight 
5. Next morning, take PCLS with airways to be examined out of incubator. Allow to warm to 
room temperature for 5 minutes 
6. Examine airways under a phase contrast microscope (with camera attached) at an 
appropriate magnification which allows cilia beating to be visible, while allowing as much 
of airway as possible to be contained in field of view (usually 20x) 
7. Take a photo of the field of view containing airway. Export the photo to a computer and 
save – these photos will be used later for the analysis. Print out the photo in a word doc 
8. Find the same field of view of the airway as was printed out. Examine airway through 
microscope for cilia beating, and mark these regions on the printout. 
9. Repeat for all slices containing airways to be examined. Afterwards, return each PCLS 
plate to the incubator 
 
Photo analysis protocol: 
1. Open Photoshop version CS3 
2. Select ‘File’  !  ‘New’  !  ‘File’  
3. Import photograph of PCLS airway 
4. Select ‘Merge down’ (right click on thumbnail) so this is now the “background” 
5. Select ‘Image’ ! ‘Adjustments’ ! ‘Desaturate’ 
6. Select ‘Layer’ ! ‘New’ ! ‘Layer’  ! ‘OK’. Don’t check ‘clipping mask’  
7. For the image ‘Layer 1’, in RHS toolbar, change the colour value to: red 253, Green 0, 
Blue 0 
8. Select brush tool and trace round the entire airway in red 
9. Select ‘Layer’ ! ‘New’ ! ‘Layer’ ! ‘OK’. Check ‘clipping mask’ 
10. For the image ‘Layer 2’, in RHS toolbar, change colour values to Red 0, Green 253, Blue 
0 
11. Refer to the paper handout, and trace areas of airway where there is cilia beating  
12. Select ‘Merge down’ 
13. Use ‘histogram’ to obtain values for the quantity of Red and Green pixels 
14. Export to Excel, and calculate amount of Green (cilia beating) as a proportion of Red 
(total airway circumference). !
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2.2.12.3.3 MitoTracker 
 
MitoTracker is a commercially available fluorescent cationic probe, which is widely 
used to assess the mitochondrial activity of cultured cells (326). MitoTracker 
passively diffuses across the plasma membrane and selectively accumulates in intact 
mitochondria due to their interior negative membrane potential (326). There are a 
variety of MitoTracker probes available which differ in spectral characteristics and 
fixability – the probe used in this thesis was MitoTracker Red CM-H2XRos 
(Molecular Probes), which has an excitation wavelength of 576 nm and an emission 
wavelength of 599 nm, and is retained after formaldehyde fixation. MitoTracker was 
explored in this thesis as a means to assess the mitochondrial activity of PCLS, with 
the aim of determining their overall viability. As the use of MitoTracker with PCLS 
has not been reported to our knowledge, experiments involved determining optimal 
concentration and incubation times. MitoTracker was diluted in cell-culture medium 
prior to use at appropriate concentrations. PCLS supernatants were removed, and the 
slices incubated with diluted MitoTracker for various periods of time in an rotating 
incubator at 1 RPM in humidified air containing 5% CO2 at 37 ºC. Following this, 
PCLS were transferred to 4 % PFA in PBS, and stored for a maximum of 24 hours 
until visualisation with a fluorescent DM 2500 microscope (Leica).  
 
2.2.12.3.4 Lung slice tissue H&E staining and Picosirius red staining 
 
At the appropriate time points, PCLS were removed from the culture media and 
immediately transferred to 4% PFA in PBS and fixed at 4 ºC for 1-2 weeks. Fixed 
PCLS were then transferred into 5 ml PBS and delivered to the Leukocyte Biology 
Histology core facility (Lorraine Lawrence, Leukocyte Biology Section, National 
Heart and Lung Institute, Imperial College London) for paraffin embedding and 
sectioning. Subsequently, PCLS were processed for H&E staining and picosirius red 
staining by the same facility. 
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3 Chapter 3: RA signalling in human chronic lung disease 
 
3.1 Introduction 
 
Emphysema is defined as abnormal, permanent enlargement of alveolar spaces distal 
to the terminal bronchioles, and comprises destruction of the alveolar walls without 
their obvious fibrosis, and a consequent decrease in gas exchange surface area (327). 
While the non-diseased adult lung in animals and humans possesses endogenous 
plasticity and capacity to undergo repair (described in introduction 1.2 (45, 328)), 
emphysema is progressive and largely irreversible, and so may represent an inability 
to initiate regenerative mechanisms (65). RA signalling has critical roles in alveolar 
maintenance and regeneration, and RA signalling deficiencies in rodent models result 
in emphysema. However, very little is known about RA signalling in adult human 
distal lung. We therefore hypothesised that RA signalling is conserved in normal 
human lung, and RA pathway alterations may contribute towards the pathogenesis of 
clinical emphysema. 
 
Vitamin A deficiency (VAD) in adult rats causes alveolar destruction, loss of gas 
exchange surface area, and reduction in lung airway and parenchymal elastic fibres – 
the pathological hallmarks of emphysema (74, 75). It was found that mice with low 
vitamin A status are more susceptible to developing emphysema after cigarette smoke 
exposure than vitamin A sufficient counterparts, suggesting a protective effect of RA 
signalling against emphysema (329). Furthermore, VAD rats exhibited reduced AT2 
cell proliferation in response to acute ozone exposure, suggesting that RA signalling 
is required for the regenerative response of the lung to injury (241). 
 
Regulation of RA pathway gene expression in whole distal lung tissue of patients with 
COPD/emphysema has not yet been investigated. However, epidemiological evidence 
suggests altered RA signalling in these diseases. Morabia et al. found intake of dietary 
vitamin A inversely correlated with airway obstruction, after adjustments for age, sex, 
caloric intake and cigarette smoking (330), although in a similar, larger study, an 
association was only apparent in current heavy smokers (331). Reduced serum retinol 
levels were associated with reduced lung function measured 5 years later in one study 
(73), and low serum retinol levels were associated with poor airflow obstruction in 
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patients with moderate to severe COPD (332). In smokers exposed to asbestos, a 
positive correlation was observed between serum retinol and forced vital capacity 
(333). Another study found a significant correlation between serum retinol levels and 
forced expiratory volume in 1 second (FEV1) after controlling for vitamin E and β-
cryptoxanthin (334). In a large population study, no relationship was observed 
between serum vitamin A (retinol) levels and FEV1 (335). However, this study found 
a significant association between FEV1 and serum β-carotene, which as well as 
possessing antioxidant properties, is a precursor in the biosynthesis of RA (335). 
Importantly, serum retinol levels vary widely in the general population and may not 
accurately reflect lung retinoid levels (336). Recent evidence suggests that local levels 
of retinol in the lung inversely correlate with severity of COPD (337), suggesting that 
a local retinoid deficiency in the lung may contribute towards the pathogenesis of the 
disease. In support of this, Paiva et al., found that vitamin A supplementation was 
associated with an improvement in lung function in COPD patients (332). 
 
Data regarding RA pathway gene expression in lung tissue of emphysema patients is 
limited. The only study to investigate this was performed by Plantier et al. (251), who 
found that cellular retinoic acid binding protein 2 (CRABP-2) was diminished in lung 
fibroblasts of patients with severe emphysema (251). Subsequent CRABP-2 
disruption in a fibroblast cell line impaired their ability to synthesise elastin, a critical 
component of alveolar walls, in response to ATRA (251). Therefore, RA pathway 
deficiencies may contribute to an inability to initiate lung regeneration in these 
patients. 
 
To investigate this hypothesis, we used RT-PCR to initially characterise the 
expression of RA pathway genes in normal human distal lung tissue. An high 
performance liquid chromatography (HPLC) method was developed to investigate 
endogenous retinoids in normal distal human lung. To investigate RA signalling in 
emphysema, patient lung tissue samples obtained from normal and emphysematous 
surgical resection specimens were analysed using Taqman-based RT-qPCR, with 
primer/probe sets specific for members of the RA signalling pathway. To obtain 
external validation and to evaluate the relevance our findings to the wider population, 
our data was compared with data from microarray studies examining transcriptional 
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profiles of emphysematous lung (338-342), obtained from the Gene Expression 
Omnibus online database repository, and Western blot and immunohistochemistry 
were used to further investigate the protein expression of a gene with differential 
regulation in emphysema, CYP26A1. 
The specific objectives were: 
 
a. to confirm the conservation of RA signalling in normal adult human lung 
tissue, in terms of RA pathway gene expression, and presence of 
endogenous retinoid species 
b. to examine the difference in RA pathway gene expression between 
histologically emphysematous and normal lung tissue 
c. to investigate the relationship between RA pathway gene expression and 
patient gas diffusing capacity 
d. to investigate the relationship between RA pathway gene expression and 
patient airflow limitation 
 
3.2 Specific Methods 
 
3.2.1 Confirmation of RA pathway gene expressed in whole human lung tissue 
 
Whole human lung tissue was obtained from Biobank, respiratory Biomedical 
Research Unit (BRU), Royal Brompton and Harefield NHS Foundation Trust, under 
BRU Advanced Lung Disease (ALD) Biobank ethics, reference number 10/H0504/9. 
RNA was extracted from ~ 30 mg whole human lung tissue using the RNeasy Mini 
Kit (Qiagen). 1 µg RNA was reverse transcribed into cDNA according to the protocol 
described (2.2.2.2). In parallel, reverse transcription reactions were performed using 
all reagents except MMLV-RT to make RT-ve cDNA. RT+ve or RT-ve cDNA was 
diluted to a working concentration of 1 ng/µl in dd H2O, and 2 µl was used per 25 µl 
reaction along with 12.5 µl SYBR Green, 2.5 µl each of forward and reverse primer 
(10 mM) and 5.5 µl dd H2O according to the protocol described (2.2.4.2). End-point 
PCR was performed for RT+ve and RT-ve cDNA simultaneously. In addition, for 
each PCR reaction, a blank control containing 2 µl dd H2O instead of cDNA was 
included to ensure absence of contamination in PCR reagents. All PCR reaction 
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products were visualised by agarose gel electrophoresis, alongside a 25 bp DNA 
ladder (Life Technologies) for comparison to determine reaction specificity, 
according to the protocol described (2.2.4.1.3). Gels were visualised with BioDoc-It 
UV Imaging System (UVP). 
 
3.2.2 High performance liquid chromatography analysis of endogenous 
retinoids 
 
Reverse-phase HPLC was performed with a method adapted from Rühl and 
Schweigert (302) according to the protocol described 2.2.8.4. A multilinear gradient 
was formed from solvent A (methanol) and solvent B (60 mM aqueous ammonium 
acetate solution:methanol (1:1, v/v)). The originial method consisted of the following 
steps: 0.0 min 90% B, 8.0 min 45% B, 17.0 min 1% B, 41.0 min 1% B and 41.5 min 
90% B, with a flow rate of adjusted at 0.7 ml/min, and 15 minutes equilibriation with 
initial eluent between runs. Based on the resulting elution profiles, the gradient was 
modified to provide better resolution of retinoid standards, and optimised with the 
following steps:  0.0 min 45% B, 20.0 min 1% B, 20.5 min 45% B, 35.0 min 45% B, 
with 0.7 ml/min flow rate and no equilibriation time between runs. Absorbance was 
measured at 354 nm. This method was used to analyse extracts from whole human 
lung tissue (protocol described 2.2.8.3). Peak elution times were determined and 
compared between standard and human lung tissue extract chromatograms to identify 
endogenous human lung retinoids. 
 
3.2.3 RA pathway gene expression in emphysema compared to normal lung 
tissue (RT-qPCR) 
 
Tissue for RT-qPCR analysis was categorised as normal or emphsyematous according 
to histology of immediately adjacent tissue regions by an experienced 
histopathologist. Damage to the alveolar walls defined tissue as emphysematous (n=9 
emphysema), whereas an absence of damage defined tissue as normal (n=10 control) 
(personal communication, Dr Angeles Montero, Consultant Histopathologist, Royal 
Brompton and Harefield Hospitals NHS Foundation Trust, London). 
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Taqman-based RT-qPCR was used to assess RA pathway gene expression in 
emphysematous compared to non-diseased whole human lung tissue. RNA was 
extracted from ~ 30 mg whole human lung tissue using the RNeasy Mini Kit 
(Qiagen). 1 µg RNA was reverse transcribed into cDNA according to the protocol 
described (2.2.2.2). cDNA was diluted to a working concentration of 1 ng/µl in dd 
H2O. Taqman-based RT-qPCR was performed in 384 well plates in a Viia7 (Applied 
Biosystems). 2.5 µl cDNA was used per 10 µl reaction along with 5 µl Taqman Fast 
Advanced Master Mix (Applied Biosystems), 0.5 µl Taqman primer/probe set, and 
2.0 µl dd H2O. Reactions were performed in triplicate according to the protocol 
described (2.2.4.3).  
 
Gene expression of RA pathway genes was normalised to the mean of the expressions 
of beta-glucuronidase (GUSB) and beta 2 microglobulin (B2M) as reference genes. 
GUSB has previously been found by our group to be the most stable reference gene 
for the analysis of whole lung tissue with RT-qPCR (343). B2M has been frequently 
used as a reference gene for mouse lung RT-qPCR analysis by members of our group 
(Dr Charlotte Dean, personal communication). Normalisation against the mean of 2 
genes was demonstrated as more accurate than against 1 gene (344), and is widely 
used for RT-qPCR data analysis. Log transformed CT values (=2-CT) of GUSB and 
B2M did not change significantly between non-diseased and emphysema patient 
samples (data not shown), therefore confirming the suitability of these housekeeping 
genes for normalisation of gene expression. 
 
For the RT-qPCR analysis, due to limited space on the PCR plates, samples were 
divided into 2 groups - those from patients with date of birth (DOB) between 1935 
and 1950 (group A), and those with DOB between 1951 and 1964 (group A), which 
were separately analysed for gene expression. Each group contained similar numbers 
of diseased and control samples. Each plate contained all group A or group B 
samples, which were simulataneously analysed for expression of both GUSB and 
B2M reference genes, and several RA pathway genes. Following PCR amplification, 
the mean was taken of each triplicate PCR reaction, which were then used to calculate 
the fold change in expression between control and diseased tissue samples for each 
RA pathway gene according to the ∆∆CT method as described (2.2.4.3.3). The mean 
of the CT values of all non-diseased samples per plate were used as the reference 
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sample for the calculation. As reference samples to control for inter-plate variation, 
two group A samples (which had previously been analysed) were included in PCR 
plates analysing group B, and two group B samples (which had previously been 
analysed) were included in PCR plates analysing group A. In all cases, gene 
expression values did not differ between plates for these reference samples, and thus 
all samples from group A and group B were pooled for the statistical analysis. Blank 
controls were run for each primer/probe set, which contained all PCR reagents with 
2.5 µl dd H2O instead of cDNA, to ensure absence of DNA contamination in PCR 
reaction products. Prior to sample analysis, the efficiency for each primer/probe set 
was ensured using serial dilutions of a reference cDNA. 
 
Patient demographics for correlation analyses were obtained from anonymised 
clinical records through a secured NHS network with full approval (Dr Matthew 
Hind, Consultant in Respiratory Physiology, RBHT NHS Foundation Trust). 
 
3.2.4 Analysis of microarray datasets from GEO database 
 
The Gene Expression Omnibus (GEO) database is a public online repository that 
archives and freely distributes MIAME (minimum information about a microarray 
experiment)-compliant raw microarray datasets (and other forms of high-throughput 
functional genomic data) submitted by the scientific community 
(http://www.ncbi.nlm.nih.gov/geo/). To obtain external validation for the RT-qPCR 
data gathered in this thesis, a search of the GEO database was performed for 
microarray datasets examining transcriptional profiles of patients with emphysema. 
Five published datasets were found according to this search criteria (Table 3.2). For 
each dataset, a search for CYP26A1 expression was performed in the study 
populations. Groups for statistical comparison were defined according to the criteria 
outlined in the associated publications (338-342). Gene expression values were 
acquired using the appropriate gene ID codes, and imported to Graphpad Prism for 
statistical analysis. 
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3.2.5 CYP26A1 protein in emphysema compared to normal lung tissue 
(Western blot) 
 
Tissue for Western blot analysis was categorised as normal (n=5) or emphsyematous 
(n=5) according to histology of immediately adjacent tissue regions, akin to tissue 
used for RT-qPCR (3.2.3). Western blot was used to determine CYP26A1 protein in 
emphysematous compared to non-diseased whole human lung tissue. Total protein 
was extracted from ~ 30 mg whole human lung tissue using a needle and syringe in 
cell lysis buffer containing protease inhibitors according to the protocol described 
(2.2.7.3). Total protein concentration was measure with Pierce BCA assay 
(Thermoscientific 2.2.7.2). Western blot was performed according to the protocol 
described (2.2.7.4). Briefly, 20 µg total protein in loading buffer was loaded into each 
lane of a NuPage 4-12% Bis-Tris gel (Invitrogen) alongside a protein ladder, and run 
at 150 V for ~1 hour. Separated proteins were transferred to nitrocellulose membrane 
which, following blocking, were probed sequentially with anti-CYP26A1 antibody 
(Sigma-Aldrich) at 1:500 in blocking buffer, and HRP-conjugated anti-rabbit 
secondary antibody at 1:5000 in blocking buffer. The following day, membranes were 
incubated sequentially with anti-β-actin antibody (Cell signalling) at 1:2000 in 
blocking buffer, and HRP-conjugated anti-rabbit secondary antibody at 1:5000. 
Membranes were incubated with ECL substrate (Thermoscientific) and visualised 
with 60 second exposure to photosensitive film. 
 
3.2.6 CYP26A1 protein in histologically normal lung tissue sections 
(immunohistochemistry) 
 
Paraffin lung tissue sections derived from histologically normal regions of lung were 
obtained from 5 patients undergoing resection, and were categorised as histologically 
normal by a histopathologist. IHC was used to determine localiasation of CYP26A1 
protein in histologically normal lung tissue. Sections were processed for IHC using 
anti-CYP26A1 antibody (Sigma-Aldrich) and visualisation with DAB, with 
haematoxylin counterstain, according to the protocol described (2.2.6.2). Anti-
CYP26A1 was used at 1:1000 diluted in PBS with 1.5 % fetal bovine serum. Slides 
were visualised with a Leica DM 2500 microscope.  
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3.3 Results 
 
3.3.1 Expression of RA pathway genes in histologically normal adult distal lung 
tissue 
 
Initially we determined expression of critical RA pathway genes in normal adult 
human distal lung tissue with end-point RT-PCR. Primers were used for retinaldehyde 
dehydrogenase (RALDH) -1, -2 and -3, cytochrome P450 family 26 (CYP26) A1, B1 
and C1, retinoic acid receptor (RAR) -α, -β and -γ, retinoid X receptor (RXR) -α, -β 
and -γ, cellular retinol binding protein (CRBP) -1 and -2, and cellular retinoic acid 
binding protein (CRABP) -1 and -2.  
 
All genes assessed were found expressed in normal adult human distal lung (Figure 
3.1). RALDH -1, -2 and -3, were all found to be expressed in all 10 donor lung tissue 
examined. CYP26A1 and B1 were found expressed in tissue from all 9 donors 
assessed, and CYP26C1 was found in 8 of 9 donors (not shown). Expression of RAR-
α, -β, -γ (10 donors) and RXR-α (7 donors), -β (2 donors) and -γ (8 donors) was 
observed in all samples assessed. Expression of CRBP-1 and -2 was also identified in 
all 9 donors examined. CRABP-1 was found in 7 of 9 donors, whereas CRABP-2 was 
expressed in all 10 donors (not shown). No bands were found in blank controls (not 
shown). 
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Figure 3.1 Retinoic acid pathway genes are expressed in histologically normal 
adult human distal lung tissue 
Whole adult human lung tissue was processed for RNA extraction and end-point RT-PCR 
performed for RA pathway genes: retinaldehyde dehydrogenase (RALDH) 1, 2, 3; 
cytochrome P450 family 26 (Cyp26) A1, B1, C1; retinoic acid receptor (RAR) α, β, γ; 
retinoid X receptor (RXR) α, β, γ; cellular retinol binding protein (CRBP) 1, 2; cellular 
retinoic acid binding protein (CRABP) 1, 2. Products were visualised on agarose gel and their 
size determined by comparison with a 25bp DNA ladder (L), which displays bands of 
multiples of 25bp with a bright band at 125bp. Resultant bands correspond to expected size of 
amplified fragments. N = 7-10 except for n=2 for RXR-β due to sample availability, 
representative RT-PCR products shown. Abbreviations: bp, base pairs; L, 25bp DNA ladder; 
RT-PCR, reverse-transcription polymerase chain reaction. 
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3.3.2 Determination of endogenous retinoids in human lung tissue with high 
performance liquid chromatography 
 
Retinoids are lipophilic molecules, and therefore high performance liquid 
chromatography (HPLC) was used to determine their presence in whole human distal 
lung tissue. Initially, a method was developed to resolve known synthetic retinoid 
standards using reverse-phase HPLC, adapted from the method of Rühl and 
Schweigert (302). Elution times for retinoid standards were: 13-cis RA 6.64 minutes, 
9-cis RA 7.15 minutes, ATRA 7.61 minutes, retinol 13.40 minutes, retinal 13.79 
minutes, and retinyl acetate 17.43 minutes (Figure 3.2A). Using this method, whole 
human lung tissue extract were analysed for endogenous retinoids. Several peaks 
were identified, including peaks at 7.63 minutes and 13.37 minutes, corresponding to 
the elution times of ATRA and retinol standards respectively (Figure 3.2B). Several 
peaks of unknown identity were also identified, for example at 3.7 minutes and 21.45 
minutes. 
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Figure 3.2 HPLC chromatograms demonstrating resolution of synthetic retinoids 
and endogenous retinoids in whole human lung tissue extract 
Representative chromatograms demonstrating elution times of A) synthetic retinoid 
standards (13-cis RA, 9-cis RA, ATRA, retinol, retinal, retinyl acetate) and B) whole 
human lung tissue extract (n=1). Y axis represents absorbance at 354 nm in 
miliabsorbance units (mAU). X axis represents elution time (minutes). Peak elution 
times were compared between standard whole human lung tissue extract 
chromatograms, and suggests the presence of ATRA and retinol in whole human 
lung. Unknown peaks were also identified (arrow heads). Abbreviations: HPLC, high 
performance liquid chromatography; 13-cis RA, 13-cis retinoic acid; 9-cis RA, 9-cis 
retinoic acid; ATRA, all-trans retinoic acid. 
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3.3.3 Patient demographics and pulmonary function measures 
 
For RT-qPCR analysis of RA pathway gene expression, a separate set of adult human 
distal lung tissue samples were used. Samples were categorised as emphysematous 
(n=9) or normal (n=10) according to histology. Patient demographics are displayed in 
Table 3.1. Clinical datasheets revealed that of the 9 patients who contributed 
histologically normal tissue samples, 2 had COPD, 1 had emphysema, 1 had lung 
cancer, 1 had colon cancer, and 4 had no associated diagnostic information. Tissue 
was obtained as 4 were undergoing lung volume reduction surgery (LVRS), and 5 
were undergoing resection for suspected tumours. Of the 10 patients who contributed 
histologically emphysematous samples, 9 had clinically diagnosed COPD and were 
undergoing LVRS, and 1 had no associated diagnostic information. There were no 
significant differences between the age at operation or patient height between control 
and emphysema groups (p > 0.05). There was a trend towards lower average patient 
weight in the emphysema group compared to control (60.0 ± 3.4 kg compared to 71.0 
kg ± 5.3 kg) which did not reach significance (p > 0.05).  
 
There were significant differences in patient lung function values between control and 
emphysema groups. FEV1, FEV1/FVC and FEV1 % predicted were significantly 
lower in emphysema compared to control (** p < 0.01, * p < 0.05 and * p < 0.05 
respectively). TLC was not different between groups (p > 0.05), while a trend toward 
lower FVC was observed in the emphysema group which did not reach statistical 
significance (p = 0.06). According to the Global Initiative for Obstructive Lung 
Disease (GOLD) guidelines (345), the majority of the patients who provided 
emphysematous tissue were categorised as very severe COPD (GOLD IV, n=6) while 
the rest of the patients were classed as severe to moderate COPD (GOLD III, n=3; 
GOLD II, n=1). In contrast, patients who contributed control tissue predominantly 
had milder disease, although were distributed across a range of GOLD stages from ‘at 
risk’ to very severe COPD (GOLD 0, n=3; GOLD II, n=2; GOLD III, n=1; GOLD IV, 
n=2). A trend towards lower VA was observed in the emphysema group (p = 0.055). 
DLCOc % predicted and KCOc % predicted were significantly lower in emphysema 
than controls (** p < 0.01).  
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Where possible, two samples with the same histology (normal or emphysematous) 
were obtained from the same patient, RT-qPCR performed in parallel, and the mean 
of their expressions taken to control for intra-patient variability. 4 out of 9 control 
patients, and 4 out of 10 emphysema patients contributed 2 samples each.  
 
No patients had been supported in intensive care at the time of operation. Out of the 
19 patients in total, 16 were ex-smokers, 1 was a current smoker (contributed normal 
tissue), and 2 had never smoked (contributed normal tissue). The range of cigarette 
smoke exposure (pack years) was greater in the control group (0.0 – 200.0) compared 
to the emphysema group (20.0 – 103.0). The median pack years was lower in control 
compared to emphysema patients (14.5 and 40.0 pack years respectively), which was 
not statistically significant (p > 0.05). All patients were Caucasian. Out of the 9 
patients who supplied normal tissue, 5 were male (56%), and out of the 10 patients 
who supplied emphysematous tissue, 4 were male (40%). 
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Table 3.1 Patient demographics and pulmonary function values associated with 
samples used for RT-qPCR (cohort 1) 
Statistical tests between control and emphysema groups were performed with Mann-
Whitney test. Data is provided as mean ± SEM or median (IQR), except for Pack 
years which is presented as median (range). * p < 0.05, ** p < 0.01. Abbreviations: 
TLC, total lung capacity (litres); FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 second (litres); FEV1 % predicted, forced expiratory volume in 1 second 
relative to the normal value predicted by patient characteristics; GOLD, Global 
Initiative for Obstructive Lung Disease; VA, alveolar volume (litres); DLCOc % 
predicted, diffusing capacity of the lung for carbon monoxide, corrected for patient 
haemoglobin (Hb) content, relative to the normal value predicted by patient 
characteristics; KCOc % predicted, transfer coefficient for uptake of CO of the lung 
per unit volume, corrected for patient Hb content, as a proportion of predicted normal 
values; ‡ smoking history available for: control = 7, emphysema = 7. 
Characteristic Control Emphysema P2value
(N=9) (N=10)
Age$at$operation$(years) 66.0$±$3.1 61.7$±$2.7 p$>$0.05
Height$(cm) 169.6$±$2.7 165.7$±$3.7 p$>$0.05
Weight$(kg) 71.0$±$5.3 60.0$±$3.4 p$>$0.05
Sex$(M/F) 5/4 4/6 N/A
TLC$(L) 6.5 (5.4 - 7.6) 6.6$(5.6$K$8.6) p$>$0.05
FVC$(L) 3.2$(2.9$K$3.7) 2.5$(2.1$K$3.3) p$=$0.06
FEV1$(L) 2.0$(1.2$K$2.3) 0.8$(0.5$K$1.3) **$p$<$0.01
FEV1/FVC$(%) 0.55$(0.35$K$0.72) 0.29$(0.24$K$0.37) *$p$<$0.05
FEV1$(%$predicted) 80.0$(36.4$K$97.5) 29.5$(25.0$K$40.2) *$p$<$0.05
GOLD$Stage$(n): N/A
0 3 0 K
I 0 0 K
II 3 1 K
III 1 3 K
IV 2 6 K
VA$(L) 4.9$(4.1$K$5.3) 3.9$(3.1$K$4.2) p$=$0.05
DLCOc$(%$predicted) 66.2$(52.3$K$81.0) 34.7$(25.3$K$40.8) **$p$<$0.01
KCOc$(%$predicted) 76.0$(57.9$K$85.5) 46.6$(34.4$K$56.0) **$p$<$0.01
Cigarette$smoke$exposure$ 22.0$(0.0$K$200.0) 40.0$(20.0$K$103.0) p$>$0.05
(pack$years)$‡
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3.3.4 Expression of RA pathway genes in histologically normal and 
emphysematous human lung tissue 
 
RA pathway gene expression was determined in histologically normal compared to 
emphysematous whole human distal lung tissue with RT-qPCR, using whole lung 
tissue samples from 9 control and 10 empysema patients (cohort 1). Taqman 
primer/probe sets were used for RALDH-1, -2 and -3 (Figure 3.3). CYP26 A1, B1 
and C1 (Figure 3.4), RAR-α, -β and -γ (Figure 3.5), RXR -α, -β and -γ (Figure 3.6), 
CRBP-1 and -2 (Figure 3.7), CRABP-1 and -2 (Figure 3.8) and lecithin retinol 
acyltransferase (LRAT) (Figure 3.9). 
 
No differences were observed in the expression of RALDH -1, -2 or -3 between 
control and emphysematous lung tissue (p > 0.05, Figure 3.3). CYP26A1 mRNA 
expression was significantly higher in emphysema compared to control (* p < 0.05). 
There was greater variability in CYP26A1 expression in emphysematous tissue 
compared to control (SD = 11.05 and 0.58 respectively) (Figure 3.4A). No difference 
was observed in the expression of CYP26 B1 or CYP26 C1 between emphysematous 
and control lung tissue (p > 0.05, Figure 3.4B, C). No differences were observed in 
the expression of RARs (p > 0.05, (Figure 3.5), RXRs (p > 0.05, Figure 3.6), CRBPs 
(p > 0.05, Figure 3.7), CRABPs (p > 0.05, (Figure 3.8) or LRAT (p > 0.05, Figure 
3.9) between emphysematous and control lung tissue. 
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Figure 3.3 Retinaldehyde dehydrogenases (RALDHs) are not differentially 
regulated in histologically normal and emphysematous adult human distal whole 
lung tissue  
Histologically non-emphysematous (‘control’, open boxes, n=9) and emphysematous 
(‘emphysema’, filled boxes, n=10) lung tissue samples were processed for RNA 
extraction. RT-qPCR was performed for A) RALDH1, B) RALDH2, and C) 
RALDH3, with expression normalised to the mean of GUSB and B2M. Statistical 
significance was assessed with Mann Whitney test. Results expressed as box and 
whisker plots with the horizontal line representing the median and the upper and 
lower bounds of the rectangular box representing IQR. Abbreviations: GUSB, beta-
glucuronidase; B2M, beta-2 microglobulin; RALDH1, retinaldehyde dehydrogenase 
1; RALDH2, retinaldehyde dehydrogenase 2; RALDH3, retinaldehyde dehydrogenase 
3; RT-qPCR, reverse-transcription quantitative polymerase chain reaction. 
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Figure 3.4 The expression of cytochrome P450 family 26 (CYP26) A1 is increased 
in histologically emphysematous compared to control human distal lung tissue, 
whereas the expression of CYP26 B1 and C1 are not  
Histologically non-emphysematous (‘control’, open boxes, n=9) and emphysematous 
(‘emphysema’, filled boxes, n=10) lung tissue samples were processed for RNA 
extraction. RT-qPCR was performed for A) CYP26A1, B) CYP26B1, and C) 
CYP26C1, with expression normalised to the mean of GUSB and B2M. Statistical 
significance was assessed by Mann Whitney test. *p<0.05. Results expressed as box 
and whisker plots with the horizontal line representing the median and the upper and 
lower bounds of the rectangular box representing IQR. Abbreviations: Abbreviations: 
GUSB, beta-glucuronidase; B2M, beta-2 microglobulin; CYP26A1, cytochrome P450 
family 26 subfamily A polypeptide 1; CYP26B1, cytochrome P450 family 26 
subfamily B polypeptide 1; CYP26C1, cytochrome P450 family 26 subfamily C 
polypeptide 1; RT-qPCR, reverse-transcription quantitative polymerase chain 
reaction. 
A 
p = 0.017 
Control Emphysema
0
5
10
35
40
C
YP
26
 A
1 
: G
U
SB
 &
 B
2M
*
B 
p = 0.18 
Control Emphysema
0
1
2
3
4
C
YP
26
 B
1 
: G
U
SB
 &
 B
2M
Control Emphysema
0.0
0.5
1.0
1.5
2.0
C
YP
26
 C
1 
: G
U
SB
 &
 B
2M
C 
p = 0.59 
 174 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Retinoic acid receptors (RARs) are not differentially regulated in 
histologically normal and emphysematous adult human distal whole lung tissue 
Histologically non-emphysematous (‘control’, open boxes, n=9) and emphysematous 
(‘emphysema’, filled boxes, n=10) lung tissue samples were processed for RNA 
extraction. RT-qPCR was performed for A) RAR-α, B) RAR-β, and C) RAR-γ, with 
expression normalised to the mean of GUSB and B2M. Statistical significance was 
assessed by Mann Whitney test. Results expressed as box and whisker plots with the 
horizontal line representing the median and the upper and lower bounds of the 
rectangular box representing IQR. Abbreviations: Abbreviations: GUSB, beta-
glucuronidase; B2M, beta-2 microglobulin; RAR-α, retinoic acid receptor alpha; 
RAR-β, retinoic acid receptor beta; RAR-γ, retinoic acid receptor gamma; RT-qPCR, 
reverse-transcription quantitative polymerase chain reaction. 
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Figure 3.6 Retinoid X receptors (RXRs) are not differentially regulated in 
histologically normal and emphysematous adult human distal whole lung tissue  
Histologically non-emphysematous (‘control’, open boxes, n=9) and emphysematous 
(‘emphysema’, filled boxes, n=10) lung tissue samples were processed for RNA 
extraction. RT-qPCR was performed for A) RXR-α, B) RXR-β, and C) RXR-γ, with 
expression normalised to the mean of GUSB and B2M. Statistical significance was 
assessed by Mann Whitney test. Results expressed as box and whisker plots with the 
horizontal line representing the median and the upper and lower bounds of the 
rectangular box representing IQR. Abbreviations: Abbreviations: GUSB, beta-
glucuronidase; B2M, beta-2 microglobulin; RXR-α, retinoid X receptor alpha; RXR-
β, retinoid X receptor beta; RXR-γ, retinoid X receptor gamma; RT-qPCR, reverse-
transcription quantitative polymerase chain reaction. 
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Figure 3.7 Cellular retinol binding proteins (CRBPs) are not differentially 
regulated in histologically normal and emphysematous adult human distal whole 
lung tissue  
Histologically non-emphysematous (‘control’, open boxes, n=9) and emphysematous 
(‘emphysema’, filled boxes, n=10) lung tissue samples were processed for RNA 
extraction. RT-qPCR was performed for A) CRBP1, and B) CRBP2, with expression 
normalised to the mean of GUSB and B2M. Statistical significance was assessed by 
Mann Whitney test. Results expressed as box and whisker plots with the horizontal 
line representing the median and the upper and lower bounds of the rectangular box 
representing IQR. Abbreviations: GUSB, beta-glucuronidase; B2M, beta-2 
microglobulin; CRBP1, cellular retinal binding protein 1; CRBP2, cellular retinol 
binding protein 2; RT-qPCR, reverse-transcription quantitative polymerase chain 
reaction. 
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Figure 3.8 Cellular retinoic acid binding proteins (CRABPs) are not 
differentially regulated in histologically normal and emphysematous adult 
human distal whole lung tissue  
Histologically non-emphysematous (‘control’, open boxes, n=9) and emphysematous 
(‘emphysema’, filled boxes, n=10) lung tissue samples were processed for RNA 
extraction. RT-qPCR was performed for A) CRABP1, and B) CRABP2, with 
expression normalised to the mean of GUSB and B2M. Statistical significance was 
assessed by Mann Whitney test. Results expressed as box and whisker plots with the 
horizontal line representing the median and the upper and lower bounds of the 
rectangular box representing IQR. Abbreviations: GUSB, beta-glucuronidase; B2M, 
beta-2 microglobulin; CRABP1, cellular retinoic acid binding protein 1; CRABP2, 
cellular retinoic acid binding protein 2; RT-qPCR, reverse-transcription quantitative 
polymerase chain reaction. 
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Figure 3.9 Lecithin retinol acyltransferase (LRAT) is not differentially regulated 
in histologically normal and emphysematous adult human distal whole lung 
tissue 
Histologically non-emphysematous (‘control’, open boxes, n=9) and emphysematous 
(‘emphysema’, filled boxes, n=10) lung tissue samples were processed for RNA 
extraction. RT-qPCR was performed for LRAT, with expression normalised to the 
mean of GUSB and B2M. Statistical significance was assessed by Mann Whitney test. 
Results expressed as median with interquartile range. Abbreviations: GUSB, beta-
glucuronidase; B2M, beta-2 microglobulin; LRAT, lecithin retinol acyltransferase; 
RT-qPCR, reverse-transcription quantitative polymerase chain reaction. 
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3.3.5 Intra-patient variability 
 
Duplicate tissue samples were obtained from 4 of 9 control patients, and 4 of 10 
emphysema patients. Expression profiles of duplicate tissue samples were used to 
determine intra-patient variability. In general, gene expression profiles of duplicate 
samples were similar. Representative graphs of intra-patient variability are given in 
Figure 3.10, which depict RALDH-1 and CYP26A1 expression in all samples used in 
this study (identical data to Figure 3.3A and Figure 3.4A). Intra-patient variability for 
expression of all RA pathway genes examined was similar (data not shown). 
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Figure 3.10 Illustration of intra-patient variability for paired tissue samples 
Expression of A) RALDH1 and B) CYP26A1 in tissue samples of normal histology 
from 9 patients (control 1-9) and in tissue of emphysematous histology from 10 
patients (emphsyema 1-10) are plotted individually to demonstrate variability within 
paired tissue samples. Paired tissue samples (control 6-9, emphysema 1-4) are 
depicted with filled circles, with a black horizontal line depicting the mean expression 
of each pair. Empty circles represent tissue samples from patients who contributed 
one tissue sample (control 1-5, emphysema 6-10). The dotted red horizontal lines 
represent the median expression for each group (Control and emphysema). 
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3.3.6 Identification of CYP26A1 upregulation in emphysema in previously 
published gene expression profile datasets 
 
We used the Gene Expression Omnibus (GEO) online database repository 
(http://www.ncbi.nlm.nih.gov/gds) to externally validate our findings in independent 
cohorts, from independent clinical settings. 5 available datasets analysed 
transcriptional profiles of emphysematous human lung (summarised in Table 3.2). 
The dataset by Golpon et al. (341) was unsuitable for our study as CYP26A1 was not 
included in their microarray platform. The remaining 4 datasets, published by Spira et 
al. (342), Fujino et al. (340), Francis et al. (339) and Campbell et al. (338) used 
microarray platforms which included CYP26A1 in the analysis, but did not identify 
CYP26A1 expression for publication.  
 
Spira et al. (342) compared whole lung tissue from emphysematous (n=18) with non-
diseased (n=12) patients. A trend towards increased CYP26A1 expression in the 
emphysema group was observed which did not reach statistical significance (p=0.3, 
Table 3.2, Figure 3.11A). A greater level of variability in the emphysema group was 
evident, compared to controls (Figure 3.11B). Fujino et al. (340) compared 
transcriptional profiles of alveolar type 2 (AT2) cells isolated from non-diseased 
(n=3) or emphysematous (n=3) lung. A trend towards increased CYP26A1 expression 
was observed in the emphysematous group, although the small n numbers precluded 
statistical analysis (Table 3.2, Figure 3.11C). Greater variability was evident in the 
emphysematous group. An analysis of all other RA pathway genes examined was 
conducted using microarray data from the study by Spira et al. No significant 
differences were observed between control and emphysema groups for any other RA 
pathway gene (data not shown). 
 
The study by Campbell et al. (338) compared gene expression with severity of 
emphysema (assessed by mean chord length, Lm) in emphysematous lungs (n=3) and 
non-diseased lungs (n=2). When CYP26A1 expression in the emphysema lungs 
(mean of 8 samples per lung, 3 lungs) was compared with expression in non-diseased 
lungs (mean of 8 samples per lung, 2 lungs) no difference was observed between the 
two groups (Table 3.2, Figure 3.11D). Francis et al. (339) compared whole lung tissue 
samples from patients with mild (KCO ≥ 75% predicted, n=10) with patients with 
 182 
moderate (KCO < 75% predicted, n=20) emphysema. No difference in CYP26A1 
expression was observed between mild and moderate emphysema (Table 3.2, Figure 
3.11E). 
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Figure 3.11 Comparison of CYP26A1 expression in emphysema from our study 
with previously published gene expression studies 
To independently validate our finding of increased CYP26A1 expression in 
emphysema, we compared our data to previously published emphysema gene 
expression databases. A search of the GEO database repository revealed 5 microarray 
datasets specifically related to transcriptional regulation in emphysema. 1 study could 
not be analysed as it did not examine CYP26A1. The remaining three studies were 
assessed for CYP26A1 expression in emphysematous lung compared to control. B) 
Spira et al. (342) (whole lung tissue, n=12 control, n=18 severe emphysema, GEO 
accession GSE1650 and C) Fujino et al. (340) (isolated alveolar type 2 cells, n=3 
control, n=3 emphysema, GEO accession GSE29133). D) Campbell et al. (338) 
(whole lung tissue, n=2 control, n=3 emphysema, GEO accession GSE27597). E) 
Francis et al. (339) (whole lung tissue, n=10 mild emphysema, n=20 moderate 
emphysema, GEO accession GSE17770. Data depicted as scatter plots with horizontal 
line representing the median. Mann Whitney Test * p<0.05. Abbreviations: 
CYP26A1, cytochrome P450, subfamily 26 A1; GEO, gene expression omnibus. 
 
 
3.3.7 Patient demographics for samples used in Western blot (cohort 2) 
 
Patient demographics for samples used in Western blot (cohort 2) are given in Table 
3.3. Due to incomplete availability of data, statistical comparisons between control 
and emphysema groups were not permitted. However, it is clear that lung function 
(FEV1, FVC) is overall better in the control group (lanes 1-5) compared to 
emphysema (lanes 6-10). As with the samples used for RT-qPCR, weight was slightly 
lower in the emphysema group compared to control. All patients in the emphysema 
group had a diagnosis of emphysematous confirmed by histology, whereas absence of 
emphysema was histologically confirmed in the control group (lanes 1-5), who tended 
to suffer from cancer. Most of the gas diffusion values were not available for the 
control patients, while those in the emphysema group had low DLCOc of less than 
50% predicted, indicative of emphysema. 
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3.3.8 CYP26A1 protein is increased in emphysematous human lung tissue 
compared to control 
 
 
CYP26A1 protein was determined in histologically normal compared to 
emphysematous lung tissue with Western blot, using homogenates of whole lung 
tissue samples from 5 control and 5 emphysema patients (cohort 2). Incubation with 
anti-CYP26A1 antibody revealed an immunoreactive band at ~56 kDa, corresponding 
to the expected size of CYP26A1 protein (Figure	  3.12 A). Incubation with anti-β-
actin antibody was used as a loading control and revealed an immunoreactive band at 
the correct size (~42 kDa). Quantification of CYP26A1 band intensity with Image J 
revealed increased CYP26A1 protein in emphysematous lung tissue compared to 
control (p = 0.095, Figure	  3.12 A, B). When normalised to band intensity of β-actin 
loading control, band intensity of CYP26A1 was significantly higher in 
emphysematous compared to control lung tissue (* p < 0.05, Figure	  3.12 C), 
confirming enrichment of CYP26A1 in emphysematous lung tissue on a protein level. 
 
 
 
 
 
 
Table 3.3 Patient demographics and pulmonary function values associated with 
samples used for Western blot (cohort 2) 
Lanes 1-10 correspond to lanes in Western blot (Figure 3.12). Lanes 1-5 are non-
emphsyematous controls, lanes 6-10 are emphysema. Abbreviations: N/A, not 
available 
 
 
 
Lane D.O.B Sex Height Weight Major5Diagnosis TLC5 FEV1 FVC DLCOc KCOc Smoking5History5
cm kg L L L
1 01/07/1928 M 170 80.6
Metastatic1well1differentiated1
urothelial1carcinoma1 5.77 2.031(87.1%) 3.111(96.5%) N/A 4.97 Ex1smoker
2 01/06/1946 M 166 77.6 NonGmucinous1adenocarcinoma N/A 2.61(96%) 3.31(94%) N/A N/A NonGSmoker
3 24/12/1958 M 178 92 Round1atelectasia N/A 3.091(87%) 4.771(106%) N/A N/A ExGsmoker,1411pack1years1
4 13/10/1951 F 160 72.3 Mucinous1adenocarcinoma 5.13 2.251(102%) 3.03L 5.2 1.21 Current1smoker,1301pack1years
5 26/02/1975 M 178.3 109.3 No1Malignancy N/A 3.211(111.5%) 3.921(118.4%) N/A N/A Ex1smoker,151pack1years
6 09/01/1966 M 174 63 Bullous1emphysema 10.081(147.7%) 1.111(29%) 4.051(88.6%) 3.131(30.5%) 0.591(36.7%) ExGsmoker,1one1pack/week
7 29/10/1975 M 188 74.1 Bulla 8.11(101.3%) 3.851(83.6%) 4.431(78.8%) 6.001(47.5%) 0.961(54.8%) ExGsmoker,1161pack1years
8 19/10/1974 M N/A 61 Emphysema N/A N/A N/A N/A N/A ExGsmoker,1101pack1years
9 01/05/1970 M 176 72.5 Emphysema/No#Malignancy 9.731(139.4%) 0.921(23.9%) 2.361(50.5%) 4.761(44.5%) 1.191(72.3%) Ex1smoker
10 29/12/1958 M 171.4 65 Severe1emphysema1 8.581(129.7%) 0.871(26.4%) 3.081(75%) 2.641(28.1%) 0.711(48.0%) ExGsmoker,1401pack1years
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Figure 3.12 Determination of CYP26A1 protein in lung tissue homogenates from 
patients with emphysema compared to control by Western blot (cohort 2) 
 
A) Total protein was extracted from whole lung tissue samples and separated by SDS-
PAGE prior to transfer to nitrocellulose membrane. Membrane was incubated with 
1:500 primary anti-CYP26A1 antibody followed by 1:2000 HRP-conjugated anti-
rabbit secondary antibody. β-actin primary antibody (1:2000) was used as loading 
control. Film was developed for 60 seconds. B) Intensity of CYP26A1 protein bands 
(56 kDa, correct size) was quantified with Image J. C) Intensity of CYP26A1 protein 
bands was normalised to intensity of corresponding β-actin protein bands (42 kDa, 
correct size). Data presented with horizontal line representing median and whiskers 
representing range. * p < 0.05 compared to control, Mann Whitney test. 
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3.3.9 Patient demographics for samples used for immunohistochemistry  
 
Patient demographics for samples used in immunohistochemistry are given in Table 
3.4. One patient declined to have information available. Total lung capacity and gas 
diffusion values were not available. The histopathology report confirmed all tissue as 
histologically normal. The available lung function values are suggestive of no or very 
mild airflow obstruction. 
 
3.3.10 Localisation of CYP26A1 protein in control human lung tissue to cells 
with morphology and localisation of alveolar macrophages 
 
To investigate the cellular sources of CYP26A1 in the human lung, 
immunohistochemistry was performed on paraffin sections of histologically normal 
regions of lung tissue derived from resection specimens. Anti-CYP26A1 antibody 
revealed localisation of CYP26A1 protein to cells with morphology and localisation 
of alveolar macrophages (Figure 3.13 A, B). CYP26A1 immunoreactivity was also 
observed in the apical side of pseudostratified airway epithelium (data not shown). As 
a negative control, an identical staining process using washing buffer instead of anti-
CYP26A1 antibody revealed no positive staining (Figure 3.13 C). Figure 3.13 A and 
B depict representative images from 2 patients. Paraffin sections of histologically 
normal lung tissue from a further 3 patients were also assessed for CYP26A1, and 
revealed the same patterns of expression, with CYP26A1 immunoreactivity in 
alveolar macrophages and airway epithelium (data not shown). 
 
3.3.11 Relationship between patient demographics and lung function measures 
 
We determined the relationship between clinical variables (age, height, weight and 
pack years) and lung function measurements (KCOc % predicted, FEV1/FVC and 
FEV1 % predicted). P values of correlations and Spearman coefficient r are given in 
Table 3.5. No clinical variables significantly correlated with lung function. Trends 
towards a positive correlation between weight and KCOc % predicted (p = 0.077, r = 
0.42), and towards a negative correlation between pack years and FEV1/FVC (p = 
0.055, r = -0.5), were observed. 
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Table 3.4 Patient demographics and pulmonary function values associated with 
samples used for immunohistochemistry 
 
 
 
 
Figure 3.13 Determination of CYP26A1 protein localisation in histologically 
normal human lung tissue with immunohistochemistry. 
 
Paraffin sections of human lung tissue derived from histologically normal regions of 
surgical resections were incubated with anti-CYP26A1 antibody. A and B depict 
alveolar regions from 2 different patients. CYP26A1-positive cells with morphology 
and localisation of alveolar macrophages are visible within alveolar spaces (arrows). 
C, non-primary antibody control, section from same patient as in A. Unlabelled 
alveolar macrophages are present (arrows). Haematoxylin was used as a counter stain. 
All images were taken at 40x original magnification. A and B are representative of a 
total of 5 patients. 
A B 
C 
D.O.B Sex Height Weight Histopathology Report FVC FEV1 FEV % Smoking History 
cm kg L L
07/02/1947 Female N/A N/A Normal N/A N/A N/A N/A
20/05/1943 Male 173 80 Normal 78% N/A 67% Ex-smoker, 32 pack years
13/08/1936 Female 162.5 67.4 Normal 1.88 (83%) 1.42 76% Ex-smoker
27/12/1936 Female 172 61.3 Normal N/A N/A N/A N/A
19/05/1943 Male 183 88 Normal 4.9 (87%) 3.62 76% Ex-smoker, 56 pack years
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3.3.12 Relationship between RA pathway gene expression and patient gas 
diffusion capacity 
 
The relationship between RA pathway gene expression and patient gas diffusion 
capacity, which gives an indication of the global integrity of the patient’s alveolar-
capillary barrier (346), was investigated for samples from cohort 1. The gas diffusion 
capacity was measured as transfer coefficient of carbon monoxide uptake in the lung 
per unit volume, corrected for haemoglobin (Hb) concentration, relative to predicted 
normal values based on the patient’s age and height (KCOc % predicted). P values of 
correlations and Spearman coefficient r are given in Table 3.6.  
 
A significant negative correlation was observed between CYP26A1 and CRABP-1 
expressions and KCOc % predicted (CYP26 A1 * p = 0.021, r = -0.52, Figure 3.14 
A; CRABP-1 * p = 0.011, r = -0.57 Figure 3.14C). A significant positive correlation 
was observed between CRBP-2 expression and KCOc % predicted (* p = 0.021, r = 
0.52 Figure 3.14B). No correlations were observed between KCOc  % predicted and 
expression of other RA pathway genes. Data points are presented as histologically 
normal (filled circles) or emphysematous tissue (empty circles) to show distribution 
of tissue histology with respect to KCOc % predicted. Emphysematous tissue tended 
to come from patients with lower KCOc % predicted values (Figure 3.14). 
 
 
 
 
 
 
 
 
 
 
 
 191 
 
 
 
Table 3.5 Relationship between lung function and clinical parameters of study 
population (cohort 1) 
Correlations between lung function measurements and available clinical parameters. 
The Spearman’s rank correlation coefficient r and the P value of the correlation are 
given. Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 
1 second (litres); FEV1 % predicted, forced expiratory volume in 1 second relative to 
the normal value predicted by patient characteristics; KCOc % predicted, transfer 
coefficient for uptake of CO of the lung per unit volume, corrected for patient 
haemaglobin content, as a proportion of predicted normal values. 
 
 
 
 
 
Lung%function%parameter !!!!!!!!!!!!!!KCOc!%!predicted !!!!!!!!!!!!!!!!!!!!!!FEV1/FVC !!!!!!!!!!!!!!FEV1!%!predicted
Clinical%parameter Spearman's!r P!value Spearman's!r P!value Spearman's!r P!value
Age 0.34 0.15 0.051 0.84 0.11 0.67
Height 0.25 0.29 0.13 0.60 0.25 0.30
Weight 0.42 0.077 -0.17 0.48 -0.030 0.90
Cigarette!smoke!exposure -0.16 0.56 -0.50 0.055 -0.42 0.12
(pack!years)
 192 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6 Relationship between RA pathway gene expression and patient gas 
KCOc % predicted (cohort 1) 
Correlations were derived between the expression of RA pathway genes in whole 
distal lung tissue, assessed by RT-qPCR and normalised to the mean of GUSB and 
B2M, and patient KCOc % predicted. P value of the correlation is given in the middle 
column, and the Spearman coefficient r is given in the right hand column. The rows in 
light blue (CYP26A1, CRBP2 and CRABP1) display correlations which are 
statistically significant (* p < 0.05). n = 19. Abbreviations: GUSB, beta-
glucuronidase; B2M, beta-2 microglobulin; RALDH1, retinaldehyde dehydrogenase 
1; RALDH2, retinaldehyde dehydrogenase 2; RALDH3, retinaldehyde dehydrogenase 
3; CYP26A1, cytochrome P450 family 26 subfamily A polypeptide 1; CYP26B1, 
cytochrome P450 family 26 subfamily B polypeptide 1; CYP26C1, cytochrome P450 
family 26 subfamily C polypeptide 1; RAR-α, retinoic acid receptor alpha; RAR-β, 
retinoic acid receptor beta; RAR-γ, retinoic acid receptor gamma; RXR-α, retinoid X 
receptor alpha; RXR-β, retinoid X receptor beta; RXR-γ, retinoid X receptor gamma; 
CRBP1, cellular retinal binding protein 1; CRBP2, cellular retinol binding protein 2; 
CRABP1, cellular retinoic acid binding protein 1; CRABP2, cellular retinoic acid 
binding protein 2; LRAT, lecithin retinol acyltransferase; RT-qPCR, reverse-
transcription quantitative polymerase chain reaction; KCOc % predicted, transfer 
coefficient for uptake of CO of the lung per unit volume as a proportion of predicted 
normal values. 
 
Gene P value of correlation  Spearman's coefficient 
  with KCOc % pred r 
      
RALDH 1 0.47 -0.18 
RALDH 2 0.94 0.02 
RALDH 3 0.28 -0.26 
CYP26 A1 0.031 * -0.49 
CYP26 B1 0.91 0.03 
CYP26 C1 0.99 0.00 
RAR α 0.38 0.21 
RAR β 0.15 -0.35 
RAR γ 0.65 0.11 
CRBP 1 0.88 0.04 
CRBP 2 0.047 * 0.46 
CRABP 1 0.032 * -0.49 
CRABP 2 0.97 -0.01 
RXR α 0.50 0.17 
RXR β 0.75 0.08 
RXR γ 0.50 0.17 
LRAT 0.73 -0.08 
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Figure 3.14 Expressions of CYP26 A1, CRBP 2 and CRABP 1 correlate with 
patient KCOc % predicted 
Plots of the correlation between A) CYP26A1, B) CRBP2 and C) CRABP1 tissue 
expression and patient KCOc % predicted from Table 3.6. Filled circles = 
histologically normal tissue, empty circles = emphysematous tissue. The p value of 
the correlation and the Spearman coefficient r are presented for each correlation. n = 
19. Abbreviations: GUSB, beta-glucuronidase; B2M, beta-2 microglobulin; 
CYP26C1, cytochrome P450 family 26 subfamily C polypeptide 1; CRBP2, cellular 
retinol binding protein 2; CRABP1, cellular retinoic acid binding protein 1; RT-
qPCR, reverse-transcription quantitative polymerase chain reaction; r, Spearman’s 
coefficient; KCOc % predicted, transfer coefficient for uptake of CO of the lung per 
unit volume as a proportion of predicted normal values. 
0 20 40 60 80 100
0.01
0.10
1
10
100
KCOc % pred
C
R
A
B
P1
 : 
G
U
SB
 &
 B
2M
C p < 0.05 
r = -0.49 
0 20 40 60 80 100
0.0
0.5
1.0
1.5
2.0
2.5
C
R
B
P2
 : 
G
U
SB
 &
 B
2M
KCOc % pred
B p < 0.05 r = 0.46 
0 20 40 60 80 100
0.1
1
10
100
KCOc % pred
C
YP
26
 A
1 
: G
U
SB
 &
 B
2M
A p < 0.05 
r = -0.49 
 194 
 
3.3.13 Relationship between RA pathway gene expression and patient airflow 
limitation measured by FEV1/FVC 
 
Gas diffusion capacity reflects the gas exchange surface of the lung, whereas 
spirometry, which measures airflow, reflects airways of the lung (347). To investigate 
the relationship between RA signalling and airflow obstruction, RA pathway gene 
expression was correlated with FEV1/FVC ratio for samples from cohort 1. The p 
values of the correlations and the associated Spearman correlation coefficient r are 
given in Table 3.7. No significant correlations between gene expression and 
FEV1/FVC were observed. Trends towards a positive correlation between RALDH-2 
and RAR-α expressions and FEV1/FVC ratio were observed which did not reach 
statistical significance (RALDH2 p = 0.083, r = 0.41; RAR-α p = 0.058, r = 0.44 
Table 3.7). 
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Gene P value of correlation  Spearman's coefficient 
  with FEV1/FVC ratio r 
      
RALDH 1 0.91 -0.03 
RALDH 2 0.083 0.41 
RALDH 3 0.13 0.36 
CYP26 A1 0.79 -0.07 
CYP26 B1 0.77 0.07 
CYP26 C1 0.67 0.10 
RAR α 0.058 0.44 
RAR β 0.76 -0.07 
RAR γ 0.65 0.11 
CRBP 1 0.88 0.04 
CRBP 2 0.55 -0.15 
CRABP 1 0.20 -0.31 
CRABP 2 0.29 0.26 
RXR α 0.29 0.26 
RXR β 0.25 0.28 
RXR γ 0.16 -0.34 
LRAT 0.80 0.06 
 
Table 3.7 Relationship between RA pathway gene expression and patient airflow 
limitation measured by FEV1/FVC ratio (cohort 1) 
Correlations were derived between the expression of RA pathway genes in whole 
distal lung tissue, assessed by RT-qPCR and normalised to the mean of GUSB and 
B2M, and the degree of patient airflow obstruction, as measured by the ratio of forced 
expiratory volume in 1 second (FEV1) to forced vital capacity (FVC). P value of the 
correlation (2 s.f.) is given in the middle column, and the Spearman coefficient r (2 
d.p.) is given in the right hand column. The rows in light green (RALDH2 and RAR-
a) display correlations which approach statistical significance (p = 0.083 and p = 
0.058 respectively). n = 19. Abbreviations: GUSB, beta-glucuronidase; B2M, beta-2 
microglobulin; RALDH1, retinaldehyde dehydrogenase 1; RALDH2, retinaldehyde 
dehydrogenase 2; RALDH3, retinaldehyde dehydrogenase 3; CYP26A1, cytochrome 
P450 family 26 subfamily A polypeptide 1; CYP26B1, cytochrome P450 family 26 
subfamily B polypeptide 1; CYP26C1, cytochrome P450 family 26 subfamily C 
polypeptide 1; RAR-α, retinoic acid receptor alpha; RAR-β, retinoic acid receptor 
beta; RAR-γ, retinoic acid receptor gamma; RXR-α, retinoid X receptor alpha; RXR-
β, retinoid X receptor beta; RXR-γ, retinoid X receptor gamma; CRBP1, cellular 
retinal binding protein 1; CRBP2, cellular retinol binding protein 2; CRABP1, cellular 
retinoic acid binding protein 1; CRABP2, cellular retinoic acid binding protein 2; 
LRAT, lecithin retinol acyltransferase; RT-qPCR, reverse-transcription quantitative 
polymerase chain reaction. 
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3.3.14 Relationship between RA pathway gene expression and patient airflow 
limitation measured by FEV1 % predicted 
 
RA pathway gene expression was correlated with FEV1 % predicted, irrespective of 
tissue histology, for samples from cohort 1. The p values of correlations and the 
associated Spearman correlation coefficient r are given in Table 3.8. No significant 
correlations between gene expression and FEV1 % predicted were observed. A trend 
towards positive correlation between RALDH-2 expression and FEV1 % predicted 
was observed which did not reach statistical significance (p = 0.078, r = 0.41 Table 
3.8). A trend towards a negative correlation between RXR-γ expression and FEV1 % 
predicted was observed which did not reach statistical significance (p = 0.074, r = -
0.42 Table 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 197 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.8 Relationship between RA pathway gene expression and patient FEV1 
% predicted (cohort 1) 
Correlations were derived between the expression of RA pathway genes in whole 
distal lung tissue, assessed by RT-qPCR and normalised to the mean of GUSB and 
B2M, and the degree of patient airway obstruction, as measured by the forced 
expiratory volume in 1 second (FEV1) compared to the normal value predicted by 
patient characteristics (age and height). P value of the correlation (2 s.f.) is given in 
the middle column, and the Spearman coefficient r (2 d.p.) is given in the right hand 
column. The rows in light green (RALDH2 and RXR-γ) display correlations which 
approaches statistical significance (p = 0.078 and p = 0.074 respectively). n = 19. 
Abbreviations: GUSB, beta-glucuronidase; B2M, beta-2 microglobulin; RALDH1, 
retinaldehyde dehydrogenase 1; RALDH2, retinaldehyde dehydrogenase 2; RALDH3, 
retinaldehyde dehydrogenase 3; CYP26A1, cytochrome P450 family 26 subfamily A 
polypeptide 1; CYP26B1, cytochrome P450 family 26 subfamily B polypeptide 1; 
CYP26C1, cytochrome P450 family 26 subfamily C polypeptide 1; RAR-α, retinoic 
acid receptor alpha; RAR-β, retinoic acid receptor beta; RAR-γ, retinoic acid receptor 
gamma; RXR-α, retinoid X receptor alpha; RXR-β, retinoid X receptor beta; RXR-γ, 
retinoid X receptor gamma; CRBP1, cellular retinal binding protein 1; CRBP2, 
cellular retinol binding protein 2; CRABP1, cellular retinoic acid binding protein 1; 
CRABP2, cellular retinoic acid binding protein 2; LRAT, lecithin retinol 
acyltransferase; RT-qPCR, reverse-transcription quantitative polymerase chain 
reaction. 
Gene P value of correlation  Spearman's coefficient 
  with FEV1 % pred r 
      
RALDH 1 0.98 -0.01 
RALDH 2 0.078 0.41 
RALDH 3 0.22 0.29 
CYP26 A1 0.39 -0.21 
CYP26 B1 0.98 -0.01 
CYP26 C1 0.54 0.15 
RAR α 0.18 0.32 
RAR β 0.62 -0.12 
RAR γ 0.65 0.11 
CRBP 1 0.89 -0.04 
CRBP 2 0.81 -0.06 
CRABP 1 0.15 -0.34 
CRABP 2 0.54 0.15 
RXR α 0.71 0.09 
RXR β 0.64 0.11 
RXR γ 0.074 -0.42 
LRAT 0.93 0.02 
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3.4 Discussion 
 
3.4.1 Summary of key findings in this chapter 
 
The initial work in this chapter confirmed the mRNA expression of critical RA 
pathway genes in histologically normal human distal lung tissue. An HPLC method 
was optimised to separate synthetic retinoid standards. A preliminary HPLC 
experiment suggested the presence of endogenous retinoic acid and retinol in normal, 
human distal lung. It was demonstrated, with RT-qPCR, that CYP26A1 mRNA is 
upregulated in histologically emphysematous regions of the distal lung, whereas other 
RA pathway genes are not. Microarray data from Spira et al. (348), obtained through 
Gene Expression Omnibus, provided external validation of this finding. Western blot 
confirmed increased levels of CYP26A1 protein in emphysematous lung tissue in an 
independent cohort of patients. Immunohistochemistry revealed localisation of 
CYP26A1 protein in cells with morphology and localisation of alveolar macrophages 
in histologically normal lung tissue sections. A post-hoc assessment of the 
relationship between RA pathway gene expression and patient gas diffusing capacity 
revealed an inverse correlation between CYP26A1 and CRABP-1 expression and 
KCOc % predicted, and a positive correlation between CRBP-2 expression and KCOc 
%. There were no significant correlations between RA pathway gene expression and 
spirometric indices of patient airflow. 
 
3.4.2 Expression of RA pathway genes in adult human distal lung tissue 
 
RA pathway mRNA expression has been characterised in the postnatal lungs of rats 
and mice (79, 349, 350). We found expression of RALDH-1, -2 and -3, CYP26A1, 
B1 and C1, RAR -α, -β, and -γ, RXR -α, -β, and -γ,  CRBP-1 and -2, and CRABP-1 
and -2, in all adult human distal lung tissue samples assessed, except for CYP26C1 
which was expressed in 8 of 9 samples, and CRABP-1 which was expressed in 7 of 9 
samples (Figure 3.1). Our observations support previously published reports (109, 
121, 251, 351-353). However, there are also several discrepancies. Xi et al. found 
expression of CYP26A1 and CYP26C1 but not CYP26B1 in adult human lung tissue 
(121). The discrepancy may reflect sampling differences between studies - Xi et al., 
did not state sample number, whereas we found CYP26B1 expression in tissue from 
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all 9 adult donors assessed. In support of our finding of CYP26B1 expression in the 
human lung, CYP26B1 is the predominant CYP26 isoform in neonatal mouse lungs 
(55).  
 
Expression of CRBP-1 in the lung has previously been found to be among the lowest 
of all human tissues (109, 353). CRBP-2 was absent from the lung in rats, instead 
found exclusively in the small intestine (354) and CRBP-2 is also abundant in the 
small intestine in humans (91); CRBP-2 expression has not previously been 
investigated in adult human lung. Our finding of both CRBP-1 and -2 expression in 
adult human lung may reflect differences in intracellular retinol transport between 
rodents and humans. The RT-PCR method we employed was not quantitative, and so 
gave no indication of CRBP-1 or -2 expression levels; RT-qPCR, using a standard 
curve comprising transcripts of known concentration, would be required to determine 
absolute CRBP-1 or -2 mRNA levels. The biological relevance of CRBP-2 expression 
in the lung is discussed later in this chapter.  
 
Previous studies reported CRABP-1 binding activity in cancerous, but not normal, 
lung tissue (355, 356). In the present study, 6 of 9 patients assessed for CRABP-1 
expression were undergoing resection for cancer, however there was no correlation 
between diagnosis and CRABP-1 expression (1 of 2 patients absent for CRABP-1 had 
cancer, and 5 of 7 present for CRABP-1 expression had cancer). As only mRNA 
expression was assessed in this study, it is possible that the discrepancy reflects post-
transcriptional mechanisms which regulate CRABP-1 binding activity in the lung. We 
found CRABP-2 expression in all 10 donors, supporting a study which found 
CRABP-2 expression in normal human lung fibroblasts (251), although CRABP-2 
was absent in adult mouse lung (350). This supports a hypothesis that cytoplasmic RA 
transport differs between human and rodent lung.  
 
3.4.3 Determination of endogenous human lung retinoids with HPLC 
 
Retinoids are lipophilic molecules, and thus we used high performance liquid 
chromatography (HPLC) to directly measure retinoids. An HPLC method was 
optimised to separate known retinoid standards (13-cis RA, 9-cis RA, ATRA, retinol, 
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retinal and retinyl acetate), adapted from Rühl and Schweigert (302). In a preliminary 
experiment using this method with a human lung tissue extract, we identified peaks 
with elution times corresponding to ATRA and retinol (Figure 3.2). Due to sample 
availability this was not repeated, thus further experiments with human distal lung 
tissue samples will be required. Identification of endogenous retinol in our study is in 
agreement with the data of Redlich et al., which found retinol at 0.15 µg/gram tissue 
in distal human lung (357). RA is the primary biologically active retinoid species 
(introduction 1.5), and has not been directly measured in human lung tissue 
previously. Our identification of RA in human distal lung tissue suggests the 
conservation of endogenous RA synthesis in normal distal human lung. This is in 
agreement with HPLC data from adult mouse lung, which identified ATRA and all-
trans retinol, as well as endogenous 4-hydroxy-4, 14-retro-retinol (14HRR) and 4-
oxo-retinoic acid (79). The unknown peak at 3.7 minutes was likely to be a polar 
compound, perhaps an oxidative product of RA metabolism, as these would be eluted 
first during reverse-phase HPLC. The peaks at 16.53 and 21.45 minutes may be non-
polar storage retinoids, as these would be eluted last during reverse-phase HPLC. This 
would be in agreement with the data of Schäffer et al. (337), which identified retinyl 
palmitate and retinyl stearate (storage retinyl esters) in distal human lung tissue. 
 
The extraction method we used was based on the method of Kane and Napoli (301), 
however as extraction efficiency was not determined, retinoid levels could not be 
quantified. This could be addressed in future studies with an internal standard, which 
allows quantification by establishing extraction efficiency, handling loss, and 
revealing handling-induced iso-merisation or degradation (358). Retinoids exhibit 
maximal absorbance at 318-383 nm, and thus we measured absorbance at 354 nm 
(358). It is possible that lipophilic, non-retinoid compounds within the extract had 
absorbance at 354 nm with similar elution times to the peaks we identified. To 
confirm the identity of the peaks we observed as retinoids, analysis of sample 
constituents using a photodiode array (PDA) will be required. PDA measures 
absorbance across a spectrum of UV wavelengths, producing an absorbance signature 
which is unique to each compound; a PDA has previously been used to confirm 
retinoid identity with HPLC (79). In summary, our observation with RT-PCR and 
HPLC support conservation of RA signalling in normal parenchymal regions of adult 
human lung. 
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3.4.4 Patient demographics and lung function values for RT-qPCR  
 
Confirmation of RA pathway gene expression in adult distal human lung tissue 
provided a basis for RT-qPCR analysis of their expression levels in chronic lung 
disease. A separate set of lung tissue samples was used, categorised according to 
histology of immediately adjacent tissue regions (n=9 emphysema, n=10 control, 
donor demographics summarised in Table 3.1). Samples were selected from age-
matched patients due to possible confounding influences of age on RA pathway gene 
expression, based on a report of decline in RALDH-3 expression with age in lung 
mesenchymal stem cells (LMSCs) in mice (255). Age and height were not 
significantly different between emphysema and control groups (p > 0.05). There was 
a trend towards lower weight in emphysema patients compared control (p = 0.06). 
This may reflect weight loss in COPD patients, which is an important independent 
risk factor for survival in COPD (359). Potential implications of reduced weight in the 
emphysema group are discussed later in this chapter. 
 
Capacity for gas uptake of the lung is assessed most widely by measuring diffusing 
capacity for carbon monoxide (DLCO; KCO is gas transfer per unit volume). Gas 
diffusion measurements give an indication of the global integrity of the alveolar-
capillary barrier; DLCO has been found useful in selection of emphysema patients 
likely to benefit from lung volume reduction surgery (LVRS) (360). Emphysema 
involves decrease in alveolar surface area with reduction in net diffusing properties of 
the alveolar-capillary barrier, therefore DLCO and KCO decline with emphysema 
severity. Significantly reduced KCOc % predicted and DLCOc % predicted were 
observed in emphysema patients compared to control (p < 0.001), indicative of 
impaired gas diffusion in these patients, and supporting the histological classification 
of the tissue.(361). 
COPD describes poorly reversible global airflow limitation, comprised of chronic 
airway obstruction (chronic bronchitis) and/or emphysema (52), and is diagnosed with 
clinical lung function tests. The most widely used test is spirometry, which assesses 
the volume and/or speed of inhaled or exhaled air and can be used to estimate airflow 
limitation in a patient (e.g. forced vital capacity (FVC), forced expiratory volume in 1 
second (FEV1), FEV1/FVC ratio) (345). FVC is the volume of air exhaled with 
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maximally forced effort starting from a maximal inspiration. A trend towards reduced 
FVC was observed in the emphysema group (p = 0.06), while the total lung capacity 
(TLC) was similar between control and emphysematous group, suggesting a mainly 
obstructive rather than restrictive phenotype in these patients (347). FEV1 is the 
volume of air exhaled in the first second of a forced expiration starting from full 
inspiration (362), and measures airflow limitation. With sufficient expiratory effort, 
the flow of air out of the lungs is limited by the elastic recoil of the lungs and the 
resistance of the airways (363). In COPD, reduction in small airway (< 2 mm 
diameter) number (364), and narrowing of small airways due to hypersecretion of 
inflammatory exudates and thickening of airway walls (365), lead to lower FEV1. In 
addition, alveolar destruction in emphysema leads to reductions in both elastic lung 
recoil pressure and radial traction on airways, further limiting airflow (366). 
Significantly reduced FEV1 (** p < 0.01) was observed in emphysema patients 
compared to controls, indicating airflow limitation in these patients. 
 
FEV1/FVC is the proportion of vital capacity exhaled in the first second of expiration. 
A post-bronchodilator FEV1/FVC ratio of less than 0.7 indicates persistent airflow 
limitation and defines COPD (345). FEV1/FVC was significantly reduced in the 
emphysema group compared to controls (* p < 0.05). The median FEV1/FVC ratio of 
the control group was 0.55, less than the threshold required to diagnose COPD (0.7), 
indicating airflow limitation in controls. Clinical patient information revealed that out 
of 9 patients who contributed control tissue, 2 had COPD and 1 had emphysema, 
suggesting disease in other regions of their lungs, which may be related to most 
control patients in our cohort being ex-smokers. 
 
FEV1 % predicted compares the maximal FEV1 of a patient with a predicted normal 
value based on age, height, ethnic group and sex (367). FEV1 % predicted is used to 
grade the severity of disease in COPD patients (with post-bronchodilator FEV1/FVC 
< 0.7) according to the Global Initiative for Chronic Obstructive Lung Disease criteria 
(GOLD) (345). FEV1 % predicted of the emphysema group was significantly lower 
than in control (* p < 0.05). The median FEV1 % predicted are 29.5% in the 
emphysema group and 80.0% in the control group, corresponding to GOLD stage 4 
and GOLD stage 1 respectively.  
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3.4.5 RA pathway mRNA expression in normal and emphysematous human 
lung tissue: dysregulation of CYP26A1 
 
We found significantly increased expression of CYP26A1 mRNA in emphysematous 
lung tissue compared to controls (p < 0.05, Figure 3.4). No other differences in RA 
pathway gene expression were observed between emphysema and controls. We next 
compared our data to 5 previously published microarray datasets with comparable 
sample sizes to ours, also addressing emphysema (338-342). These studies did not 
identify altered RA pathway expression based on their significance criteria. However, 
the complete microarray datasets were publicly available through the Gene 
Expression Omnibus (GEO) online database repository. This provided an opportunity 
to test the reproducibility of our finding in independent cohorts from independent 
clinical settings. Summaries of the 5 studies are outlined in Table 3.2. 
 
Spira et al (342) (GEO accession GSE1650) used whole lung tissue from 12 resection 
patients with mild/no airflow limitation, and from 18 patients with clinically and 
radiologically confirmed severe emphysema undergoing LVRS. We found a trend 
toward increased expression of CYP26A1 in lung tissue from patients with severe 
emphysema compared to control. This did not reach statistical significance (p = 0.3) 
which may be due to an outlier in the control group. Outliers are common in human 
datasets, reflecting normal variability of the population and the heterogeneity of 
disease. Fujino et al. (340) (GEO accession GSE29133) used isolated alveolar type 2 
(AT2) cells from normal (n=3) and emphysema patients (n=3). The small sample size 
precluded statistical analysis, however a trend towards increased CYP26A1 
expression was observed in AT2 cells in emphysematous lungs.  
 
The distribution of CYP26A1 expression in control and emphysema groups in the 
studies by Spira et al. and Fujino et al. resembles our study, with clustering around 
the median in the control group suggesting minimal variation in normal lung tissue, 
and a high degree of variability in the emphysema group. This supports the 
reproducibility of our observations in distinct cohorts of patients in different clinical 
settings, and increases the probability that our observations are applicable to the wider 
population of COPD patients. 
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Three additional microarray studies investigated transcriptional profiles of 
emphysema lung, published by Campbell et al. (338) (GEO accession GSE27597), 
Francis et al. (339) (GEO accession GSE17770) and Golpon et al. (341) (GEO 
accession GSE1122). Campbell et al. (338) used 2 normal lungs and 6 COPD lungs. 
However, of the COPD lungs, 1 was from a patient with alpha-1 antitrypsin (AAT) 
deficiency, 1 was from a patient with both von Willebrand disease (VWD) and 
hypertension, and 1 was from a patient without emphysema. In the remaining samples 
(n=2 control, n=3 emphysema), no difference in CYP26A1 expression between 
emphysema and control was observed. The discrepancy with our data may reflect the 
small sample size used, and variability between cohorts. Francis et al. (339) compared 
transcriptional profiles of moderate to mild emphseyma. There was no significant 
difference in CYP26A1 expression, suggesting that CYP26A1 expression may not 
differ between patient with mild and moderate emphysema. The final study by 
Golpon et al. (341) did not include CYP26A1 in the microarray platform. Several 
microarray studies have examined distal whole lung tissue of COPD patients (368-
371), however they did not specifically investigate emphysematous tissue, and thus 
were excluded from our study. 
 
We used Western blot to determine levels of CYP26A1 protein in homogenates of 
emphysematous and control lung tissue samples, from a separate cohort of patients 
(cohort 2). Incubation with anti-CYP26A1 antibody revealed an immunoreactive band 
at ~56 kDa, corresponding to the expected size of CYP26A1 (131). Quantification of 
band intensity showed a trend towards increased CYP26A1 protein compared to 
control (p = 0.095, Figure 3.12 B). Bands at ~100 kDa and ~200 kDa were visible on 
the blot following incubation with anti-CYP26A1 antibody (data not shown). Their 
intensity correlated with the 56 kDa band, and may be dimers and quadramers of 
CYP26A1 respectively. To control for protein loading, membranes were incubated 
with antibody for beta actin, which has been used previously for normalising protein 
expression in human emphysema lung tissue (372, 373). Normalisation of CYP26A1 
band intensity to beta actin showed significantly increased CYP26A1 protein in 
emphysema compared to control (p < 0.05, Figure 3.12 C). Observation of increased 
CYP26A1 protein in emphysematous lung tissue supports the physiological relevance 
of the RT-qPCR data described above. Furthermore, this data is derived from an 
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independent cohort, supporting the generalisation of the finding to the wider 
population of emphysema patients. 
 
To identify possible sources of CYP26A1 in the human lung, we used 
immunohistochemistry on paraffin sections of lung tissue derived from histologically 
normal regions of resection specimens. Immunoreactivity of CYP26A1 was observed 
in cells with morphology and localisation of alveolar macrophages (Figure 3.13). 
Immunoreactivity was also observed in the apical surface of airway epithelium (not 
shown). Non-primary controls revealed no positive staining, indicating staining was 
specific. Immunoreactivity of CYP26A1 was not observed in any other alveolar cell 
type, including alveolar type 1 or type 2 cells. This is in accordance with the 
expression pattern of CYP26A1 in lung from Human Protein Atlas, which shows high 
CYP26A1 expression in alveolar macrophages, while it is absent in pneumocytes 
(http://www.proteinatlas.org/ENSG00000095596/tissue/lung). We did not have 
access to paraffin sections of emphysematous lung tissue, to determine whether the 
expression pattern of CYP26A1 is similar in emphysematous lung or whether other 
cell types express CYP26A1 in emphysema to account for the increased CYP26A1 
protein we observed. However, smokers who develop severe emphysema exhibit 
accumulation of alveolar macrophages compared to smokers with normal lung 
function (374). Thus, increased levels of CYP26A1-positive alveolar macrophages in 
lung tissue in emphysema could account for the high CYP26A1 mRNA and protein 
levels we observed in emphysematous lung tissue. 
 
From our study it cannot be determined if upregulated CYP26A1 expression is an 
aetiologic factor in emphysema (375). However, current knowledge of RA signalling 
suggests increased CYP26A1, resulting in RA degradation, could have a role in 
emphysema aetiology and/or pathogenesis. CYP26A1, B1 and C1 are enzymes which 
catalyse RA catabolism, and with RALDH-1, -2 and -3, regulate local RA availability 
(4). CYP26A1 is the predominant CYP26 isoform in the human liver (55). CYP26A1 
has high specificity for RA, and high catalytic hydroxylase activity compared to other 
isoforms (376), therefore it is plausible that increased CYP26A1 in the lung would 
cause local RA depletion. RA levels have not been measured in the lungs of 
emphysema patients, however a recent study reported reduced storage retinoid levels 
in the lungs of COPD patients (337). Increased CYP26A1 could mimic vitamin A 
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deficiency, which leads to emphysema in the lungs of rats (74, 75). It has been 
suggested that ineffective repair mechanisms contribute to the pathogenesis of 
emphysema (377). Therefore, it could be hypothesised that increased CYP26A1 
contributes to an inability to initiate RA-mediated lung regeneration in emphysema. 
 
Altered CYP26A1 expression may result in disruption of the protease/antiprotease 
balance, which is observed in the lungs of emphysema patients (378). Overexpression 
of CYP26A1 in dysplastic Barret’s oesophageal cells resulted in upregulation of 
matrix-metalloproteinase (MMP) -3 and downregulation of tissue inhibitor of 
metalloproteinase (TIMP) -1 and TIMP-2 (379). RA itself may have protective effects 
against proteolytic damage in the lung. RA inhibited neutrophil elastase (NE)-
mediated secretion of MMP-3 by human lung fibroblasts, resulting in inhibition of 
collagen degradation in vitro (380). In another study, RA downregulated MMP-9 and 
upregulated TIMP-1 in alveolar macrophages isolated from patients with emphysema 
(288). Therefore, it is possible that increased CYP26A1-mediated RA degradation 
could reduce the protective effects of endogenous RA against proteolytic damage, 
which could contribute to the pathogenesis of emphysema. 
 
The reasons for increased CYP26A1 in emphysematous lung cannot be determined 
from our study, but may be related to proximal events in the pathogenesis of 
emphysema such as inflammation, tissue ischemia, oxidative stress or impaired 
energy metabolism (381). Cigarette smoke exposure, the main risk factor for 
emphysema, results in local depletion of RA in the lungs of ferrets in vivo (382, 383). 
In rat lungs, cigarette smoke caused a local retinol depletion which was associated 
with progression of emphysema (278). In another study, cigarette smoke induced the 
upregulation of several cytochrome P450 enzymes in ferret lung fibroblasts in vitro, 
which caused increased RA catabolism (384). It was possible that chronic cigarette 
smoke exposure caused the CYP26A1 upregulation in our study population. We 
therefore performed a post-hoc analysis of the relationship between cigarette smoke 
exposure (pack-years) and CYP26A1 expression, however there was no significant 
correlation (data not shown). In addition, cigarette smoke exposure in the emphysema 
group was not significantly different to control (p > 0.05). The relationship between 
lung dysfunction and cigarette smoke exposure is not simply dose-dependent, and 
susceptibility to COPD in response to smoking is highly variable within the general 
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population (385). Therefore, it is unlikely that cigarette smoke exposure accounted for 
the increase in CYP26A1 expression we observed. 
 
Another possible explanation is variance in the CYP26A1 gene. Several single 
nucleotide polymorphisms (SNPs) have been identified in the CYP26A1 gene (386-
389), which have functional consequences on RA catabolism in vitro (387, 388). 
These have not hitherto been linked to human disease, and how they relate to gene 
expression in vivo and lung function has not been investigated. It is plausible that 
CYP26A1 genetic variation could alter gene expression levels, causing different 
transcriptional patterns which may be associated with emphysema. 
 
The human CYP26A1 gene is highly inducible by RA owing to 3 RAREs and one 
half-site RARE in its promoter (131). It was thus possible that CYP26A1 upregulation 
was caused by increased endogenous RA signalling. However, we did not observe 
increased expression of RA synthesising enzymes (RALDH-1, -2, or -3) in the 
emphysema group, and a local retinoid deficiency has previously been observed in the 
lungs of COPD patients (337). An alternative explanation is RA-independent 
induction of CYP26A1. For example, maintenance of CYP26A1 expression has been 
demonstrated in the zebrafish embryo in the absence of endogenous RA synthesis, 
caused by RALDH inhibitor diethylaminobenzaldehyde (DEAB) (390, 391), or with 
morpholino-induced RALDH2 knockdown (391).  
 
An RA-independent mechanism for CYP26A1 induction may be through Wnt 
signalling. The Wnt pathway is driven by interactions between Wnt ligands and the 
Frizzled (FZD) family of receptors, and has important roles in organogenesis, 
patterning, and repair of many organs including the lung, while aberrant Wnt 
signalling has been linked to cancer, fibrosis and inflammatory diseases (392). 
CYP26A1 is a direct target of the Wnt/β-catenin/T-cell factor (TCF) pathway (the 
canonical Wnt pathway) (390). Numerous reports indicate increased Wnt signalling in 
the lungs of patients with COPD. The Wnt pathway ligands WNT10b (72) and WNT4 
(393) were upregulated in lung tissue from COPD patients, and canonical Wnt 
signalling was increased in fibroblasts of patients with COPD (394). Furthermore, 
WNT4 expression was higher in bronchial epithelial cells of COPD patients compared 
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to healthy smokers (395). The role of Wnt signalling in COPD is controversial 
however, and decreased expression of canonical Wnt pathway genes has been 
observed in small airway (396) and alveolar (72) epithelium of COPD patients. 
Nevertheless, Wnt signalling as a possible upstream mediator of CYP26A1 induction 
in emphysematous lung may warrant further investigation. Cdx2, a homeobox 
transcription factor involved in patterning during development and upregulated in 
certain cancers, can also directly induce CYP26A1 expression (397), and CYP26A1 
and B1 have been induced by the peroxisome-proliferator activated receptor (PPAR)-
γ agonist pioglitazone in primary human hepatocytes (398). These RA-independent 
mechanisms may account for our observation of increased CYP26A1 induction in 
emphysematous lung. 
 
3.4.6 Intra-patient variability 
 
To evaluate intra-patient variability, duplicate lung tissue samples were assessed from 
4 patients who contributed normal tissue, and from 4 patients who contributed 
emphysematous tissue. Within-patient variability was small relative to variation 
between individuals (Figure 3.10). Due to sample availability, duplicate samples were 
from the same piece of resected tissue from these patients and so gave an indication of 
variability over a limited area of lung. However, this data provides confidence in the 
consistency and reproducibility of the gene expression analysis method we used. Our 
data is in accordance with previous transcriptional profiling studies, which found 
limited regional variability of expression within patients compared to variability 
between patients (341, 399). 
 
3.4.7 Relationship between clinical variables and lung function parameters 
 
We next investigated the relationship between gene expression and quantitative 
measurements of lung function. Emphysema is a heterogeneous disease, often with 
varying degrees of damage across the lung (400). Quantitative data regarding the 
severity of damage within tissue samples was not available to us. However, the 
clinical datasheets included gas diffusing capacity (KCOc % predicted), a quantitative 
measure of the global integrity of the alveolar capillary membrane, thus reflecting 
global emphysema severity (346). We therefore investigated the relationship between 
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RA pathway gene expression and KCOc % predicted. The correlation analysis was 
performed on all tissue samples (n=19) irrespective of their histology.  
 
Initially, the relationship between clinical variables (age, height, weight and cigarette 
smoke exposure in pack years) and lung function measurements (KCOc % predicted, 
FEV1/FVC and FEV1 % predicted) was assessed to evaluate potentially confounding 
variables (401) (Table 3.5). No significant correlations were observed. A trend 
towards a positive correlation was observed between weight and KCOc % predicted 
(p = 0.077, r = 0.42), reflecting the trend towards reduced weight in patients who 
contributed emphysematous tissue. Additionally, a trend towards a negative 
correlation between pack years and FEV1/FVC (p = 0.055, r=0.5) was observed. This 
could suggest that associations between gene expression and KCOc % predicted or 
FEV1/FVC are partly explained by weight or cigarette smoke exposure respectively. 
It may therefore be appropriate to adjust for any relationship with weight or pack 
years by fitting the data to regression model. However, this would make assumptions 
about the form of the effect (e.g. linear or exponential) of weight on KCOc % 
predicted, or of pack years on FEV1/FVC, in our study population, which cannot be 
determined with the sample size in this study (401). Further studies using a larger 
population with a broad range of weights and/or pack years would be necessary to 
determine their effect on lung function before a regression model can be developed. 
Therefore, we investigated the relationship between gene expression and lung 
function without adjustments for weight or cigarette smoke exposure.  
 
3.4.8 Relationship between RA pathway gene expression and patient gas 
diffusing capacity 
 
We found a significant inverse correlation between CYP26A1 expression and KCOc 
% predicted (i.e. low gas diffusing capacity was associated with high expression of 
CYP26A1) (p < 0.05, r = -0.49, Figure 3.14). This supported our previous finding of 
increased CYP26A1 expression in emphysematous lung tissue samples, and suggests 
that upregulation of CYP26A1 may also reflect a global, phenotypic manifestation of 
emphysema.  
 
We also found a significant positive correlation between CRBP-2 and KCOc % 
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predicted (low gas diffusing capacity was associated with decreased CRBP-2 
expression) (p < 0.05, r = -0.49, Figure 3.14). CRBP-2 is primarily expressed in the 
small intestine (91) and channels retinol to lecithin:retinol acyltransferase (LRAT) for 
conversion into retinyl esters for storage (described in introduction 1.5.4 (402)). 
CRBP-2 has been detected in the perinatal mouse lung where its expression peaks 
during alveolar septation (350), however its expression was low in the adult lung 
(350). In CRBP-2 knockout mice, no lung phenotype was reported, suggesting a 
minimal role for CRBP-2 in mouse lung (403), however a role for CRBP-2 in the 
adult human lung has not been explored. Despite its low basal levels of expression, it 
is possible that decreased CRBP-2 in the adult human lung could lead to reduction in 
the esterification of retinoids into storage forms. This may contribute to the recently 
described reduction in retinyl esters in severe COPD (337).  
 
The positive correlation between CRBP-2 and gas diffusing capacity was independent 
of tissue histology, as we did not find decreased CRBP-2 mRNA expression in 
emphysematous tissue. A possible explanation is that CRBP-2 downregulation is a 
global change in COPD patients. This could contribute to reduction in gas transfer 
efficiency, which may precede local emphysematous destruction. A possible reason 
for a global alteration in CRBP-2 expression could be variation in the CRBP-2 gene. 
Recently a SNP in the CRBP2 gene was found, which had a significant association 
with plasma homocysteine (Hcy) levels (404). It was suggested that genetic variants 
in CRBP2 are associated with congenital diaphragmatic hernia (CDH), as the CRBP2 
gene is located in a region which is recurrently affected in CDH patients (405). This 
suggests a role for CRBP-2 in human lung development. An association with CRBP2 
variants and emphysema has not been investigated, but it is possible that they could 
affect CRBP-2 mRNA expression and give rise to a global pattern of expression 
contributing to emphysema progression in adults. 
 
We also observed a significant inverse correlation between cellular retinoic acid 
binding protein 1 (CRABP-1) expression and KCOc % predicted (i.e. low gas 
diffusing capacity was associated with increased CRABP-1 expression) (p < 0.05, r = 
-0.49, Figure 3.14). CRABP-1 serves to enhance RA degradation by transporting RA 
to CYP26 enzymes. Overexpression of CRABP-1 in F9 teratocarcinoma cells 
diminished their sensitivity to RA-induced differentiation (125), and increased the 
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catabolism of RA to inactive polar metabolites (126). Our observations suggest that 
increased RA degradation through the CRABP-1-CYP26 axis may be associated with 
increasing emphysema severity. 
 
As with CRBP-2, the correlation between CRABP-1 expression and gas diffusion 
capacity was independent of histology, suggesting a global gene expression change 
that may precede the development of emphysema lesions. Two SNPs have been 
identified in the promoter region for the closely related binding protein CRABP-2, 
which have been linked to familial combined hyperlipidemia (FCHL) (406), however 
no genetic variations of the CRABP-1 gene have been identified thus far. It remains to 
be determined if genetic variation could account for altered CRABP-1 expression. 
 
In our analyses, KCOc % predicted was used rather than DLCOc % predicted. KCO 
and DLCO differ in that DLCO is the product of KCO and VA (alveolar volume). We 
repeated the gene expression analyses using DLCOc % predicted as the quantitative 
variable. Similar to KCOc % predicted, significant correlations were found between 
CYP26A1, CRBP-2 and CRABP-1 with DLCOc % predicted, whereas no other 
significant correlations were found (data not shown). 
 
3.4.9 Relationship between RA pathway gene expression and patient airflow 
obstruction 
 
It has been proposed that emphysematous destruction and small airway dysfunction 
arise through distinct mechanisms in COPD (407). Furthermore, small airway disease 
precedes the development of emphysema in the pathogenesis of COPD (364, 408). 
Therefore, investigating the relationship between RA pathway alterations and airflow 
obstruction may provide insights into the role of RA signalling in proximal events in 
COPD pathogenesis. We therefore assessed the relationship between RA pathway 
genes expression and spirometric indices, which measure airflow obstruction (342).  
 
We did not find significant correlations between RA pathway gene expression and 
FEV1 % predicted (Table 3.8). A trend towards positive correlation was observed 
between RALDH-2 and FEV1% predicted, however this did not reach significance (p 
= 0.078, r = 0.41). We also observed a trend towards negative correlation between 
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RXR-γ and FEV1 % predicted (p = 0.074, r = -0.42).  Similarly, no significant trends 
were observed between RA pathway gene expression and FEV1/FVC, although trends 
towards positive correlations were observed for RALDH-2 (p = 0.083, r = 0.41) and 
RAR-α (p = 0.058, r = 0.44, Table 3.7).  
 
Our study was designed to compare gene expression between histologically normal 
and emphysematous lung tissue, and was not designed to include patients with a 
broad range of FEV1 % predicted values. Most patients in our population had 
FEV1/FVC < 0.7, suggesting moderate to severe airflow obstruction. Therefore, 
further experiments using a cohort with a broad range of spirometric values are 
required to investigate relationship between RA signalling and airflow obstruction.  
 
3.4.10 Limitations and future work 
 
 
There are several limitations to our study. Emphysema is likely to reflect co-ordinated 
pathological process between different lung cell types. An inherent limitation of using 
whole tissue is that the contribution of specific cell types may be diluted. For 
example, Plantier et al. reported CRABP-2 downregulation in lung fibroblasts from 
patients with emphysema (251), whereas we did not observe differences in CRABP-2 
mRNA expression in the emphysema group. This may be due to other cell types 
within whole tissue samples masking the transcriptional profile of fibroblasts. To 
determine which cell types exhibit transcriptional changes, specific cell types, such as 
fibroblasts, could be isolated from control or emphysematous lung for RT-qPCR 
analysis. However, this approach is complicated by the effect of isolation protocols 
and culture conditions on gene expression. In situ hybridisation using whole lung 
tissue sections may therefore be useful in determining transcriptional changes in 
specific cell types.  
 
There was no information regarding cellular content of the emphysematous and 
normal tissue samples used for the RT-qPCR and Western blot. Therefore, it is 
possible they contained variable amounts of parenchymal, airway and blood vessel 
tissue, and inflammatory cells (368). In particular, inflammatory cell influx increases 
in the distal lung in emphysema (409), which may account for the increased 
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CYP26A1 mRNA and protein we observed. Immunohistochemistry for CYP26A1 in 
histologically normal lung tissue sections suggested alveolar macrophages were the 
primary source of CYP26A1 in the distal lung. Immunohistochemistry for CYP26A1 
protein in emphysematous lung tissue was not possible due to lack of availability of 
emphysematous lung sections, however this would be necessary to determine whether 
the increased CYP26A1 in emphysema was due to increased numbers of CYP26A1-
positive alveolar macrophages or due to increased CYP26A1 expression in 
pneumocytes. We observed a trend towards increased CYP26A1 expression in 
isolated AT2 cells from the microarray dataset by Fujino et al. (340) suggesting that 
the alveolar epithelium may partly contribute to the increased CYP26A1 expression in 
emphysematous tissue. 
 
There is considerable phenotypic heterogeneity within emphysema patients, with 
different patterns of destruction across the lung (400). Furthermore, emphysema 
patients often exhibit different rates of lung function decline (410). This heterogeneity 
may reflect distinct pathological mechanisms, which may account for the variability 
in CYP26A1 mRNA expression we observed in the emphysema group. It is possible 
that altered CYP26A1 regulation represents a distinct emphysema phenotype, which 
may affect prognosis. Our analysis was cross-sectional, and there was no information 
about the study population at a later time point. It would therefore be interesting to 
determine whether patients with upregulated CYP26A1 had a different prognosis than 
other emphysematous patients.  
 
Clinical information available for our study population included age, gender, height, 
weight, smoking history, pathological diagnoses, and lung function measurements. 
While the patients were largely matched for these parameters, there was a trend 
towards lower weight in the emphysema group, and there was a trend towards a 
positive correlation between weight and KCOc % predicted. Weight loss due to 
cachexia is an important extrapulmonary manifestation of COPD, and a frequent 
comorbidity particularly associated with emphysema (411). These patients do not 
respond to high oral nutritional therapy (412) suggesting metabolic disturbances and 
an underlying primary pathology. There is a possibility that weight loss independently 
partially accounts for the relationships we observed between CYP26A1, CRBP-2 and 
CRABP-1 and KCOc % predicted. Our study was not appropriately designed to assess 
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the effect of weight on gene expression, however it is interesting to note that the 
patients with the lowest weight also exhibited the highest CYP26A1 expression, 
whereas no discernable relationship was observed between weight and CRBP-2 or 
CRABP-1 expression. It is possible that severe weight loss in emphysema represents a 
phenotype of the disease associated with increased CYP26A1 expression. However 
further studies using an independent cohort of patients with a broad range of weights 
will be needed to address this hypothesis. 
 
We did not have access to certain clinical information such as body composition, 
exacerbation frequency, hypoxaemia, dyspnea, systemic diseases, oxygen use, or 
medications. Patients with worse airflow limitation may be more likely to use inhaled 
corticosteroids, which may affect retinoid signalling in the lung. Further studies are 
required to separate effects of medication on RA pathway regulation from those 
related to disease. 
 
From our observations, we hypothesise that local RA degradation through increased 
CYP26A1 activity may contribute to emphysema. To investigate this hypothesis 
further, it will be important to directly measure RA levels in emphysematous lung 
tissue. The HPLC protocol we developed was capable of separating synthetic retinoid 
standards, and applied to whole lung tissue, resulted in a signal that suggested the 
presence of RA. Use of a standard curve with dilutions of known concentrations of 
RA will be required to quantitatively measure RA levels in the human lung. This 
approach could be used to compare RA levels between normal and emphysematous 
lung tissue. Use of a photodiode array (PDA) detector could then be used to confirm 
the identity of the retinoid peaks in tissue extracts. These studies will be critical to 
supporting the biological relevance of our gene expression data.  
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4 Chapter 4: RA signalling in alveolar epithelial repair 
 
4.1 Introduction 
 
The internal surface of the alveolar epithelium is lined predominantly by AT1 cells, 
which have an attenuated cytoplasm and are highly susceptible to injury (413). Lung 
injury is associated with disruption of alveolar epithelial integrity and function. 
Histological evidence from patients in the early phase of acute respiratory distress 
syndrome (ARDS) demonstrated AT1 cell necrosis and denudation of the septal 
capillary basement membrane (232). Alveolar epithelial repair is critical in restoration 
of the blood-gas barrier after injury (414), and involves proliferation, spreading and 
migration of AT2 cells over the basement membrane, eventually differentiating into 
AT1 cells to regenerate the alveolar epithelium (22). 
 
The in vitro epithelial scratch assay is an established model for epithelial repair and 
has been extensively characterised for many different cell types including the alveolar 
epithelium (415, 416). In the assay, an artificial gap or ‘wound’ is introduced to a cell 
monolayer, typically with a pipette tip to create a linear scratch on the monolayer 
surface (305). Adherens junctions between the cells of the monolayer are disrupted by 
the scratch, allowing generation of focal adhesions containing integrin-matrix 
interactions at the wound edge. This induces intracellular signalling cascades which 
involve downstream targets such as the MAPK family, GTPases and cytoskeletal 
elements (417), resulting in cell polarisation, protusion of lamellopodia and fillipodia 
into the opening, and the initiation of cell migration (418). 
 
A role for RA signalling in alveolar epithelial repair has not been investigated. 
However, a role for RA signalling in promoting repair has been reported in other 
epithelial cell types. ATRA increased migration of primary human nasal airway 
epithelial cells following NaOH injury to monolayers in vitro, and up-regulated 
transforming growth factor-beta 1 (TGF-β1), matrix metalloproteinase 9 (MMP-9), 
hepatocyte growth factor receptor (HGF-R), and β1-integrin, factors known to 
participate in epithelial migration and repair (419). ATRA improved corneal epithelial 
wound healing after abrasion, (420) and topical RA administration before wound 
induction augmented porcine skin epithelial wound healing (421). However, ATRA 
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inhibited migration of human retinal pigment epithelial cells (422) suggesting RA 
signalling has different roles in epithelial repair depending on tissue origin. 
 
ATRA induced alveolar regeneration in various in vivo models of chronic alveolar 
insufficiency, a process involving alveolar epithelial proliferation and increase in 
alveolar surface area (introduction 1.10, (80, 212, 265)). In vitro studies reported a 
protective effect of ATRA from alveolar epithelial injury. RA protected A549 cells 
from cigarette smoke extract (CSE)-induced intracellular reactive oxygen species 
(ROS) generation, insulin-like growth factor binding protein-2 (IGFBP2) production, 
and cell death (423). ATRA also protected A549 cells against elastase damage, by 
inhibiting elastase-mediated caspase-3 induction and proteolytic activity (424). 
Furthermore, RA protected a neonatal rat AT2 cell line from hyperoxia-induced 
growth arrest by reducing the interaction of p21CIP1 with cyclin E-CDK2 complexes 
(425), and from the growth inhibitory effects of TGF-β (426).  
 
Therefore, we hypothesised that RA signalling regulates alveolar epithelial repair. To 
test this hypothesis, A549 cells and primary human AT2 (hAT2) cells were 
interrogated in an in vitro scratch assay, and a pharmacological approach used to 
modulate RA signalling. A549 cells are a widely used human AT2 cell line, derived 
from an adult with alveolar adenocarcinoma, and share many phenotypic features 
with primary human AT2 cells (303, 415, 427). The scratch assay has been used to 
identify several factors which regulate alveolar epithelial repair, including IL-1β in 
pulmonary oedema from patients with acute lung injury (ALI) (428), vascular 
endothelial growth factor (VEGF) (429) and keratinocyte growth factor (KGF) (430). 
 
The aim of the work in this chapter was to investigate the role of RA signalling in 
alveolar epithelial repair. The specific objectives were: 
 
a. to explore the effect of exogenous ATRA on A549 and hAT2 cell wound 
healing 
b. to explore the effect of pharmacological RA pathway inhibition on A549 
and hAT2 wound healing 
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4.2 Specific Methods 
 
4.2.1 Confirming expression of RA receptors in A549 cells 
 
RNA was collected from monolayers grown from five different flasks of A549 cells 
(at different passage numbers). Following reverse transcription, end-point PCR was 
conducted using primers for RAR-α, RAR-β and RAR-γ (primer sequences provided 
in Table 2.1. PCR cycling conditions are given in Table 2.2, with the exception that 
an annealing temperature of 56 ºC was used. PCR reactions containing either RT-ve 
cDNA, or H2O (blank control) were performed in parallel under identical reaction 
conditions to assess for DNA contamination. Presence of RA receptor expression was 
confirmed by visualising PCR products by agarose gel electrophoresis. 
 
4.2.2 Determination of effect of RA pathway modulation on wound healing 
response of A549 cells 
 
A549 cells were seeded into 48-well plates at 3.5-3.8 x 104 per well and grown to 
confluence. Cells were quiesced in serum free media for 2-24 hours. Supernatants 
were then aspirated and a linear scratch generated on the monolayers with a P200 
pipette tip according to the described protocol (2.2.10.1.2). Following this, cells were 
washed twice with PBS before incubation with assay medium in humidified 5% CO2 
air at 37 ºC, for the specified periods of time. To validate the assay, the wound 
healing of cells in serum-free medium was compared with medium supplemented 
with 10% FBS. To investigate the effect of RA pathway stimulation on wound 
healing, cells were incubated with ATRA at the indicated concentrations either in 
serum-free, 10% FBS, or 10% charcoal stripped medium (Gibco). To investigate the 
effect of RA pathway inhibition on wound healing, cells were incubated with 
BMS493 (Sigma-Aldrich) at the indicated concentrations in 10% FBS medium. 
Digital images were acquired immediately after scratch and at the end of the 
incubation, at the same point of the scratch. Images were imported into Image J 
analysis software, and the denuded area measured. The area covered by migrating 
cells over the incubation time was calculated by subtracting the denuded area at the 
end of the incubation from the denuded area immediately after scratch. The data from 
each well was used as an individual data point for the statistical analysis. For each 
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analysis, data from two independent experiments were pooled, unless otherwise 
stated. Toxicity of treatments was assessed in parallel with the MTT assay on cells 
cultured in 96-well plates according to the described protocol (2.2.12.1). 
 
4.2.3 Determining A549 cell transcriptional response to RA  
 
A549 cells were seeded into 6-well plates at 4.5-5.0 x 105 per well and grown to 
confluence. Following this, supernatants were aspirated and cells washed once with 
PBS before being incubated with treatment compounds at the indicated concentrations 
for the specified periods of time. Transcriptional response to ATRA was assessed by 
incubating cells with ATRA (Sigma-Aldrich) in culture media, whereas the ability of 
the pan-RAR antagonist BMS493 (Sigma-Aldrich) to abrogate the transcriptional 
effect of RA was assessed by incubating cells either with ATRA alone or with ATRA 
plus BMS493 at various concentrations. Following incubation, cells were washed 
once with PBS before being harvested for RNA extraction according to the described 
protocol (2.2.2.1.1). SYBR-Green based RT-qPCR was performed for RAR-β (primer 
sequence provided in Table 2.1) with GAPDH (Quantitect, Qiagen) as a reference 
gene, according to the described protocol (2.2.4.2). 
 
4.2.4 Determining the effect of RA pathway stimulation on proliferation in 
response to scratch wound 
 
The effect of RA pathway stimulation on the proliferation of A549 cells in response 
to a scratch wound was performed with immunohistochemistry for phospho-serine 10 
(histone 3). Cells were seeded into Lab-tek II 8-well chamber slides (Nunc) at 80,000 
cells per well, and grown to confluence. Cells were quiesced in serum free media for 
2-24 hours. Following this, cells were washed twice with PBS, and a linear scratch 
generated on the monolayer with a P200 pipette tip. Cells were then washed twice 
with PBS and incubated with 400 µl DMEM-1 supplemented with 2mM glutamine, 
10% FBS (heat inactivated), 100 U/ml penicillin and 100 µg/ml streptomycin, and 
either without or with ATRA (10 µM) for 18 hours. Following this cells were washed 
and immunohistochemistry performed according to the described protocol (2.2.6.3) 
using antibody for phospho-ser 10 (H3) (Cell signalling technologies) diluted 1:500 in 
PBS-BT, with Alexa Fluor 488nm diluted 1:500 into PBS-BT as the secondary 
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antibody. Following immunohistochemistry, slides were visualised with a DM 2500 
fluorescent microscope (Leica) at 10x magnification, and one image of the centre of 
each well was acquired for DAPI and secondary antibody channels with QWin V3 
software (Leica). To quantify proliferation, images were imported into Image J. Total 
number of nuclei per field of view was quantified by first converting the image to 
greyscale, and then transforming it into binary with the same threshold set for all 
images. Number of individual units was quantified with the ‘analyze particles’ 
feature. The number of phospho-ser 10 (H3) positive cells in the corresponding 
secondary antibody channel images were counted manually, and divided by the total 
number of nuclei to obtain a value for the percentage of proliferating cells per field of 
view. 
 
4.2.5 Determination of effect of RA pathway modulation on wound healing 
response of hAT2 cells 
 
Primary hAT2 cells were isolated from whole human lung tissue according to the 
original protocol by Witherden and Tetley (304) as described (2.2.9.2.2). On day 4 
following quiescence in serum-free media, a linear scratch was generated on the 
monolayer with a P200 pipette tip, before the cells were gently washed once with PBS 
and treatment media added to wells. To investigate the effect of RA pathway 
modulation on hAT2 wound healing, ATRA or BMS493 at the indicated 
concentrations was added in culture media to the wells. Cells were imaged under a 
phase contrast microscope and photographs taken at the point where the linear scratch 
intersected the etched groove on the underside of the plate. Cells were incubated in 
humidified 5% CO2 air at 37 ºC for 18 hours. After this, images were taken at the 
same point where the scratch intersected the groove. Wound closure in 18 hours was 
quantified with Image J.  
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4.3 Results 
 
4.3.1 Validation of A549 in vitro scratch assay  
 
To validate the scratch assay, wound closure was compared between A549 cells 
incubated in serum-free medium and 10% FBS-supplemented medium. 10% FBS- 
media induced significantly greater wound closure compared to serum-free media 
after 16 hours incubation (p < 0.001, Figure 4.1) Serum-free and 10% FBS media 
were therefore used as controls in subsequent experiments. 
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Figure 4.1 A549 cells exhibit significant closure of a scratch wound after 16 
hours in 10% FBS media. 
A scratch wound was generated on a confluent monolayer of A549 cells with a P200 
pipette tip, and the cells incubated either without serum or with 10% FBS for 16 
hours. Digital images were taken at 0 hours and 16 hours, and the area covered by cell 
migration quantified using image analysis software (Image J). Data presented as mean 
+/- SEM, n=24 per group (2 independent experiments) *** p < 0.001 when compared 
to serum free condition, Unpaired t-test. FBS, foetal bovine serum. 
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4.3.2 Expression of RARs in A549 cells 
 
End point RT-PCR using primers specific to RAR-α, -β and -γ mRNA revealed 
expression of all three receptors in A549 cells (Figure 4.2). 
 
4.3.3 The effect of ATRA on wound closure of A549 cells in serum-free media 
 
To assess the effect of ATRA on A549 wound closure, scratched A549 monolayers 
were incubated with varying concentrations of ATRA (0.01 to 10 µM) in serum-free 
media for 16 hours. There was no significant effect of ATRA at any concentration 
(Figure 4.3A). To confirm A549 cells respond to ATRA, A549 cells were incubated 
with ATRA (1 µM) and induction of RAR-β mRNA expression assessed by RT-
qPCR (431). Significant up-regulation of RAR-β was observed after 4 and 20 hours 
(* p < 0.05, ** p < 0.01 Figure 4.3B). 
 
 
 
.  
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Figure 4.2 A549 cells express retinoic acid receptors (RARs) 
A549 cells from 5 different flasks (1-5) were harvested and processed for RNA 
extraction. End-point RT-PCR was performed for RAR-α, RAR-β, RAR-γ, and 
reaction products visualized on agarose gel alongside a 25bp DNA ladder (L). For 
each sample, RT positive reactions (+) were run alongside RT negative control 
reactions (-) to assess for DNA contamination in reagents. Resultant bands correspond 
to expected size of amplified fragments: RAR-α 97 bp, RAR-β 70 bp, RAR-γ 103 bp. 
DNA contamination is absent except for RT-ve lane of sample 4 for RAR-α (red 
arrow). Abbreviations: RAR, retinoic acid receptor; L, 25bp DNA ladder; B, blank 
control; bp, base pairs; ATRA, all-trans retinoic acid; RT, reverse transcriptase; RT-
PCR, reverse-transcription polymerase chain reaction. 
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Figure 4.3 ATRA has no effect on A549 wound healing in serum-free media, 
despite increasing RAR-β  mRNA expression in these cells.  
A) Confluent A549 cells were scratched with a P200 pipette tip and incubated with 
serum free medium, 10% FBS medium alone, or with serum free medium containing 
ATRA (0.01, 0.1, 1, 10 µM) for 16 hours. Epithelial closure was quantified with 
Image J. Data presented as mean +/- SEM, n=10 per group (2 independent 
experiments). **** p < 0.0001 compared to serum free condition, one-way ANOVA 
with Dunnett’s post test. B) Confluent A549 cells were incubated in serum free 
medium alone (white boxes) or with 1 µM ATRA (black boxes). Cells were harvested 
either immediately (0 hours) or after 4 or 20 hours and RNA extracted. RT-qPCR was 
performed for RAR-β with expression normalised to GAPDH. Results expressed as 
mean +/- SEM, n=4 (per group). * p < 0.05, ** p < 0.01 untreated compared to RA-
treated group at corresponding time point, Kruskall Wallis with Dunn’s post test. 
Abbreviations: ATRA, all-trans retinoic acid; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; RAR-β, retinoic acid receptor beta; RT-qPCR, reverse-transcription 
quantitative polymerase chain reaction. 
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4.3.4 The effect of ATRA on wound closure of A549 cells in 10% FBS-
supplemented media 
 
To determine if ATRA requires factors present in FBS to have effect, scratched A549 
monolayers were incubated in varying concentrations of ATRA (0.01 to 10 µM) 
added to 10% FBS-supplemented media. There was no effect of ATRA at any 
concentration (Figure 4.4A). To confirm A549 cells respond to ATRA, A549 cells 
were incubated with ATRA (1 µM) and induction of RAR-β mRNA expression 
assessed by RT-qPCR. Significant upregulation of RAR-β was observed at 4 hours (* 
p < 0.05), which returned to baseline at 20 hours (Figure 4.4B).  
 
4.3.5 The effect of ATRA on wound closure of A549 cells in 10% charcoal 
stripped serum-supplemented media 
 
To exclude the possibility that retinoids present in FBS were masking the effect of 
added ATRA, 10% charcoal stripped serum (CSS) was used to supplement the 
medium instead of FBS. 10% CSS medium alone induced wound closure significantly 
greater than serum-free medium (p < 0.0001), and significantly less than 10% FBS 
medium (p < 0.0001). ATRA added to 10% CSS medium had no effect on wound 
closure at any concentration (Figure 4.5). 
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Figure 4.4 ATRA has no effect on A549 wound healing in 10% FBS-media, 
despite increasing RAR-β  mRNA expression in these cells.  
A) Confluent A549 cells were scratched with a P200 pipette tip and incubated either 
with serum free medium, with 10% FBS medium alone, or with 10% FBS medium 
containing ATRA (0.01, 0.1, 1, 10 µM) for 20 hours. Epithelial closure was 
quantified with Image J. Data presented as mean +/- SEM, n=10 per group (2 
independent experiments). **** p  < 0.0001 compared to 10% FBS, one-way 
ANOVA with Dunnett’s post test. B) Confluent A549 cells were incubated in 10% 
FBS medium either alone (white boxes) or containing 1 µM ATRA (black boxes). 
Cells were harvested immediately (0 hours) or after 4 or 20 hours and RNA extracted. 
RT-qPCR was performed for RAR-β with expression normalised to GAPDH. Results 
expressed as mean +/- SEM, n=3 per group (3 independent experiments). * p < 0.05 
untreated compared to RA-treated group at corresponding time point, Kruskall Wallis 
with Dunn’s post test.  Abbreviations: ATRA, all-trans retinoic acid; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; RAR-β, retinoic acid receptor beta; RT-
qPCR, reverse-transcription quantitative polymerase chain reaction. 
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Figure 4.5 ATRA has no effect on A549 wound healing in media supplemented 
with charcoal stripped serum.  
A) Confluent A549 cells were scratched with a P200 pipette tip and incubated with 
either with serum free medium, 10% CSS medium, 10% FBS medium, or with 10% 
CSS medium containing ATRA (0.01, 0.1, 1, 10 µM) for 20 hours. Epithelial closure 
was quantified with Image J. Data presented as mean +/- SEM, n=8 per group (2 
independent experiments). **** p<0.0001 compared with CS, one-way ANOVA with 
Dunnett’s post test. Abbreviations: CSS, charcoal stripped serum; FBS, foetal bovine 
serum; ATRA, all trans-retinoic acid. 
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4.3.6 The effect of the pan-RAR antagonist BMS493 on wound closure of A549 
cells in 10% FBS 
 
To determine whether endogenous RA signalling is necessary for A549 wound 
closure, scratched A549 monolayers were incubated in 10% FBS-supplemented 
media containing varying concentrations of BMS493 (0.01 to 100 µM). A549 wound 
closure was significantly inhibited by BMS493 (100 µM) compared to 10% FBS-
supplemented medium (p < 0.0001, Figure 4.6A).  
 
To determine transcriptional effects of BMS493, A549 cells were incubated with 
BMS493 (0.01 to 100 µM) and induction of RAR-β mRNA expression assessed by 
RT-qPCR. RAR-β expression was significantly inhibited by BMS493 in a 
concentration-dependent manner (* p < 0.05 at 0.01µM, ** p < 0.01 at 0.1 µM to 10 
µM, Figure 4.6B). Inhibition of RAR-β expression was maximal at BMS493 (1 µM) 
– higher doses of BMS493 had no further inhibiting effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 229 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 The pan-RAR antagonist BMS493 inhibits A549 wound closure only 
at the highest dose, whilst inhibiting RAR-β  mRNA expression over a broad 
range of doses.  
A) Confluent A549 cells were scratched with a p200 pipette tip and incubated either 
with 10% FBS-supplemented medium alone, with serum-free medium, or with 10% 
FBS-supplemented medium containing BMS493 (0.01, 0.1, 1, 10, 100 µM) for 18 
hours. Epithelial closure was quantified using Image J. Data presented as mean +/- 
SEM, n=12 per group (2 independent experiments). **** p < 0.0001 compared with 
10% FBS, one-way ANOVA with Dunnett’s post test. B) Confluent A549 cells were 
incubated with medium supplemented with 10% FBS either alone (control) or with 
BMS493 (0.001, 0.01, 0.1, 1, 5, 10, 100 µM) for 4 hours and RNA extracted. RT-
qPCR for RAR-β was performed with expression normalised to GAPDH. Results are 
expressed as mean +/- SEM, n=3 per group. * p <0.05, ** p < 0.01 compared to 10% 
FBS group, unpaired t-test. Data presented as mean ± SEM. Abbreviations: ATRA, 
all-trans retinoic acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RAR-β, 
retinoic acid receptor beta; FBS, foetal bovine serum. 
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4.3.7 Effect of BMS493 on A549 wound closure and viability 
 
A narrow range of BMS493 concentrations (10 to 250 µM) was investigated. A 
concentration-dependent inhibition of A549 wound closure was observed, reaching 
significance at BMS493 (50 µM) compared to 10% FBS (p < 0.001) (Figure 4.7 
A). Serum-free medium, used as a positive control, significantly reduced A549 wound 
closure compared to 10% FBS (p < 0.0001). 
 
Toxicity of BMS493 in A549 cells was determined with the MTT assay, with 1% 
Triton-X treated A549 cells as a positive control. Triton-X significantly reduced cell 
respiration compared to 10% FBS media (p < 0.0001). BMS493 (75 µM to 1000 µM 
BMS493) significantly reduced A549 respiration A549 cells (p< 0.01 to p < 0.0001), 
however BMS493 (50 µM) did not cause significant cell toxicity (p > 0.05, Figure 
4.7B).  
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Figure 4.7 Dose response curves for BMS493 between 10 µM and 250 µM reveal 
a dose (50 µM) which causes significant inhibition of wound healing without 
significant toxicity.  
A) Confluent A549 cells were scratched with a p200 pipette tip and incubated with 
serum free medium, with 10% FBS medium alone, or with 10% FBS medium 
containing BMS493 (10, 25, 50, 75, 100, 250 µM) for 18 hours. Epithelial closure 
was quantified using Image J. Data presented as mean +/- SEM, n=8 per group (2 
independent experiments). *** p<0.001, **** p < 0.0001 compared to 10% FBS, 
one-way ANOVA with Dunnett’s post test. B) Confluent A549 cells were incubated 
with 10% FBS supplemented medium alone, with 1% Triton-X, or with 10% FBS 
supplemented medium containing BMS493 (10, 25, 50, 75, 100, 250, 1000 mM) for 
24 hours, and viability assessed with 15 minute incubation with MTT reagent. The 
amount of reduced formazan was determined spectrophotometrically at 550nm. Data 
presented as mean +/- SEM, n=8 per group (2 independent experiments). ** p < 0.01, 
**** p < 0.0001 compared to 10% FBS, one-way ANOVA with Dunnett’s post test. 
Abbreviations: FBS, foetal bovine serum. 
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4.3.8 ATRA could not rescue inhibition of A549 wound closure by BMS493 
 
To determine whether the inhibition of A549 wound closure by BMS493 (50 µM) is 
mediated by RARs, scratched A549 monolayers were incubated with BMS493 (50 
µM) in combination with varying concentrations of ATRA (0.01 to 10 µM). BMS493 
(50 µM) caused inhibition of A549 wound closure that could not be rescued by 
ATRA at any concentration (Figure 4.8A).  
 
To confirm ATRA could rescue BMS493 inhibition of gene transcription, A549 cells 
were incubated with BMS493 (50 µM) and varying concentrations of ATRA (0.01 to 
10 µM) and induction of RAR-β mRNA expression assessed by RT-qPCR. BMS493 
(50 µM) significantly inhibited RAR-β mRNA expression (p < 0.05) compared to 
control, whereas ATRA (1 and 10 µM) significantly increased BMS493-inhibited 
RAR-β expression (p < 0.05 and p < 0.01, Figure 4.8B). 
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Figure 4.8 ATRA cannot rescue inhibition of wound healing by BMS493 (50 
µM), but can reverse inhibition of RAR-β  mRNA expression by BMS493 (50 
µM) 
A) Confluent A549 cells were scratched with a p200 pipette tip, and incubated either 
with serum-free medium, with 10% FBS medium, with 10% FBS-medium containing 
BMS493 (50 µM) alone, or with 10% FBS medium containing BMS493 (50 µM) plus 
ATRA (0.01, 0.1, 1, 10 µM) for 20 hours. Epithelial closure was quantified with 
Image J. Data presented as mean +/- SEM, n=8 per group (2 independent 
experiments). **** p<0.0001 compared to BMS493 (50 µM), one-way ANOVA with 
Dunnett’s post test. B) Confluent A549 cells were incubated with 10% FBS medium 
(control), with 10% FBS medium containing BMS493 (50 µM), or with 10% FBS 
medium containing BMS493 (50 µM) plus ATRA (0.01, 0.1, 1, 10 mM) for 4 hours, 
and RNA collected. RT-qPCR for RAR-β was performed with expression normalised 
to GAPDH. Results are expressed as mean +/- SEM, n=5 per group* p < 0.05, *** p 
< 0.001, Kruskall Wallis with Dunn’s post test, all columns compared to BMS493 
µM.  
 
A 
Serum
free
10%
FBS
BMS493
50 µM
0.01 0.1 1 10
0
1
2
3
4
5
6
A
re
a 
co
ve
re
d 
af
te
r s
cr
at
ch
 
(x
10
5  p
ix
el
s)
BMS493 (50 µM) 
+ Concentration of ATRA (µM)
********
Control BMS493
50 µM
0.01 0.1 1 10
0.0
0.5
1.0
1.5
2.0
2.5
3.0
R
A
R
b 
: G
A
PD
H
BMS493 (50 µM) 
+ Concentration of ATRA (µM)
* * ***
B 
 234 
4.3.9 The effect of ATRA on A549 proliferation following scratch 
 
The effect of a scratch wound with or without ATRA on A549 proliferation was 
determined with IHC for phosphorylated serine 10 of histone H3 (phospho-ser 10 H3) 
(432). A scratch wound, either without or with ATRA (1 µM), had no effect on the 
localisation of A549 proliferation at 18 hours compared to unscratched cells (Figure 
4.9A). Quantification of proliferating cells revealed low levels of proliferating cells in 
unscratched cells (~3 % of total cells). A scratch wound, either without or with ATRA 
(1 µM), had no effect on numbers of proliferating A549 cells (Figure 4.9B). 
 
4.3.10 The effect of RA pathway modulation on wound closure response of 
primary human alveolar type 2 (hAT2) cells 
 
To determine the role of RA signalling in hAT2 wound closure, hAT2 cells were 
scratched and incubated with varying concentrations of ATRA (0.01 to 10 µM) added 
to serum free medium, with 10% FBS medium as a positive control. No significant 
difference was observed between serum-free and 10% FBS medium, or with any 
concentration of ATRA (Figure 4.10A). 
 
To investigate the effect of RA pathway inhibition on wound closure, hAT2 cells 
were scratched and incubated with varying concentrations of BMS493 (0.01 to 10 
µM) added to 10% FBS medium, with serum-free medium as a positive control. No 
significant difference was observed between serum-free and 10 % FBS medium, or 
with any concentration of BMS493 (Figure 4.10B). 
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Figure 4.9 ATRA does not alter the extent or localisation of A549 proliferation in 
the scratch assay.  
A) Confluent A549 cells were scratched with a p200 pipette tip, and incubated in 10% 
FBS medium alone, or in 10% FBS medium containing 10 µM ATRA for 18 hours. 
Cells were fixed in 4% PFA before processing for immunohistochemistry. 
Proliferation was determined by incubation with antibody specific for phospho-ser 10 
H3 (Cell Signaling Technology), counterstained with DAPI for nuclear staining, and 
visualised using a wide-field fluorescent microscope. Representative images from 2 - 
3 replicates shown. Original magnification 4x. B) Data from A) quantified using 
Image J software. Data presented as mean +/- SEM, n=2-3 per group. Abbreviations: 
ATRA, all-trans retinoic acid; DAPI, 4',6-diamidino-2-phenylindole (nuclear stain); 
FBS, foetal bovine serum; PFA, paraformaldehyde. 
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Figure 4.10 Modulating RA signalling has no effect on hAT2 wound closure  
A) Confluent isolated primary human alveolar type 2 (hAT2) cells were scratched 
with a p200 pipette tip and incubated either with serum free medium, with 10% FBS 
medium, or with 10% FBS medium containing ATRA (0.01, 0.1, 1, 10 µM) for 18 
hours. Epithelial closure was quantified using Image J. Data presented as mean +/- 
SEM, n=5-9 per group (2 independent experiments). B) Confluent isolated hAT2 cells 
were scratched with a p200 pipette tip and incubated either with serum-free medium, 
with 10% FBS medium, or with 10% FBS medium containing BMS493 (0.01, 0.1, 1, 
10 µM) for 18 hours. Epithelial closure was quantified using Image J. Data presented 
as mean +/- SEM, n=5-9 per group (2 independent experiments). For A) and B), one-
way ANOVA with Dunnett’s post test did not detect any significant differences. 
Abbreviations: ATRA, all-trans retinoic acid; FBS, foetal bovine serum. 
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4.4 Discussion 
 
4.4.1 Summary of key findings in this chapter 
 
The work in this chapter confirmed that A549 cells close a scratch wound 
significantly faster in 10% FBS-supplemented media than in serum-free media. A549 
cells responded to ATRA in both serum-free and 10% FBS media by up-regulating 
RAR-β mRNA expression. However, ATRA did not have an effect on A549 wound 
closure when added to serum-free, 10% FBS, or 10% CSS media. ATRA did not alter 
the extent or localisation of A549 cell proliferation after a scratch wound. Primary 
human alveolar type 2 (hAT2) cells exhibited similar wound closure in 10% FBS and 
serum-free media. ATRA did not have an effect on hAT2 wound closure. The pan-
RAR antagonist BMS493 abolished RAR-β mRNA expression in A549 cells over a 
broad range of concentrations, indicating inhibition of RA signalling. BMS493 
inhibited A549 wound closure at 50 µM, a concentration which did not cause 
significant toxicity. However, inhibition of wound closure could not be rescued with 
ATRA, indicating BMS493 inhibited A549 wound closure independently of the RA 
pathway. We therefore concluded that RA signalling is not necessary for A549 wound 
closure. BMS493 did not influence wound closure of primary hAT2 cells, supporting 
the idea that RA signalling is not involved in alveolar epithelial repair.  
 
4.4.2 Validation of the scratch assay 
 
The scratch assay measures the area covered by migrating cells following a scratch 
over a defined incubation period. Initial experiments validated the scratch assay by 
comparing wound closure in serum-free medium with 10% FBS-supplemented 
medium. FBS contains an undefined mixture of cytokines and biologically active 
molecules which augment wound closure, and is widely used as the positive control in 
the in vitro scratch assay (433, 434). 10% FBS significantly increased A549 wound 
closure compared to serum-free medium, as previously described (430).  
 
The time required for wound closure depends on the initial size of the scratch. During 
incubation, the size of the denuded area in the 10% FBS medium control was 
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continually monitored, as this exhibited the fastest wound healing (305). A total 
incubation time was used which allowed the greatest migration of cells in 10% FBS 
medium without the two cell fronts meeting to close the wound, as this would induce 
contact inhibition of motility and prevent accurate quantification of wound closure 
(435). The scratches were generated manually and so between experiments, the size 
of the scratches differed. Thus, the incubation time was adjusted for each experiment 
according to wound closure in the 10% FBS condition, which served as an internal 
control, and varied from 16 to 20 hours. However, within experiments the size of the 
scratches exhibited variability of less than 10% (data not shown).  
 
The time required for wound closure also depends on the cell type used. For example, 
astrocytes take around 5 times longer to close a scratch wound than fibroblasts and 
epithelial cells (436). Consistent with our study, 18 hours has previously been used as 
incubation time for A549 cells and primary human AT2 cells in the scratch assay 
(428, 437).  
 
4.4.3 ATRA does not affect A549 wound closure 
 
To investigate the role of RA signalling in alveolar epithelial wound closure, 
scratched A549 monolayers were incubated with varying concentrations of ATRA in 
serum-free media. The rationale for using serum-free media was that it might allow a 
stimulating effect of ATRA to be detected – serum-free media is frequently used in 
the scratch assay for treatments expected to stimulate wound closure (437). However, 
ATRA in serum-free media had no effect on A549 wound closure (Figure 4.3).  
 
We next hypothesised that additional factors present in FBS may be necessary for 
ATRA to stimulate A549 wound closure. However, ATRA added to 10% FBS-
supplemented medium had no effect compared to 10% FBS medium alone (Figure 
4.4). This could have been for at least two reasons. Firstly, it was possible that the 
wound closure in 10% FBS medium represented the maximum rate of wound closure 
possible by A549 cells. Therefore, addition of ATRA would have no additive effect. 
Secondly, it was possible that endogenous retinoids in FBS were masking the effect 
of added ATRA. To address these possibilities, but to retain factors in FBS potentially 
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necessary for ATRA to stimulate A549 wound closure, 10% charcoal stripped serum 
(CSS) was used to supplement the medium instead of FBS.  
 
Charcoal stripping depletes FBS of lipophilic molecules which may have biological 
activity that interferes with the scratch assay, such as steroids, peptide hormones, 
thyroid hormones, and lipids, including retinoids (438). Wound closure in 10% CSS 
was significantly greater than wound closure in serum free conditions, indicating that 
non-lipid factors remained in CSS which stimulated A549 wound closure. However 
10% CSS resulted in wound closure of ~50% less than 10% FBS, indicating that 
lipids present in FBS, removed by charcoal stripping, stimulated A549 wound 
closure. To determine if retinoids are one of these, ATRA was added in increasing 
concentrations to 10% CSS medium, but did not have an effect at any concentration 
(Figure 4.5).  
 
Since these experiments were conducted, a study by Wang et al. (2013) (439) was 
published, which investigated the effect of ATRA and a synthetic retinoid ATPR on 
A549 wound closure in the scratch assay. They found a small but statistically 
significant inhibition of A549 wound closure with 5 mg/L ATRA, and a larger 
significant inhibition with 10 mg/L ATRA (439). 5 mg/L and 10 mg/L ATRA are the 
equivalent of 16.6 µM, and 33.3 µM respectively. These concentrations were not used 
in our study as ATRA precipitated in culture media at concentrations above 10 µM. 
Precipitation of ATRA was not investigated in the study by Wang et al, nor was 
ATRA toxicity at higher concentrations, and thus the inhibition they observed may be 
due to either or both of these phenomena. 
 
4.4.4 ATRA has transcriptional activity in A549 cells 
 
ATRA stimulates the RA pathway and exerts its biological effects by binding to 
retinoic acid receptors (RARs), which reside as heterodimers with retinoid X 
receptors (RXRs) in the nucleus. The ligand-receptor complex binds to consensus 
sequences in retinoic acid response elements (RAREs) in the promoter regions of 
target genes, initiating their transcription (introduction 1.5.9 (440)). A549 cells 
expressed RAR-α, -β and -γ mRNA, in agreement with a previous report (441).  
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It was hypothesised that the lack of effect of ATRA on A549 wound closure was due 
to unresponsiveness to ATRA on a transcriptional level. To investigate this, A549 
cells were incubated with ATRA and the expression of RAR-β assessed by RT-qPCR. 
Expression of RAR-β is widely used to confirm RA pathway activation as the RAR-β 
gene contains a RARE in its promoter region (431). ATRA (1 µM) was assessed as 
this concentration had greatest stimulatory effects on both epithelial and 
mesenchymal cells in an ex vivo neonatal mouse lung culture system (244). ATRA (1 
µM) resulted in significant upregulation of RAR-β expression in both 10% FBS and 
in serum-free conditions at 4 hours (* p < 0.05, Figure 4.3B, Figure 4.4B), indicating 
ATRA has transcriptional activity in A549 cells. RAR-β expression returned to 
baseline after 20 hours in the 10% FBS condition. Therefore, RA pathway activation 
by ATRA (1 µM) in 10% FBS may be transient, which could account for the lack of 
effect on A549 wound closure. Continuous addition of ATRA to 10% FBS media 
over the period of the scratch assay might be necessary to ensure continual RA 
pathway activation. 
 
Induction of RAR-β expression by ATRA was greater at both 4 and 20 hours in 
serum-free media compared to 10% FBS media, which might reflect lower levels of 
basal RA signalling in the absence of endogenous retinoids in FBS. Significant 
upregulation of RAR-β expression by ATRA (1 µM) was observed at 20 hours (** p 
< 0.05, Figure 4.4B). Therefore, the inability of ATRA to stimulate A549 wound 
closure was unlikely to be due to lack of biological activity at later time points. From 
these data, we concluded that while ATRA has transcriptional activity in A549 cells, 
ATRA does not stimulate A549 wound closure.  
 
4.4.5 Endogenous RA signalling is not critical for alveolar epithelial wound 
closure 
 
We investigated the role of endogenous RA signalling in alveolar epithelial wound 
closure using the competitive pan-RAR inverse agonist BMS493 in the A549 scratch 
assay. Addition of a range of concentrations of BMS493 in 10% FBS media revealed 
significant inhibition at 50 µM (p < 0.001), which became more apparent at higher 
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concentrations (Figure 4.7A). As these are relatively high concentrations of 
compound, it was assessed whether inhibition of wound closure was due to toxicity 
by using the MTT assay. Significant reduction in respiration was observed at 
BMS493 (75 µM, p < 0.05), which became more severe at higher concentrations. 
BMS493 (50 µM) did not significantly reduce cell respiration (Figure 4.7B), so the 
inhibition of A549 wound closure at BMS493 (50 µM) was not likely to be due 
increased cell death.  
 
BMS493 antagonises RA signalling by competitively stabilising the association of 
RAR/RXR heterodimers with transcriptional co-repressors (442). If 50 µM BMS493 
inhibited A549 wound closure by competitively antagonising RAR activation, 
sufficient ATRA should out-compete BMS493 to rescue wound closure. Receptor-
level competition between RA and BMS493 in vitro has been demonstrated 
previously. Mollard et al. found that RA inhibited branching morphogenesis of 
explanted embryonic mouse lungs, and that this was prevented by co-administration 
of BMS493 (204). Conversely, Wendling et al. found that BMS493 (1 µM) induced 
developmental defects in E8.0 mouse embryos in vitro, and that co-administration of 
RA could prevent the defects and rescue normal development (443). 
 
We assessed whether ATRA could rescue BMS493-inhibited RAR-β mRNA 
expression. BMS493 significantly inhibited RAR-β expression at 50 µM (p < 0.05), 
and ATRA (1 and 10 µM) rescued RAR-β expression (Figure 4.8B). This is in 
agreement with the binding affinities of ATRA and BMS493, which bind to RAR-α 
with Kd of 0.4 and 4 nM respectively (157). Therefore, RA binds to RAR-α with a 
10-fold higher affinity than BMS493. ATRA was unable to rescue the inhibition of 
wound closure by BMS493 (50 µM, Figure 4.8A), indicating that BMS493 inhibited 
A549 wound closure independently of the RA pathway. The mechanism by which 
BMS493 (50 µM) inhibited A549 wound closure is unclear from our study. Wendling 
et al. similarly found that BMS493 (50 µM) caused severe defects in mouse embryos 
in vitro that could not be rescued with RA (443). The authors suggested that high 
concentrations of BMS493 might have detergent properties, which may have 
contributed to the inhibition of A549 wound closure we observed without effecting 
cell respiration. 
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4.4.6 ATRA did not influence the extent or localisation of A549 proliferation in 
the scratch assay 
 
It was demonstrated in primary rat AT2 cells, that wound closure in the scratch assay 
predominantly reflected inward migration and spreading of cell sheets on either side 
of the scratch, rather than proliferation (416). It was therefore possible that ATRA 
stimulated proliferation of AT2 cells after scratch, which was not detected in the 
scratch assay. In support of this idea, RA-induced lung regeneration in the rat elastase 
model involved alveolar epithelial proliferation, which was not observed in normal 
rats given RA, suggesting RA promoted proliferation only during repair (265). In 
vitro, ATRA induced proliferation of subconfluent primary adult rat AT2 cells, 
whereas at confluence RA decreased their proliferation (240), suggesting reduction in 
cell-cell contacts is stimulated RA-induced proliferation. Therefore, we hypothesised 
that ATRA might induce proliferation of A549 cells after a scratch wound, and that 
this may localise at the wound edge where cell-cell contacts have been disrupted. In 
support of the idea that RA can stimulate proliferation of an alveolar epithelial cell 
line, ATRA was found to induce proliferation of a neonatal rat AT2 cell line in a 
concentration dependent manner (426).  
 
To investigate this, we used IHC for phopho-ser 10 H3 to assess proliferation of 
unscratched and scratched A549 cells, compared to scratched A549 cells incubated 
with ATRA (1 µM). The amino-terminus of histone H3 is phosphorylated at serine 10 
during late G2 interphase, and remains phosphorylated until chromosome 
decondensation in telophase, thereby giving an indication of mitotic cells (432) This 
experiments was performed with 10% FBS media. The rationale was that FBS led to 
the greatest wound closure in the scratch assay, and as FBS promotes cell 
proliferation in vitro, endogenous factors in FBS may be required for ATRA to 
stimulate proliferation. There was no difference in localisation of proliferating cells 
between unscratched and scratched A549 cells without ATRA treatment, in 
agreement with previous data from primary rat AT2 cells (416). Furthermore, there 
was no difference with scratched A549 cells in ATRA compared to 10% FBS Figure 
4.9. Quantification of stained cells revealed a basal level of ~3% proliferating cells in 
the unscratched condition. The experiment was initially designed for 4 wells per 
condition, however due to non-adherence of cells, only 2-3 wells per condition were 
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suitable for use and statistical analyses were not permitted. From this data, there did 
not appear to be a difference in extent of proliferation between unscratched cells, and 
scratched cells either without or with ATRA treatment, however further experiments 
are required to confirm this. 
 
There are several possible explanations for the lack of effect of ATRA on A549 
proliferation during wound closure. While 10% FBS in the media is likely to account 
for the basal level of ~3% proliferating cells, this may have masked any effect of 
ATRA on proliferation. According to this idea, a lower concentration of FBS (such as 
2%) may be required to permit cell proliferation while allowing the effect of ATRA to 
be detected. The discrepancy between our data, and the evidence that RA induced a 
concentration-dependent increase in proliferation of a neonatal rat AT2 cell line 
(described above, (426)), may be explained by RA having a greater proliferation-
inducing effect in cells from juvenile lungs. It was hypothesised that ATRA 
stimulated growth by modifying pre-existing active growth pathways, rather than by 
activating dormant pathways (444). Thus, RA may be able to induce proliferation of 
immature AT2 cells, but not adult AT2 cells.  
 
Another reason could be altered cell cycle regulation in A549 cells compared to adult 
primary AT2 cells. The A549 cell line was derived from a malignant adenocarcinoma 
(303), and harbours a gain-of-function K-ras point mutation (445) resulting in its 
constitutive activation. This results in excessive activation of downstream factors such 
as mitogen activated protein kinase kinases (MAPKK) MEK1 and MEK2 (446), 
causing aberrant cell cycle regulation and excessive proliferation compared to normal 
adult AT2 cells. Therefore, in contrast to subconfluent primary adult rat AT2 cells 
(described above, (240)), A549 cells may be refractory to the growth stimulatory 
effects of RA. Assessing RA-induced proliferation with primary human AT2 cells 
will be necessary to address this. 
 
4.4.7 RA pathway modulation does not affect primary human AT2 wound 
closure 
 
It was possible that the lack of effect of ATRA on A549 wound closure may be due to 
alterations in the cell line, and may not be representative of normal AT2 cells. To 
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address this hypothesis, primary human AT2 cells (hAT2) cells were used in the 
scratch assay. Cells were incubated for 18 hours with varying concentrations of 
ATRA in serum-free media, or with varying concentrations of BMS493 in 10% FBS 
media, with 10% FBS media alone and serum-free media as controls.  
 
In contrast to A549 cells, hAT2 wound closure was similar between 10% FBS media 
and serum-free media (Figure 4.10). A possible explanation is that basal hAT2 
migration was inherently high, as the hAT2 cells in this study were cultured on 
collagen-1 coated plates. It was demonstrated using a Boyden chamber-based assay 
that collagen-1 coated membranes promoted primary rat AT2 migration via 
interactions with α1β2-integrin even in serum-free media, whereas cells did not 
migrate through uncoated membranes (447). Collagen-1 coating of multi-well plates 
was used in our study to isolate human hAT2 cells based on greater adhesion to 
collagen compared to other cell types present in lung tissue. This may also explain the 
lack of effect of ATRA in stimulating hAT2 cell migration in the scratch assay, as 
hAT2 migration may have been maximal due to the collagen-1 substrate. To address 
this issue, an alternative method to isolate hAT2 cells without the need for collagen 
coating may be required, such as using fluorescent activated cell sorting (FACS) 
based on expression of the surface marker HTII-280 (448). We also found no effect of 
BMS493 on hAT2 wound closure at any concentration, indicating that inhibition of 
RA signalling did not influence hAT2 migration. In support of the data obtained from 
A549 cells, this suggests that endogenous RA signalling is not required for alveolar 
epithelial repair.  
 
Our finding that ATRA does not stimulate either A549 or primary hAT2 wound 
closure is in contrast to data from primary human nasal epithelial cells cultured on 
collagen-1, which exhibited increased wound closure in the presence of 1 µM ATRA 
in both a NaOH injury model and a plug-induced wound closure assay (419). At 72 
hours, a small but significant increase in wound closure was observed in cells treated 
with ATRA, whereas at earlier time points (24 and 48 hours), no difference was 
observed. The discrepancy may be due to ATRA requiring a longer period to 
stimulate migration, which was missed due to the shorter incubation time (18 hours) 
used in our study. However, epithelial cells along the respiratory tract are 
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phenotypically distinct (5), thus the discrepancy may be due to the differences in RA 
response between nasal epithelial and alveolar epithelial cells. 
 
4.4.8 Summary and limitations 
 
In aggregate, our observations led us to conclude that RA signalling is not directly 
involved in alveolar epithelial repair. ATRA did not influence A549 cell migration or 
proliferation in the scratch assay, and ATRA had no effect on hAT2 cell wound 
closure. Inhibition of RA signalling with BMS493 inhibited A549 wound closure at 
50 µM, but this effect was independent of the RA pathway. Furthermore, BMS493 
had no effect on hAT2 cell wound closure. This appears to contrast with previously 
published in vivo reports of increased AT2 cell number during RA-induced lung 
regeneration in animal models of emphysema (80, 212, 265). There may be several 
explanations for this: 
 
1.) The scratch assay we used was a single-cell culture system involving only AT2 
cells. However, it is possible that epithelial regeneration during RA-induced lung 
regeneration in vivo is an indirect effect of RA-induced secretion of paracrine factors 
by regenerating endothelial cells or fibroblasts (414). In support of this idea, 
stimulation of epithelial proliferation by RA in an organotypic embryonic lung culture 
occurred via mesenchyme-derived paracrine signals (244). For example, 
lipofibroblasts may be direct targets of RA, and a source of epithelial-directed 
paracrine factors during RA-induced lung regeneration. Lipofibroblasts express RAR-
α, -β and -γ and retinoid binding proteins (449), synthesised elastin in response to 
ATRA in vitro (450), and in adult lungs in vivo, are closely associated with AT2 cells 
(245). During severe parenchymal damage, proliferation and spreading of AT2 cells 
over the partially denuded basement membrane is accompanied by an increase in 
fibroblast number and a rise in epithelial-fibroblast contacts (451). It is possible that 
fibroblasts are direct targets of ATRA during RA-induced lung regeneration, and 
direct contact between epithelial cells and fibroblasts may be necessary to transmit 
growth-stimulating signals to the alveolar epithelium. An absence of fibroblasts could 
explain the lack of effect of ATRA on alveolar epithelial wound closure in the scratch 
assay. 
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2.) Endothelial contact and/or endothelial-derived paracrine factors have influenced 
wound closure in the scratch assay. In an alveolocapillary model system, in which 
A549 cells and human pulmonary microvascular endothelial cells (HLMVECs) were 
cultured on opposing sides of a 1 µm porous membrane to mimic the blood gas 
barrier, surfactant protein A (SP-A) stimulated A549 wound closure (452). In the 
absence of HLMVECs however, SP-A inhibited A549 wound closure, suggesting a 
critical role of endothelial cell secreted factors, or direct epithelial-endothelial 
contacts. Endothelial-derived paracrine factors, or angiocrine factors, were 
demonstrated to be critical in initiating and sustaining lung regeneration lung 
following PNX (263). Left PNX resulted in sequential vascular endothelial growth 
factor receptor 2 (VEGFR2)- and fibroblast growth factor receptor 1 (FGFR1)- 
dependent secretion of matrix metalloproteinase 14 (MMP14) by capillary endothelial 
cells. MMP14 in turn, proteolytically released epidermal growth factor (EGF)-like 
fragments, which activated EGF receptors (EGFRs) to stimulate alveolar epithelial 
regeneration. Thus, the alveolar epithelial regeneration during RA-induced lung 
regeneration in vivo may be secondary to direct effects of RA on the endothelium. 
The hypothesis that ATRA directly stimulates HLMVECs forms the basis of the next 
chapter. 
 
3.) Finally, it is possible that during RA-induced lung regeneration, ATRA is acting 
directly on a sub-population of multipotent alveolar progenitor cells, rather than AT2 
cells. Several candidates for alveolar progenitor cells have been identified which are 
able to give rise to multiple alveolar cell types (Introduction 1.2.2). For example, a 
subpopulation of naphthalene-resistant Clara cells localised to the bronchoalveolar 
duct junction (14) also express the multipotent marker stem cell antigen 1 (Sca-1) and 
surfactant protein C (SP-C), and could be induced to differentiate into cell clusters 
composed of Clara cells, AT2 and AT1 cells on basement membrane extract 
(Matrigel) in vitro (25). Termed bronchioalveolar stem cells (BASCs) they were 
found to replenish up to 25% of total AT2 cells during compensatory lung growth in 
young mice (26). In an H1N1 influenza mouse model of parenchymal destruction and 
regeneration, a population of p63+ Krt5+ cells contributed to alveolarisation, and 
after isolation and in vitro culture on Matrigel, developed into alveolar-like structures 
(29). The discovery of new candidate alveolar progenitor cells has led to new possible 
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targets for pharmacological induction of lung regeneration in vivo (453). Whether 
previously established lung regeneration-inducing interventions such as ATRA act on 
alveolar progenitor cells remains to be established. 
 
4.4.9 Future work 
 
Our observations have led us to conclude that RA signalling is unlikely to be directly 
involved in alveolar epithelial wound repair. It would therefore be of interest to study 
the relationship between alveolar epithelial cells and other lung cell types during RA-
induced lung regeneration. Conditioned media (CM) from RA treated HLMVECs or 
lipofibroblasts could be used to stimulate alveolar epithelial cells in the scratch assay, 
to investigate the role of RA-induced paracrine factors on alveolar epithelial wound 
closure. It would be important to exclude the effect of residual exogenous ATRA in 
the CM by washing the cells several times after incubation with RA (426). The 
influence of direct cell-cell contacts between epithelial cells and other pulmonary cell 
types during wound repair in the presence of RA stimulation could be interrogated 
using co-culture models (244, 452).  
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5 Chapter 5: RA signalling in human lung microvascular angiogenesis 
 
5.1 Introduction 
 
The cellular targets of RA in the adult human lung are unknown. Angiogenesis is the 
formation of new blood vessels from a pre-existing vasculature (454), and is 
necessary for reconstitution of the alveolar-capillary barrier after pneumonectomy 
(PNX) and during RA-induced lung regeneration (Introduction 1.3). We therefore 
hypothesised that RA might directly stimulate angiogenesis in human lung 
microvascular endothelial cells (HLMVECs). 
 
Angiogenesis is critical for lung regeneration. During post-PNX lung growth, the 
regions of tissue exposed to the greatest mechanical stretch exhibit most pronounced 
alveolar growth, and correspond to areas of greatest angiogenesis (42). Inhibition of 
angiogenesis through suppression of endothelial nitric oxide synthase (eNOS), a 
critical mediator of vascular endothelial growth factor (VEGF)-induced angiogenesis, 
impaired alveolarisation during post-PNX lung growth in mice (455). Several lines of 
evidence suggest that induction of lung angiogenesis can stimulate alveolar 
regeneration. In a rat model of hyperoxia-induced bronchopulmonary dysplasia 
(BPD), overexpression of VEGF145 led to increased lung capillary density and 
promoted new alveolar growth (456). Moreover, VEGF administration enhanced 
alveolarisation during post-PNX lung growth in mice (261), and after hyperoxic lung 
injury in rats (262).  
 
A direct role for RA in stimulating human lung microvascular angiogenesis has not 
yet been investigated. However, RA stimulated angiogenesis of bovine aortic 
endothelial cells (BAEC) (457), human umbilical vein endothelial cells (HUVECs) in 
co-culture with normal human dermal fibroblast (NHDF) (310), and human foreskin-
derived microvascular endothelial cells cultured on a human fibrin matrix (307). 
Conversely, an anti-angiogenic effect of RA has been reported in the chick 
chorioallantoic membrane (CAM) assay (458-460), and RA inhibited the production 
of pro-angiogenic factors in promyelocytic leukaemia and human endothelial cell 
lines (461, 462). These discrepancies may reflect heterogeneity in phenotype of 
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endothelial cells derived from different tissues, and thus the effects of RA on 
angiogenesis may be dependent on tissue source (463-465). Therefore, primary 
human lung microvascular endothelial cells (HLMVECs) were used in the present 
study to investigate the role of RA signalling in human lung microvascular 
angiogenesis. 
 
Lung microvascular endothelial cells are thought to be direct targets of RA. 
Microvascular endothelial cells derived from adult mouse lung upregulated cellular 
retinol binding protein 1 (CRBP1) in response to ATRA (208). In the lungs of rats 
with congenital diaphragmatic hernia (CDH) resulting from prenatal nitrofen 
exposure, RA preserved the expression of VEGFR1 and VEGFR2, which are 
predominantly expressed in endothelial cells (466, 467). Furthermore, the induction of 
lung regeneration by ATRA in the dexamethasone mouse model of BPD (Introduction 
1.5.3) was associated with increased VEGFR2 expression (214). In a canine model of 
post-PNX lung growth, ATRA increased the incidence of double capillaries and 
amplified the volumes of endothelial cells and capillary blood, consistent with 
angiogenesis, while leaving epithelial components unchanged (259). Furthermore, 
ATRA stimulated proliferation of human foetal lung capillary precursor cells (468), 
suggesting that adult human lung endothelial cells respond to ATRA. 
 
To address the hypothesis that RA directly stimulates human lung microvascular 
angiogenesis, we interrogated HLMVECs in an in vitro Matrigel-based angiogenesis 
assay. This is a widely used model of angiogenesis that has been characterised for 
endothelial cells of diverse tissue origins, including the lung microvascular 
endothelium (306, 469, 470). Matrigel is a basement membrane extract derived from 
murine Engelbreth-Holm-Swarm (EHS) sarcoma, composed of ~ 60% laminin, 30% 
collagen IV, and 8% entactin (471). In the assay, endothelial cells are seeded onto 
Matrigel, whereupon they cease to proliferate and spontaneously form a network of 
tubular structures containing a lumen and polarised cytoplasmic organelles 
reminiscent of capillary networks in vivo (472). This involves several processes which 
occur during angiogenesis in vivo such as migration, proteolytic degradation of the 
underlying matrix, directional chemotaxis, cell polarisation and cytoskeletal 
reorganisation (473). The Matrigel-based angiogenesis assay has been used to identify 
factors involved in the regulation of lung microvascular angiogenesis including 
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sphingosine 1-phosphate (474), epoxygenase (475), the JNK pathway (476), and the 
axonal guidance cue Ephrin B2 (477). 
 
The aim of the work in this chapter was to investigate the role of RA signalling in 
human lung microvascular angiogenesis. 
 
The specific objectives were: 
 
a. to explore the effect of exogenous ATRA on HLMVEC capillary tube 
formation 
b. to examine the regulation of downstream angiogenic factors that may 
mediate the effects of ATRA 
c. to investigate the RA receptor(s) responsible for mediating the effect of 
ATRA using RA receptor-selective agonists 
 
5.2 Specific Methods 
 
5.2.1 HLMVECs 
 
The HLMVECs used in these experiments were derived from 3 different donors from 
either Lonza and Promocell (2 donors from Lonza, 1 donor from Promocell). The 
cells were characterised by both companies with positive staining for von 
Willebrand's Factor (VIII) antigen and platelet endothelial cell adhesion molecule -1 
(PECAM-1/ CD31), and with negative staining for α-SMA. Lonza in addition used 
positive staining for acetylated low-density lipoprotein (Ac-LDL) to characterise 
cells. HLMVECs obtained from Lonza have been used for Matrigel-based 
angiogenesis experiments (474-476), whereas HLMVECs obtained from Promocell 
have not, however no differences were found in cellular morphology, passage time, or 
the ability to form tubes, between cells from the different donors. 
 
The culture media sold for use by both Lonza and Promocell for HLMVEC culture 
consists of a basal medium with supplementary growth factors to be added prior to 
use. The supplements were identical for both sets of media and consisted of defined 
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quantities of VEGF165, insulin-like growth factor long R3 (R3-IGF-1), bFGF (FGF2), 
epidermal growth factor (EGF), ascorbic acid, hydrocortisone, and FBS (Table 2.6). 
In addition, culture media from Lonza contained GA-1000 (gentamycin and 
amphotericin), whereas media from Promocell did not contain antibiotics. 
Hydrocortisone inhibits angiogenesis of human endothelial cells (478), and FBS 
contains retinoids which may interfere with the assay (479), and therefore freshly 
prepared medium containing all supplements except hydrocortisone and FBS was 
used for angiogenesis experiments. In preliminary experiments, the media from both 
companies was used interchangeably for cells from all 3 donors with no effects on 
either growth in culture or angiogenesis on Matrigel.  
 
5.2.2 Determination of optimum seeding density for HLMVEC tube assay 
 
To determine optimum seeding density for HLMVECs in the Matrigel-based 
angiogenesis assay, cells were seeded at varying concentrations (~20,400, 25,500 or 
31,250 cells per cm2, [4,000, 5,000 and 6,125 cells per well of a µ-slide Angiogenesis 
plate (Ibidi) respectively]) onto solidified Matrigel (growth factor reduced, BD 
Biosciences) according to the protocol described (2.2.10.2.3). Slides were incubated 
for 4 hours in humidified 5% CO2 air at 37 ºC, and digital images acquired with under 
a phase contrast microscope (Olympus).  
 
5.2.3 Determining expression of RA receptors in HLMVEC 
 
Expression of RA receptors in HLMVECs was assessed by performing end-point 
PCR for RAR-α, RAR-β and RAR-γ (primer sequences provided in Table 2.1. PCR 
cycling conditions are given in Table 2.2, with the exception that an annealing 
temperature of 56 ºC was used. PCR products were visualised by 3% agarose gel 
electrophoresis.  
 
5.2.4 Determining HLMVEC transcriptional regulation by RA 
 
To determine whether cells were responsive to RA on a transcriptional level, 
HLMVECs were seeded into 6-well plates at 1.0 x 105 per well and grown to 
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confluence. Following this, cells were incubated with ATRA at the indicated 
concentrations in culture media, after which RNA was collected. Taqman based RT-
qPCR was performed for RAR-β normalised to the mean of GUSB and B2M 
(2.2.4.3). All Taqman primer/probe sets were pre-designed, inventoried assays from 
Applied Biosystems (primer information is given in Table 2.3). RT-qPCR data were 
analysed with the ∆∆CT method (2.2.4.3.3) 
 
5.2.5 Determining effect of RA pathway modulation on HLMVEC angiogenesis 
 
To investigate the effect of RA pathway modulation on HLMVEC angiogenesis, 
various retinoid compounds were used in the Matrigel-based angiogenesis assay: 
ATRA (Sigma-Aldrich), BMS493 (pan-RAR antagonist, Sigma-Aldrich), Am580 
(RAR-α agonist, Sigma-Aldrich), BMS453 (RAR-β agonist, Tocris Bioscience), 
CD1530 (RAR-γ agonist, Tocris Bioscience), and ER 50891 (RAR-α antagonist, 
Tocris Bioscience). For specific details of concentrations, see figure legends. 
HLMVECs were seeded at 5000 cells per well of a µ-slide Angiogenesis plate (Ibidi) 
in treatment medium onto solidified Matrigel according to the protocol described 
(2.2.10.2.3). Slides were incubated for 4 hours in humidified 5% CO2 air at 37 ºC. For 
all experiments except RAR selective agonist experiments, 3 non-overlapping images 
were taken per well, total tube length per field of view quantified and the mean of 3 
images calculated. The mean was used in the statistical analysis. For RAR selective 
agonist experiments, an image of the whole well was taken, and total tube length per 
well quantified with Image J. This value was used for the statistical analysis. Toxicity 
of compounds was assessed in parallel with the WST-1 reagent on confluent 
HLMVECs in 96-well plates according to the protocol described (2.2.12.2). 
 
5.2.6 Transcriptional regulation of candidate angiogenic factors by ATRA 
 
To investigate potential downstream angiogenic factors regulated by ATRA in 
HLMVEC, cells seeded into 6-well plates at 1 x 105 per well were grown to 
confluence and incubated with ATRA at the indicated concentrations for 4 hours in 
humidified 5% CO2 air at 37 ºC, and RNA collected. Taqman-based RT-qPCR was 
performed in 384-well plates in a ViiA7 (Applied Biosystems) according to the 
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protocol described (2.2.4.3.2). Expressions of VEGFA, VEGFR1 (FLT-1), VEGFR2 
(KDR) and Midkine were assessed, normalised to the mean of GUSB and B2M (as 
for whole human lung tissue, Chapter 3.2.3). All Taqman primer/probe sets were pre-
designed, inventoried assays from Applied Biosystems (primer information is given in 
Table 2.3. RT-qPCR data was analysed with the ∆∆CT method (2.2.4.3.3). 
 
 
 
5.3 Results 
 
5.3.1 Determination of optimal seeding density for in vitro angiogenesis of 
human lung microvascular endothelial cells (HLMVECs) 
 
To investigate the effect of ATRA on angiogenesis in HLMVEC, a seeding density 
was determined to support low levels of tube formation in serum-free (control) 
conditions, but low enough so an effect from a stimulus could be detected. A range of 
seeding densities was tested: 20,400, 25,500 and 31,250 cells per cm2 (4,000, 5,000 
and 6,125 cells per well respectively). Densities higher than 31,250 cells per cm2 
resulted in a lawn of confluent cells from which no tube network developed (data not 
shown). With 20,400 cells per cm2 no tubes formed (Figure 5.1A), at 25,500 cells per 
cm2 a low level of tube formation could be observed (Figure 5.1B) and at 31,250 cells 
per cm2 an intricate tube network was present (Figure 5.1C). Therefore, a density of 
25,500 cells per cm2 was used for subsequent experiments to investigate ATRA-
induced HLMVEC angiogenesis. 
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Figure 5.1 25,500 cells per cm2 was the optimum seeding density for HLMVEC 
angiogenesis assay 
HLMVECs seeded at varying densities on solidified Matrigel in angiogenesis µ-slides 
(Ibidi) were incubated for 4 hours at 37 ºC. Following this, digital images were 
acquired and the resulting capillary networks inspected visually. Arrows in B) 
indicate example tubes. 
 
20,400 cells per cm2 
25,500 cells per cm2 
A	  
B	  
C	  
31,250 cells per cm2 
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5.3.2 Expression of RARs in HLMVECs, and the effect of ATRA on HLMVEC 
transcriptional activity and viability 
 
End point RT-PCR using primers specific to RAR-α, -β and -γ, revealed expression 
of all three receptors in HLMVECs (Figure 5.2A). To confirm HLMVECs respond to 
ATRA, HLMVECs were treated with varying concentrations of ATRA (0.001 to 10 
µM) or vehicle (DMSO), for 4 hours, and the induction of RAR-β assessed (431). A 
concentration-dependent induction of RAR-β was observed, which reached 
significance at 1 and 10 µM (p<0.05, Figure 5.2B), whereas DMSO had no effect.  
 
ATRA did not significantly affect cell respiration, indicating ATRA is not toxic up to 
10 µM in HLMVECs (Figure 5.2C). Taken together, these data validated the use of 
ATRA up to 10 µM in the HLMVEC angiogenesis assay. 
 
5.3.3 The effect of increasing concentrations of ATRA on HLMVEC 
angiogenesis 
 
To investigate the role of ATRA in HLMVEC angiogenesis, HLMVECs were seeded 
onto solidified Matrigel in angiogenesis µ-slides in serum-free media without or with 
varying concentrations of ATRA (0.01 to 10 µM). ATRA at 10 µM significantly 
increased the mean total length of tubes per field of view (p<0.05) (Figure 5.3A). No 
effect was observed with lower concentrations of ATRA or with DMSO (Figure 5.3A 
& B). Induction of HLMVEC angiogenesis by 10 µM ATRA was evident upon visual 
inspection (Figure 5.3C).  
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Figure 5.2 HLMVECs expressed retinoic acid receptors, and responded to 
ATRA on a transcriptional level in a dose dependent manner at non-toxic 
concentrations 
A) HLMVEC RNA was extracted, end-point RT-PCR performed to assess retinoic 
acid receptors (RARs) expression, and reaction products visualised on agarose gel 
alongside a 25bp DNA ladder (L, bright band at 125bp). Resultant bands correspond 
to expected size of amplified fragments: RAR-α 97 bp, RAR-β 70 bp, RAR-γ 103 bp. 
B) HLMVECs were incubated without treatment (control), with vehicle (DMSO), or 
with ATRA (0.001, 0.01, 0.1, 1, 10 µM) for 4 hours, and RNA extracted. RT-qPCR 
for RAR-β was performed with expression normalised to mean of GUSB and B2M. 
n=4 per group, * p<0.05 compared to DMSO, Kruskall Wallis with Dunn’s post test. 
C) HLMVECs were incubated with ATRA (0.1, 1, 10 µM) or without (control) for 4 
hours, and viability assessed after 2 hour incubation with WST-1 reagent. The amount 
of reduced formazan in the supernatants was spectrophotometrically determined at 
450 nm. Kruskall Wallis with Dunn’s post test revealed no significant differences, 
n=3 per group. All results expressed as mean +/- SEM. Abbreviations: L, 25bp DNA 
ladder; bp, base pairs; ATRA, all-trans retinoic acid; GUSB, beta-glucuronidase; 
B2M, beta-2 microglobulin; RAR-β, retinoic acid receptor beta; RT-qPCR, reverse-
transcription quantitative polymerase chain reaction 
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Figure 5.3 HLMVEC capillary tube formation was augmented by ATRA (10 
µM)  
A) HLMVECs seeded at 25,500 cells per cm2 on Matrigel were incubated for 4 hours 
without treatment (control), or with ATRA (0.01, 0.1, 1, 10 µM), or C) with vehicle 
(DMSO). 3 digital images were acquired per well, the total length of tubes per field 
quantified using image analysis software (Image J), and the mean calculated. Results 
are expressed as mean +/- SEM, n=6 per group. * p < 0.05 compared to control, 
Kruskall Wallis with Dunn’s post test. Representative images for each group are 
shown in B). Original magnification 10 x. Abbreviations: ATRA, all-trans retinoic 
acid; DMSO, dimethyl sulfoxide. 
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5.3.4 The effect of the pan-RAR antagonist BMS493 on ATRA-induced 
HLMVEC angiogenesis 
 
The pan-RAR antagonist BMS493 (10 µM) significantly inhibited ATRA-induced 
angiogenesis (p<0.05) and reduced the total length of tubes to a level comparable to 
control (Figure 5.4A). Incubation of cells with treatments followed by WST-1 reagent 
demonstrated a significant reduction in respiration with ATRA (10 µM)  + BMS493 
(10 µM)  (p<0.05, (Figure 5.4B). This suggests that the inhibition of ATRA-induced 
angiogenesis by BMS493 may have been caused by non-specific toxicity. 
 
5.3.5 Investigation into angiogenic factors mediating ATRA-induced HLMVEC 
angiogenesis 
 
To identify downstream factors responsible for mediating ATRA-induced HLMVEC 
angiogenesis, the regulation of several candidate angiogenic factors was examined 
using RT-qPCR. Induction of VEGFA mRNA expression was observed with ATRA 
(10 µM) Figure 5.5A), whereas no effect was seen on VEGFA expression with lower 
concentrations of ATRA. No effect on the expression of VEGFR1, VEGFR2, or 
Midkine was observed with any concentration of ATRA (Figure 5.5B-D). To 
determine whether induction of VEGFA mRNA by ATRA (10 µM) resulted in 
increased secreted VEGFA protein, supernatants from ATRA treated HLMVECs 
were examined by VEGFA ELISA, however no VEGFA was detected (data not 
shown). 
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Figure 5.4 ATRA-stimulation HLMVEC angiogenesis was inhibited by pan-RAR 
antagonist BMS493 (10 µM). This concentration also reduced cell viability 
A) HLMVECs seeded at 25,500 cells per cm2 on Matrigel were incubated for 4 hours 
either with ATRA (10 µM) alone, in combination with BMS 493 (1 or 10 µM) or 
without treatment (control). 3 photographs were taken per well, the total length of 
tubes per field quantified using image analysis software (Image J), and the mean 
taken. n=6 per group. * p<0.05, ** p<0.01, Kruskall Wallis with Dunn’s post test. 
Representative images for each group are shown in B). Original magnification 10 x. 
 C) HLMVECs were incubated either with ATRA (10 µM) in combination with 
DMSO, in combination with BMS 493 (0.1, 1, 2, 5, 10 µM), or without treatment 
(control) for 4 hours and viability assessed with WST-1 reagent. The amount of 
reduced formazan in the supernatants was spectrophotometrically determined at 450 
nm. n=3 per group. * p<0.05 compared to control, Kruskall Wallis with Dunn’s post 
test. Results are expressed as mean +/- SEM. Abbreviations: RA, retinoic acid; 
DMSO, dimethyl sulfoxide. 
Control ATRA 
10µM
1 10
0.0
0.5
1.0
1.5
2.0
To
ta
l t
ub
e 
le
ng
th
 
re
la
tiv
e 
to
 c
on
tr
ol
ATRA 10 µM 
+ BMS493 (µM)
** *
A	  
Control ATRA 
10 µM 
+ DMSO
0.1 1 2 5 10
0.00
0.05
0.10
0.15
0.20
A
bs
or
ba
nc
e 
45
0n
m
:6
00
nm
   ATRA 10 µM
+ BMS493 (µM)
*
C	  
B	  
Control ATRA 10 µM 
ATRA 10 µM  
+ BMS493 10 µM 
ATRA 10 µM  
+ BMS493 1 µM 
 260 
 
 
 
  
Figure 5.5 Regulation of candidate angiogenic factor mRNA expression by 
ATRA. VEGFA was induced by ATRA (10 µM), but VEGFR1, VEGFR2 or 
midkine were not regulated by ATRA 
HLMVECs were incubated with ATRA (0.001, 0.01, 0.1, 1, 10 µM), without 
(control) or with vehicle (DMSO) for 4 hours, and RNA extracted. RT-qPCR was 
performed for A) VEGFA, B) VEGFR1, C) VEGFR2 and D) Midkine, with 
expression normalised to the mean of GUSB and B2M. Results expressed as mean +/- 
SEM, n=5 per group. ** p<0.01, * p < 0.05 compared to DMSO group, Kruskall 
Wallis with Dunn’s post test. Abbreviations: ATRA, all-trans retinoic acid; GUSB, 
beta-glucuronidase; B2M, beta-2 microglobulin; RAR-β, retinoic acid receptor beta; 
RT-qPCR, reverse-transcription quantitative polymerase chain reaction; VEGFA, 
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vascular endothelial growth factor A; VEGFR1, vascular endothelial growth factor 
receptor 1; VEGFR2, vascular endothelial growth factor receptor 2. 
 
5.3.6 Toxicity of RAR agonists in HLMVECs 
 
Incubation of cells with Am580, BMS453, or CD1530 (0.1 to 10 µM) followed by 
WST-1 reagent did not demonstrate significant effects on cell respiration. A trend 
towards reduced HLMVEC respiration was observed with BMS453 (10 µM) and 
CD1530 (10 µM) although this did not reach significance (Figure 5.6B and C). This 
validated the use of each agonist at concentrations up to at least 1 µM. 
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Figure 5.6 Toxicity of RAR-selective agonists 
HLMVECs were incubated for 4 hours with either A) Am580 (RAR-α selective 
agonist) B) BMS453 (RAR-β selective agonist) or C) CD1530 (RAR-γ selective 
agonist) at various concentrations (0.1, 1 or 10 µM), and viability assessed with WST-
1 reagent. The amount of reduced formazan in the supernatants was 
spectrophotometrically determined at 450 nm. All results expressed as mean +/- SEM, 
n=3 per group. *** p < 0.001 compared to control, unpaired t-test. 
 
 
A	  
Control 0.1 1 10
0.0
0.2
0.4
0.6
0.8
1.0
A
bs
or
ba
nc
e 
45
0n
m
:6
00
nm
Am580 (µM)B	  
Control 0.1 1 10
0.0
0.2
0.4
0.6
0.8
1.0
A
bs
or
ba
nc
e 
45
0n
m
:6
00
nm
BMS453 (µM)
***
C	  
Control 0.1 1 10
0.0
0.2
0.4
0.6
0.8
1.0
1.2
A
bs
or
ba
nc
e 
45
0n
m
:6
00
nm
CD1530 (µM)
***
 263 
5.3.7 The effect of RA pathway agonists on HLMVEC angiogenesis 
 
To investigate the RAR(s) responsible for mediating ATRA-induced HLMVEC 
angiogenesis, cells were incubated with varying concentrations of Am580 (0.01 to 
1000 nM), BMS 453 (1 to 1000 nM), or CD1530 (1 to 1000 nM) in the angiogenesis 
assay. A concentration-dependent induction of HLMVEC angiogenesis by Am580 
(RAR-α selective agonist) was observed, reaching significance at 1 nM (p<0.05). 
This effect diminished with higher concentrations up to 1000 nM (Figure 5.7A). No 
effect of BMS453 or CD1530 on HLMVEC angiogenesis was observed at any 
concentration (Figure 5.7B and C). This suggests RAR-α, and not RAR-β or RAR-γ, 
mediates ATRA-induced HLMVEC angiogenesis. 
 
5.3.8 The effect of the RAR-α  selective antagonist ER58091 on ATRA-induced 
HLMVEC angiogenesis 
 
The RAR-α selective antagonist ER50891 (10 µM) significantly inhibited ATRA-
induced angiogenesis (p<0.001), reducing the total length of tubes to a level 
comparable to serum-free control (Figure 5.8A).  
 
Incubation of cells with treatments followed by WST-1 reagent demonstrated a 
significant reduction in respiration with ATRA (10 µM) and ER50891 (10 µM)  
(p<0.05, Figure 5.8B). This suggests that the inhibition of ATRA-induced 
angiogenesis by BMS493 may have been caused by non-specific toxicity. 
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Figure 5.7 HLMVEC angiogenesis was stimulated by the RAR-α  selective 
agonist Am580 (1 nM), whereas RAR-β  and RAR-γ  agonists had no effect 
HLMVECs seeded at 25,500 cells per cm2 on Matrigel were incubated for 4 hours 
either without treatment (control), with ATRA (10 µM), or with A, B) Am580 (0.01, 
0.1, 1, 10, 100 or 1000 nM), C, D) BMS453 (1, 10, 100, 1000 nM), or E,F) CD1530 
(1, 10, 100, 1000 nM). Digital images were acquired of each well and the total length 
of tubes per field quantified using image analysis software (Image J). Data presented 
as ± SEM, n=6-15 per group. * p < 0.05 compared to control, Kruskall Wallis with 
Dunn’s post test. Representative images for each group are shown in B, D and F. 
Original magnification 4 x. Compounds tested at same time, same controls used for 
all experiments. Abbreviations: ATRA, all-trans retinoic acid; DMSO. 
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Figure 5.8 ATRA-stimulation of HLMVEC angiogenesis was inhibited by the 
RAR-α  selective antagonist ER50891 (10 µM), a concentration which also 
reduced cell viability 
A) HLMVECs seeded at 25,500 cells per cm2 on Matrigel were incubated for 4 hours 
without treatment (control), with ATRA (10 µM) alone, or with 10 µM ATRA in 
combination with ER58091 (1, 5, 10 µM). 3 digital images were taken per well, the 
total length of tubes per field quantified using image analysis software (Image J), and 
the mean taken. n=3 per group. ** p < 0.01, *** p < 0.001, Kruskall Wallis with 
Dunn’s post test. B) HLMVECs were incubated either without treatment (control), 
with ATRA (10 µM) in combination with vehicle (DMSO), or with 10 µM ATRA in 
combination with ER58091 (0.1, 1, 2, 5, 10 µM), for 4 hours and viability assessed 
with WST-1 reagent. The amount of reduced formazan in the supernatants was 
spectrophotometrically determined at 450 nm. Results are expressed as mean +/- 
SEM, n=3 per group. * p<0.05 compared to control, Kruskall Wallis with Dunn’s post 
test. Abbreviations: ATRA, all-trans retinoic acid; DMSO, dimethyl sulfoxide. 
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5.4 Discussion 
 
5.4.1 Summary of key findings in this chapter 
 
The work in this chapter established an optimum seeding density (25,500 per cm2) for 
HLMVECs in the in vitro angiogenesis assay. HLMVECs express retinoic acid 
receptors (RARs), and respond to ATRA by up-regulating RAR-β mRNA expression. 
ATRA stimulated HLMVEC angiogenesis at 10 µM, a concentration that did not 
affect cell viability. The pan RAR-antagonist BMS493 inhibited ATRA-stimulated 
HLMVEC angiogenesis, however the combination of BMS493 and ATRA 
significantly reduced respiration, suggesting that the inhibitory effect may reflect 
toxicity. HLMVECs up-regulated VEGFA mRNA in response to ATRA (10 µM). 
However, VEGFA protein secretion could not be confirmed with ELISA. HLMVECs 
upregulated VEGFR2 in response to ATRA (1 and 10 µM). ATRA did not alter 
expression of VEGFR1 (FLT-1) or midkine. Am580 (1 nM) stimulated HLMVEC 
angiogenesis, suggesting that ATRA-induced HLMVEC angiogenesis is mediated by 
RAR-α. The RAR-α selective antagonist ER50891 inhibited ATRA-induced 
HLMVEC angiogenesis, however the combination of treatments at these 
concentrations significantly reduced respiration, suggesting that the inhibitory effect 
reflected toxicity. In aggregate, ATRA stimulated HLMVEC angiogenesis, possibly 
via RAR-α activation and autocrine VEGF signalling.  
 
5.4.2 Establishment of the model 
 
Initial experiments determined the optimum seeding density for HLMVECs in the in 
vitro angiogenesis assay. Angiogenesis relies on sufficient inter-cellular distance for 
paracrine stimulation by chemoattractive factors secreted by neighbouring cells, 
leading to directional cell migration (454), and so the seeding density must be high 
enough to support this. ~25,500 cells/cm2 resulted in low levels of tube formation in 
serum-free media, and allowed stimulation by ATRA to be detected. A comparable 
density (40,000 cell per 1.7 cm2 well) has been used for HLMVECs in the 
angiogenesis assay for the investigation of epoxygenase-induced angiogenesis (475). 
Therefore, this seeding density was used for all experiments.  
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The ability to form a capillary network in the Matrigel-based angiogenesis assay is a 
defining characteristic of endothelial cells (480), and occurs rapidly via predictable 
steps. Endothelial cells attach to the Matrigel substrate within the first hour, and 
migrate toward each other over the next 2 to 4 hours to form capillary-like tubes, 
which mature by 6 to 16 hours. After 24 hours, cells undergo apoptosis and tubes 
deteriorate (306). A 4 hour incubation time was previously optimised in our lab for 
human pulmonary artery endothelial cell (hPAEC) angiogenesis on Matrigel, as by 
this time a network of capillaries was visible (481). After 4 hours in the present study, 
the HLMVEC network had a similar appearance to hPAECs at the same time point 
(481), therefore a 4 hour incubation time was used for all experiments. 
 
Previous studies using the angiogenesis assay have measured various features of the 
capillary network, such as total length of tubes, number of intersections between 
capillaries, length and number of individual tubes, and network lacunarity (the degree 
of space in the network) (482). We used total tube length as it is easy and rapid to 
quantify with image analysis software (Image J), and has been widely used to 
measure the effects of angiogenic factors on angiogenesis, including ATRA in human 
umbilical vein endothelial cells (HUVECs) (309, 310).  
 
5.4.3 ATRA has transcriptional activity in HLMVECs  
 
RA exerts its effects through binding to its cognate type 2 nuclear receptors RARs 
(chapter 1.7.7 (149)). HLMVECs expressed RAR -α, -β and -γ mRNA, suggesting 
these cells have the capacity to respond to RA (Figure 5.2). Furthermore, ATRA 
induced RAR-β mRNA expression in a concentration-dependent manner, reaching 
significance at 1 and 10 µM (p<0.05), indicating that HLMVECs are transcriptionally 
responsive to ATRA. Concentrations of 0.01 to 10 µM were assessed as higher 
concentrations resulted in RA precipitating in media. RAR-β expression was chosen 
as the RAR-β promoter contains a RA response element (RARE) (431), and 4 hours 
was chosen to correspond with the incubation time in the angiogenesis assay. Our 
data are in agreement with a previous report in rat lung microvascular cells, in which 
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ATRA induced cellular retinol binding protein 1 (CRBP1) mRNA expression in a 
concentration-dependent manner (208). 
 
5.4.4 ATRA (10 µM) stimulated HLMVEC angiogenesis 
 
 
In HLMVECs, ATRA (10 µM) stimulated formation of a capillary network with 
significantly greater total tube length compared to either serum-free media or other 
concentrations of ATRA (p<0.05, Figure 5.3). There was no difference in total tube 
length between cells in serum-free media and media containing ATRA at 1 µM or 
below. Our data are in agreement with previous reports of a pro-angiogenic role for 
ATRA in bovine aortic endothelial cells (BAECs), HUVECs and human foreskin-
derived microvascular endothelial cells (HMVECs) (307, 310, 457). ATRA 
stimulated foreskin-derived HMVEC angiogenesis at 1 µM (307), whereas other 
studies found lower concentrations were effective. In a study by Gaetano et al., 
BAECs were pre-treated with ATRA for 72 hours prior to incubation on Matrigel for 
18 hours, and ATRA stimulated angiogenesis with a peak effect at 0.1 µM (457). 
Saito et al., used a HUVEC/normal human dermal fibroblast (NHDF) co-culture, and 
found that 1 nM ATRA stimulated HUVEC tube formation at 4 days significantly 
more than control media (310).  
 
The relatively high concentration of ATRA needed (10 µM) to stimulate HLMVEC 
angiogenesis in the present study may reflect the presence of cellular retinoic acid 
binding proteins (CRABPs). CRABPs bind retinoic acid with high affinity (483) and 
sequester exogenous ATRA or promote its degradation (125, 484), therefore 10 µM 
ATRA may be necessary to overcome their presence. Another possible explanation is 
ATRA-induced CYP26A1 expression, which catalyses the degradation of ATRA 
(131). The CYP26A1 promoter contains three RAREs and one half RARE-site, which 
result in the CYP26A1 gene being highly inducible by ATRA (485). The expression 
of CYP26A1 in whole human lung tissue homogenates was demonstrated earlier in 
this thesis (Chapter 3). Induction of CYP26A1 by ATRA in HLMVECs may result in 
high concentrations (10 µM) of ATRA being required to overcome CYP26A1-
mediated ATRA catabolism to stimulate angiogenesis. Future experiments 
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investigating the regulation of CYP26A1 in HLMVECs by ATRA will be necessary 
to address this hypothesis.  
 
A further possibility is that 10 µM ATRA was necessary to stimulate angiogenesis 
within the 4 hours incubation in the present study, compared to the longer incubations 
used in the previously mentioned studies. Pre-incubation of HLMVECs with ATRA 
prior to seeding on Matrigel may help to determine whether lower concentrations of 
ATRA can stimulate HLMVEC angiogenesis. 
 
The effects of RA on angiogenesis are controversial. An anti-angiogenic effect of RA 
was reported in the chick chorioallantoic membrane (CAM) assay (458-460), via 
downregulation of Tie2 (angiopoeitin receptor) in underlying mural cells and 
interference with endothelial-mural cell interactions (486). RA inhibited the 
production of the pro-angiogenic factors vascular endothelial growth factor (VEGF) 
in HL-60 cells, a human promyelocytic cell line (461), and ETS-1 in a human 
endothelial cell line (462), suggesting that the effects of RA on angiogenesis may be 
cell type dependent. There is considerable heterogeneity amongst endothelial cells 
from different tissues, and this is reflected both in their capacity for angiogenesis on 
basement membrane substrates in vitro and in response to cytokines (487). For 
example, TNF-α down-regulated PECAM-1 in HUVECs, and up-regulated PECAM-
1 in human dermal microvascular endothelial cells (348). This may account for the 
discrepancies between our data and previous reports. 
 
To determine whether ATRA-induced HLMVEC angiogenesis acts via RARs, 
HLMVECs were co-incubated with ATRA (10 µM) and various concentrations of the 
pan-RAR antagonist BMS493 in the angiogenesis assay (442). BMS493 (10 µM) 
significantly inhibited ATRA-induced HLMVEC angiogenesis (p<0.05, Figure 5.4). 
However, experiments with WST-1 reagent demonstrated significant reduction in 
HLMVEC viability with ATRA (10 µM) and BMS493 (10 µM) (p<0.05), suggesting 
that inhibition of ATRA-induced angiogenesis by BMS493 (10 µM) may in part be 
due to non-specific toxicity. However, subsequent studies with RAR selective 
agonists supported the idea that the effect of ATRA was mediated by specific RARs.  
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5.4.5 ATRA up-regulated VEGFA, but did not affect regulation of VEGFR1, 
VEGFR2 or Midkine in HLMVECs 
 
 
To investigate the mechanism of ATRA-induced HLMVEC angiogenesis, we 
assessed the effect of 4 hour ATRA incubation on mRNA regulation of candidate 
angiogenic factors. Vascular endothelial growth factor A (VEGFA) has important 
roles in endothelial cell survival, permeability and angiogenesis through interaction 
with its receptors VEGF receptor 1 (VEGFR1, FLT-1) and VEGF receptor 2 
(VEGFR2, Flk-1 in rats, KDR in humans) (467). VEGFA and VEGFR2 are regulated 
by RA, and are critical for alveolar development and regeneration (214, 310, 488, 
489). VEGF and VEGFR1 expression was reduced in the lungs of infants with BPD 
along with disrupted vasculature, suggesting a role in developmental lung 
angiogenesis in humans (490). Midkine is an RA-responsive pro-angiogenic factor 
upregulated during alveolar development (218).  
 
ATRA (10 µM) induced up-regulation of VEGFA mRNA in HLMVECs, which was 
not observed at concentrations of 1 µM or below (Figure 5.5). ATRA also induced 
VEGFR2 expression in a concentration-dependent manner, reaching significance at 1 
and 10 µM (p<0.05). These data suggest VEGFA and VEGFR2 may be involved in 
mediating the pro-angiogenic effect of ATRA (10 µM) in HLMVECs. Increased 
VEGFA protein secretion could not be determined with ELISA (data not shown), 
perhaps because the sensitivity of the ELISA was insufficient due to the short 
incubation time (4 hours). Experiments with HLMVECs with longer incubation times 
will be required to address this hypothesis. Another possibility is that VEGFA is 
controlled by post-transcriptional mechanisms in HLMVECs (491). Nonetheless, our 
data is in agreement with the study by Saito et al. which showed that ATRA-
stimulated HUVEC angiogenesis was mediated by NHDF-derived VEGF, which 
signalled through VEGFR2 in HUVECs, suggesting that ATRA-stimulated 
angiogenesis is mediated by VEGF-VEGFR2 signalling in diverse cell types (310).  
 
RA induced VEGF expression in various other cell types. RA up-regulated VEGF 
mRNA in retinoblastoma cells by increasing protein levels of the transcription factor 
Sp1 through post-translational mechanisms, which then bound to GC rich sequences 
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in the promoter region of VEGF (492). ATRA up-regulated VEGF in 
bronchioalveolar carcinoma cells through a similar mechanism (493). In addition, 
ATRA induced VEGF expression in aortic smooth muscle cells through 
phosphorylation of p44/p42 MAP kinase (494). To determine whether VEGF 
signalling is critical for ATRA-induced HLMVEC angiogenesis, future experiments 
involving co-incubation of HLMVECs with ATRA and the VEGFR1 and 2 inhibitor 
SU-5416, with VEGFA neutralising antibodies, or with RNA interference-mediated 
VEGF receptor knockdown, will be required (310, 495, 496). 
 
VEGFR2 is the major mediator of the biological activities of VEGF, including its pro-
angiogenic properties (467). Our data are in agreement with the study by Saito et al. 
which showed ATRA directly stimulated VEGFR2 expression in HUVECs (310), and 
suggest that ATRA regulates VEGFR2 expression in diverse cell types. Furthermore, 
our data are in accordance with a study which showed that RA-induced lung 
regeneration in the Dex mouse model (described in introduction 1.5.3) was associated 
with increased VEGFR2 expression (214). While, whole lung tissue homogenates 
were used in this study and so it is unclear in which cell types VEGFR2 was 
upregulated, our data suggest that the microvascular endothelium may be a direct 
target of RA during lung regeneration by upregulating VEGFR2 in this model. 
 
VEGF signalling through VEGFR2 has pro-angiogenic activity in diverse endothelial 
cell types. Endothelial cells extend VEGFR2-expressing filopodia in response to 
VEGF gradients established by both soluble and matrix-bound isoforms (497). 
Activation of VEGFR2 and its subsequent internalisation initiates angiogenesis 
through a variety of molecular mechanisms, including nuclear translocation of 
phosphorylated STAT3 (498), and mitogen-associated protein kinase (MAPK) 
activation and phospholipase C-γ (PlC-γ) phosphorylation (499). Future work will 
involve elucidating the mechanism by which VEGF might mediate ATRA-induced 
HLMVEC angiogenesis. 
 
VEGFR1 and Midkine were not regulated by ATRA in HLMVECs. Midkine was 
reported to be up-regulated in alveolar walls during alveolarisation in rats, and 
induced in the lungs of Dex-treated rats which had been rescued with RA (500). The 
 273 
lack of effect of ATRA on Midkine mRNA expression in HLMVECs suggests that 
other alveolar cell types act as the source of Midkine after ATRA administration in 
the lung. 
 
5.4.6 The RAR-α  selective agonist Am580 (1 nM) stimulated HLMVEC 
angiogenesis 
 
To investigate the retinoic acid receptor(s) that mediate ATRA-induced HLMVEC 
angiogenesis, various RAR-selective pharmacological agonists were used in the 
angiogenesis assay: Am580 (RAR-α agonist), BMS453 (RAR-β agonist), and 
CD1530 (RAR-γ agonist). Am580 is a retinoidal benzanilide derivative with selective 
affinity for RAR-α (501). Am580 binds to the ligand-binding domain (LBD) of RAR-
α at a critical region between amino acids 403 and 410, decreasing the affinity of all 
co-repressor motifs for RAR-α to facilitate gene transcription (502, 503). Am580 
stimulated HLMVEC angiogenesis (Figure 5.7A), the extent of tube formation being 
comparable to that stimulated by ATRA at 10 µM. Hence it is possible that RAR-α 
activation mediated the induction of HLMVEC angiogenesis by ATRA. This was 
further supported by the lack of effect of BMS453 (RAR-β agonist), and CD1530 
(RAR-γ agonist) on HLMVEC angiogenesis at any concentration (Figure 5.7B and 
C). 
 
The effect of Am580 exhibited a bi-phasic concentration-dependent curve with a bell-
shaped appearance, with a peak effect at 1 nM. A bell-shaped concentration response 
is characterised by stimulation at low concentration, followed by loss of this effect at 
higher concentrations, and is common in the induction of angiogenesis by angiogenic 
factors (504). A bell-shaped response was described for Am580-induced stimulation 
of bFGF in BAECs (457). The loss of angiogenic stimulation by Am580 at 100 nM or 
higher in the present study could be explained by decreased specificity of Am580 for 
RAR-α. The Kd of Am580 for RAR-α is 10 nM, whereas for RAR-β it is 74 nM 
(505). Therefore, at 100 nM more than half the available RAR-β is bound to Am580, 
which could negate the stimulatory effect of Am580. 
 
Am580 and ATRA have similar binding affinities for RAR-α (10 nM and 16 nM 
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respectively) (505), however we found that Am580 stimulated angiogenesis at a lower 
concentration than ATRA (1 nM compared to 10 µM). A possible explanation is the 
negligible affinity of Am580 for CRABPs (about 1/1000 that of ATRA), and/or 
resistance of Am580 to catabolism by CYP26 enzymes (506, 507). Therefore, while 
ATRA is either sequestered by CRABPs or degraded by CYP26s, Am580 may be free 
to activate RAR-α at lower concentrations.  
 
To confirm that ATRA-induced HLMVEC angiogenesis is mediated by RAR-α 
activation, the RAR-α selective antagonist ER50891 was used in the angiogenesis 
assay in combination with ATRA (10 µM) to investigate whether RAR-α antagonism 
could inhibit ATRA-induced angiogenesis. 10 µM ER 50891 significantly inhibited 
10µM ATRA-induced HLMVEC angiogenesis (p<0.001). However, experiments 
with WST-1 reagent demonstrated significant reduction in HLMVEC viability with 
10 µM ATRA and 10 µM ER58091 (p<0.05), suggesting that inhibition of ATRA-
induced tube formation by 10 µM ER50891 was due to toxicity. 
 
RAR-α activation has previously been implicated in ATRA-stimulated angiogenesis. 
ATRA induction of bFGF expression in BAECs was critical for ATRA-stimulated 
angiogenesis, and this induction was inhibited with a RAR-α selective antagonist, and 
reproduced with Am580 (457). In the study by Saito et al., ATRA-induced HUVEC 
angiogenesis was mediated by at least two RARs, as the RAR-α agonist Am80 and 
the RAR-γ agonist CD437 could replicate the effects of ATRA (310). In another 
study, selective RAR-α activation with Am580 had the same effect as ATRA on 
eNOS phosphorylation at Ser1177, leading to increase in production of the pro-
angiogenic factor NO in human dermal microvascular endothelial cells (508).  
 
No pharmacological agonist or antagonist is 100% selective and the possibility of 
non-specific effects cannot be excluded. Therefore, further experiments using 
alternative methods to selectively activate or inactivate RAR-α are required to 
confirm our findings. For example, a vector containing dominant negative RAR-α 
(509), small interfering RNA (siRNA), or morpholinos specific for RAR-α to 
selectively ablate RAR-α could be used. Additionally, transfection with a vector 
containing human RAR-α (508) could be used to determine whether overexpression 
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of RAR-α can stimulate HLMVEC angiogenesis, which would support the hypothesis 
that ATRA-stimulated HLMVEC angiogenesis is mediated by RAR-α activation. 
 
5.4.7 Summary and Limitations 
 
We demonstrated that ATRA (10 µM) stimulated HLMVEC angiogenesis in a 
Matrigel-based angiogenesis assay. Furthermore, the RAR-α agonist Am580 (1 nM) 
stimulated HLMVEC angiogenesis, whereas the RAR-β and RAR-γ agonists 
BMS453 and CD1530 had no effect. ATRA-induced HLMVEC angiogenesis was 
associated with the induction of VEGFA and VEGFR2, suggesting a mechanism 
involving VEGF signalling through VEGFR2. From these observations, together with 
the observations that ATRA does not influence alveolar epithelial repair (Chapter 4), 
we hypothesise that ATRA-induced lung regeneration in vivo and the biological 
effects observed with ATRA treatment in clinical trials (Introduction 1.10 and 1.11.) 
are mediated in part by direct stimulation of lung microvascular angiogenesis by 
ATRA. This hypothesis is discussed in the General Discussion (Chapter 7.4).  
 
The Matrigel-based angiogenesis assay has several limitations. Matrigel consists of 
laminin, collagen IV and entactin, while in vivo the alveolar basement membrane 
contains other components such as type V collagen, chondroitin sulfate, chondroitin 
and heparin sulfate proteoglycan and fibronectin (510). Basement membrane 
components exert biological effects on cells through receptor-mediated interactions, 
and it is possible that the additional basement membrane components in vivo will 
modify the response of HLMVECs to ATRA via mechanisms not represented in the 
Matrigel-based angiogenesis assay. Another issue is that effects of paracrine signals 
or cell-cell contacts with other cell types were not determined in our study. In vivo, 
microvascular endothelial cells are in contact with AT1 cells via a fused basement 
membrane, and are associated with fibroblasts via cytoplasmic processes (209). 
Therefore, other cell types may modulate the angiogenic response of HLMVECs to 
ATRA or RAR-α agonists in vivo. To address the relevance of our findings to human 
lungs in vivo, experiments investigating ATRA-induced microvascular angiogenesis 
in a more complex biological system of alveolar regeneration would be highly 
informative. We have begun to address this with the development of a model of 
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human alveolar repair using precision cut lung slices (PCLS) derived from human 
lung tissue. The development of this model forms the basis of the next chapter. 
 
5.4.8 Future Work  
 
 
Mechanisms other than VEGF signalling are likely to be involved in ATRA-induced 
HLMVEC angiogenesis. Several studies have reported regulation of the plasminogen 
activator (PA) system by RA. UPA and tissue-type plasminogen activator (tPA) are 
serine proteases that convert plasminogen to its active form plasmin, a proteolytic 
enzyme that degrades extracellular matrix, resulting in context-specific endothelial 
migration and angiogenesis (511). In human foreskin-derived HMVECs, ATRA-
induced angiogenesis was mediated by the urokinase-plasminogen activator (u-PA)/u-
PA receptor complex (307). It was demonstrated that RA induced expression of uPA 
in BAECs through RAR-mediated recruitment of Sp1, which augmented its 
interaction with the uPA GC box (512). In another study, ATRA stimulated the 
secretion of tPA from HUVECs through RAR-α activation (513). Furthermore, tPA 
contains a RARE in its promoter region, suggesting direct transcriptional control by 
RA (514). It would therefore be interesting to investigate the role of the PA system 
during ATRA-induced HLMVEC angiogenesis. 
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6 Chapter 6: Development of a model of human alveolar repair with 
precision cut lung slices (PCLS) 
 
6.1 Introduction 
 
The present chapter is focussed on development of an ex vivo model of human 
alveolar regeneration using precision-cut lung slices (PCLS) derived from adult 
human distal lung tissue. PCLS is a model system in which fresh lung tissue is cut 
into small discs (500 µm thick, 8 mm diameter) which can be maintained in culture 
for extended periods (515). The aim of PCLS is to explore molecular or cellular 
aspects of lung biology in a complex system relevant to lung in vivo.  
 
Human alveolar regeneration is ethically and technically challenging to study in vivo, 
and previous studies are limited to measurements of biomarkers in bronchoalveolar 
lavage or plasma (e.g. matrix metalloproteinases [MMPs]) (288), or physiological 
parameters such as gas diffusion capacity, spirometry or quality of life (289). More 
recently, magnetic resonance imaging (MRI) with inhalation of hyperpolarized 
helium-3 was used to demonstrate alveolarisation following left-pneumonectomy in 
an adult patient (45). However, these techniques are of inadequate sensitivity and 
specificity for studying repair at a cellular level. Animal models have provided 
information about cellular and molecular events involved in lung regeneration 
(described in introduction 1.2), however their relevance to humans is qualified by 
critical inter-species differences in physiology, anatomy and immunology (516). 
Human PCLS might therefore represent a promising alternative for the study of 
human lung regeneration.  
 
PCLS may offer several additional advantages over in vivo animal models. Control 
and treatment groups can be obtained from the same organ, reducing the experimental 
variation. As atmosphere and media constituents can be regulated, and potentially 
confounding systemic influences such as extra-pulmonary metabolism and 
immunological factors can be removed, PCLS have the potential for greater 
experimental control than in vivo models (517). Compared to in vitro cell-culture 
systems, PCLS are multi-layer aggregates that preserve the cellular heterogeneity and 
structural complexity of lung tissue found in vivo. Consequently, normal cellular 
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interactions remain intact both between cells and their underlying extracellular matrix 
(317, 518).  
 
PCLS is an attractive model system for human lung regeneration, as many slices can 
be produced rapidly from a single organ, minimising the number of donors and 
quantities of treatment required. However, many of the aspects which make PCLS an 
attractive model preclude its use for biochemical, protein or gene expression analysis 
(317). Thus, PCLS will not supplant in vivo animal or in vitro human models of lung 
repair, but may provide a useful complementary approach (519). 
 
Data regarding long-term culture (> 7 days) of PCLS derived from adult human 
peripheral lung is extremely limited, with only one study demonstrating preservation 
of architecture determined by light microscopy for 10 days (520). Long-term 
maintenance of human PCLS in culture may be necessary for the study alveolar 
regeneration, which in vivo may take several days or weeks (described in introduction 
1.2). PCLS have been derived from the peripheral lung of mice, hamsters, guinea 
pigs, monkeys, horses and humans (317). Murine PCLS have reportedly been cultured 
for up to 60 days (521), and hamster PCLS for 4-6 weeks (318), however most studies 
using PCLS have maintained slices for less than 7 days, with preservation of PCLS 
viability rarely demonstrated for more than a few days (317, 522). 
 
Human PCLS have previously been used to investigate diverse aspects of human lung 
physiology including drug metabolism (523), efficiency of gene transfer using 
lentiviral vectors (524) and neural-mediated bronchoconstriction (525). Various 
models of injury have been applied to human PCLS, such as mechanical stretch (526), 
drug-induced toxicity (527) and stimulation of the innate cytokine response with 
immunomodulators such as lipopolysaccharide (LPS) (528), however alveolar repair 
has not been demonstrated with human PCLS.  
 
The aim of this chapter was to investigate the utility of human PCLS for the 
development of an ex vivo model of human alveolar regeneration.  
 
The specific aims were to investigate: 
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1) How well lung tissue is preserved through the slicing process 
2) Whether foetal bovine serum (FBS) supplementation improves the 
maintenance of human PCLS in culture 
3) How well PCLS are maintained for long periods of time in culture, in 
terms of viability and cellular behaviour 
 
The goal with this line of investigation is to use the PCLS model to investigate the 
molecular processes involved in human alveolar regeneration. We would have a 
particular interest in examining the role of RA signalling during human alveolar 
repair processes. For example, according to the data gathered in this thesis (Chapter 
5), it would be of great interest to assess the effect of ATRA incubation on the 
microvascular endothelium using the PCLS model. Unfortunately due to time 
constraints and limited tissue availability, we were not able to apply the PCLS model 
to the study of RA signalling within this PhD project. 
 
6.2 Specific Methods 
6.2.1 PCLS generation 
 
Whole right middle or lingular lobes from donors 1, 2, 3, 4 and 5 were inflated with 
low-melt agarose using the instillation method according to the protocol described 
(2.2.11.3.2). Lung tissue from donor 6 was obtained from a patient undergoing 
surgical resection for carcinoma removal. As this specimen was a smaller portion of 
lung tissue surrounded partially by a visceral membrane, it was inflated with low-melt 
agarose using the injection method according to the protocol described (2.2.11.3.1). 
For each experiment, enough PCLS were prepared to allow several slices to be 
harvested at the appropriate time points for different purposes.  
 
6.2.2 Assessment of PCLS 
 
6.2.2.1 Paraffin embedding and H&E staining 
 
Two slices per time point were transferred to 4% PFA and fixed for 1-2 weeks at 4 ºC, 
processed for paraffin embedding and stained with H&E (pig and human PCLS) and 
picosirius red staining (pig PCLS). 
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H&E stained slices were examined under a DM 2500 microscope (Leica). For the 
nuclear counting, 10 random fields of view at 20x magnification were acquired for 
each H&E stained PCLS slide (2 sections per slide, 5 fields of view per section). 
Images were imported into Image J, and total nuclei per field quantified using the 
‘cell counter’ plugin. To normalise to length of alveolar wall, alveolar septae were 
traced with the ‘freehand line’ tool and quantified using the ROI manager. Nuclei per 
length of alveolar wall was calculated per field of view by dividing total number of 
nuclei per field by the total alveolar wall length per field. This value was calculated 
for each field of view, 10 fields of view per PCLS. Owing to low n numbers (1 slice 
per time point) the value for each field of view was used in the statistical analysis.   
 
6.2.2.2 Picosirius Red 
 
PSR is a strongly anionic dye which binds to basic groups in collagen, parallel with 
the axis of the collagen fibre. This enhances fibrillar collagen’s natural birefringence 
and allows it to be visible with polarised-light microscopy (529). Thin collagen fibres 
appear green, and larger collagen fibres appear yellow or orange/red. Quantification 
of PSR-bound collagen is possible using fully polarised light with appropriate 
software, although this was not permitted within the time frame of the project. In the 
present study, half-polarised light was used to outline the PCLS architecture whilst 
allowing PSR stained collagen to be visible. 10 random fields of view at 20x 
magnification with half-polarised light were acquired for each PSR stained PCLS 
slide (2 sections per slide, 5 fields of view per section) using a DM 2500 microscope 
(Leica). 
 
6.2.2.3 IHC 
 
Unstained, paraffin-embedded PCLS sections (2 sections on each slide per PCLS) 
were used for IHC. Primary antibodies used were alpha-smooth muscle actin (Gene 
Tex), aquaporin 5 (Santa Cruz), PECAM-1 (Sigma-Aldrich), pro-surfactant protein C 
(Millipore), RALDH 1 (Sigma-Aldrich) and RALDH 2 (Sigma-Aldrich). Secondary 
antibodies used were Alexa Fluor 488 donkey anti-goat (Molecular Probes), Alexa 
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Fluor 594 rabbit anti-mouse (Molecular Probes) and Alexa Fluor 594 goat anti-rabbit 
(Molecular Probes). Paraffin tissue sections were rehydrated and antigen retrieval 
performed according to the protocol described (2.2.6.1). Following this, IHC was 
performed with primary and secondary antibodies at the concentrations indicated 
(Table 2.5) according to the protocol described (2.2.6.2). Immunofluorescence was 
visualised with a DM 2500 microscope (Leica) and digital images acquired with 
QWin V3 software (Leica). 
 
6.2.2.4 LDH assay 
 
LDH release was measured up to day 11 using the Cytotoxicity Detection Kit (Roche) 
according to the manufacturer’s instructions, on PCLS from donors 1 and 2. Six slices 
from different cores were used per experiment. During the wash step every 24 hours, 
the medium being replaced was harvested, centrifuged at ~12,000 rpm to remove cell 
debris and stored at 4 ºC until the end of the experiment. Therefore, the absorbance 
reading at each time point reflects the LDH released into the supernatant over a 24 
hour period. As a positive control, three slices on day 1 were lysed with 1% Triton-X 
to cause maximum LDH release, and the medium harvested as above. As a negative 
control, fresh PCLS media (not used for PCLS culture) was harvested as above. An 
aliquot of medium (100 µl) was transferred into corresponding wells of an optically 
clear 96-well flat bottom microplate in triplicate, and reaction mixture (100 µl: 
containing diaphorase/NAD+ mixture with iodotetrazolium chloride and sodium 
lactate) was added. After 30 minutes incubation, the optical density was measured at 
450 nm using an EL800 plate reader (Biotek). 
 
6.2.2.5 Ciliary beating 
 
Examination of ciliary beating was performed on PCLS derived from donors 1 and 2. 
For the first experiment, only 2 of 5 slices were ultimately suitable for the experiment, 
with the airways in the other 3 slices either remaining contracted or exhibiting a 
complete absence of any beating cilia; for the second experiment all 5 slices were 
suitable. Due to the low numbers of slices, the ciliary beating values were treated as 
individual data points, with the mean of all 7 slices taken for the statistical analysis. 
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At each time point (days 1, 2, 4, 6 and 8), the airways individual slices were 
microscopically examined for ciliary beating in the epithelial-luminal border, which 
was recorded as a proportion of the total circumference of the airway lumen according 
to the protocol outlined (2.2.12.3.2). 
 
6.2.2.6 WST-1 assay 
 
Initial experiments involved optimising the incubation time for WST-1 with pig 
PCLS. On day 1, slices were incubated with WST-1 diluted 1:10 in 1 ml culture 
media for 1, 2 and 4 hours in humidified 5% CO2 air at 37 ºC. Supernatants were 
collected, serial dilutions prepared (1, 0.5, 0.1 and 0.01 in culture media) and the 
amount of reduced formazan spectrophotometrically determined at 450 nm. The 
curves generated for serial dilutions of medium for each incubation time were linear, 
suggesting that all incubation times generated absorbances within the linear range of 
the assay. The absorbance reading of the supernatant from the 4 hour incubation was 
highest suggesting greatest sensitivity of the assay after a 4 hour incubation, and thus 
this incubation time was used for subsequent experiments.  
 
WST-1 was used to compare baseline net metabolic activity on day 1 of PCLS 
derived from donors 9 and 10. Immediately after washing on day 1, 4 slices were 
incubated with WST-1 diluted 1:10 in 1 ml culture media for 4 hours in humidified 
5% CO2 air at 37 ºC. A blank control used WST-1 diluted 1:10 in 1 ml culture media 
and incubated without a slice. For positive controls, 2 slices were incubated with 1% 
Triton X in 1 ml PBS for 15 minutes. Supernatants were aspirated and the slices were 
individually incubated with WST-1 diluted 1:10 in 1 ml culture media for 4 hours in 
humidified 5% CO2 air at 37 ºC. After incubation, supernatants were collected and 
stored at -80 ºC. Upon thawing, all supernatants (from PCLS from donors 9 and 10) 
were examined at the same time – the amount of reduced formazan 
spectrophotometrically determined at 450 nm. 
 
WST-1 was used to measure change in net metabolic activity over time in culture for 
pig PCLS (2 slices each day up to 6 days, comparing PCLS incubated in serum-free 
media with 10% FBS supplemented media), and for human PCLS (derived from 
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donor 10, 4 slices per day on days 1, 3, 7, 10, 14 and 21, in serum-free culture). At the 
same time each day, 2 slices were incubated in WST-1 diluted 1:10 in 1 ml culture 
medium for 4 hours in humidified 5% CO2 air at 37 ºC. Blank and positive (Triton X) 
controls were performed as before.  
 
6.2.2.7 MitoTracker 
 
MitoTracker (Molecular Probes) was used to examine the preservation of cell 
viability through the slicing process with PCLS derived from donor 6. Initial 
experiments involved optimising incubation time and reagent concentration according 
to the manufacturer’s instructions. Immediately after washing on day 1, PCLS were 
incubated in culture medium containing MitoTracker at 100 nM or 250 nM. PCLS 
were incubated in humidified 5% CO2 air at 37 ºC for 45 minutes, 1 hour 15 minutes, 
or 2 hours. Immediately following incubation, PCLS were transferred to 4 % PFA and 
stored for up to 24 hours at 4 ºC. PCLS were then visualised with a fluorescent DM 
2500 microscope (Leica) and images acquired using QWin V3 software (Leica). 
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6.3 Results 
 
6.3.1 Patient demographics of human donor lungs 
 
Patient demographics for each lung are given in Table 6.1. 5 whole lungs (donors 1, 2, 
3, 4 and 5), and 1 tissue specimen from a surgical lung resection patient (donor 6) 
were obtained. The mean age of the donors was 58.2 (± S.D. 12.5).  
 
All donors who contributed whole lung had died due to brain haemorrhage. Donors 1 
and 2 had a history of hypertension, and donor 4 had a history of gastroesophageal 
reflux disease (GERD) whereas other donors had no medical conditions of note. 
Donor 1 had a history of cocaine use, and donor 4 had a history of marijuana and 
crack use. 
 
Donors had variable smoking history. Donor 3 had never smoked, while donors 1, 4 
and 6 were current smokers with ~6, 45 and ~ 52 pack years respectively. Donor 2 
quit smoking over 30 years ago and smoked an unknown quantity previously. Donor 
5 smoked a total of 18 packs, and quit 1 year ago.  
 
Lung tissue exhibited variability in gross appearance between donors, with examples 
provided in Figure 6.1. Donors 1 and 4 (current smokers) appeared black, with soot 
and tar deposits throughout. Donors 2 (quit over 30 years ago) and 3 (never smoker) 
appeared light pink without black deposits. 
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Donor	   Age	   Sex	   Smoking	  History	  
Cause	  of	  
death	  
Notes/medical	  
history	  
1	   58	   F	   1	  pack	  per	  week	   CVA,	  2nd	  ICH	   Hypertension,	  
	  	   	  	   	  	  
x	  40	  years	  
	  	  
Cocaine	  use	  
2	   64	   M	   Unknown	  quantity,	  	   ICH	  -­‐	  Stroke	   Hypertension	  
	  	   	  	   	  	  
quit	  over	  30	  yrs	  ago	  
	  	   	  	  
3	   60	   F	   Never	  smoked	   CVA,	  2nd	  ICH	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
4	   57	   M	   1	  1/2	  PPD	  x	  30	  years	   CVA,	  2nd	  ICH	   GERD,	  	  
	  	   	  	   	  	   	  	   	  	   Marijuana,	  Crack	  
use	  
5	   36	   M	   Total	  18	  packs,	   CVA,	  2nd	  ICH	   	  	  
	  	   	  	   	  	   	  last	  smoked	  1	  year	  
ago	  
	  	   	  	  
6	   74	   F	  
20	  -­‐	  25	  cigarettes	  a	  
day	   N/A	   N/A	  
	  	   	  	   	  	  
	  x	  52	  years	  
	  	   	  	  
 
Table 6.1 Patient information associated with human donor lungs 
All lobes used in this study were obtained from whole human lungs unfit for 
transplantation, which subsequently underwent EVLP for reconditioning, with the 
exception of tissue from donor 6 which was obtained during surgical resection for 
lung carcinoma. No medical history was available for donor 6. Donors 3 and 4 had no 
previous medical issues of relevance. Donors 1 and 2 were Black while donors 3, 4, 5 
and 6 were Caucasian. Abbreviations: EVLP, ex vivo lung perfusion; PPD, packs per 
day; CVA 2nd ICH, cerebrovascular accident secondary to intracerebral haemorrhage; 
GERD, gastroesophageal reflux disease. 
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Figure 6.1 Variability in appearance of lung tissue from different donors 
Gross appearance of agarose-inflated middle lobe from A) donor 4 and B) donor 2 
(patient information in Table 6.1), after agarose had been allowed to cool and solidify. 
The middle lobe from donor 2 (B) has a pink, healthy appearance with minimal tar 
deposition under the pleural surface, whereas the middle lobe from donor 4 (D) has a 
mottled black appearance on the pleural surface. A) and C) depict agarose-inflated 
lobes after being cut into ~2cm thick serial sections prior to coring. A) is the middle 
lobe from donor 1, and C) is from donor 3. The lobe from donor 1 (A) has large areas 
of black deposits within the parenchyma, which appear in small clusters and are more 
numerous in the more central regions of the lobe (left of picture). The lobe from 
donor 3 (C) appears pink and healthy throughout the lobe. Donor information is given 
in Table 6.1. The presence of black deposits in the tissue from donors 4 and 1 are 
probably caused by their extensive smoking history, whereas donor 2 quit over 30 
years ago, and donor 3 never smoked, probably contributing to a lack of black 
deposits within their lung tissue. 
 
 
 
 
D Donor 4 
B Donor 2 
C Donor 3 
A 
Donor 1 
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6.3.2 Characterising the effects of slicing on human PCLS 
 
Initial experiments determined preservation of PCLS architecture, viability and 
cellular composition after slicing. Additionally, the expression of retinaldehyde 
dehydrogenase (RALDH) 1 and 2, which catalyse local retinoic acid (RA) synthesis 
was assessed. PCLS were harvested on day 1 of culture immediately after the final 
wash step.  
 
6.3.2.1 Preservation of tissue architecture after slicing 
 
H&E staining revealed good preservation of lung parenchymal architecture. Alveolar 
septal integrity was maintained, and numerous cell nuclei were present within 
alveolar septal walls (Figure 6.2). 
 
6.3.2.2 Preservation of human PCLS net metabolic activity after slicing 
 
The net metabolic activity of day 1 PCLS, determined with WST-1 reagent, was 
significantly lower from donor 4 than from donor 5 (p < 0.05, Figure 6.3). As 
negative controls, media alone was incubated with WST-1 (blank control), and dead 
PCLS (treated with 1% Triton-X) were incubated with WST-1. Negative controls 
exhibited similar, negligible absorbances. 
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Figure 6.2 Preservation of human PCLS tissue architecture through slicing 
Human PCLS generated from donor 3 (patient information in Table 6.1). Immediately 
after initiation of slice culture (day 1), PCLS were fixed in 4% Pfa for 1-2 weeks, 
paraffin-embedded, and processed for sectioning and H&E staining. A) 10x, B) 20x, 
C) 40x, D) 63x original magnification. Representative images from 2 slices shown. 
Abbreviations: PCLS, precision-cut lung slices; Pfa, paraformaldehyde; H&E, 
haematoxylin and eosin. 
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Figure 6.3 Preservation of human PCLS viability (net metabolic activity) 
through slicing. Variability in basal PCLS viability obtained from different 
donors 
A comparison of viability (determined by net metabolic activity) of PCLS on day 1, 
generated from donors 4 and 5 (patient information in Table 6.1). Immediately after 
initiation of slice culture (day 1), slices were washed and incubated with WST-1 
reagent at 37 ºC for 4 hours. The amount of reduced formazan in the supernatants was 
spectrophotometrically determined for all PCLS at the same time at 450 nm. Media 
(B) and Triton-X treated slice supernatant (Tx) incubated with WST-1 were included 
as negative controls. n=4 slices on day 1. * p < 0.05, Mann Whitney test comparing 
donor 4 day 1 with donor 5 day 1. 
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6.3.2.3 Preservation of human PCLS mitochondrial viability after slicing 
 
As a surrogate measure of PCLS viability, mitochondrial membrane potential 
integrity was assessed with MitoTracker. Incubation conditions were optimised as 
250nM Mitotracker for 1 hour 15 minutes due to clear signal and low background 
fluorescence. With these conditions, multiple cells containing positively stained 
mitochondria were observed throughout PCLS, including within alveolar walls 
(Figure 6.4A & B). Numerous positively stained cells were visible on the surface of 
airway epithelia (data not shown). A negative control, PCLS treated with 1% Triton X 
for 15 minutes, exhibited no positive MitoTracker signal (Figure 6.4C).  
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Figure 6.4 Preservation of human PCLS viability (mitochondrial activity) 
through slicing 
Human PCLS generated from donor 6 (patient information in Table 6.1). Immediately 
after initiation of slice culture (day 1), PCLS were incubated in 250 nM Mitotracker 
for 1 hour 15 minutes at 37 ºC, prior to fixing in 4% Pfa and examination with 
fluorescent microscopy. Day 1 PCLS at A) 10x and B) 20x original magnification. 
Representative images from 2 PCLS shown. B) Slice treated with 1% Triton-X prior 
to Mitotracker incubation was examined as a negative control (10x original 
magnification). Representative images shown. 
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6.3.2.4 Preservation of lung cell types within human PCLS after slicing 
 
Cellular composition of PCLS was determined using immunohistochemistry (IHC) 
for cell-specific markers: pro-surfactant protein C (pro-SPC) for alveolar type 2 
(AT2) cells (530), aquaporin 5 (AQ5) for alveolar type 1 (AT1) cells (531), alpha-
smooth muscle actin (α-SMA) for smooth-muscle cells and myofibroblasts (532), and 
platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31) for endothelial cells 
(533).  
 
Initially, the effect of cryosectioning on human PCLS was determined. 
Cryosectioning damaged the architecture of the PCLS tissue, making the structural 
features of the parenchyma indiscernible (data not shown). Therefore, paraffin-
embedded PCLS tissue was used for IHC. 
 
Paraffin embedding preserved tissue architecture, allowing alveolar septal walls to be 
easily identified (Figure 6.5 and Figure 6.6). IHC for pro-SPC antibody revealed 
cytoplasmic staining of cells in the alveolar walls, and particularly in the alveolar 
septal junctions, corresponding to the localisation of AT2 cells (Figure 6.5 A-C). IHC 
for AQ5 revealed thin bands of positive staining in the lining of the alveolar walls 
(Figure 6.5 D-F), corresponding to the distribution of AQ5 on the apical membrane of 
AT1 cells (531). IHC for α-SMA revealed strong positive staining around airways, 
corresponding to the localisation of smooth muscle cells (SMCs) in these regions 
(532) (Figure 6.6 A-C). IHC for PECAM-1 revealed positive staining within alveolar 
walls corresponding to the distribution of microvascular capillaries within alveolar 
septae (190) (Figure 6.6 D-F). As negative controls, identical staining processes using 
washing buffer instead of pro-SPC, AQ5, αSMA or PECAM-1 antibodies, with the 
corresponding secondary antibodies, revealed no positive staining (data not shown), 
demonstrating that the positive signals were specific for the proteins examined. 
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Figure 6.5 Immunohistochemistry – retains phenotype immediately after slicing 
(cell-markers) 
Human PCLS generated from donor 3 (patient information in Table 6.1). Immediately 
after initiation of slice culture (day 1), PCLS were processed for paraffin-embedding 
and immunohistochemistry performed for pro SPC (A-C, original magnification 40x) 
and AQ5 (D-F, original magnification 100x). A) DAPI, B) pro SPC, C) Overlay. 
Positive staining (white arrows). D) DAPI, E) AQ5, F) Overlay. Positive staining 
(white arrows). Representative alveolar regions shown. Abbreviations: PCLS, 
precision-cut lung slices; pro SPC, pro-surfactant protein-C; AQ5, aquaporin 5; 
DAPI, 4',6-diamidino-2-phenylindole. 
Pro SPC AQ5  
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Figure 6.6 Immunohistochemistry – retains phenotype immediately after slicing 
(cell-markers) 
Human PCLS generated from donor 3 (patient information in Table 6.1). Immediately 
after initiation of slice culture (day 1), PCLS were processed for paraffin-embedding 
and immunohistochemistry performed for aSMA (A-C, original magnification 40x) 
and PECAM-1 (D-F, original magnification 100x). A) DAPI, B) αSMA, C) Overlay. 
Positive staining (white arrows). D) DAPI, E) AQ5, F) Overlay. Positive staining 
(white arrows). Representative alveolar regions shown. Abbreviations: PCLS, 
precision-cut lung slices; αSMA, alpha-smooth muscle actin; PECAM-1, 
platelet/endothelial cell adhesion molecule-1 (CD31); DAPI, 4',6-diamidino-2-
phenylindole. 
αSMA PECAM-1 
A 
B 
C 
D 
E 
F 
 295 
6.3.2.5 Preservation of RALDH-1 and RALDH-2 expression within human 
PCLS after slicing 
 
IHC for RALDH-1 revealed positive staining within alveolar walls, and at alveolar 
septal junctions (Figure 6.7A-C). IHC for RALDH-2 revealed limited positive 
staining, primarily localised to the interstitium surrounding airways (Figure 6.7D-F). 
As a negative control, an identical staining process using washing buffer instead of 
RALDH-1 and RALDH-2 antibodies revealed no positive staining (data not shown). 
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Figure 6.7 Immunohistochemistry – expression of RA synthesizing enzymes in 
human PCLS 
Human PCLS generated from donor 3 (patient information in Table 6.1). Immediately 
after initiation of slice culture (day 1), PCLS were processed for paraffin-embedding 
and immunohistochemistry performed for RALDH1 (A-C, original magnification 
40x) and RALDH2 (D-F, original magnification 100x). A) DAPI, B) RALDH1, C) 
Overlay. Positive staining (white arrows). D) DAPI, E) RALDH2, F) Overlay. 
Positive staining (white arrows). Representative alveolar regions shown. 
Abbreviations: PCLS, precision-cut lung slices; RALDH1, retinaldehyde 
dehydrogenase 1; RALDH2, retinaldehyde dehydrogenase 2; DAPI, 4',6-diamidino-2-
phenylindole. 
RALDH 1 RALDH 2 
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6.3.3 Investigating FBS-supplementation for PCLS culture  
 
10% FBS-supplemented media was compared to serum-free media for PCLS culture 
for 6 days. For these experiments, PCLS derived from one set of pig lungs were used 
due to the limited availability of human lung tissue at the time.  
 
6.3.3.1 Effect of 6 days incubation in 10% FBS on porcine PCLS tissue 
architecture 
 
H&E staining of day 1 PCLS revealed preservation of parenchymal architecture, 
maintenance of alveolar septal integrity and numerous nuclei within alveolar septal 
walls (Figure 6.8 A and B). At day 6, PCLS incubated in 10% FBS exhibited striking 
differences to PCLS incubated in serum-free media. PCLS incubated in 10% FBS 
exhibited extensive, diffuse connective tissue deposits resembling fibrotic scarring. 
Widespread alveolar septal wall thickening, and increased cellularity at septal 
junctions with increased numbers of nuclei, was observed (Figure 6.8 C and D). Upon 
gross visual inspection, PCLS incubated in 10% FBS had a curled-up appearance and 
had shrunk in size compared to slices on day 1 (not shown).  
 
In contrast, at day 6, PCLS incubated in serum-free media exhibited minor levels of 
focal matrix deposition. Alveolar septal walls retained a slender morphology, which 
had attenuated in parts suggesting loss of cellularity. Upon gross visual inspection, 
they appeared as flat, circular discs resembling freshly prepared day 1 PCLS (not 
shown). In summary, porcine PCLS cultured in serum-free media for 6 days had 
better-preserved histology than PCLS cultured in 10% FBS (Figure 6.8 E and F). 
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Figure 6.8 Effect of FBS-supplementation on maintenance of porcine PCLS 
H&E stained paraffin sections of porcine PCLS harvested on day 1 (A, B), and on day 
6 of culture in FBS-supplemented media (C, D) and serum-free media (E, F). 20 x 
original magnification (A, C, E) and 40 x original maginification (B, D, F). 
Representative alveolar regions from 2 slices per time point shown. Abbreviations: 
H&E, haematoxylin and eosin; PCLS, precision-cut lung slices; FBS, foetal bovine 
serum. 
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6.3.3.2 Effect of 6 days incubation in 10% FBS on porcine PCLS collagen 
content 
 
The effect of 6 days incubation in 10% FBS on porcine PCLS collagen content was 
determined with picosirius red (PSR) (Figure 6.9 C-E).  
 
On day 1, PCLS exhibited few, thin areas of red and green birefringence (Figure 6.9 
C), indicating the presence of thick and thin collagen fibres within alveolar walls. At 
ay 6, PCLS incubated in 10% FBS exhibited extensive strong birefringence appearing 
predominantly red, suggesting the assembly of thick collagen fibres (Figure 6.9 D). In 
contrast, at day 6, PCLS incubated in serum-free media exhibited sporadic focal red 
birefringence, indicating low levels of thick collagen fibre deposition (Figure 6.9  E). 
This birefringence appeared predominantly in the tips of alveolar septae (Figure 6.9 
E). In summary, PCLS cultured for 6 days exhibited increased collagen deposition 
compared to day 1 PCLS. However, this was greatly exaggerated in PCLS cultured in 
10% FBS compared to serum-free media.  
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Figure 6.9 Effect of FBS-supplementation on collagen deposition in porcine 
PCLS 
Picosirius red (PSR)-stained paraffin sections of porcine PCLS. A) An example of a 
PSR-stained porcine PCLS section under fully polarised light. Thick collagen fibres 
appear yellow or orange/red, whereas thin collagen fibres appear green. B) The same 
section as in A) under non-polarised light. While under fully polarised light only 
collagen is visible due to birefringence, under normal light all basic proteins are 
visible as pale red. C-E) depict PSR-stained porcine PCLS under partially polarised 
light. C) PSR-stained porcine PCLS harvested on day 1. D) PSR-stained porcine 
PCLS on day 6 of culture in FBS-supplemented media. E) PSR-stained porcine PCLS 
on day 6 of culture in serum-free media. Representative alveolar regions from 2 slices 
per time point shown. Abbreviations: PCLS, precision-cut lung slices; FBS, foetal 
bovine serum. 
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6.3.3.3 Effect of 6 days incubation in 10% FBS on porcine PCLS net metabolic 
activity 
 
On day 1, PCLS incubated in 10% FBS and serum-free media exhibited similar 
metabolic activity, determined by WST-1. Metabolic activity of PCLS in serum-free 
media remained constant for 6 days. In contrast, metabolic activity of PCLS in 10% 
FBS increased at day 2 and remained higher than PCLS in serum-free media for 6 
days (Figure 6.10 B). As negative controls, media alone was incubated with WST-1 
(blank control), and dead PCLS (treated with 1% Triton-X) were incubated with 
WST-1. Negative controls exhibited similar negligible absorbances. The mean daily 
metabolic activity of porcine PCLS incubated in 10% FBS over 6 days was 
significantly higher than PCLS in serum-free culture (p < 0.01) Figure 6.10 C.  
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Figure 6.10 Effect of FBS-supplementation on net metabolic activity of porcine 
PCLS 
A) Optimisation of incubation time for WST-1 with porcine PCLS. Immediately after 
initiation of slice culture (day 1), slices were washed and incubated with WST-1 
reagent at 37 ºC for either 1, 2 or 4 hours. Supernatants were collected and serial 
dilutions prepared (1, 0.5, 0.1, 0.01). The amount of reduced formazan in the 
supernatants was spectrophotometrically determined at 450 nm. B) Porcine PCLS 
were incubated in serum-free media (blue line) or FBS-supplemented media (red line) 
for up to 6 days in culture. At the same time each day, PCLS were washed and 
incubated with WST-1 for 4 hours. Supernatants were collected and the amount of 
reduced formazan generated spectrophotometrically determined at 450 nm. Blank 
control (media incubated with WST-1) and dead day 1 slice (treated with 1% Triton-
X, then incubated with WST-1) were included as negative controls. C) Mean net 
metabolic activity over 6 days of porcine PCLS incubated in FBS-supplemented 
media (red) compared with serum-free media (blue). All data expressed as mean ± 
SEM. ** p < 0.01, Mann Whitney test. Abbreviations: PCLS, precision-cut lung 
slices; FBS, foetal bovine serum. 
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6.3.4 The effect of serum-free culture on long-term maintenance of human 
PCLS 
 
Experiments with porcine PCLS indicated that 10% FBS supplementation was not 
suitable for PCLS culture. Therefore, the effect of long-term culture (up to 22 days) of 
human PCLS in serum-free media was investigated.  
 
6.3.4.1 The effect of serum-free culture on maintenance of human PCLS 
histology 
 
H&E stained day 1 PCLS exhibited well preserved parenchymal architecture with 
numerous nuclei within alveolar septal walls (Figure 6.11A) (as observed previously 
[Figure 6.2]). On day 8, a reduction in numbers of nuclei within alveolar walls was 
observed, suggesting loss of cellularity, although connective tissue elements of 
alveolar walls remained (Figure 6.11 B). On day 15, a clear reduction in alveolar wall 
nuclei compared to day 1 was observed (Figure 6.11 C). On day 22, nuclei were 
nearly absent, while alveolar septal walls exhibited reduction in eosin intensity, 
suggesting loss of connective tissue elements (Figure 6.11D).   
 
Quantification of nuclei relative to alveolar wall length, revealed nuclear numbers 
declined significantly (p < 0.05) by day 8 in culture to ~ 50% of day 1. Nuclear 
number declined further at day 15 (p < 0.001 compared to day 1), and diminished 
further by day 22 (p < 0.0001 compared to day 1) (Figure 6.11 E). 
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Figure 6.11 Maintenance of human PCLS in serum-free culture 
Human PCLS generated from donor 4 (patient information in Table 6.1). Light 
micrographs of H&E stained paraffin sections of human PCLS at A) day1, B) day 8, 
C) day 15 and D) day 22. Representative alveolar regions from 2 slices at each time 
point shown. E) Number of nuclei per length of alveolar wall in human PCLS 
incubated in serum-free media on days 1, 8, 15 and 22. Data expressed as mean ± 
SEM. * p< 0.05, *** p < 0.001, **** p < 0.0001 compared to day 1. n = 10 randomly 
sampled fields of view from 2 slices at each time point, one-way ANOVA with 
Dunnett’s post test. Abbreviations: PCLS, precision-cut lung slices; FBS, foetal 
bovine serum; H&E, haematoxylin and eosin. 
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6.3.4.2 The effect of serum-free culture on human PCLS lactate dehydrogenase 
release 
 
As a surrogate measure of PCLS viability, daily lactate dehydrogenase (LDH) release 
was measured. Initial experiments demonstrated that supernatant from freshly washed 
day 1 PCLS exhibited low LDH activity similar to media alone (blank control).  
In contrast, PCLS killed with 1% Triton-X (positive control) had significantly higher 
LDH activity than fresh day 1 PCLS (p < 0.0001) (Figure 6.12A). Serial dilutions of 
dead PCLS supernatant demonstrated that LDH activity fell within the linear range of 
the kit (r = 1.00, p < 0.01) without need for further dilutions (Figure 6.12B). 
 
Daily LDH release increased up to day 2, declined until day 4, and then rose up to day 
8. After day 8, the pattern of LDH release became more erratic (Figure 6.12C). 
Compared to the absorbance of PCLS killed with 1% Triton-X (positive control), 
levels of LDH release remained low over the duration of culture.  
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Figure 6.12 Effect of serum-free culture on LDH release from human PCLS  
Human PCLS generated from donors 1 and 2 (patient information in Table 6.1). A) 
Validation of LDH assay. Immediately after initiation of slice culture (day 1), 
supernatants from PCLS treated with 1% Triton-X (lysed) or from untreated PCLS 
were assessed for LDH activity. LDH activity from media alone was included as a 
blank control. Data expressed as mean ± SEM. n = 16 slices from 2 experiments. 
**** p < 0.0001, Kruskall Wallis with Dunn’s post test. B) Establishing linear range 
of LDH assay. Supernatants from PCLS treated with 1% Triton-X on day 1 were 
collected and serial dilutions prepared (1, 0.5, 0.2, 0.1, 0.02, 0.01) which were 
assessed for LDH activity. The p value of the correlation and the Spearman 
coefficient r are given. C) Daily LDH release from human PCLS cultured in serum-
free media for up to 11 days. At the same time each day, PCLS supernatant was 
collected and stored at 4 ºC until use, and fresh media replaced. At the end of the 
experiment, LDH activity in all supernatants were assessed simultaneously. n = 5-11 
slices per time point from 2 individual experiments, expressed as mean ± SEM. LDH 
activity of media alone (-) and from supernatant from day 1 PCLS treated with 1% 
Triton-X (+) were included as negative and positive controls respectively. 
Abbreviations: PCLS, precision-cut lung slices; LDH, lactate dehydrogenase. 
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6.3.4.3 The effect of serum-free culture on human PCLS airway ciliary beating 
 
As a further surrogate measure of PCLS viability, the proportion of airway lumen 
covered in actively beating cilia was measured. There was wide variation in ciliary 
beating between PCLS at each time point including day 1 (Figure 6.13). 6 out of 7 
slices retained some ciliary beating by day 4 in culture, whereas by day 6 no PCLS 
exhibited beating cilia. The mean level of ciliary beating declined steadily over the 6 
days in serum-free culture reaching significance at day 6 (p < 0.001) (Figure 6.13). 
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Figure 6.13 Effect of serum-free culture on airway epithelial ciliary beating of 
human PCLS 
Human PCLS generated from donors 1 and 2 (patient information in Table 6.1). 
Human PCLS containing small airways were prepared and inspected microscopically 
on days 1, 2, 4, 6 and 8 for the presence of beating cilia lining the airway lumen. 
Graph depicts decline in ciliary beating over time. Cilia beating of individual PCLS 
are depicted as coloured lines (2 slices from lung 1 in blue, 5 slices from lung 2 in 
red). The mean ± SEM of all PCLS from both experiments is plotted in black, * 
p<0.05, *** p<0.001, Kruskall Wallis with Dunn’s post test. Abbreviations: PCLS, 
precision-cut lung slices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 2 4 6 8
0
20
40
60
80
100
Day
%
 o
f a
irw
ay
 w
ith
 b
ea
tin
g 
ci
lia
 b
ea
tin
g
*** *
 309 
6.3.4.4 The effect of serum-free culture on net metabolic activity of human 
PCLS 
 
Net metabolic activity of PCLS, determined with WST-1, declined from day 1 until 
day 7, after which it rose at day 10, before declining again at day 15, remaining at this 
level until the end of the experiment at day 21 (Figure 6.14).  As negative controls, 
WST-1 was incubated with media only (blank control) or with PCLS treated with 1% 
Triton X (dead control), which each gave similarly negligible absorbances. 
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Figure 6.14 Effect of serum-free culture on human PCLS viability (net metabolic 
activity determined by WST-1) 
Human PCLS generated from donor 5 (patient information in Table 6.1), cultured in 
serum-free media. On days 1, 3, 7, 14, and 21 PCLS were washed and incubated with 
WST-1 for 4 hours, and supernatants collected and stored at -80 ºC until use. At the 
end of the experiment, the amount of reduced formazan in the supernatants was 
spectrophotometrically determined at 450 nm. A blank control (media only incubated 
with WST-1) and dead day 1 slice (treated with 1% Triton-X, then incubated with 
WST-1) were included as negative controls. Each data point represents the mean ± 
SEM of 4 slices. 
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6.4 Discussion 
 
6.4.1 Summary of key findings in this chapter 
 
Human PCLS retained tissue architecture, metabolic activity, mitochondrial viability, 
and distribution of AT1, AT2, endothelial and smooth muscle cells through the slicing 
process. Human PCLS also maintained RALDH-1 and RALDH-2 protein expression, 
suggesting capacity for endogenous RA synthesis. In long-term culture, human PCLS 
architecture was maintained for up to 4 weeks. LDH release increased after 4 days, 
airway cilia beating was absent at 6 days, and numbers of alveolar septal wall nuclei 
declined within the first week. Therefore, human PCLS may be suitable for a model 
of human alveolar regeneration for up to 1 week of serum-free culture. Experiments 
with porcine PCLS demonstrated that 10% FBS-supplementation caused structural 
distortion, excessive collagen deposition and increased net metabolic activity, and 
therefore is inappropriate for long-term PCLS culture. 
 
6.4.2 Patient demographics 
 
There was considerable variability between donors in terms of smoking and medical 
history, owing to the use of human donor lungs unfit for transplantation. A history of 
smoking may affect the initial quality and viability of lung tissue used for PCLS 
generation (515). Variability in smoking history corresponded with gross appearance 
of the tissue. For example, tissue from donors 1 and 4 (current smokers) appeared 
black with tar and soot deposits on the pleural surface and throughout the 
parenchyma. In contrast, tissue from donors 2 and 3 (quit 30 years ago and never 
smoker respectively) appeared healthy and pink throughout (Figure 6.1). The effect of 
smoking history on basal net metabolic activity of PCLS was addressed in a 
preliminary experiment using WST-1 (described below). Donors 1 and 2 had a history 
of hypertension, and donor 4 had a history of gastroesophageal reflux disease 
(GERD). The effects of a history of hypertension or GERD on human PCLS were not 
addressed within this study.  
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6.4.3 Characterising the effects of slicing on human PCLS 
 
6.4.3.1 Preservation of human PCLS tissue architecture after slicing 
 
Histological assessment of day 1 human PCLS revealed good preservation of tissue 
architecture, alveolar septal wall integrity and cellularity (Figure 6.2). This is in 
agreement with published reports of maintenance of tissue architecture in PCLS from 
rat, hamster and human (317-319). Lung tissue is inherently spongy, and instillation 
of low-melt agarose provides rigidity which facilitates slicing and aids in obtaining 
PCLS with consistent thickness (317). Agarose installation also ensures maintenance 
of alveolar patency after transfer to culture media. 
 
6.4.3.2 Preservation of human PCLS net metabolic activity after slicing 
 
The WST-1 reagent has previously been applied to human PCLS to investigate the 
toxicity of an H1N1 vaccine/nanoparticle combination (534). When cells die, they 
rapidly lose the ability to convert WST-1 into formazan (321). Therefore, the 
absorbance of reduced formazan product indicates net metabolic activity of PCLS, 
which was used as a surrogate measure of PCLS viability. On day 1, PCLS from 
donor 5 had significantly higher net metabolic activity than donor 4 (p < 0.05, Figure 
6.3). This suggests variability in PCLS baseline viability which may be due to donor-
specific factors (515). Donor 4 was an older patient (57 years old) with an extensive 
history of smoking, whereas donor 5 was a younger patient (36 years old) who had 
smoked less and quit 1 year prior to death. Therefore, factors such as age of patient 
and smoking history might affect the basal viability of PCLS. Due to limited tissue 
availability, further experiments will be required to determine the effect of smoking 
history on PCLS viability. The use of WST-1 reagent to determine PCLS viability has 
limitations. An assumption is that metabolic activity of individual cells remains 
constant until cell death. However, the level of WST-1 reduction may be affected by 
conditions that affect cell metabolism, such as depletion of essential nutrients or 
glucose, or changes in pH (321). Different cell types within the PCLS may reduce 
WST-1 at different rates, and therefore the absorbance may reflect the activity of 
some cell types and not others (321). Viable cells which are quiescent or dormant may 
give low levels of WST-1 reduction, and so may be indistinguishable from non-viable 
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cells (322). A further limitation is that there is no positive control (a ‘perfectly viable’ 
slice) so there is no way to determine the proportion of cells within a PCLS that are 
metabolically active. One way to address this may be to use a fluorescent dye (such as 
MitoTracker) that is selectively taken up by actively metabolising cells, followed by 
microscopy to identify viable cells.  
 
6.4.3.3 Preservation of human PCLS mitochondrial viability after slicing 
 
MitoTracker was used to determine mitochondrial membrane potential integrity as a 
surrogate measure of PCLS viability. With optimal incubation conditions (250 nM 
with 1 hour 15 minute incubation), numerous positively stained mitochondria, 
indicating viable cells, were visible within alveolar walls (Figure 6.4). Stained cells 
were particularly numerous in the lumen of airways, which may reflect greater 
exposure to the dye in these regions. PCLS used for MitoTracker staining were 
derived from resected tissue (donor 6), and so had not been through the organ 
procurement procedure outlined in Figure 2.10 , which included a period of cold 
transport followed by EVLP. Therefore, it is possible that cells in PCLS from lungs 
post-EVLP would display different patterns of mitochondrial viability. Further 
investigations using PCLS from lungs post-EVLP are required. 
 
MitoTracker stained-PCLS were visualised with a wide-field fluorescent microscope, 
which allowed the MitoTracker signal from individual cells to be observed in the 3-
dimensional context of the surrounding tissue. An inherent limitation is the inability 
to focus on one plane and achieve higher resolution, such as with confocal 
microscopy. Furthermore, the proportion of viable cells within the slice cannot be 
quantified with MitroTracker as dead cells are not labelled. One way to address this 
may be to use a membrane-impermeable counter-stain such as ethidium homodimer-1 
(EthD-1), which fluoresces only in the nuclei of dead cells (described below).  
 
6.4.3.4 Preservation of lung cell types within human PCLS after slicing 
 
Cellular heterogeneity of human PCLS after slicing was determined with IHC for 
cell-specific markers. Pro-surfactant protein C (pro-SPC) is a widely used specific 
marker for alveolar type 2 (AT2) cells (4). IHC for pro-SPC revealed positive staining 
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of cells in the alveolar walls, and particularly in the alveolar septal junctions (Figure 
6.5), in accordance with distribution of AT2 cells within human lung tissue in vivo 
(530). Pro-SPC staining was cytoplasmic, as pro-SPC is localised to endoplasmic 
reticulum, Golgi, and multivesicular bodies in AT2 cells (535). Aquaporin 5 (AQ5) is 
a cell surface protein distributed on the apical membrane of alveolar type 1 (AT1) 
cells (531), and is thus used as a AT1 specific marker. The AQ5 antibody revealed 
thin bands of positive staining in the alveolar walls (Figure 6.5), corresponding to the 
distribution of AT1 cells. AQ5 staining to was occasionally difficult to identify, 
which probably reflected the limited surface area of the AT1 cellular membrane 
available for staining in a thin (5 µm) tissue section.  
 
Alpha smooth muscle actin (α-SMA) is expressed by a number of lung cell types such 
as smooth muscle cells (SMCs), pericytes, septal tip cells, and type VA 
myofibroblasts (a population of myofibroblasts distinguished by co-expression of 
vimentin and α-SMA) (532). Strong positive staining of α-SMA in tissue surrounding 
larger vessels and airways of human PCLS was observed, corresponding to the 
distribution of SMCs in these regions (Figure 6.6). Differentiation of resident alveolar 
fibroblasts into α-SMA- expressing myofibrolasts is a feature of pulmonary fibrosis 
(536). No positive α-SMA staining was observed in parenchymal regions of tissue, 
suggesting that freshly prepared PCLS did not contain fibrotic parenchyma. 
Assessment of α-SMA expression within PCLS parenchyma may be useful to 
determine emergence of fibrosis during culture. Platelet/endothelial cell adhesion 
molecule-1 (PECAM-1; CD31) is a component of endothelial cell intercellular 
junctions (533). PECAM-1 is also expressed on the surface of platelets, neutrophils, 
monocytes and some types of T-cells, cell types which are blood-derived and not 
present in PCLS. Therefore, within human PCLS, PECAM-1 is specific for 
endothelial cells. Positive PECAM-1 staining was observed within the alveolar septal 
walls corresponding to the distribution of microvascular capillaries (190) (Figure 6.6). 
Larger vessels were also stained positive, and were distinguished from capillaries by 
their size and the presence of interstitial components surrounding the outer layer of 
the lumen.  
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Negative controls, performed to assess non-specific binding of secondary antibody, 
revealed no positive staining (data not shown). Therefore, these data confirm that the 
distribution of both cell types of the alveolar epithelium (AT1 and AT2 cells), and 
two constituent lung cell types (α-SMA-expressing SMCs and endothelial cells) are 
preserved through slicing in human PCLS. IHC for these markers may serve as a 
useful method to investigate changes in cellular composition of PCLS in culture. 
 
6.4.3.5 RALDH-1 and RALDH-2 expression in human PCLS 
 
IHC for RALDH-1 and RALDH-2 revealed distinct patterns of expression. IHC for 
RALDH-1 revealed positive staining within alveolar walls and at septal junctions, 
whereas RALDH-2 antibody revealed limited staining, mainly localised to 
interstitium surrounding airways Figure 6.7. RALDH-1 and RALDH-2 protein 
expression in human lung parenchyma in vivo has not previously been described. 
RALDH-1 and RALDH-2 catalyse the irreversible oxidation of retinaldehyde to RA 
(described in introduction 1.7 (440)), and display distinct temporal and spatial 
patterns of expression during murine development (113), suggesting distinct 
regulatory mechanisms. The distinct patterns of RALDH-1 and RALDH-2 protein 
expression in human PCLS suggest distinct functions and/or regulatory mechanisms 
in human lung. The localisation of RALDH-1 to septal junctions corresponds to the 
distribution of pulmonary lipofibroblasts, which synthesise and secrete RA in rat lung 
and were suggested as a primary source of RA in vivo (208). Our observations fit with 
a hypothesis that RALDH-1 is expressed in lipofibroblasts in adult human lung. Co-
staining with RALDH-1 and adipocyte differentiation-related peptide (ADRP), a 
marker of lipofibroblasts (537), may help to determine RALDH-1 expression in 
lipofibroblasts. The source of RALDH-2 expression is unclear, but may be within 
interstitial cells surrounding small airways. Pulmonary interstitial cells are a 
heterogeneous population consisting of SMCs, pericytes, septal tip cells, and 
myofibroblasts, and for which there are a paucity of markers (22). IHC using 
RALDH-2 antibodies with H&E staining may be useful to identify cellular sources of 
RALDH-2 expression based on morphology. Our observations of RALDH-1 and 
RALDH-2 protein expression suggest capacity for endogenous RA synthesis in 
human PCLS.  
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These data cannot easily be extrapolated to human lung tissue in vivo as PCLS tissue 
had undergone handling, including cold transport, EVLP, and slicing, which may 
have affected RALDH-1 and RALDH-2 localisation. It was demonstrated that slicing 
itself caused injury to rat PCLS, particularly portions of tissue cut by the slicer, which 
stimulated the expression of mitogenic factors (538). Further studies using PCLS 
from fresh resected tissue would be necessary to determine the effect of ex vivo 
handling on RALDH-1 and RALDH-2 distribution. 
 
6.4.4 Investigating foetal bovine serum-supplementation for PCLS culture 
(porcine PCLS) 
 
We hypothesised that a PCLS model of human alveolar repair would require culture 
conditions that promote repair in response to injury. Chapter 3 in this thesis described 
stimulation of AT2 cell wound healing in a scratch assay with 10% foetal bovine 
serum (FBS). FBS contains a high content of defined and undefined embryonic 
trophic factors. We hypothesised that 10% FBS would promote PCLS repair to a 
greater degree than serum free media. Most PCLS studies have used serum-free 
media, including those assessing long-term culture of rodent slices (318, 521). 
However, these studies were aimed at maintenance of viability without induction of 
repair. A few PCLS studies have used FBS supplementation. PCLS from rat lung 
maintained histology when cultured in 10% FBS for 8 hours (539). Another study 
reported maintenance of rat PCLS protein synthesis for 7 days in 10% FBS, although 
a swelling of the interstitium was noted (538). These studies were limited to rat 
PCLS, which may respond to FBS differently from human PCLS. Furthermore, these 
studies did not examine metabolic activity or collagen content, which may be affected 
by FBS. Therefore, we investigated 10% FBS on metabolic activity and collagen 
content of PCLS. As human lungs were not available at the time, porcine PCLS were 
used. Porcine PCLS have been used previously for the study of porcine susceptibility 
to viral infection (540). Porcine lung were an appropriate substitute for human lung 
due to close similarities in alveolar dimensions compared with other mammals such 
as rodents (541, 542).  
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6.4.4.1 Effect of 6 days incubation in 10% FBS on porcine PCLS tissue 
architecture 
 
Porcine PCLS cultured in 10% FBS displayed widespread alveolar septal wall 
thickening, with more connective tissue within septal walls and increased cellularity 
at septal junctions Figure 6.8. This resembled the interstitial swelling noted by Vallan 
et al. with rat PCLS cultured in 10% FBS (538), although porcine PCLS exhibited 
this to a much greater extent. This may reflect inter-species differences in tissue 
sensitivity to trophic factors contained in FBS. The increased cellularity is suggestive 
of excessive fibroblast activity, which may be stimulated to proliferate by 10% FBS. 
Porcine PCLS cultured in serum-free media appeared better preserved, with minor 
levels of focal matrix deposition, and the morphology of alveolar septal walls 
remained similar to day 1 PCLS. The alveolar walls of pig PCLS in serum-free media 
had attenuated in some places, suggesting loss of cellularity, which may reflect death 
of alveolar cells within the first week of culture.  
 
6.4.4.2 Effect of 6 days incubation in 10% FBS on porcine PCLS collagen 
content 
 
Collagen content of porcine PCLS was determined with PSR staining, and 
visualisation under partially polarised light, which allowed both an outline of PCLS 
architecture and PSR stained collagen to be visible Figure 6.9. On day 1, porcine 
PCLS exhibited a few, thin areas of red and green birefringence. This indicates the 
presence of thick and thin collagen fibres inherent in alveolar walls, possibly 
reflecting the presence of collagen IV and V in the alveolar basement membrane 
(510). On day 6, porcine PCLS cultured in 10% FBS exhibited strong red 
birefringence indicative of assembly of thick collagen fibres. This suggests fibrotic 
processes, as pulmonary fibrosis is associated excessive deposition of collagen I and 
III (510). The outline of the tissue architecture indicated that large areas of interstitial 
thickening did not contain collagen owing to absence of birefringence, implying 
deposition of matrix proteins other than collagen. Day 6 porcine PCLS incubated in 
serum-free media exhibited focal red birefringence, indicating minor levels of thick 
collagen fibre deposition, confined to the tips of the alveolar septae. Alveolar septal 
tips are the location of platelet derived growth factor receptor alpha (PDGFR-α) - 
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expressing myofibroblast progenitors during secondary septation in the developing 
lung (543). It is possible that these cells contributed to collagen deposition in human 
PCLS. IHC for PDGFR-α could be used to determine if myofibroblast progenitors are 
present in PCLS alveolar septal tips. 
 
6.4.4.3 Effect of 6 days incubation in 10% FBS on porcine PCLS metabolic 
activity 
 
Porcine PCLS incubated in 10% FBS exhibited increased net metabolic activity, 
compared to serum-free culture, determined by WST-1 reduction Figure 6.10. This 
was evident at day 2, and remained higher than serum-free culture until day 6. The 
mean daily metabolic activity was significantly higher with 10% FBS compared to 
serum-free incubation (p < 0.01). The increased metabolic activity in 10% FBS may 
be due to increased cell number, or increased metabolic activity in individual cells 
(322). The cell type(s) stimulated by FBS is unclear. However, these data together 
with observations of septal wall thickening and collagen deposition, suggest increased 
fibroblast activity or proliferation. To further investigate this, IHC for α-SMA could 
be used to determine myofibroblast differentiation within the parenchyma, a hallmark 
of pulmonary fibrosis in vivo (536). Pulmonary fibrosis represents a highly abnormal 
repair response (544), and therefore we concluded that 10% FBS-supplementation is 
unsuitable for PCLS culture. Serum-free media better preserved porcine PCLS 
architecture, metabolic activity and collagen content over 6 days, and therefore was 
used for all experiments with human PCLS. 
 
6.4.5 Determination of effects of serum-free culture on human PCLS 
 
Human PCLS tissue architecture was preserved up to 22 days in serum-free culture. 
Nuclear number was quantified relative to alveolar wall length to account for 
variability in tissue content between fields of view.  Nuclear number relative to 
alveolar septal wall length declined significantly by day 8 (p < 0.05), and further 
declined by day 16 and 22 (p < 0.001 and p < 0.0001 compared to day 1 respectively) 
Figure 6.11. This suggests that tissue viability declined within the first week of 
serum-free culture. Data regarding long-term maintenance of PCLS is limited. One 
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study reported maintenance of human PCLS alveolar architecture for up to 10 days 
using light microscopy, with stable lactate dehydrogenase (LDH) release over 5 days 
(520). Three previous studies reported long-term culture of rodent PCLS in serum-
free media. Maintenance of rat PCLS alveolar architecture and stable protein 
synthesis was reported for 7 days (538), and preservation of intact alveolar epithelium 
demonstrated in rat PCLS with electron microscopy at 14 days (545). Preservation of 
murine PCLS was reported for 60 days in serum-free media, with retention of AT1, 
AT2 and fibroblast morphology determined by electron microscopy, although the 
capillary endothelium was absent by day 7 (521). The more rapid deterioration of 
human PCLS we observed may reflect that human tissue is more delicate than rodent 
lung, coupled with the variable quality of tissue from human lungs unfit for 
transplantation. 
 
Quantitative nuclear counts were derived from PCLS from a single donor (donor 4) 
due to limited tissue availability. It is possible that PCLS viability may differ between 
tissue from different donors, due to variation in initial tissue quality and patient 
characteristics (546). As demonstrated earlier, basal metabolic activity of PCLS from 
donor 4 was lower than observed for donor 5. Therefore, tissue from donor 4 this may 
have been of low initial quality, which could contribute to faster deterioration in 
culture. Further studies using PCLS obtained from different donors will be required. 
 
6.4.5.1 LDH release of human PCLS in serum-free culture 
 
Lactate dehydrogenase (LDH) is a cytosolic enzyme which is released into the 
supernatant after loss of cellular membrane integrity, and is a widely used marker of 
cell death for in vitro cell culture studies (323). Daily LDH release increased up to 
day 2, which might reflect leakage from cells damaged during the slicing procedure 
(Figure 6.12). Damage to cells on the cut surfaces of the slice was demonstrated in rat 
liver slices, and thus 2 days may be required for dead cells to slough off and cellular 
debris to be removed following slicing of human PCLS (527, 547). LDH release 
declined between day 2 and day 4, which may indicate stabilisation of the slice in 
culture. LDH release rose between day 4 and day 8, which may reflect increased cell 
death caused by culture conditions. After day 8, the pattern of LDH release became 
more erratic, which may reflect variable damage to a residual population of cells 
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within the slice. The data suggests that human PCLS viability was maintained for up 
to 4 days in culture, whereas after 4 days viability declined. 
 
Compared to LDH released from day 1 PCLS killed with 1% Triton-X (the positive 
control), levels of LDH release were low and remained low up to 11 days. However, 
total LDH content of PCLS after day 1 was not measured. Therefore, LDH released 
after day 1 was not calculated as a proportion of total LDH content. Wohlsen et al. 
quantified LDH release as a proportion of total LDH content of human PCLS by 
lysing additional PCLS at every time point to induce maximal LDH release (325). 
This method may be useful to provide further information about human PCLS 
viability. A limitation inherent in the LDH assay is that the cell type(s) that release 
LDH are not known. Use of IHC co-staining for cell-specific markers together with 
indicators of cellular death, such as terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) staining to measure DNA fragmentation during apoptosis, 
could be used to determine death of different cell populations within PCLS. 
 
6.4.5.2 Effect of serum-free culture on human PCLS cilia beating 
 
Measurements of the proportion of airway lumen covered in beating cilia were used 
as a surrogate measure of human PCLS viability. The molecular motor which drives 
ciliary beating is powered by ATP hydrolysis, and therefore cilia beating reflects 
cellular metabolic activity (324). Measurement of ciliary beating has been used to 
demonstrate human PCLS viability for 3 days (325). We demonstrated that 6 of 7 
human PCLS examined displayed beating cilia at day 4, whereas by day 6 it was 
absent in all PCLS (325) (Figure 6.13). This suggests that human PCLS retained some 
degree of viability for 4 days, whereas by 6 days the tissue was completely dead. 
 
Measurement of ciliary beating as an indicator of PCLS viability has several 
limitations. Distinguishing beating or non-beating cilia is sometimes difficult, and the 
assay we used was binary and ignored different frequencies of ciliary beating. The 
assay only considered metabolic activity of airway epithelium, whereas alveolar cell 
viability is most relevant for the development of a model of alveolar repair. However, 
an advantage is that it does not involve destruction of the slice, so longitudinal 
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measurements can be made for each PCLS. Furthermore, the decline in ciliary beating 
paralleled the decline in nuclear staining and the pattern of LDH leakage outlined 
earlier. Together, these data suggest that human PCLS remain viable for 4 days in 
serum-free culture. 
 
6.4.5.3 Effect of serum-free culture on human PCLS net metabolic activity 
 
Net metabolic activity of human PCLS declined from day 1 to day 7, and apart from 
an increase at day 10, remained at the level of day 7 PCLS until day 21 (Figure 6.14). 
The decline in WST-1 reduction until day 7 may reflect decline in cell number or a 
reduction in levels of individual cell metabolic activity. (322). The former explanation 
is more likely, as it corresponds with the decline in alveolar wall nuclei, and increase 
in LDH release over the first week of serum-free culture described earlier. The rise in 
WST-1 reduction in day 10 PCLS is difficult to interpret and may reflect technical 
error. PCLS from only 1 donor were used, so further experiments with more donors 
will be required. 
 
6.4.6 General discussion about PCLS model 
 
6.4.6.1 Media composition 
 
Each cell type within the lung parenchyma may have different nutritional 
requirements and so may respond to culture differently (548, 549). Therefore, a single 
culture media may not sustain all cell types within PCLS for long periods, and tissue 
deterioration is likely to be an inherent limitation of the model. Placke and Fisher 
(318) compared various media for long-term culture of hamster PCLS, and found that 
media with high concentrations of essential amino acids (minimal essential medium, 
MEM) maintained viability better. The PCLS culture protocol we adopted has been 
previously used for sheep and rat PCLS (524, 550), with RPMI 1640 substituted for 
DMEM as recommended for human tissue culture (Natasha Madge, personal 
communication). RPMI 1640 contains essential amino acids at concentrations 
comparable to MEM, and is frequently used for primary human cell culture. Like 
MEM, RPMI 1640 uses a bicarbonate-based buffering system, which was shown to 
better preserve organ slices than Hepes-based media (549). Furthermore, RPMI 1640 
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is unique in containing glutathione, an antioxidant with important roles in lung 
epithelial and endothelial maintenance (551), and is therefore suitable for PCLS 
culture. 
  
Placke and Fisher (318) included insulin, hydrocortisone, and retinyl acetate in culture 
media for hamster PCLS, which were not included in our protocol. The reasons for 
their inclusion were not given by the authors, but hydrocortisone and insulin in 
combination support the proliferation of rat AT2 cells in culture (552) and maintain 
surfactant synthesis of foetal human lung explants (553). Furthermore, 
glucocorticoids inhibit fibroblast proliferation (554), so hydrocortisone may prevent 
excessive proliferation of fibroblasts within PCLS. Retinyl acetate (an esterified form 
of retinol) is a major storage form of vitamin A in the lung (349), and is hydrolysed 
by lung retinyl ester hydrolases (REHs) to retinol, and converted into RA  (555). RA 
signalling has important roles in maintaining alveoli in vivo (Introduction 1.11.3). 
Therefore, retinyl acetate supplementation may improve the maintenance of human 
PCLS viability in culture.  
 
6.4.6.2 Alternative viability parameters 
 
Viability parameters used in previous reports include measuring protein or DNA 
synthesis (538) or intracellular ATP, IHC for markers of proliferation (phospho-serine 
10 H3) or apoptosis (caspase-3), and evaluation of drug metabolism (7-
Ethoxycoumarin) (515, 518, 556). Measurements of protein synthesis may be a useful 
indicator of viability as it requires integration of several intermediary metabolic 
pathways (557). Measurements of protein and DNA synthesis traditionally require the 
use of radiolabelled substrates which were not available for the present study. 
Intracellular ATP content of PCLS can be measured with a bioluminescence assay, 
which involves homogenisation of PCLS and incubation with a luciferin-luciferase 
solution – the resultant luminescence is a reflection of the ATP content of the PCLS 
(558). However, these methods do not provide information about the proportion of 
viable to non-viable cells within PCLS, which may be important for determining 
initial PCLS viability. 
One way to quantify the initial viability of PCLS may be to use Mitotracker with a 
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membrane-impermeable counter-stain such as ethidium homodimer-1 (EthD-1), 
which fluoresces only in the nuclei of dead cells. As EthD-1 has an emission 
wavelength of 617 nm, it can be distinguished from MitoTracker with appropriate 
filters. The use of MitoTracker in conjunction with EthD-1 has not been described, 
but may allow viable cells to be distinguished from dead cells within a PCLS. 
Confocal microscopy would then allow quantification of viable cells relative to the 
number of dead cells. 
 
A commercially available dye combination, the Live/Dead assay (Invitrogen) contains 
calcein AM, which selectively fluoresces in living cells, as well as Eth-D1, and was 
used recently by Neuhaus et al. to measure human PCLS viability (534). In 
preliminary experiments we used the Live/Dead assay to measure human PCLS 
viability, however we could not detect a calcein-AM signal, possibly due to lack of 
dye penetration (data not shown). Future work in our laboratory will use a 
combination of MitoTracker and Eth-D1. MitoTracker is advantageous over calcein-
AM as viable cells positively stained with MitroTracker appear as discrete points and 
can be counted, whereas calcein-AM fluoresces throughout the cytoplasm, causing 
positively stained cells to appear merged together. 
 
6.4.6.3 Limitations of the model 
 
Unlike lung tissue in vivo, human PCLS in culture are not exposed to mechanical 
forces caused by tidal breathing. Mechanical stretch is necessary for the induction and 
maintenance of post-PNX lung regeneration in dogs (37), and therefore may be 
required for induction of regeneration in human PCLS. Recently, a technique was 
developed in which cultured rat PCLS were stretched biaxially at a magnitude 
roughly corresponding to alveolar distension in vivo (559). This system could be used 
provide a pro-regenerative stimulus to human PCLS, while improving the in vivo 
relevance of the model. 
 
Lack of an alveolar air-liquid interface is an inherent limitation of the model, as 
alveolar spaces of PCLS in culture fill with culture media. In vivo, alveolar spaces 
become fluid-filled either due oedema or due to inhalation of fluid, which can both 
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affect alveolar epithelial phenotype (428, 560). The presence of an air-liquid interface 
is necessary to maintain airway epithelial cells in vitro (561), although this has not 
been demonstrated for the alveolar epithelium (562). A further limitation is the 
vasculature is no longer perfused, and so circulating cells such as immune or 
progenitor cells are absent. However, this can also be an advantage due to greater 
control over experimental conditions. Due to these limitations, human PCLS will not 
supplant in vivo experiments. However, human PCLS represent a promising avenue 
for the study of complex processes involved in human lung regeneration (519). 
 
6.4.7 Future considerations for alveolar injury/repair model 
6.4.7.1 Method of injury 
 
To develop of an alveolar injury/repair model with human PCLS, it will be important 
to stimulate an injury that induces repair processes representative of repair in vivo. 
Lung injury in vivo can vary in extent of damage, cell types affected, and whether the 
injury is acute or chronic. Furthermore, the repair response varies with type of injury 
in vivo (Introduction 1.2 (5)). Therefore, the method of injury must be chosen to 
address specific hypotheses about a repair response of interest.  
 
Lung injury can involve alveolar epithelial death with preservation of the underlying 
basement membrane (BM), or more substantial damage to the lung tissue with loss of 
alveolar units, including death of alveolar epithelial and interstitial cells, destruction 
of the capillary endothelium, and loss of underlying matrix (414). Epithelial loss with 
BM preservation is often a feature of clinical acute lung injury (ALI), which can 
occur in response to pneumonia or inhalation of an injurious agent (563). In some 
cases, such as after pneumococcal pneumonia, ALI can resolve through clearance of 
the pathogen by the immune system followed by BM re-epithelialisation to 
reconstitute the alveolar-capillary barrier (544). The use of human PCLS to study 
alveolar BM re-epithelialisation could use an injury involving selective death of 
alveolar epithelial type 1 (AT1) cells with instillation of phospholipase A2 into 
airspaces during EVLP, prior to slicing (564). This might allow the study of the 
cellular and molecular events involved in alveolar epithelial reconstitution by AT2 
cells. Injury to both AT1 and AT2 cells in human PCLS could be used to investigate 
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repair involving putative progenitor cells of the alveolar epithelium such as 
bronchoalveolar stem cells (BASCs) (25) or p63-expressing bronchiolar epithelial 
cells (29), both of which were demonstrated to contribute to alveolar regeneration in 
the adult mouse. 
 
Loss of alveolar units is a consequence of pneumonectomy, which results in a rapid 
regenerative response in the remaining lobe(s) in smaller animals (39) and was 
recently reported in a human patient (45). Loss of alveolar units is also a feature of 
emphysema, which does not spontaneously reverse in adult humans, but can be 
reversed by ATRA administration in animal models (Introduction 1.5). Generation of 
PCLS from lung of animal models of emphysema or from human emphysematous 
lung tissue has not yet been described. Treatment with RA might allow investigation 
into the cellular and molecular events involved during RA-induced lung regeneration.  
 
6.4.7.2 Measuring lung regeneration 
 
It will be important to establish relevant biomarkers of lung regeneration in this 
model. There is limited data about human lung regenerative processes, but such 
biomarkers may be derived from animal models. Microarray studies investigating 
regenerating mouse lungs post-PNX revealed early upregulation of genes involved in 
cell-cell interactions and downregulation of pro-inflammatory factors (565). 
Transcriptional analysis following injury may provide information about regeneration 
within PCLS, and will require recovery of high quality RNA. We were unable to 
extract RNA from human PCLS of sufficient quality and concentration for qPCR 
analysis, despite using 5 slices per time point (data not shown). A previous group has 
also reported difficulty in recovering RNA from lung slices (318). Alternatively, IHC 
for biomarkers of lung regeneration could be used. 
 
The experiment must be long enough for regeneration biomarkers to be observed. 
Regeneration is initiated rapidly after injury in the lungs of mice in vivo. Localised 
cauterisation to mouse lungs resulted in increased alveolar cell DNA synthesis within 
24 hours (566). Initiation of post-PNX lung growth in adult mice is observed by 3 
days following operation (43). However, the kinetics of lung regeneration can differ 
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dramatically between species. Post-PNX regeneration is completed within 21 days in 
adult mice (43), compared 16 months in adult dogs (567). In the bronchial epithelium 
of human subjects, injury led to evidence of re-epithelialisation by day 7 (568). The 
kinetics of alveolar regeneration in vivo in humans are unknown. Human PCLS may 
therefore be useful to study the kinetics of human alveolar regeneration. 
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7 Chapter 7: General Discussion 
 
RA has evolutionarily conserved roles in regeneration of diverse organs and animals 
across phylogeny. For example, RA signalling is critical for amphibian limb 
regeneration (176), zebrafish heart and fin regeneration (179, 181), and tunicate 
whole body regeneration (173, 174). RA was demonstrated to modulate endogenous 
lung regeneration in adult mammals, and can stimulate lung regeneration in animal 
models of emphysema (described in Introduction 1.10). These data suggest retinoids 
could be used to modulate human chronic lung diseases. However, clinical trials 
investigating retinoids for emphysema have been disappointing, although evidence for 
biological activity was observed. Several questions are raised by these studies. Which 
cell types are direct targets of RA during RA-induced lung regeneration in animal 
models of chronic lung disease? What are the cellular and molecular mechanisms? 
How do animal studies of RA-induced lung regeneration translate to man? There is 
extremely limited information concerning the role of RA signalling in the adult 
human lung – the only studies to date have investigated the effects of RA on alveolar 
macrophages obtained from bronchoalveolar lavage (BAL) from patients (288, 569, 
570). However, no studies have investigated RA signalling in regenerative processes 
of constituent cells of the human lung parenchyma, partly due to a lack of 
physiologically relevant models of human alveolar repair (571). Therefore an 
important question is how can we develop better, more physiologically relevant 
models of human alveolar regeneration, which circumvent the inherent limitations of 
single-cell in vitro cell culture models? It is important that these issues are addressed 
to provide further insights into how retinoids can be used for treatment of human 
chronic lung diseases. The work presented in this thesis was conducted to address 
these critical questions. 
 
7.1 Hypotheses and aims 
 
This thesis aimed to investigate the role of RA signalling in regenerative processes in 
the adult human lung. Two complementary approaches were employed. Firstly, the 
transcriptional regulation of the RA pathway in lung tissue of patients with 
emphysema, a disease which may be driven by ineffective lung regeneration, was 
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investigated. Secondly, the effect of RA pathway modulation on regenerative 
processes in the two cell types of the ACM, AT2 epithelial cells, and HLMVECs 
which comprise the capillary network, was explored. Additional work involved a 
preliminary investigation into the use of PCLS derived from adult human lung tissue 
for development of a model of human alveolar regeneration. 
 
7.2 Summary of key findings 
 
7.2.1 RA signalling is conserved in adult human lung tissue 
 
Initial work in this thesis provided evidence that the RA signalling machinery is 
conserved in adult human lung tissue. RA synthesising enzymes (RALDH-1, -2 and -
3), RA degrading enzymes (CYP26A1, B1 and C1), cellular retinoid binding proteins 
(CRBP-1 and -2, and CRABP-1 and -2) and RA receptors (RAR-α, -β, -γ and RXR-
α, -β and -γ) were found expressed in whole tissue homogenates from adult human 
distal lung tissue. An HPLC method was optimised to separate known synthetic 
retinoid standards, and a preliminary experiment with an extract of whole human lung 
tissue suggested the endogenous presence of retinol and the biologically active 
retinoid ATRA. 
 
7.2.2 RA signalling is dyresgulated in emphysema 
 
CYP26A1, which degrades RA, was upregulated in histologically confirmed 
emphysematous lung tissue. This was demonstrated on both an mRNA and protein 
level. Confirmation of this finding was found in the microarray datasets of Spira et al 
(2004) (342) Fujino et al (2012) (340). Immunohistochemistry demonstrated 
CYP26A1 expression in cells with morphology and localisation of alveolar 
macrophages in histologically normal lung tissue sections. Additional RA pathway 
disturbances consistent with reduced RA availability correlated with physiological 
parameters in emphysema patients. Specifically, expression of CYP26A1 and 
CRABP-1, which both mediate RA degradation, were increased in patients with worst 
gas diffusing capacity, and CRBP-2 expression, which facilitates RA storage, was 
decreased in patients with worst gas diffusing capacity. These results are consistent 
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with a hypothesis that local RA deficiency contributes to an inability of the lung to 
initiate repair.  
 
7.2.3 RA signalling in lung cell regenerative processes 
  
A scratch assay, with pharmacological RA pathway modulation, was used to assess 
the role of RA signalling in human AT2 cell migration in response to injury. RA 
stimulated expression of an RA-responsive gene (RAR-β) in A549 cells, however RA 
pathway stimulation or inhibition did not affect wound healing in either A549 cells or 
primary hAT2 cells. In addition, RA pathway stimulation had no effect on A549 
proliferation following scratch. From this we concluded that RA signalling is not 
directly involved in alveolar epithelial wound healing in this model, and therefore the 
alveolar epithelium may not be a direct target of RA signalling during lung 
regeneration. 
 
A Matrigel-based assay was used to investigate the role of RA signalling in 
HLMVEC angiogenesis. RA stimulated RAR-β expression in HLMVECs, and RA 
(10µM) stimulated HLMVEC angiogenesis. The pan-RAR antagonist BMS493 
inhibited RA-mediated HLMVEC angiogenesis, however the combination of drugs 
reduced cellular viability, and thus it is possible that the inhibition was due to 
increased cell death. The RAR-α selective agonist Am580 (1nM) stimulated 
HLMVEC angiogenesis, while no effect was observed with agonists selective for 
either RAR-β or RAR-γ, providing evidence that RA-stimulated HLMVEC 
angiogenesis is mediated by RAR-α activation. ATRA (10µM) induced upregulation 
of VEGFA and VEGFR2, suggesting a mechanism of ATRA-stimulated HLMVEC 
angiogenesis through the VEGF-VEGFR2 axis. 
 
7.2.4 Development of a PCLS model of human lung regeneration 
 
We addressed the inherent limitations of single-cell in vitro culture models by 
investigating PCLS derived from adult human lung tissue for development of a 
complex, more physiologically relevant model of human alveolar regeneration. The 
ultimate aim with this is to apply the PCLS model to investigate the role of RA 
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signalling in human alveolar repair. Human PCLS retained tissue architecture and 
metabolic activity, mitochondrial activity and expression of cell-specific markers for 
AT1, AT2, endothelial and smooth muscle cells, through the slicing process. 
Additionally, human PCLS maintained expression of RALDH-1 and RALDH-2, 
suggesting of RA-synthesising capacity. In long term culture, PCLS architecture was 
maintained for 4 weeks. LDH release increased after 4 days, and airway epithelial 
cilia beating and alveolar septal cellularity declined within the first week of culture. 
Thus, human PCLS may be amenable to development of a model of human alveolar 
regeneration during culture of up to 1 week. With porcine PCLS, 10% FBS led to 
increased matrix deposition and architectural changes suggestive of excessive 
fibroblast activity, and thus is inappropriate for long-term lung PCLS culture. Human 
PCLS could be a powerful tool to help understand the cellular and molecular 
regulation of human alveolar regeneration. Using a pharmacological approach to 
modulate RA signalling in PCLS may help elucidate its role in the process. However, 
due to time constraints and limited tissue availability, application of the PCLS model 
to study RA signalling was not accomplished within this PhD project. 
 
7.3 Key limitations and future work 
 
7.3.1 RA signalling in emphysema 
 
Chapter 3 demonstrated that RA pathway dysregulation in emphysema occurs on a 
transcriptional level. The limitations of this work are described in 3.4.10, and include 
that the localisation of CYP26A1 expression in emphysematous lung tissue were not 
assessed. The HPLC method we optimised could be used to investigate retinoid levels 
in emphysematous lung tissue. However, further elucidation of the endogenous 
retinoid profile of normal human lung tissue will be important, as retinoid metabolism 
may be dynamic in the normal adult human lung as it is in the adult mouse lung (79). 
 
As with cross-sectional gene expression analyses in general, from our study the causal 
relationship between CYP26A1 and emphysema cannot be established. Animal 
models using conditional CYP26A1 induction in the adult lung, such as with 
generation of transgenic mice, or with gene transfection, would help elucidate the role 
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of CYP26A1 in emphysema. An advantage of transgenic mice is the possibility of 
placing the CYP26A1 transgene under the control of a cell-specific promoter, and 
thus inducing the gene in specific cell types. This approach was used to conditionally 
induce the Notch 1 intracellular domain, together with a GFP reporter, under the 
control of the keratin 5 (KRT5) promoter and thus specifically in basal cells in the 
airways of mice (10). Inclusion of a GFP reporter allowed the visualisation of cells in 
which the transgene has been successfully activated. A similar approach with 
CYP26A1, CRABP-1, or conditional ablation of CRBP-2 would allow the pulmonary 
consequences of such gene alterations in adult animals to be investigated. 
 
No transgenic animals in which RA signalling can be conditionally disrupted in adult 
tissues have been generated thus far. Animals with germline RA pathway disruptions 
have been generated, such as animals with targeted disruptions in RARs, RXRs, 
RALDHs, CRBPs and CYP26s (described in Introduction 1.7). However, these 
animals lack the disrupted gene throughout development and therefore phenotypic 
abnormalities in the adult may be due to disrupted development rather than adult 
disease processes. One method to disrupt RA signalling in adult animals is with 
maintenance of a VAD diet (229, 247). Limitations to this approach include that VAD 
takes a long time to develop (several months), as liver retinoid stores must be totally 
depleted, and that VAD disrupts RA signalling non-specifically in many tissue types, 
causing potentially confounding systemic effects. Alternative methods to disrupt RA 
signalling in the adult tissues have included the use of non-specific RALDH inhibitors 
(e.g. disulphiram) (176), and RNA interference (173).  
 
7.3.2 RA signalling in the regulation of regenerative processes in cell types of 
the human ACM 
 
Chapter 4 demonstrated that RA pathway modulation did not influence either A549 or 
primary hAT2 wound healing in a scratch assay, and thus we concluded that RA 
signalling is not directly involved in alveolar epithelial repair. It is important to note 
that other processes are involved in alveolar regeneration, such as AT2 cell 
proliferation and AT2 to AT1 differentiation. We found proliferation of A549 cells 
following scratch was unaffected by ATRA. However, it will be important to confirm 
this finding in primary hAT2 cells, as regulation of proliferation may differ between 
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A549 cells and hAT2 cells. Differentiation of AT2 to AT1 cells is frequently 
investigated using an in vitro transdifferentiation assay. In this model, freshly isolated 
AT2 cells are maintained in culture, whereupon they lose expression of AT2 markers 
and increase expression of AT1 markers, while changing from a cuboidal to a 
squamous AT1-like morphology over the course of 8 days (234). Pharmacological 
modulation of RA signalling in this assay may help elucidate the role of the RA 
pathway in this process.  
 
Chapter 5 demonstrated that ATRA stimulated HLMVEC angiogenesis in Matrigel-
based angiogenesis assay. The limitations of the assay are described in Chapter 5.4.7 
and include differences between Matrigel substrate and BM in vivo, as well as the 
absence of other lung cell types which may regulate HLMVEC behaviour. The 
absence of other cell types is a key limitation inherent in single-cell in vitro culture 
systems. The lung parenchyma is composed of alveolar epithelial, endothelial and 
interstitial cells, which includes various populations of resident lung fibroblasts. Lung 
fibroblasts were demonstrated to synthesise elastin in response to RA in vitro (249, 
251, 450). Elastin is a key component of alveolar septal walls, and contributes to the 
elastic properties of the lung. Thus, it is possible that fibroblasts are a direct target of 
RA during lung regeneration in addition to HLMVECs. 
 
It is possible that RA directly stimulates paracrine signalling during lung 
regeneration. Co-culture experiments with AT2 or HLMVECs and interstitial cells 
would be useful to investigate this hypothesis. However, interstitial cells are a 
heterogenous population for which there is a paucity of specific markers (22). We 
addressed this issue by investigating human PCLS for development of a model of 
human alveolar regeneration, described in Chapter 6. The limitations of PCLS are 
discussed in 6.4.6.3, and include the filling of airspaces with culture liquid, and 
absence of mechanical forces present in vivo due to the effect of tidal breathing. 
However, maintenance of intercellular interactions, and the retention of cell type 
heterogeneity, suggest that PCLS may be more physiologically relevant than single-
cell models. 
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7.4 A model for the role of RA signalling in human lung regeneration: RA 
stimulates regeneration through induction of lung microvascular 
angiogenesis 
 
The work presented in this thesis suggests that RA signalling regulates regenerative 
mechanisms in the adult human lung. A summary of how our data map onto the 
originally proposed model of the role of RA signalling in human lung regeneration is 
presented in Figure 7.1.  
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Proposed model of how RA signalling regulates adult human lung 
regeneration.  
The green boxes summarise the results obtained in this thesis, and are mapped onto 
the original hypothesis. In this model, increased RA degradation through the CRABP-
1-CYP26A1 axis, coupled with decreased retinoid esterification by decreased CRBP-
2, contributes to decreased RA levels and a consequent deficiency in RA-mediated 
regeneration, which has a role in the pathogenesis of emphysema. In conditions of RA 
sufficiency or after RA administration, RA can stimulate microvascular angiogenesis 
through RAR-α activation, mediated in part through the VEGF pathway, which in 
turn has a role in stimulating regeneration of the other cellular compartments in the 
lung. The role of RA in influencing lung interstitial cell behaviour during regenerative 
processes was not investigated in this thesis. 
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Furthermore, our data led us to hypothesise that RA-induced lung regeneration is 
mediated at least in part by direct stimulation of lung microvascular angiogenesis via 
RAR-α activation.  
 
Previously published data supports this hypothesis. Stimulation of lung angiogenesis 
per se can induce partial alveolar regeneration (section 5.1). For example, 
administration of VEGF, a well-known angiogenic factor, enhanced alveolarisation 
following PNX in adult mice (261), and after hyperoxic lung injury in rats (262). In a 
rat model of hyperoxia-induced BPD, VEGF145 overexpression promoted new 
alveolar growth with increased lung capillary density (456). Our data demonstrated 
that ATRA induced angiogenesis in lung microvascular endothelial cells, and 
stimulated VEGFA and VEGFR2 gene expression. Thus, it is possible that RA 
induces lung regeneration at least in part through lung microvascular angiogenesis. 
 
Several lines of evidence support a role for RAR-α in mediating RA-induced lung 
regeneration through microvascular angiogenesis. In mice lacking RAR-α, alveoli 
appear normal at 14 days, but fail to continue to develop properly between 14 and 50 
days (221). This implicates RAR-α in late alveolarisation, a period in which 
remodelling of the microvascular network is critical (190). In adult mice with 
emphysema, an RAR-α agonist induced alveolar regeneration, although the cellular 
target(s) were not identified (283). However, evidence from canine post-PNX lung 
growth links RA-induced lung regeneration to the microvascular endothelium. ATRA 
treatment following right-PNX in dogs induced an increase in alveolar density 
associated with a 50% increase in endothelial capillary density and increased double 
capillary profiles, whereas the epithelial volume was unchanged (259). Thus, ATRA 
appears to directly stimulate microvascular angiogenesis during lung regeneration in 
this model. Although the RAR responsible for mediating this effect was not identified 
in this study, our data provides evidence that ATRA-induced lung angiogenesis is 
mediated by RAR-α. 
 
It would be interesting to further investigate this hypothesis using in vivo models. In 
the study by Maden, an RAR-α agonist induced alveolar regeneration in mice with 
Dex-induced emphysema (283), however this approach did not target a specific lung 
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cell type. An experimental approach specifically activating RAR-α in the lung 
microvascular endothelium, for example conditional induction of a dominant active 
RAR-α, could be informative. These transgenic mice have not been generated thus 
far, but could be useful to test this hypothesis. In these mice, emphysema could be 
induced (e.g. with intratracheal elastase instillation, chronic cigarette smoke exposure, 
or disrupted alveolarisation with GCs (51)). Once the emphysematous lesions 
stabilise, one could investigate whether conditional induction of a dominant active 
RAR-α transgene in the lung microvascular endothelium can induce alveolar 
regeneration. 
 
We also found that ATRA (10 µM) directly induced VEGFA expression in 
HLMVECs. Induction of HLMVEC VEGF by ATRA may induce alveolarisation 
through other mechanisms. VEGF was reported to directly stimulate AT2 migration 
(572), proliferation (573) and surfactant production (574). In another study, VEGFA 
activated endothelial VEGFR2 stimulating HGF production, which in turn stimulated 
epithelial branching morphogenesis (575). It is therefore possible that ATRA could 
induce VEGF in HLMVECs, which could in turn directly stimulate alveolar epithelial 
cells to promote regeneration. We did not detect any VEGFA protein in supernatants 
of HLMVECs treated with ATRA using ELISA, and therefore to support the 
physiological relevance of this finding it will be important to confirm upregulation of 
VEGFA on a protein level. As discussed in Chapter 5.4.8, it is possible that RA 
stimulates HLMVEC angiogenesis via angiogenic factors we did not examine such as 
angiopoeitin-2 and HGF, which are upregulated by ATRA in HUVECs (310). 
 
7.5 Clinical relevance of findings 
 
Induction of CYP26A1 in lungs of emphysema patients may have consequences for 
prospective RA-based therapeutic approaches. Increased CYP26A1 activity could 
lower the sensitivity of lung tissue to the pro-regenerative effects of RA therapy, and 
it is possible that this contributed to the ineffectiveness of RA in clinical trials (250, 
289). In support of this idea, overexpression of CYP26A1 in HeLa cells led to 
increased RA degradation, rendering the cells hyposensitive to RA (576). Prospective 
therapies for emphysema could include, for example, retinoic acid metabolism-
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blocking agents (RAMBAs) which inhibit CYP26A1 activity. Examples of RAMBAs 
are liarozole and talarozole which already have approval for clinical use and are 
widely used to treat skin conditions (577). Interestingly, CYP26A1 is downregulated 
during goldfish optic nerve regeneration (578), supporting the notion that inhibition of 
CYP26A1 activity is permissive for regeneration. Inhibition of CYP26A1 in lungs of 
patients through co-administration of RAMBAs could be a useful strategy to improve 
the local bioavailability of RA, thus permitting its pro-regenerative effects. 
 
An alternative retinoid-based therapeutic approach for emphysema is synthetic 
retinoids such as the RAR-γ selective agonist Palovarotene. As described earlier 
(Introduction 1.11.4) a recent clinical trial with Palovarotene for emphysema reported 
a beneficial effect in patients with lower lobe disease (295). Identification of selective 
agonists as therapeutic alternatives to ATRA is appealing as ATRA has pleiotropic 
effects mediated by interaction with all three RARs. Minimising activation of un-
needed RARs may help reduce unwanted, potentially toxic side effects. Furthermore, 
unlike ATRA, synthetic RAR-selective agonists do not induce their own catabolism 
and thus lower therapeutically effective doses may be achievable. 
 
Our finding that RAR-α activation can stimulate HLMVEC angiogenesis in vitro, 
together with reports that RAR-α agonists can stimulate lung regeneration in mice 
(283), suggests that RAR-α agonists may be useful therapeutic tools for the induction 
of regeneration in the adult human lung. The exploration of RAR-α for treatment of 
lung diseases would benefit from more physiologically relevant models of human 
lung repair. In this regard, human PCLS could be a powerful experimental tool. 
Ongoing work in our lab involves the development of an EVLP model of human 
acute lung injury (ALI). Investigating the role of RA signalling in human lung 
regeneration in this model is an exciting future possibility.  
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